0	"Intravenous <e1>azithromycin</e1>-induced <e2>ototoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1	"Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of <e1>dihydrotachysterol</e1> by rifampicin, could have led to <e2>increased calcium-release</e2> into the circulation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2	"Unaccountable severe <e1>hypercalcemia</e1> in a patient treated for hypoparathyroidism with <e2>dihydrotachysterol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3	"METHODS: We report two cases of <e1>pseudoporphyria</e1> caused by <e2>naproxen</e2> and oxaprozin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4	"METHODS: We report two cases of <e1>pseudoporphyria</e1> caused by naproxen and <e2>oxaprozin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5	"<e1>Naproxen</e1>, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating <e2>erythropoietic protoporphyria</e2> in the pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6	"RESULTS: A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

7	"RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with tense bullae and <e2>cutaneous fragility</e2> on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

8	"RESULTS: A 44-year-old man taking <e1>naproxen</e1> for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

9	"RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on <e1>oxaprozin</e1> for rheumatoid arthritis presented with <e2>tense bullae</e2> and cutaneous fragility on the face and the back of the hands."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

10	"BACKGROUND: How to best treat psychotic patients who have had past <e1>clozapine</e1>-induced agranulocytosis or <e2>granulocytopenia</e2> remains a problem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

11	"CONCLUSION: The results suggest that olanzapine may be useful in treating patients with <e1>clozapine</e1>-induced <e2>granulocytopenia</e2> without the risk of recurrence of hematologic side effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

12	"Prolonged severe <e1>5-fluorouracil</e1>-associated <e2>neurotoxicity</e2> in a patient with dihydropyrimidine dehydrogenase deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

13	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and <e2>neurologic toxicity</e2> that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

14	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, <e2>prolonged myelosuppression</e2>, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

15	"We describe the side effects of <e1>5-FU</e1> in a colon cancer patient who suffered <e2>severe mucositis</e2>, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

16	"This case suggests that <e1>BH-AC</e1>, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible <e2>encephalopathy syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

17	"We report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of <e2>BH-AC</e2> (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

18	"We report a case of reversible <e1>encephalopathy syndrome</e1> in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and <e2>idarubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

19	"In one case, the readministration of <e1>riluzole</e1> was followed by the relapse of <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

20	"We report the cases of two patients who developed acute <e1>hepatitis</e1> after taking <e2>riluzole</e2> at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

21	"<e1>Lupus-like syndrome</e1> caused by <e2>5-aminosalicylic acid</e2> in patients with inflammatory bowel disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

22	"Although the two local anesthetics usually do not cause <e1>methemoglobinemia</e1>, we suspect that the displacement of <e2>lidocaine</e2> from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

23	"<e1>Methemoglobinemia</e1> after axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

24	"<e1>Methemoglobinemia</e1> after axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

25	"We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with <e2>bupivacaine</e2> and additional injection of lidocaine in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

26	"We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant <e1>methemoglobinemia</e1> after an axillary block with bupivacaine and additional injection of <e2>lidocaine</e2> in the operative field."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

27	"Detection of activated eosinophils in nasal polyps of an <e1>aspirin</e1>-induced <e2>asthma</e2> patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

28	"An episode of subacute <e1>encephalopathy</e1> after the infusion of a moderate dose of <e2>methotrexate</e2> (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

29	"We believe that this represents an unusual case of moderate-dose <e1>MTX</e1>-induced <e2>neurotoxicity</e2> in a patient with gastric cancer, which has not previously been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

30	"We describe a life threatening side effect of acute <e1>epoprostenol</e1> infusion (<e2>pulmonary edema</e2>) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

31	"A 14-year-old girl with newly diagnosed SLE developed a <e1>pruritic bullous eruption</e1> while on <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

32	"<e1>Hydroxyurea</e1>-induced <e2>acute interstitial pneumonitis</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

33	"The clinical course suggests that the <e1>interstitial pneumonitis</e1> was induced by <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

34	"This is the first case of <e1>hydroxyurea</e1>-induced <e2>acute interstitial pneumonitis</e2> reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

35	"Allergic and <e1>irritant contact dermatitis</e1> to <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

36	"<e1>Calcipotriol</e1> (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas <e2>allergic reactions</e2> are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

37	"<e1>Calcipotriol</e1> (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause <e2>irritation of the skin</e2>, whereas allergic reactions are less common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

38	"The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an <e1>irritant type of reaction</e1> after treatment with <e2>calcipotriol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

39	"<e1>Myotonia</e1> associated with sarcoidosis: marked exacerbation with <e2>pravastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

40	"<e1>Pravastatin</e1> is associated with <e2>myotonia</e2> in animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

41	"This case suggests that sarcoidosis and <e1>pravastatin</e1>, two entities not frequently associated with <e2>myotonia</e2>, may interact in a synergistic manner to produce severe clinical <e2>myotonia</e2> in humans."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

42	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or <e2>angioedema</e2>, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

43	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, urticaria and/or angioedema, or a <e2>systemic anaphylactoid reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

44	"Hypersensitivity to <e1>aspirin</e1> can be manifested as acute asthma, <e2>urticaria</e2> and/or angioedema, or a systemic anaphylactoid reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

45	"CONCLUSION: Fixed drug <e1>eruption</e1> is associated with many drugs but this is the first such report with <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

46	"Fixed drug <e1>eruption</e1> in hands caused by <e2>omeprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

47	"The objective of this report is to describe a case of fixed drug <e1>eruption</e1> that occurred during <e2>omeprazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

48	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with <e1>diffuse erythema</e1> and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

49	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and <e1>fever up to 39 degrees C</e1> one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

50	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, <e1>malaise</e1>, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

51	"A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and <e1>pustules</e1> on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

52	"<e1>Acute generalized exanthematous pustulosis</e1> induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

53	"We report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) induced by <e2>salazosulfapyridine</e2> in a patient with ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

54	"CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with <e1>olanzapine</e1> developed an <e2>elevated serum CK concentration</e2> with a peak concentration of 4000 IU/L (normal < 230)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

55	"DISCUSSION: <e1>Olanzapine</e1>, like other atypical antipsychotic drugs, may cause <e2>muscle injury with concomitant elevations of serum CK</e2> of muscle origin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

56	"Marked <e1>elevation of serum creatine kinase</e1> associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

57	"OBJECTIVE: To report a case of marked <e1>elevation of serum creatine kinase</e1> (CK) associated with <e2>olanzapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

58	"<e1>Diclofenac</e1>-associated <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

59	"This patient, who had a history of osteoarthritis, had severe <e1>hepatitis</e1> 5 weeks after being started on <e2>diclofenac</e2> for increasing pain in the joints."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

60	"<e1>2-CdA</e1> induces <e2>lymphocytopenia</e2>, which may explain the improvement in this patient's psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

61	"One case of <e1>priapism</e1> occurred during <e2>heparin</e2> therapy for a previous surgical operation to the knee is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

62	"<e1>Priapism</e1> as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

63	"The association between <e1>heparin</e1> and priapism is often recognized; <e2>abnormal platelet aggregation</e2> could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

64	"The association between <e1>heparin</e1> and <e2>priapism</e2> is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

65	"It carries a well-known risk of neutropenia and <e1>agranulocytosis</e1>, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

66	"It carries a well-known risk of <e1>neutropenia</e1> and agranulocytosis, which necessitates the immediate discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

67	"OBJECTIVE: We report a patient who developed neutropenia on <e1>clozapine</e1>, but behind the cell count decrease showed to be a <e2>diurnal variation of the white blood cells</e2> (WBC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

68	"<e1>Acute neutrophilic dermatosis</e1> induced by <e2>all-trans-retinoic acid</e2> treatment for acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

69	"Findings on discontinuation and rechallenge supported the assumption that the <e1>hair loss</e1> was a side effect of the <e2>paroxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

70	"<e1>Hair loss</e1> associated with <e2>paroxetine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

71	"We report on a 37-year-old female who complained of moderate <e1>hair loss</e1> during <e2>paroxetine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

72	"CONCLUSION: Patients with <e1>insulin</e1> allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant <e2>protamine allergy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

73	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

74	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, <e2>angioedema</e2>, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

75	"METHODS: The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

76	"METHODS: The patient required <e1>insulin</e1> desensitization for <e2>severe urticaria</e2>, angioedema, and occasional wheezing resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

77	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

78	"METHODS: The patient required <e1>insulin</e1> desensitization for severe urticaria, angioedema, and occasional <e2>wheezing</e2> resulting from her <e1>insulin</e1> dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

79	"OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH <e1>insulin</e1>, as well as standard <e1>insulin</e1> desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular <e1>insulin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

80	"OBJECTIVE: The purpose of this study was to determine whether desensitization to <e1>NPH insulin</e1>, as well as standard insulin desensitization, could control <e2>allergic symptoms</e2> in a patient allergic to both NPH and regular insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

81	"Patients receiving <e1>neutral protamine Hagedorn (NPH) insulin</e1> are at increased risk for the development of <e2>protamine hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

82	"<e1>Protamine allergy</e1> as a complication of <e2>insulin</e2> hypersensitivity: A case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

83	"She continued to receive regular <e1>insulin</e1> 4 times per day over the following 3 years with only occasional <e2>hives</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

84	"The patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

85	"The patient had recurrence of urticaria and <e1>angioedema</e1> a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

86	"The patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

87	"The patient had recurrence of <e1>urticaria</e1> and angioedema a year and a half later, at which point the <e2>NPH</e2> was stopped and she was desensitized to regular insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

88	"A 5-month-old infant became <e1>lethargic</e1> and poorly responsive after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

89	"A 5-month-old infant became lethargic and <e1>poorly responsive</e1> after receiving 1 drop of <e2>brimonidine</e2> in each eye."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

90	"An 11-day-old infant became lethargic and <e1>apneic</e1> after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

91	"An 11-day-old infant became <e1>lethargic</e1> and apneic after a single drop of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

92	"Apparent <e1>central nervous system depression</e1> in infants after the use of topical <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

93	"CONCLUSIONS: Topical <e1>brimonidine</e1> may be associated with <e2>central nervous system depression</e2> in infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

94	"PURPOSE: To report two cases in which topical <e1>brimonidine</e1> resulted in apparent <e2>central nervous system depression</e2> and unresponsiveness in an infant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

95	"Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with <e2>elevated hepato-biliary enzymes</e2> and transient biliary stasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

96	"Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of <e1>ceftriaxone</e1> with elevated hepato-biliary enzymes and <e2>transient biliary stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

97	"<e1>Hepato-biliary abnormalities</e1> secondary to <e2>ceftriaxone</e2> use: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

98	"<e1>Anterior lumbosacral radiculopathy</e1> after intrathecal <e2>methotrexate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

99	"Reported are three children who developed <e1>progressive paraparesis</e1> after intrathecal <e2>methotrexate</e2> administration followed by complete or partial recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

100	"During the first days of <e1>arsenic trioxide</e1> treatment a rapid <e2>decrease in the D-dimers</e2> was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

101	"During the first days of <e1>arsenic trioxide</e1> treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a <e2>slight decrease in peripheral blood leukocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

102	"A 22-year-old black man developed fever, <e1>chills</e1>, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

103	"A 22-year-old black man developed fever, chills, <e1>fatigue</e1>, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

104	"A 22-year-old black man developed <e1>fever</e1>, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

105	"A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a <e1>generalized, pruritic, macular eruption</e1> 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

106	"A 22-year-old black man developed fever, chills, fatigue, <e1>night sweats</e1>, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting <e2>minocycline</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

107	"With the negative viral serologies, the clinical picture was most consistent with an infectious <e1>mononucleosis-like syndrome</e1> produced by the<e2> minocycline</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

108	"We conclude that the presence of this metabolic defect combined with topical <e1>5-FU</e1> (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of <e2>life-threatening toxicity</e2> after treatment with a topical drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

109	"We now report the first known cancer patient who developed <e1>life-threatening complications</e1> after treatment with topical <e2>5-FU</e2> and was shown subsequently to have profound DPD deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

110	"An <e1>acute ischaemic event</e1> associated with the use of <e2>venlafaxine</e2>: a case report and proposed pathophysiological mechanisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

111	"The association of <e1>venlafaxine</e1> treatment with <e2>ischaemic events</e2> could be explained by its unique pharmacological and haemodynamic properties."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

112	"This is the first report of a possible association between an <e1>acute cardiovascular event</e1> and <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

113	"We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with <e1>venlafaxine</e1>, and developed <e2>acute myocardial ischaemia</e2> within the first week of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

114	"Apparent <e1>cyclophosphamide</e1> (cytoxan) <e2>embryopathy</e2>: a distinct phenotype?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

115	"The purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with multiple congenital anomalies and to establish an apparent <e1>CP</e1> <e2>embryopathy</e2> phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

116	"The purpose of this report is to document a new case of in utero <e1>CP</e1> exposure with <e2>multiple congenital anomalies</e2> and to establish an apparent <e1>CP</e1> embryopathy phenotype."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

117	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, <e2>blepharophimosis</e2>, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

118	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, <e2>craniosynostosis</e2>, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

119	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, <e2>developmental delay</e2>, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

120	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and <e2>distal limb defects</e2> including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

121	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, <e2>flat nasal bridge</e2>, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

122	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including <e2>hypoplastic thumbs</e2> and oligodactyly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

123	"The reported cases of in utero exposure to <e1>cyclosposphamide</e1> shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and <e2>oligodactyly</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

124	"We conclude that (a) <e1>cyclophosphamide</e1> is a <e2>human teratogen</e2>, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

125	"In all cases, <e1>seizures</e1> were controlled by withdrawal of <e2>phenytoin</e2> and reduction of drug levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

126	"Paradoxical <e1>seizures</e1> in <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

127	"We present three patients with paradoxical <e1>seizures</e1>; their serum <e2>phenytoin</e2> levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

128	"CONCLUSIONS: This case suggests that <e1>losartan</e1> can induce late-onset <e2>angioedema</e2> in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

129	"<e1>Losartan</e1>-induced <e2>angioedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

130	"OBJECTIVE: To report a case of <e1>angioedema</e1> associated with <e2>losartan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

131	"The incidence of <e1>angioedema</e1> secondary to <e2>losartan</e2>, an angiotensin II receptor antagonist, is unknown."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

132	"We report the case of a female acromegalic patient in whom multiple <e1>hepatic adenomas</e1> appeared soon after <e2>danazol</e2> treatment for uterine fibromatosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

133	"<e1>Heparin</e1>-induced <e2>thrombocytopenia</e2> is a rare and serious complication of anticoagulation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

134	"Pediatric <e1>heparin</e1>-induced <e2>thrombocytopenia</e2>: management with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

135	"There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with <e1>heparin</e1>-induced <e2>thrombocytopenia</e2>, especially in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

136	"We report the successful treatment of <e1>heparin</e1>-induced thrombocytopenia and subsequent <e2>hemorrhagic complications</e2> postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

137	"We report the successful treatment of <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

138	"<e1>Taxane</e1>-induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

139	"We report a case of <e1>glaucoma</e1> induced by <e2>doxetaxel</e2> therapy for metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

140	"Acute <e1>hyperphosphatemia</e1> caused by <e2>sodium phosphate</e2> enema in a patient with liver dysfunction and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

141	"We report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of sodium phosphate and <e2>sodium biphosphate</e2> (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

142	"We report a case of acute <e1>hyperphosphatemia</e1> secondary to rectal administration of <e2>sodium phosphate</e2> and sodium biphosphate (Fleet enema)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

143	"<e1>Prolongation of the QT interval</e1> and ventricular tachyarrhymias have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

144	"Prolongation of the QT interval and <e1>ventricular tachyarrhymias</e1> have been described in patients on <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

145	"We report a case of recurrent <e1>torsades de pointes</e1> following treatment with pentavalent antimonial drugs and <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

146	"Emphasis is given to the differentiation of <e1>diphenylhydantoin</e1> induced <e2>gingival hyperplasia</e2> from the angiomatous enlargement of the gingiva before any treatment is planned."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

147	"A 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

148	"A 66-year-old Japanese woman with severe scleroderma developed <e1>anemia</e1> and thrombocytopenia due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

149	"A 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to D-penicillamine (<e2>D-Pen</e2>) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

150	"A 66-year-old Japanese woman with severe scleroderma developed anemia and <e1>thrombocytopenia</e1> due to <e2>D-penicillamine</e2> (D-Pen) treatment, although the leukopenia was not markedly severe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

151	"Cessation of <e1>D-Pen</e1> and the start of corticosteroid therapy were followed by recovery from <e2>bicytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

152	"In vitro <e1>inhibition of hematopoiesis</e1> in a patient with systemic sclerosis treated with <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

153	"These findings suggest that <e1>bicytopenia</e1> in this patient was caused by <e2>D-Pen</e2> and may be due to different sensitivities in the hematopoietic lineage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

154	"A 48-year-old woman who was treated for thyrotoxicosis with <e1>methimazole</e1> developed <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

155	"Postoperative <e1>hypocalcemic tetany</e1> caused by fleet phospho-soda preparation in a patient taking <e2>alendronate sodium</e2>: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

156	"Postoperative <e1>hypocalcemic tetany</e1> caused by <e2>fleet phospho-soda</e2> preparation in a patient taking alendronate sodium: report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

157	"This case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

158	"This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and <e1>hypocalcemic tetany</e1> after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

159	"This case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative hypophosphatemia and <e2>hypocalcemic tetany</e2> after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

160	"This case report describes a patient who was previously prescribed <e1>alendronate</e1> (Fosamax) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

161	"This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative <e1>hypophosphatemia</e1> and hypocalcemic tetany after bowel preparation with <e2>Fleet Phospho-Soda</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

162	"This case report describes a patient who was previously prescribed alendronate (<e1>Fosamax</e1>) and presented with postoperative <e2>hypophosphatemia</e2> and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

163	"Described here are 2 patients who developed <e1>thrombotic microangiopathy</e1> of the kidneys after receiving high cumulative doses of the new anticancer drug <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

164	"Thrombotic microangiopathy with <e1>renal failure</e1> in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

165	"<e1>Thrombotic microangiopathy</e1> with renal failure in two patients undergoing <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

166	"The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom <e1>B-cell non-Hodgkin's lymphoma</e1> was diagnosed 9 months after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

167	"The relationship between <e1>infliximab</e1> treatment and <e2>lymphoma</e2> in Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

168	"The second is a 29-year-old man with CD in whom <e1>nodular sclerosing Hodgkin's lymphoma</e1> was diagnosed 3 weeks after infusion with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

169	"We describe the clinical course of 2 patients with Crohn's disease (CD) in whom <e1>lymphoma</e1> was diagnosed after treatment with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

170	"<e2>Codeine</e2> intoxication in the neonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

171	"We report a case of <e2>codeine</e2> intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

172	"<e1>Hydroxyurea</e1> (HU) and sodium phenylbutyrate (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

173	"Hydroxyurea (HU) and <e1>sodium phenylbutyrate</e1> (SPB) have been shown to <e2>increase fetal hemoglobin</e2> (Hb F) levels in patients with thalassemia intermedia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

174	"Of the four patients who responded to <e1>HU</e1> with an <e2>increase in total Hb</e2>, all reported symptomatic improvement and three have not required further transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

175	"Prolonged responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or <e2>hepatic toxicity</e2> and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

176	"Prolonged responses were achieved with low doses of <e1>HU</e1> (3-10 mg/kg/day) and higher doses were associated with <e2>mild reversible hematologic</e2> or hepatic toxicity and no further increases in Hb."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

177	"Sodium phenylbutyrate was added to treatment with <e1>HU</e1> in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

178	"<e1>Sodium phenylbutyrate</e1> was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite <e2>increasing Hb F</e2> levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

179	"We conclude that low-dose <e1>HU</e1> therapy in patients with thalassemia intermedia may <e2>increase total Hb</e2> levels sufficiently to eliminate the need for transfusions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

180	"We describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with <e2>HU</e2> alone or in combination with SPB."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

181	"We describe the clinical response, as determined by <e1>increases in total Hb</e1> and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with <e2>SPB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

182	"A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of <e1>oolong tea</e1> that eventually reached 15 L each day, became <e2>delirious</e2> and was admitted to a psychiatric hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

183	"After abstinence from <e1>oolong tea</e1> his <e2>delirium</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

184	"Severe rhabdomyolysis following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

185	"Severe rhabdomyolysis following massive ingestion of <e1>oolong tea</e1>: <e2>caffeine intoxication</e2> with coexisting hyponatremia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

186	"Severe <e1>rhabdomyolysis</e1> following massive ingestion of oolong tea: <e2>caffeine</e2> intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

187	"Severe <e1>rhabdomyolysis</e1> following massive ingestion of <e2>oolong tea</e2>: caffeine intoxication with coexisting hyponatremia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

188	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the <e2>delirium</e2>, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

189	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe <e2>hyponatremia</e2> has been reported to cause rhabdomyolysis on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

190	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

191	"The clinical course suggests that <e1>caffeine</e1>, which is present in oolong tea, was mainly responsible for the <e2>rhabdomyolysis</e2> as well as the delirium, although severe hyponatremia has been reported to cause <e2>rhabdomyolysis</e2> on rare occasions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

192	"The possibility of severe <e1>rhabdomyolysis</e1> should be considered in a patient with water intoxication due to massive ingestion of <e2>caffeine</e2>-containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

193	"The possibility of severe rhabdomyolysis should be considered in a patient with <e1>water intoxication</e1> due to massive ingestion of <e2>caffeine</e2>-containing beverages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

194	"We hypothesize that <e2>caffeine</e2> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

195	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the <e2>coexisting hyponatremia</e2>, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

196	"We hypothesize that <e1>caffeine</e1> toxicity <e2>injured the muscle cells</e2>, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

197	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the <e2>potassium depletion</e2> induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

198	"We hypothesize that <e1>caffeine</e1> toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

199	"After the addition of <e1>citalopram</e1>, a desmethylclomipramine plasma level increase and an <e2>8-hydroacy-desmethylclomipramine plasma level decrease</e2> were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

200	"After the addition of <e1>citalopram</e1>, a <e2>desmethylclomipramine plasma level increase</e2> and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

201	"We report 3 cases of HIV-1 infected patients who experienced symptomatic <e1>angiolipomas</e1> shortly after starting antiretroviral therapy including the protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

202	"<e1>Elevated serum triglycerides</e1> with <e2>clozapine</e2> resolved with risperidone in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

203	"In two patients <e1>clozapine</e1> was reinstated after risperidone was discontinued; <e2>serum triglyceride levels increased</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

204	"This increase when <e1>clozapine</e1> was switched to risperidone and vice versa is consistent with our previous report of <e2>elevated serum triglyceride levels</e2> in <e1>clozapine</e1>-treated patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

205	"Intravenous <e1>valproate</e1> associated with significant <e2>hypotension</e2> in the treatment of status epilepticus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

206	"To our knowledge, this is the first report of significant <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> in the treatment of status epilepticus in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

207	"We report a case of severe <e1>hypotension</e1> associated with intravenous <e2>valproate</e2> used to treat status epilepticus in an 11-year-old girl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

208	"In both patients the <e1>rippling phenomena worsened</e1> with <e2>pyridostigmine</e2> treatment but markedly improved after immunosuppression with azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

209	"A diagnosis of masked <e2>theophylline</e2> poisoning should be considered in similar situations involving a rapid decrease of insulin requirements."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

210	"Salicylate <e1>intoxication</e1> was excluded, and <e2>theophylline</e2> was finally incriminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

211	"<e2>Theophylline</e2> intoxication mimicking diabetic ketoacidosis in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

212	"This compound, used by adults in the child's home, had caused accidental <e2>theophylline</e2> poisoning, mimicking diabetic ketoacidosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

213	"Methylene blue in the treatment and prevention of <e2>ifosfamide</e2>-induced encephalopathy: report of 12 cases and a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

214	"Ten to 15% of patients treated with <e1>ifosfamide</e1> develop an <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

215	"We conclude that MB is an effective treatment for <e2>ifosfamide</e2>-induced encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

216	"<e1>Portal vein thrombosis</e1> in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of <e2>F VIII</e2> after intramural jejunal bleeding--successful thrombolysis under heparin therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

217	"We report on a 14-year-old boy with severe haemophilia A who developed a <e1>portal vein thrombosis</e1> during continuous infusion of <e2>F VIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

218	"A 60-year-old woman with diabetes mellitus (type 2) developed an <e1>acute icteric hepatitis-like illness</e1> 6 weeks after the initiation of <e2>gliclazide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

219	"<e1>Gliclazide</e1>-induced <e2>acute hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

220	"In conclusion, this case strongly suggests that <e1>gliclazide</e1> can induce <e2>acute icteric liver necro-inflammation</e2> which may be misdiagnosed clinically as acute viral hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

221	"We believe that this is the first description of <e1>acute hepatitis</e1> caused by an idiosyncratic adverse reaction to <e2>gliclazide</e2> or to one of its metabolites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

222	"We describe the case of <e1>acute hepatitis</e1> induced by <e2>gliclazide</e2>, a second generation sulfonylurea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

223	"Caution is, therefore, needed to prevent undesired accumulation of <e1>TCA</e1> that may lead to protracted <e2>Cushing's syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

224	"<e1>Cushing's syndrome</e1> persisted more than 6 months while <e2>TCA</e2> concentrations remained detectable for at least 80 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

225	"The presented patient was treated with 200 mg <e1>TCA</e1> and developed <e2>Cushing's syndrome</e2> 6 weeks later (cortisol and ACTH concentrations were below limits of detection, <e1>TCA</e1> concentrations were > 3 micrograms/l)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

226	"Both had impaired lung function and <e1>abnormal computed tomographic scans</e1>, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

227	"Both had <e1>impaired lung function</e1> and abnormal computed tomographic scans, and their condition improved when <e2>nitrofurantoin</e2> was withdrawn and corticosteroid treatment commenced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

228	"<e1>Bronchiolitis obliterans organising pneumonia</e1> associated with the use of <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

229	"The case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of bronchiolitis obliterans organising pneumonia (<e2>BOOP</e2>), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

230	"The case histories are presented of two patients who developed lung disease associated with the use of <e1>nitrofurantoin</e1> with histological features of <e2>bronchiolitis obliterans organising pneumonia</e2> (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

231	"The case histories are presented of two patients who developed <e1>lung disease</e1> associated with the use of <e2>nitrofurantoin</e2> with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

232	"The favourable outcome in these two patients contrasts with the <e1>fatal outcome</e1> of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

233	"The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of <e2>nitrofurantoin</e2> induced BOOP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

234	"The spectrum of <e1>nitrofurantoin</e1> <e2>lung injury</e2> continues to widen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

235	"The two middle aged women presented with <e1>respiratory symptoms</e1> after prolonged treatment with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

236	"We suggest that the previous classification of <e2>nitrofurantoin</e2> induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

237	"Intravenous administration of levodopa ameliorated a refractory <e1>akathisia</e1> case induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

238	"The present report illustrates a rare case of refractory <e1>akathisia</e1> after <e2>interferon-alpha</e2> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

239	"The present report illustrates a rare case of refractory akathisia after <e1>interferon-alpha</e1> treatment and also that levodopa treatment would be theoretically and practically useful in reducing the <e2>neurotoxicity</e2> associated with <e1>interferon-alpha</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

240	"<e1>Acute erythroid leukemia</e1> after <e2>cyclophosphamide</e2> therapy for multiple myeloma: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

241	"The development of erythroid leukemia plus <e1>carcinoma</e1> in these two men suggests mutagenic change secondary to <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

242	"<e1>Scleroderma-like reaction</e1> induced by uracil-tegafur (<e2>UFT</e2>), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

243	"<e1>Scleroderma-like reaction</e1> induced by <e2>uracil-tegafur</e2> (UFT), a second-generation anticancer agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

244	"This is the first report of <e2>UFT</e2>-induced scleroderma-like reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

245	"We report a case of a <e1>scleroderma-like reaction</e1> induced by long-term administration of <e2>UFT</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

246	"<e1>Central nervous system manifestations</e1> of an <e2>ibuprofen</e2> overdose reversed by naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

247	"<e1>Ibuprofen</e1> overdose is usually characterized by GI upset, <e2>dizziness</e2>, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

248	"<e1>Ibuprofen</e1> overdose is usually characterized by <e2>GI upset</e2>, dizziness, and mild sedation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

249	"<e1>Ibuprofen</e1> overdose is usually characterized by GI upset, dizziness, and <e2>mild sedation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

250	"Presently, treatment of acute <e2>ibuprofen</e2> intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

251	"We report the case of an 11-month-old female infant with a <e1>depressed level of consciousness</e1> after ingestion of <e2>ibuprofen</e2> whose mental status markedly improved with administration of naloxone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

252	"<e1>Flecainide</e1>-associated pneumonitis with <e2>acute respiratory failure</e2> in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

253	"<e1>Flecainide</e1>-associated <e2>pneumonitis</e2> with acute respiratory failure in a patient with the LEOPARD syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

254	"<e1>Flecainide</e1> is a rare cause of <e2>hypersensitivity pneumonitis</e2>, and few cases have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

255	"We describe a case of <e1>interstitial hypoxaemiant pneumonitis</e1> probably related to <e2>flecainide</e2> in a patient with the LEOPARD syndrome, a rare congenital disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

256	"<e1>Sagittal sinus thrombosis</e1> associated with transient free protein S deficiency after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

257	"Sagittal sinus thrombosis associated with <e1>transient free protein S deficiency</e1> after <e2>L-asparaginase</e2> treatment: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

258	"We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a <e1>seizure</e1> during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

259	"We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated <e1>transient ischemic attacks</e1> followed by a seizure during consolidation treatment with <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

260	"We report on a young adolescent with <e1>benign intracranial hypertension</e1> which we attribute to the use of <e2>minocycline</e2> for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

261	"We report 2 patients who developed <e1>polyarteritis nodosa</e1> following <e2>vaccination against hepatitis B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

262	"In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose <e1>methotrexate</e1> therapy might have promoted the development of <e2>lung cancer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

263	"This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with <e1>cocaine</e1>-induced <e2>refractory coronary vasospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

264	"However, as illustrated by these and other cases reported to date, the onset of <e1>troglitazone</e1>-induced <e2>liver injury</e2> is insidious and temporally variable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

265	"It remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

266	"It remains to be seen whether the <e1>hepatotoxicity</e1> associated with <e2>troglitazone</e2> is a drug-class effect or specific to <e2>troglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

267	"Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of <e1>troglitazone</e1> without significant <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

268	"The three reported cases demonstrate that <e1>troglitazone</e1> is an idiosyncratic hepatotoxin that can lead to <e2>irreversible liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

269	"<e1>Troglitazone</e1>-induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

270	"<e1>Nitrofurantoin</e1>-induced <e2>lung disease</e2>: two cases demonstrating resolution of apparently irreversible CT abnormalities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

271	"We present two cases of <e1>nitrofurantoin</e1>-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated <e2>distortion of the lung parenchyma</e2>, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

272	"We present two cases of <e1>nitrofurantoin</e1>-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

273	"We present two cases of <e1>nitrofurantoin</e1>-induced <e2>pulmonary toxicity</e2> in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

274	"We present two cases of <e1>nitrofurantoin</e1>-induced pulmonary toxicity in which the initial HRCT showed a <e2>widespread reticular pattern</e2> and associated distortion of the lung parenchyma, thought to represent established fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

275	"<e1>Fluoxetine</e1>-related <e2>death</e2> in a child with cytochrome P-450 2D6 genetic deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

276	"The medical examiner's report indicated <e1>death</e1> caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

277	"The medical examiner's report indicated death caused by <e2>fluoxetine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

278	"This is the first report of a <e1>fluoxetine</e1>-related <e2>death</e2> in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

279	"A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a <e1>spinal cord lesion</e1> following the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

280	"<e1>Spinal cord infarction</e1> during use of <e2>zolmitriptan</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

281	"The temporal relationship suggests that the <e1>spinal cord infarction</e1> may be related to the use of <e2>zolmitriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

282	"CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a <e1>hypersensitivity</e1> reaction to <e2>carboplatin</e2> after nine courses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

283	"This regimen could prove useful for other patients who develop <e1>hypersensitivity</e1> reactions to <e2>carboplatin</e2> and allow therapy to continue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

284	"Perinatal vasoconstrictive <e1>renal insufficiency</e1> associated with maternal <e2>nimesulide</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

285	"This is the first report of an <e1>adverse effect of fetal renal circulation</e1> by maternal ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

286	"Although the <e1>t-AML</e1> developed following oral <e2>etoposide</e2> therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

287	"<e1>Secondary leukemia</e1> in a child with neuroblastoma while on oral <e2>etoposide</e2>: what is the cause?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

288	"The authors present a case of <e1>t-AML</e1> that developed in a child with metastatic neuroblastoma 18 months after he received oral <e2>etoposide</e2>, given for palliation purpose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

289	"BACKGROUND: <e1>Cyanamide</e1>, an aversive agent widely used in Japan, is known to induce various degrees of <e2>hepatic lesion with ground-glass inclusion bodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

290	"Case 2: A 43-year-old male alcoholic remained completely abstinent with <e1>cyanamide</e1> treatment for 5 years and complained of <e2>general fatigue</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

291	"Case 3: A 29-year-old female alcoholic complained of general <e1>fatigue</e1> and a slight fever after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

292	"Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight <e1>fever</e1> after 1.5 years of abstinence with <e2>cyanamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

293	"Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking <e1>cyanamide</e1> for 3 years showed slight <e2>elevation of serum transaminases</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

294	"CONCLUSION: In some abstainers who take <e1>cyanamide</e1> for several years, thin septum-like liver fibrosis progresses along with the emergence of <e2>ground-glass hepatocytes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

295	"CONCLUSION: In some abstainers who take <e1>cyanamide</e1> for several years, thin <e2>septum-like liver fibrosis</e2> progresses along with the emergence of ground-glass hepatocytes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

296	"<e1>Cyanamide</e1>-induced <e2>liver dysfunction</e2> after abstinence in alcoholics: a long-term follow-up study on four cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

297	"When <e1>cyanamide</e1>-treated alcoholics relapse into drinking, more severe <e2>inflammation</e2> develops in the liver."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

298	"A patient with an allergy to a macrolide antibiotic was given <e1>tacrolimus</e1> and developed a <e2>sudden cutaneous reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

299	"A 77-year-old woman with no history of epilepsy presented a probable <e1>nonconvulsive status epilepticus</e1> while receiving continuous intravenous <e2>morphine</e2> for back pain relating to vertebral metastasis of a malignant lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

300	"A <e1>generalized tonic-clonic seizure</e1> occurred a few minutes after injection of the morphine antagonist <e2>naloxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

301	"<e1>Nonconvulsive status epilepticus</e1>: the role of <e2>morphine</e2> and its antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

302	"Spontaneous <e1>bacterial peritonitis</e1> induced by intraarterial <e2>vasopressin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

303	"Although the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (<e2>EPS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

304	"Although the literature on the use of <e1>risperidone</e1> in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of <e2>extrapyramidal symptoms</e2> (EPS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

305	"Three months following splenectomy, <e1>multiple abscesses</e1> occurred in the muscles of both thighs while the patient was receiving the third course of the <e2>CHOP</e2> regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

306	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and hepatitis in association with <e2>anti-native DNA antibodies</e2> and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

307	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, rash and <e2>hepatitis</e2> in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

308	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed <e2>polyarthritis</e2>, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

309	"After seven months' continuous treatment for suspected tuberculosis with rifampicin and <e1>ethambutol</e1> a nine-year-old boy developed polyarthritis, <e2>rash</e2> and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

310	"Polyarthritis, hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

311	"Polyarthritis, hepatitis and <e1>anti-native DNA antibodies</e1> after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

312	"Polyarthritis, <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

313	"Polyarthritis, <e1>hepatitis</e1> and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

314	"<e1>Polyarthritis</e1>, hepatitis and anti-native DNA antibodies after treatment with <e2>ethambutol</e2> and rifampicin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

315	"<e1>Polyarthritis</e1>, hepatitis and anti-native DNA antibodies after treatment with ethambutol and <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

316	"A case of <e1>normotensive scleroderma renal crisis</e1> after high-dose <e2>methylprednisolone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

317	"<e1>HUS</e1> has been reported after several anticancer chemotherapies and most often after <e2>mitomycin C</e2>-based chemotherapy regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

318	"<e1>Severe hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

319	"<e1>Severe hemolytic uremic syndrome</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

320	"We present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with <e2>carboplatin</e2> and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

321	"We present a case of <e1>HUS</e1> in an advanced ovarian cancer patient treated with carboplatin and <e2>gemcitabine</e2>, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

322	"An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with <e1>valproate</e1> for epilepsy, especially if they develop <e2>menstrual cycle disturbances</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

323	"BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and <e1>hyperandrogenism</e1> seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

324	"BACKGROUND: Reproductive endocrine disorders characterized by <e1>menstrual disorders</e1>, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

325	"BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, <e1>polycystic ovaries</e1>, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

326	"BACKGROUND: <e1>Reproductive endocrine disorders</e1> characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with <e2>sodium valproate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

327	"CONCLUSIONS: The 3 cases presented here illustrate the development of <e1>reproductive endocrine disorders</e1> after the initiation of <e2>valproate</e2> therapy in women with epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

328	"OBJECTIVE: To describe the development of <e1>valproate</e1>-related <e2>reproductive endocrine disorders</e2> in women with epilepsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

329	"PATIENTS: Three patients developed a <e1>reproductive endocrine disorder</e1> during treatment with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

330	"RESULTS: Replacing <e1>valproate</e1> with lamotrigine resulted in a decrease in <e2>serum testosterone</e2> concentrations in all 3 women."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

331	"The polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had gained weight and developed <e2>amenorrhea</e2> while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

332	"The polycystic changes disappeared from the ovaries in 2 of the women after <e1>valproate</e1> therapy was discontinued, and the 2 women who had <e2>gained weight</e2> and developed amenorrhea while being treated with <e1>valproate</e1> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

333	"The <e1>polycystic changes</e1> disappeared from the ovaries in 2 of the women after <e2>valproate</e2> therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with <e2>valproate</e2> lost weight and resumed menstruating after the change in medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

334	"However, recurrent <e1>staphylococcus aureus sepsis</e1> developed during <e2>CyA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

335	"Recurrent septicemia with <e1>lethal</e1> outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

336	"Recurrent <e1>septicemia</e1> with lethal outcome during and after <e2>cyclosporine</e2> therapy in severe ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

337	"A 60 year-old woman with chronic renal failure developed acute <e1>proximal muscle weakness</e1> after receiving a regular dosage of <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

338	"<e1>Colchicine</e1>-induced <e2>myopathy</e2> in renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

339	"Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of <e1>colchicine</e1>-induced <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

340	"Muscle biopsy revealed variation in muscle fiber size and few <e1>vacuolated fibers</e1> which were features of <e2>colchicine</e2>-induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

341	"Muscle biopsy revealed <e1>variation in muscle fiber size</e1> and few vacuolated fibers which were features of <e2>colchicine</e2>-induced myopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

342	"A third patient experienced <e1>disabling neurotoxicity</e1> in the extremity of a prior ulnar nerve and tendon transposition after receiving <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

343	"Phantom limb pain as a manifestation of <e1>paclitaxel</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

344	"<e1>Phantom limb pain</e1> as a manifestation of <e2>paclitaxel</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

345	"Physicians should be aware that <e1>PLP</e1> can occur after initiation of <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

346	"We describe 2 patients with prior amputation who experienced <e1>phantom limb pain</e1> (PLP) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

347	"We describe 2 patients with prior amputation who experienced phantom limb pain (<e1>PLP</e1>) after receiving <e2>paclitaxel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

348	"Skin manifestations of a case of <e1>phenylbutazone</e1>-induced <e2>serum sickness-like reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

349	"<e1>Skin manifestations</e1> of a case of <e2>phenylbutazone</e2>-induced serum sickness-like reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

350	"Our experience supports hemodialysis for ESRF patients with <e2>atenolol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

351	"Allergic reaction to <e1>gemfibrozil</e1> manifesting as <e2>eosinophilic gastroenteritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

352	"We describe a case of <e1>EGE</e1> manifested as an allergy to <e2>gemfibrozil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

353	"This is the second report of <e1>lactic acidosis</e1> in a patient on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

354	"This is the second report of <e1>lactic acidosis</e1> in a patient on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

355	"We present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on stavudine and <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

356	"We present an AIDS patient with severe and prolonged <e1>lactic acidosis</e1> on <e2>stavudine</e2> and lamivudine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

357	"<e1>Ataxia</e1> caused by <e2>propafenone</e2> has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

358	"A wide variety of <e1>adverse central nervous system effects</e1> have been reported in association with <e2>propafenone</e2>; dizziness is the most common."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

359	"A wide variety of adverse central nervous system effects have been reported in association with <e1>propafenone</e1>; <e2>dizziness</e2> is the most common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

360	"<e1>Propafenone</e1>-induced <e2>ataxia</e2>: report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

361	"We describe 3 elderly patients with moderate to severe <e1>ataxia</e1> that occurred while they were taking <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

362	"A 74-year-old man received oral administration of <e1>pilsicainide</e1>, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed <e2>loss of consciousness</e2> two days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

363	"When <e1>pilsicainide</e1> is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid <e2>life-threatening arrhythmias</e2> due to high plasma concentrations of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

364	"The cases are important in documenting that drug-induced <e1>dystonia</e1>s do occur in patients with dementia, that <e2>risperidone</e2> appears to have contributed to <e1>dystonia</e1> among elderly patients, and that the categorization of dystonic reactions needs further clarification."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

365	"Provocation of <e1>non-convulsive status epilepticus</e1> by <e2>tiagabine</e2> in three adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

366	"The events of <e1>non-convulsive status epilepticus</e1> subsided following reduction in <e2>tiagabine</e2> dosages."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

367	"This is the first report of <e1>non-convulsive status epilepticus</e1> provoked by <e2>tiagabine</e2> in adolescent patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

368	"There have been many reports of probable <e1>lithium</e1>-induced <e2>organic brain syndromes</e2> occurring when serum <e1>lithium</e1> levels are within or close to the therapeutic range."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

369	"When the acute manic state is characterized by marked psychotic symptoms and <e1>intense anxiety</e1>, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

370	"When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe <e1>lithium</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

371	"When the acute manic state is characterized by marked <e1>psychotic symptoms</e1> and intense anxiety, it may be associated with increased vulnerability to the development of severe <e2>lithium</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

372	"Protease inhibitor-induced <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

373	"Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

374	"Protease inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

375	"Protease inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed progressive ataxia related to <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

376	"Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed <e1>progressive ataxia</e1> related to <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

377	"Protease inhibitors (<e1>ritonavir</e1> and saquinavir) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

378	"Protease inhibitors (ritonavir and <e1>saquinavir</e1>) were added to the treatment and the patient developed <e2>progressive ataxia</e2> related to carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

379	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and <e2>clinical toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

380	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, <e2>diminishing carbamazepine metabolism</e2> and provoking an increase in serum levels and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

381	"<e1>Ritonavir</e1> acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an <e2>increase in serum levels</e2> and clinical toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

382	"The patient was diagnosed with <e2>carbamazepine</e2> toxicity related to the introduction of ritonavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

383	"The patient was diagnosed with <e1>carbamazepine toxicity</e1> related to the introduction of <e2>ritonavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

384	"<e1>Anaphylaxis</e1> to <e2>calcitonin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

385	"CONCLUSION: We have introduced a case of <e1>anaphylaxis </e1>by <e2>calcitonin</e2> that suggest an IgE mediated hypersensitivity reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

386	"The intramuscular challenge test with 25 UI of <e1>Miacalcic</e1> was positive with an immediate <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

387	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

388	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, <e1>conjunctivitis</e1> and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

389	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

390	"We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and <e1>perspiration</e1> immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

391	"We introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon <e2>calcitonin</e2> with nasal spray or intramuscular administration (Calsynar)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

392	"We introduce a case of a sixty years old woman with several previous episodes of <e1>rhinitis</e1>, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (<e2>Calsynar</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

393	"<e1>Minocycline</e1> as a cause of drug-induced <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

394	"<e1>Minocycline</e1>-induced <e2>autoimmune hepatitis</e2> is usually identical to sporadic <e2>autoimmune hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

395	"We describe the clinical and liver biopsy morphologic features for 4 patients with <e1>minocycline</e1>-induced <e2>autoimmune hepatitis</e2> (group 1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

396	"<e1>L-asparaginase</e1>-provoked seizures as singular expression of <e2>central nervous toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

397	"<e1>L-asparaginase</e1>-provoked <e2>seizures</e2> as singular expression of central nervous toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

398	"Patients treated with <e1>L-asparaginase</e1> may present with <e2>hemorrhagic</e2> and thrombotic cerebrovascular events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

399	"Patients treated with <e1>L-asparaginase</e1> may present with hemorrhagic and <e2>thrombotic cerebrovascular events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

400	"We report a case of <e1>seizure</e1> associated with <e2>L-asparaginase</e2> therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

401	"Eighty-two patients with various malignancies who received imipenem/<e1>cilastatin</e1> 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

402	"Eighty-two patients with various malignancies who received <e1>imipenem</e1>/cilastatin 143 times for <e2>neutropenic fever</e2> between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

403	"Incidence of <e1>seizures</e1> in pediatric cancer patients treated with imipenem/<e2>cilastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

404	"Incidence of <e1>seizures</e1> in pediatric cancer patients treated with <e2>imipenem</e2>/cilastatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

405	"<e1>Proconvulsive</e1> tendency of imipenem/<e2>cilastatin</e2> is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

406	"<e1>Proconvulsive</e1> tendency of <e2>imipenem</e2>/cilastatin is one of its well-known side effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

407	"Three of these patients had <e1>convulsions</e1> attributed to imipenem/<e2>cilastatin</e2>; 3.6% of the patients had seizure, or 2% of imipenem/<e2>cilastatin</e2> administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

408	"Three of these patients had <e1>convulsions</e1> attributed to <e2>imipenem</e2>/cilastatin; 3.6% of the patients had seizure, or 2% of <e2>imipenem</e2>/cilastatin administrations was followed by a seizure attack."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

409	"Three of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

410	"Three of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

411	"Three of these patients had convulsions attributed to imipenem/<e1>cilastatin</e1>; 3.6% of the patients had <e2>seizure</e2>, or 2% of imipenem/<e1>cilastatin</e1> administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

412	"Three of these patients had convulsions attributed to <e1>imipenem</e1>/cilastatin; 3.6% of the patients had <e2>seizure</e2>, or 2% of <e1>imipenem</e1>/cilastatin administrations was followed by a <e2>seizure</e2> attack."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

413	"<e1>Gabapentin</e1>-induced mood changes with <e2>hypomanic</e2> features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

414	"<e1>Gabapentin</e1>-induced <e2>mood changes</e2> with hypomanic features in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

415	"We report two adults who received <e1>gabapentin</e1> (GBP) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

416	"We report two adults who received gabapentin (<e1>GBP</e1>) and subsequently developed <e2>behavioural side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

417	"<e1>Acute pancreatitis</e1> in a child with idiopathic ulcerative colitis on long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

418	"We describe a 10-year-old boy with ulcerative colitis who developed <e1>acute pancreatitis</e1> while on long-term treatment with <e2>5-aminosalicylic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

419	"CONCLUSION: Marked <e1>visual field constriction</e1> appears to be associated with <e2>vigabatrin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

420	"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with <e1>vigabatrin</e1>-attributed <e2>visual field constriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

421	"PURPOSE: Symptomatic <e1>visual field constriction</e1> thought to be associated with <e2>vigabatrin</e2> has been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

422	"The current study investigated the visual fields and visual electrophysiology of eight patients with known <e1>vigabatrin</e1>-attributed <e2>visual field loss</e2>, three of whom were reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

423	"The <e1>field defects</e1> and some electrophysiological abnormalities persist when <e2>vigabatrin</e2> therapy is withdrawn."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

424	"<e1>Depressive symptoms</e1> disappeared after <e2>interferon</e2> therapy was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

425	"Treatment of chronic hepatitis C with interferon alpha (<e1>IFN-alpha</e1>) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

426	"Treatment of chronic hepatitis C with <e1>interferon alpha</e1> (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe <e2>psychiatric side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

427	"While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent <e1>changes in serotonergic or noradrenergic neurotransmission</e1> caused by <e2>IFN-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

428	"Intensive high-flux hemodiafiltration is often used in the management of <e2>vancomycin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

429	"Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of <e2>vancomycin</e2> toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

430	"We describe 2 children with cerebral palsy who suffered significant <e1>morbidity</e1> immediately after treatment with <e2>hyperbaric oxygen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

431	"A 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of 4% hydroquinone in sorbolene cream and <e2>0.1% tretinoin cream</e2> to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

432	"A 33-year-old male presented with <e1>brown discolouration of the fingernails</e1> following the application of <e2>4% hydroquinone in sorbolene cream</e2> and 0.1% tretinoin cream to the face intermittently for 9 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

433	"<e1>Nail staining</e1> from <e2>hydroquinone</e2> cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

434	"<e1>Gangrene</e1> of the fingertips after <e2>bleomycin</e2> and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

435	"<e1>Gangrene</e1> of the fingertips after bleomycin and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

436	"This supports the well-reported potential of <e1>bleomycin</e1> to trigger <e2>acral vascular toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

437	"We describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

438	"We describe a 57-year-old man with acral erythrocyanosis progressing to <e1>acute digital ischemia</e1> and gangrene that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

439	"We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (<e2>bleomycin</e2> and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

440	"We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and <e1>gangrene</e1> that developed after combined chemotherapy (bleomycin and <e2>methotrexate</e2>) used to treat a metastatic squamous cell carcinoma of the hypopharynx."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

441	"<e1>Diarrhea-associated over-anticoagulation</e1> in a patient taking <e2>warfarin</e2>: therapeutic role of cholestyramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

442	"We present a case of significant over-anticoagulation temporally associated with a bout of protracted <e1>diarrhea</e1> in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

443	"We present a case of significant <e1>over-anticoagulation</e1> temporally associated with a bout of protracted diarrhea in a patient on <e2>warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

444	"<e1>MI</e1> related to the use of activated and non-activated <e2>PCCs</e2> predominantly affects young patients who often have no preceding history of, or risk factors for, <e1>MI</e1> and tends to be associated with large cumulative doses of concentrate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

445	"Recombinant VIIa concentrate in the management of bleeding following <e1>prothrombin complex concentrate</e1>-related <e2>myocardial infarction</e2> in patients with haemophilia and inhibitors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

446	"We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following <e1>PCC</e1>-related <e2>MI</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

447	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

448	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

449	"Even after a strict warning, he took another <e1>quinine</e1> tablet that evening, which triggered his fifth episode of severe <e2>thrombocytopenia</e2>, and confirmed the etiology of <e1>quinine</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

450	"Occult <e1>quinine</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

451	"Only after three subsequent episodes of severe, symptomatic <e1>thrombocytopenia</e1> over the next four weeks did he say, upon repeat questioning, that he had continued to take <e2>quinine</e2> for night leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

452	"An 8-year-old child with familial Mediterranean fever exhibited signs of <e2>colchicine</e2> intoxication while receiving prophylactic doses of the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

453	"CONCLUSION: To the best of our knowledge, this is the first time <e2>colchicine</e2> intoxication in this age group has been described in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

454	"Near fatal acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

455	"<e1>Near fatal</e1> acute <e2>colchicine</e2> intoxication in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

456	"<e1>Acute myeloid leukemia</e1> and lung cancer occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

457	"Acute myeloid leukemia and <e1>lung cancer</e1> occurring in a chronic lymphocytic leukemia patient treated with <e2>fludarabine</e2> and autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

458	"We describe the exceptional development of <e1>AML</e1> and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

459	"We describe the exceptional development of AML and <e1>lung cancer</e1> in a patient with previously diagnosed CLL in minimal residual disease status after <e2>fludarabine</e2> treatment followed by autologous peripheral blood stem-cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

460	"In 2 of the 3 cases the patients were also taking <e1>lithium carbonate</e1> and beta-blockers, both of which could have contributed to the <e2>incontinence</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

461	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors <e2>paroxetine</e2> and sertraline, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

462	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and <e2>sertraline</e2>, as well as a third who developed this side effect on venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

463	"In the present paper the authors describe 2 female patients who developed <e1>incontinence</e1> secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

464	"This concerns 2 male patients who experienced <e1>incontinence</e1> while taking <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

465	"Case studies in <e1>heparin</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

466	"Major points illustrated are, (1) occurrence of <e1>HIT</e1> with any dose or form of <e2>heparin</e2>; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to <e2>heparin</e2> and disappearance of <e1>HIT</e1> antibodies over time."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

467	"Type II <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> (HIT) is an immunological disorder characterized by antibodies to <e1>heparin</e1>-platelet factor 4 complexes and a high risk of thrombotic complications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

468	"After several unrevealing medical work-ups, he was found to have a high blood <e2>lead</e2> level (122 microg/dL); he has a history of scraping and sanding <e2>lead</e2> paint without adequate protective measures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

469	"It also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of <e2>hypertension</e2>, and raises the issue of whether <e1>lead</e1>-induced <e2>hypertension</e2> constitutes a subset of <e2>hypertension</e2> that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

470	"It also highlights a current major etiologic question, that is, whether and to what degree <e1>lead</e1> exposure contributes to the development of hypertension, and raises the issue of whether <e1>lead</e1>-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

471	"Poorly controlled hypertension in a painter with chronic <e2>lead</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

472	"This case demonstrates an occupational activity (construction) that has now become the dominant source of <e1>lead</e1> exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic <e1>lead</e1> toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

473	"<e1>Severe rash</e1>, including the Stevens-Johnson syndrome (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

474	"Severe rash, including the Stevens-Johnson syndrome (<e1>SJS</e1>), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

475	"Severe rash, including the <e1>Stevens-Johnson syndrome</e1> (SJS), is the major toxicity of <e2>nevirapine</e2> and is described in the package labeling with a prominent, boxed warning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

476	"<e1>Stevens-Johnson syndrome</e1> caused by the antiretroviral drug <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

477	"Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of <e1>nevirapine</e1>-associated <e2>SJS</e2> has been documented in the dermatology literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

478	"We describe 2 cases of <e1>SJS</e1> related to <e2>nevirapine</e2> use and review the literature on this newly recognized association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

479	"Oral intake and <e1>acarbose</e1> were withheld and the <e2>ileus</e2> spontaneously resolved after 2 days."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

480	"There is evidence that the angiotensin II receptor antagonist, <e1>losartan</e1>, <e2>increases urate excretion</e2> by reducing reabsorption of urate in the renal proximal tubule."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

481	"<e1>Atrial fibrillation</e1> occurring in a patient taking <e2>etanercept</e2> plus methotrexate for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

482	"<e1>Atrial fibrillation</e1> occurring in a patient taking etanercept plus <e2>methotrexate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

483	"A review of the literature revealed two other cases of <e1>hepatic angiosarcoma</e1> in patients after long-term <e2>cyclophosphamide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

484	"<e1>Hepatic angiosarcoma</e1> occurring after <e2>cyclophosphamide</e2> therapy: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

485	"We propose that <e1>cyclophosphamide</e1> be added to the list of exposures potentially associated with <e2>hepatic angiosarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

486	"<e1>ARA-C</e1> is frequently associated with <e2>dermatologic toxicity</e2>, but this is only the second case of toxic epidermal necrolysis described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

487	"<e1>ARA-C</e1> is frequently associated with dermatologic toxicity, but this is only the second case of <e2>toxic epidermal necrolysis</e2> described in connection with this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

488	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed <e2>bullous lesions on the hands and soles that disseminated, evolving to necrosis</e2>, sepsis, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

489	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and <e2>death</e2> on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

490	"On the fifth day after administration of a high dose of <e1>ARA-C</e1> (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, <e2>sepsis</e2>, and death on the 22nd day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

491	"<e1>Toxic epidermal necrolysis</e1> after the use of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

492	"We report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

493	"We report a fatal case of toxic epidermal necrolysis (<e1>TEN</e1>) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

494	"We report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of cytosine arabinoside (<e2>ARA-C</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

495	"We report a fatal case of <e1>toxic epidermal necrolysis</e1> (TEN) resulting from a high dose of <e2>cytosine arabinoside</e2> (ARA-C)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

496	"<e1>Quetiapine</e1> and <e2>obsessive-compulsive symptoms</e2> (OCS): case report and review of atypical antipsychotic-induced OCS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

497	"<e1>Quetiapine</e1> and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

498	"<e1>Quetiapine</e1> and obsessive-compulsive symptoms (<e2>OCS</e2>): case report and review of atypical antipsychotic-induced <e2>OCS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

499	"The first known report of <e1>quetiapine</e1> <e2>exacerbating OCS</e2> in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

500	"He was diagnosed with possible <e1>serotonin syndrome</e1>; his symptoms resolved after <e2>clomipramine</e2> was stopped but before clozapine was restarted eight days later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

501	"OBJECTIVE: To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving <e2>clomipramine</e2> after clozapine was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

502	"OBJECTIVE: To report on the possible development of <e1>serotonin syndrome</e1> in a patient receiving clomipramine after <e2>clozapine</e2> was withdrawn from the treatment regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

503	"Possible <e1>serotonin syndrome</e1> associated with <e2>clomipramine</e2> after withdrawal of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

504	"Possible <e1>serotonin syndrome</e1> associated with clomipramine after withdrawal of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

505	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

506	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, <e2>agitated</e2>, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

507	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

508	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began <e2>behaving oddly</e2>, started sweating profusely, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

509	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

510	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and <e2>confused</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

511	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

512	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, <e2>shivering</e2>, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

513	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

514	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started <e2>sweating profusely</e2>, shivering, and became tremulous, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

515	"The day after clozapine was stopped, while he was still receiving <e1>clomipramine</e1> 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

516	"The day after <e1>clozapine</e1> was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became <e2>tremulous</e2>, agitated, and confused."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

517	"<e1>Quinine</e1> induced <e2>coagulopathy</e2>--a near fatal experience."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

518	"The cause of his bleeding was a <e1>severe thrombocytopoaenia</e1>, induced by chronic ingestion of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

519	"Dose-dependent <e1>olanzapine</e1>-associated <e2>leukopenia</e2>: three case reports."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

520	"These cases suggest the possibility that, in some patients, leukopenia or <e1>agranulocytosis</e1> during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

521	"These cases suggest the possibility that, in some patients, <e1>leukopenia</e1> or agranulocytosis during <e2>olanzapine</e2> treatment might be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

522	"We report three cases of patients who developed <e1>leukopenia</e1> during <e2>olanzapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

523	"CONCLUSION: This case illustrates a potential link between dermatologic and ocular <e2>5-FU</e2> toxicities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

524	"Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and <e1>5-FU</e1>-induced <e2>ectropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

525	"DISCUSSION: Patients with <e1>5-FU</e1>-induced <e2>ectropion</e2> experience tender, red, scaled lids, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

526	"DISCUSSION: Patients with <e1>5-FU</e1>-induced ectropion experience <e2>tender, red, scaled lids</e2>, making contact lens wear difficult."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

527	"<e1>Ectropion</e1> secondary to bolus injection of <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

528	"Exacerbation of <e1>5-FU</e1> <e2>dermatologic toxicities</e2> in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

529	"Presented is a case of <e1>acute renal failure</e1> induced by <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

530	"<e1>Renal failure</e1> associated with <e2>acetazolamide</e2> therapy for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

531	"This sulfonamide like nephropathy should be differentiated from <e1>acetazolamide</e1>-related <e2>calcium phosphate nephrolithiasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

532	"<e1>Ischaemic colitis</e1> in a patient taking <e2>meloxicam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

533	"Symptoms and <e1>endoscopic lesions</e1> quickly regressed within 1 week of <e2>meloxicam</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

534	"We describe a patient who presented with <e1>bloody diarrhoea</e1> after 15 mg <e2>meloxicam</e2> daily for 10 days for osteoarthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

535	"We suggest that <e1>meloxicam</e1> might have <e2>intestinal toxic effects</e2> when taken in high doses, because of reduced COX-2 selectivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

536	"As these cases revealed, close monitoring of blood chemistry is mandatory after starting <e1>spironolactone</e1>, and patients should be advised to stop <e1>spironolactone</e1> immediately if <e2>diarrhoea</e2> develops."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

537	"In patients with chronic heart failure, <e1>spironolactone</e1> added to conventional treatment may lead to <e2>serious and, occasionally, fatal hyperkalaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

538	"In some cases this seems to happen because <e1>spironolactone</e1> causes <e2>diarrhoea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

539	"<e1>Serious adverse events</e1> experienced by patients with chronic heart failure taking <e2>spironolactone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

540	"We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with <e1>oxaliplatin</e1> and developed a peculiar <e2>dermnatitis</e2> in the irradiated field after being exposed to subsequent chemotherapy with <e1>oxaliplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

541	"An 11-year-old boy developed a <e1>severe enteropathy</e1> 2 years after initiation of <e2>clofazimine</e2> treatment for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

542	"<e1>Clofazimine</e1> <e2>enteropathy</e2> caused by crystal deposition can be life-threatening."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

543	"<e1>Clofazimine</e1> enteropathy caused by crystal deposition can be <e2>life-threatening</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

544	"<e1>Clofazimine</e1> <e2>enteropathy</e2> in a pediatric bone marrow transplant recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

545	"She developed a <e1>severe urticarial rash</e1> 3 weeks following initiation of therapy with <e2>Enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

546	"We cared for a patient with progressive renal impairment who presented with <e1>blurred vision</e1>, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

547	"We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and <e1>cardiac failure</e1> due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

548	"We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

549	"We cared for a patient with progressive renal impairment who presented with blurred vision, <e1>QRS broadening</e1> and cardiac failure due to chronic <e2>cibenzoline</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

550	"Indolent <e1>aspergillus arthritis</e1> complicating <e2>fludarabine</e2>-based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

551	"We describe two patients with <e1>aspergillus arthritis of the knee joint</e1> following <e2>fludarabine</e2>-based non-myeloablative stem cell transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

552	"CONCLUSION: The present findings suggest that <e1>fluvoxamine</e1> can cause <e2>increased libido</e2> in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

553	"<e1>Increased libido</e1> in a woman treated with <e2>fluvoxamine</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

554	"OBJECTIVE: The aim of this paper is to describe a case of <e1>increased libido</e1> during <e2>fluvoxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

555	"RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an <e1>increased libido</e1> with the administration of <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

556	"The <e1>increased libido</e1> disappeared after <e2>fluvoxamine</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

557	"An infant who developed <e1>pancreatitis</e1> during <e2>meglumine antimoniate</e2> treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

558	"Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed <e1>pancreatitis</e1> caused by <e2>meglumine antimoniate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

559	"CONCLUSIONS: This case report showed that the clinical appearance of <e1>Hashimoto's disease</e1> after <e2>IFN-alpha</e2> therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

560	"Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop <e1>autoimmune thyroiditis</e1>, in order to make a early diagnosis of thyroid disorders during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

561	"Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of <e1>thyroid disorders</e1> during the <e2>IFN-alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

562	"<e1>Hashimoto's disease</e1> during <e2>interferon-alpha</e2> therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

563	"OBJECTIVES: The authors described a case of <e1>Hashimoto's disease</e1> during interferon-alpha (<e2>IFN-alpha</e2>) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

564	"OBJECTIVES: The authors described a case of <e1>Hashimoto's disease</e1> during <e2>interferon-alpha</e2> (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

565	"During dose-finding studies for intravenous proton pump inhibitors <e1>omeprazole</e1> and pantoprazole, three of six young female volunteers receiving <e1>omeprazole</e1> and two young female volunteers receiving pantoprazole developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

566	"During dose-finding studies for intravenous proton pump inhibitors omeprazole and <e1>pantoprazole</e1>, three of six young female volunteers receiving omeprazole and two young female volunteers receiving <e1>pantoprazole</e1> developed <e2>peripheral edema</e2> within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

567	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, <e2>lansoprazole</e2>, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

568	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors <e2>omeprazole</e2>, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

569	"<e1>Pheripheral edema</e1> was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or <e2>pantoprazole</e2> for 7-15 days for peptic acid diseases in recommended standard doses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

570	"<e1>Motor fluctuations</e1> appear after 2-3 years of <e2>levodopa</e2> treatment, and affect at least 50% of patients after five years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

571	"CONCLUSION: Significant <e1>weight loss</e1> is a potential adverse event in patients with rheumatoid arthritis treated with <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

572	"<e1>Leflunomide</e1>-associated <e2>weight loss</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

573	"METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if <e1>weight loss</e1> had occurred as an adverse event in patients treated with <e2>leflunomide</e2> between November 1998 and January 2000."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

574	"OBJECTIVE: To determine the frequency of <e1>weight loss</e1> in patients treated with <e2>leflunomide</e2> for rheumatoid arthritis at an arthritis referral center."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

575	"RESULTS: Five of 70 patients who had begun <e1>leflunomide</e1> therapy had significant <e2>weight loss</e2> that could not be linked to other identifiable etiologies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

576	"It is increasingly recognized that dose adjustment of oral <e1>valacyclovir</e1> in renal failure is necessary to avoid <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

577	"<e1>Neurotoxicity</e1> of <e2>valacyclovir</e2> in peritoneal dialysis: a pharmacokinetic study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

578	"She developed <e1>neurotoxicity</e1> with an adjustment dosage of <e2>valacyclovir</e2> for a cutaneous zoster infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

579	"<e1>Avascular necrosis of the femoral head</e1> in patients with prostate cancer treated with <e2>cyproterone acetate</e2> and radiotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

580	"We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of <e1>cyproterone acetate</e1> prior to radical or palliative pelvic irradiation, and who subsequently developed <e2>femoral head avascular necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

581	"<e1>Levofloxacin</e1> induced <e2>polymorphic ventricular tachycardia</e2> with normal QT interval."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

582	"We report the first case of <e1>polymorphic ventricular tachycardia</e1> with normal QT interval associated with the oral use of <e2>levofloxacin</e2> in the absence of other etiologies known to cause these arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

583	"So far, few cases of <e1>pulmonary side effects</e1> caused by <e2>ticlopidine</e2> have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

584	"Special care should be taken when <e1>pulmonary symptoms</e1> appear in association with <e2>ticlopidine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

585	"<e1>Ticlopidine</e1>-induced <e2>interstitial pulmonary disease</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

586	"We report a case of <e1>interstitial pulmonary disease</e1> that occurred together with lymphocytic colitis during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

587	"We report a case of interstitial pulmonary disease that occurred together with <e1>lymphocytic colitis</e1> during treatment with <e2>ticlopidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

588	"A patient that received <e1>methadone</e1> for cancer-associated pain developed <e2>myoclonus</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

589	"<e1>Methadone</e1>-induced <e2>myoclonus</e2> in advanced cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

590	"OBJECTIVE: To report a case of <e1>fatal hyperkalemia</e1> owing to <e2>succinylcholine</e2> administration in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

591	"<e1>Succinylcholine</e1>-induced <e2>hyperkalemia</e2> in a patient with mucositis secondary to chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

592	"We believe that mucositis was a contributing factor to this case of <e1>fatal hyperkalemia</e1> after administration of <e2>succinylcholine</e2>, with a mechanism similar to that reported with thermal injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

593	"<e1>Cutaneous seeding</e1> after ultrasound-guided percutaneous <e2>ethanol injection</e2> for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

594	"We describe a case of needle-track <e1>cutaneous seeding</e1> of hepatocellular carcinoma (HCC) after sonographically guided percutaneous <e2>ethanol injection</e2> (PEI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

595	"<e1>Adenosine</e1>-induced <e2>ventricular fibrillation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

596	"However, <e1>adenosine</e1> shortens the antegrade refractoriness of accessory atrioventricular connections and may cause <e2>acceleration of the ventricular rate</e2> during atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

597	"We observed <e1>ventricular fibrillation</e1> in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

598	"After the dose of <e1>methylprednisolone</e1> was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the <e2>psychotic reaction</e2> disappeared a few hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

599	"Continuous EEG monitoring is helpful in managing <e1>seizures</e1> that occur as a complication of <e2>CBZ</e2> OD, after the course of recovery or worsening, and in providing assistance with prognosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

600	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes <e2>cortical hyperexcitability</e2>, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

601	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and <e2>cranial nerve areflexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

602	"Massive <e1>CBZ</e1> OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a <e2>profound burst-suppression EEG pattern</e2>, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

603	"Massive <e1>CBZ</e1> OD may produce a <e2>reversible encephalopathy</e2> that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

604	"Massive plasmocytosis due to <e1>methimazole</e1>-induced <e2>bone marrow toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

605	"<e1>Massive plasmocytosis</e1> due to <e2>methimazole</e2>-induced bone marrow toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

606	"To our knowledge this is the first report of pancytopenia due to <e1>MMI</e1>, where the usual hypoplasia found is replaced by <e2>massive plasmocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

607	"To our knowledge this is the first report of <e1>pancytopenia</e1> due to <e2>MMI</e2>, where the usual hypoplasia found is replaced by massive plasmocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

608	"We report a case of <e1>fulminant hepatic failure</e1> associated with <e2>didanosine</e2> and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

609	"This report details a case of <e1>bilateral avascular necrosis of the femoral heads</e1> in a patient receiving 'standard' doses of <e2>dexamethasone</e2> as part of the antiemetic regimen used in cisplatin-based combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

610	"Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following <e1>hemorrhage</e1> may have been favored by <e2>metformin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

611	"An obese patient, not diabetic, treated with <e1>metformin</e1> for some weeks, was referred to us with <e2>severe inferior digestive hemorrhage</e2>, diagnosed with Meckel's diverticulum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

612	"<e1>Digestive hemorrhage</e1> caused by a Meckel's diverticulum in a <e2>metformin</e2>-treated patient: is there any connection?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

613	"<e1>Ulcer became worse</e1> after tobramycin and <e2>gentamycin</e2> treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

614	"<e1>Ulcer became worse</e1> after <e2>tobramycin</e2> and gentamycin treatment for 2 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

615	"Possible linkage of <e1>amprenavir</e1> with <e2>intracranial bleeding</e2> in an HIV-infected hemophiliac."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

616	"The <e1>bleeding</e1> resolved on discontinuation of <e2>APV</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

617	"We report the occurrence of spontaneous <e1>intracranial bleeding</e1> in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving <e2>amprenavir</e2> (APV)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

618	"According to the Naranjo probability scale, the relationship of <e1>gemcitabine</e1> treatment with <e2>cutaneous eruption</e2> in our patient is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

619	"CONCLUSIONS: We report the first case of <e1>gemcitabine</e1>-induced <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

620	"<e1>Linear immunoglobulin A bullous dermatosis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

621	"OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (<e1>LABD</e1>) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

622	"OBJECTIVE: To report a case of <e1>linear immunoglobulin (Ig) A bullous dermatosis</e1> (LABD) induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

623	"Twenty-four hours after the administration of <e1>gemcitabine</e1>, a <e2>symmetric, bullous, herpetiform eruption</e2> appeared on his trunk and upper limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

624	"<e1>Vancomycin</e1> is the most frequently implicated drug, but other agents have been reported to cause <e2>LABD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

625	"Although <e1>taxol</e1> has shown significant activity in advanced ovarian cancer, <e2>peripheral neuropathy</e2> is likely to become the major dose-limiting toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

626	"A rare case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> 25 days after treatment with weekly <e2>paclitaxel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

627	"We describe a case of advanced ovarian carcinoma who developed <e1>difficulty walking</e1> because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

628	"We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and <e1>loss of proprioception</e1> 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

629	"We describe a case of advanced ovarian carcinoma who developed difficulty walking because of <e1>marked pain</e1> in the lower extremities and loss of proprioception 25 days after treatment with weekly <e2>taxol</e2> (80 mg/m(2)x3)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

630	"Relief by naloxone of <e1>morphine</e1>-induced <e2>spasm</e2> of the sphincter of Oddi in a post-cholecystectomy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

631	"We present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated pain consistent with <e2>biliary colic</e2>; the pain resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

632	"We present the case of a patient who had undergone cholecystectomy previously, but in whom <e1>morphine</e1> given in the Emergency Department precipitated <e2>pain</e2> consistent with biliary colic; the <e2>pain</e2> resolved promptly after administration of naloxone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

633	"<e1>Myasthenia gravis</e1> during low-dose <e2>IFN-alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

634	"A patient with rheumatoid arthritis developed an acute <e1>intrahepatic cholestasis</e1> after 100 mg of <e2>sodium aurothiomalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

635	"<e1>Acute lung injury</e1> associated with <e2>5-fluorouracil</e2> and oxaliplatinum combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

636	"<e1>Acute lung injury</e1> associated with 5-fluorouracil and <e2>oxaliplatinum</e2> combined chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

637	"Diarrhoea, T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

638	"Diarrhoea, T-CD4+ lymphopenia and <e1>bilateral patchy pulmonary infiltrates</e1> developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

639	"<e1>Diarrhoea</e1>, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

640	"<e1>Diarrhoea</e1>, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

641	"Diarrhoea, <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and <e2>5-fluorouracil</e2> for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

642	"Diarrhoea, <e1>T-CD4+ lymphopenia</e1> and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with <e2>oxaliplatinum</e2> and 5-fluorouracil for unresectable rectum carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

643	"It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with oxaliplatinum and <e2>5-fluorouracil</e2> regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

644	"It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a <e1>pulmonary adverse reaction</e1>, a feature never previously associated with <e2>oxaliplatinum</e2> and 5-fluorouracil regimens."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

645	"BACKGROUND: <e1>Accutane</e1> a <e2>teratogenic</e2> prescription drug licensed to treat severe, recalcitrant nodular acne."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

646	"RESULTS: The estimated number of <e1>Accutane</e1> prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used <e2>teratogenic</e2> drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to <e1>Accutane</e1> in 1999."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

647	"A 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed interstitial pneumonitis with a <e2>high fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

648	"A 62-year-old woman treated with <e1>pranlukast</e1> for 2 months developed <e2>interstitial pneumonitis</e2> with a high fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

649	"Acute <e1>interstitial pneumonia</e1> induced by <e2>ONO-1078</e2> (pranlukast), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

650	"Acute <e1>interstitial pneumonia</e1> induced by ONO-1078 (<e2>pranlukast</e2>), a leukotriene receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

651	"An asymptomatic HIV-infected woman experienced right-sided <e1>renal colicky pain</e1> during treatment with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

652	"<e1>Indinavir</e1>-associated nephrolithiasis and chronic <e2>interstitial nephritis</e2> were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

653	"<e1>Indinavir</e1>-associated <e2>nephrolithiasis</e2> and chronic interstitial nephritis were the only possible causes identified in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

654	"<e1>Papillary necrosis</e1> associated with the HIV protease inhibitor <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

655	"Physicians should be aware that <e1>indinavir</e1> <e2>nephrolithiasis</e2> may cause papillary necrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

656	"Physicians should be aware that <e1>indinavir</e1> nephrolithiasis may cause <e2>papillary necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

657	"The HIV protease inhibitor <e1>indinavir</e1> may cause nephrolithiasis and <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

658	"The HIV protease inhibitor <e1>indinavir</e1> may cause <e2>nephrolithiasis</e2> and interstitial nephritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

659	"The renal consequences of <e1>indinavir</e1>-associated <e2>nephrotoxicity</e2> are uncertain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

660	"We report a case of <e1>papillary necrosis</e1> in a patient treated with <e2>indinavir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

661	"We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked <e1>decline in glomerular filtration rate</e1> in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

662	"CONCLUSIONS: <e1>LTG</e1> overdose may result in a severe but reversible <e2>encephalopathy</e2>, a previously undescribed phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

663	"Evaluation revealed elevated serum <e2>LTG</e2> levels and no other etiology for encephalopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

664	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with <e2>lamotrigine</e2> (LTG) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

665	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (<e2>LTG</e2>) and valproic acid (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

666	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and <e2>valproic acid</e2> (VPA) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

667	"METHODS: A 55-year-old woman became <e1>stuporous</e1> after overdose with lamotrigine (LTG) and valproic acid (<e2>VPA</e2>) tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

668	"PURPOSE: To report that acute <e1>lamotrigine</e1> poisoning may result in severe <e2>encephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

669	"<e1>Stupor</e1> from <e2>lamotrigine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

670	"The cause of death was determined to be <e1>acute intoxication</e1> by <e2>olanzapine</e2>, and the manner of death was accidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

671	"This article describes the case of a 25-year-old man found <e1>dead</e1> at home who had been prescribed <e2>olanzapine</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

672	"<e1>Lichenoid drug eruption</e1> to <e2>salsalate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

673	"This <e1>eruption</e1> emerged after 1 month of therapy with <e2>salsalate</e2>, persisted for as long as <e2>salsalate</e2> was administered, and cleared within 3 weeks of discontinuing the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

674	"We describe a patient who experienced a <e1>lichenoid eruption</e1> after the initiation of <e2>salsalate</e2> for relief of arthritic pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

675	"<e1>Amphotericin B</e1>-induced <e2>seizures</e2> in a patient with AIDS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

676	"CASE SUMMARY: A 46-year-old African-American man experienced recurrent <e1>grand mal seizures</e1> during intravenous infusion of <e2>amphotericin B</e2>, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

677	"CONCLUSIONS: <e1>Amphotericin B</e1> seems to be the probable cause of the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

678	"Despite administration of phenytoin and lorazepam, the <e1>seizures</e1> persisted and occurred only during <e2>amphotercin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

679	"<e1>Didanosine</e1> also has a potential for inducing <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

680	"OBJECTIVE: To report a case of multiple episodes of <e1>seizure</e1> activity in an AIDS patent following <e2>amphotericin B</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

681	"The time course of events suggested that <e1>amphotericin B</e1> was the cause of the <e2>seizures</e2> in this AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

682	"To date, only three cases of <e1>seizures</e1> associated with <e2>amphotericin B</e2> have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

683	"<e1>Vocal cord paralysis</e1> as a consequence of peritonsillar infiltration with <e2>bupivacaine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

684	"We present the case of a 5-year-old girl who developed <e1>bilateral vocal cord paralysis</e1> following preoperative peritonsillar <e2>bupivacaine</e2> infiltration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

685	"A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete <e1>right bundle branch block</e1> after ingestion of 10 g and 4 g of <e2>carbamazepine</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

686	"<e1>Carbamazepine</e1> induced <e2>right bundle branch block</e2> in a Greenlandic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

687	"<e1>Cicatricial entropion</e1> associated with chronic <e2>dipivefrin</e2> application."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

688	"CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including <e1>dipivefrin</e1> is a possible mechanism of action for <e2>entropion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

689	"Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of <e1>cicatricial entropion</e1> after at least 2 years of twice-a-day application of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

690	"PURPOSE: To report patients who presented to the oculoplastics department for repair of <e1>cicatrical entropion</e1> after topical use of <e2>dipivefrin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

691	"A 34-year-old lady developed a <e1>constellation of dermatitis</e1>, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

692	"A 34-year-old lady developed a constellation of dermatitis, <e1>fever</e1>, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

693	"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and <e1>hepatitis</e1>, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

694	"A 34-year-old lady developed a constellation of dermatitis, fever, <e1>lymphadenopathy</e1> and hepatitis, beginning on the 17th day of a course of oral <e2>sulphasalazine</e2> for sero-negative rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

695	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

696	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often <e2>fatal</e2>, immunoallergic reaction to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

697	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

698	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e1>sulphasalazine</e1> syndrome", a rare, but often fatal, <e2>immunoallergic reaction</e2> to <e1>sulphasalazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

699	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

700	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week <e2>sulphasalazine</e2> syndrome", a rare, but often fatal, immunoallergic reaction to <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

701	"The 3-week <e2>sulphasalazine</e2> syndrome strikes again."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

702	"Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the <e1>SIADH</e1> was most likely to have been induced by administration of <e2>CDDP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

703	"Syndrome of inappropriate secretion of ADH (<e1>SIADH</e1>) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

704	"<e1>Syndrome of inappropriate secretion of ADH</e1> (SIADH) following <e2>cisplatin</e2> administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

705	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

706	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

707	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

708	"We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

709	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (<e2>CDDP</e2>) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

710	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with <e2>cisplatin</e2> (CDDP) and vindesine (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

711	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (<e2>VDS</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

712	"We report a patient with pulmonary adenocarcinoma complicated by the <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) following systemic chemotherapy with cisplatin (CDDP) and <e2>vindesine</e2> (VDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

713	"After extensive neurological 'work up', we realized that the <e1>anisocoria</e1> was related to the transdermal <e2>scopolamine</e2> patch that we had prescribed for weaning off the opioid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

714	"<e1>Anisocoria</e1> from transdermal <e2>scopolamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

715	"<e1>De novo absence status</e1> of late onset following withdrawal of <e2>lorazepam</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

716	"The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a <e1>nonconvulsive generalized status epilepticus</e1> following acute withdrawal of <e2>lorazepam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

717	"Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

718	"Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent <e1>severe neurotoxicity</e1> of polychemotherapy by avoiding <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

719	"The disease predisposes to severe <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

720	"We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed <e1>severe motor neuropathy</e1> 3 weeks after the first cycle of treatment including 2 mg of <e2>vincristine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

721	"Acute <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

722	"Acute <e1>asymptomatic hepatitis</e1> in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

723	"This report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of <e2>amodiaquine</e2> and artesunate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

724	"This report describes an unexpected drug-induced <e1>hepatitis</e1> in a previously healthy young woman exposed to 2 doses of amodiaquine and <e2>artesunate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

725	"<e1>Systemic allergic contact dermatitis</e1> to <e2>8-methoxypsoralen</e2> (8-MOP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

726	"<e1>Systemic allergic contact dermatitis</e1> to 8-methoxypsoralen (<e2>8-MOP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

727	"We describe a patient who had a <e1>systemic allergic contact dermatitis</e1> to <e2>8-MOP</e2> develop during her second course of PUVA treatment for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

728	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, <e2>abdominal pain</e2>, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

729	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with <e2>confusion</e2>, abdominal pain, and distention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

730	"A 33-year-old man with a history of recreational <e1>benztropine</e1> abuse presented to the emergency department with confusion, abdominal pain, and <e2>distention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

731	"<e1>Agranulocytosis</e1> and granulocytopenia associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

732	"Agranulocytosis and <e1>granulocytopenia</e1> associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

733	"CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of <e1>agranulocytosis</e1> while using <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

734	"METHOD: We describe three case-reports concerning <e1>haematological adverse effects</e1> of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

735	"RESULTS: <e1>Quetiapine</e1> was associated with leucopenia in two patients and clinically apparent <e2>agranulocytosis</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

736	"RESULTS: <e1>Quetiapine</e1> was associated with <e2>leucopenia</e2> in two patients and clinically apparent agranulocytosis in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

737	"CONCLUSIONS: There is very little published information regarding <e1>ofloxacin</e1>-induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

738	"However, a large case-control study included three cases of either <e1>Stevens-Johnson syndrome</e1> or toxic epidermal necrolysis associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

739	"However, a large case-control study included three cases of either Stevens-Johnson syndrome or <e1>toxic epidermal necrolysis</e1> associated with <e2>ofloxacin</e2> use, but no details of the cases were given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

740	"It is hoped that this case report creates awareness that <e1>ofloxacin</e1>-induced <e2>toxic epidermal necrolysis</e2> is possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

741	"OBJECTIVE: To report a fatal case of <e1>toxic epidermal necrolysis</e1> in a man who was treated with oral <e2>ofloxacin</e2> for epididymitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

742	"<e1>Ofloxacin</e1>: a probable cause of <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

743	"This report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

744	"This report rules out other causes of <e1>toxic epidermal necrolysis</e1> and implicates <e2>ofloxacin</e2> in what appears to be an atypical presentation of drug-induced <e1>toxic epidermal necrolysis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

745	"A boy with chronic neutropenia and recurrent inflammatory skin lesions developed <e1>multiple erythematous nodules</e1> following administration of <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

746	"A girl with cystic fibrosis and cyclic neutropenia developed an <e1>erythematous papular eruption</e1> without fever or neutrophilia 7 months after commencing therapy with <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

747	"<e1>Neutrophilic dermatoses</e1> in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (<e2>G-CSF</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

748	"<e1>Neutrophilic dermatoses</e1> in two children with idiopathic neutropenia: association with <e2>granulocyte colony-stimulating factor</e2> (G-CSF) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

749	"Painful <e1>neutrophilic skin lesions</e1> were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

750	"Painful <e1>neutrophilic skin lesions</e1> were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

751	"<e1>Painful</e1> neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (<e2>G-CSF</e2>) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

752	"<e1>Painful</e1> neutrophilic skin lesions were observed in two children receiving <e2>granulocyte colony-stimulating factor</e2> (G-CSF) for treatment of idiopathic neutropenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

753	"We believe that these skin eruptions belong to a spectrum of <e1>neutrophilic dermatoses</e1> that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

754	"We believe that these <e1>skin eruptions</e1> belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by <e2>G-CSF</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

755	"There is a putative role of <e1>liothyronine</e1> administration in precipitating or activating <e2>hyperthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

756	"<e1>Triiodothyronine</e1>-induced <e2>thyrotoxicosis</e2> in ophthalmic Graves disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

757	"This case report describes the development of asymptomatic visual field defects (<e1>VFDs</e1>) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

758	"This case report describes the development of asymptomatic <e1>visual field defects</e1> (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive <e2>tiagabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

759	"<e1>Pulmonary toxicity</e1> with <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

760	"This is the second report of <e1>acute lung injury</e1> and diffuse alveolar damage caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

761	"This is the second report of acute lung injury and <e1>diffuse alveolar damage</e1> caused by <e2>mefloquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

762	"This report presents a case of <e1>acute lung injury</e1> developing within hours after administration of <e2>mefloquine</e2> for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

763	"An adult male presented with <e1>central blindness</e1> after ingesting <e2>methanol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

764	"Reversal of severe <e1>methanol</e1>-induced <e2>visual impairment</e2>: no evidence of retinal toxicity due to fomepizole."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

765	"Extra caution should be taken in using <e1>octreotide</e1> or its long-acting analog in patients otherwise predisposed to <e2>intrahepatic bile stasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

766	"Gallstones and <e1>bile sludge</e1> are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

767	"<e1>Gallstones</e1> and bile sludge are common side effects of <e2>octreotide</e2> therapy but rarely become symptomatic or require treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

768	"<e1>Hepatolithiasis</e1> (intrahepatic stone) during <e2>octreotide</e2> therapy for acromegaly: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

769	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> <e2>alters bile acid composition</e2> and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

770	"In addition to its known effect on <e1>gallbladder stasis</e1>, <e2>octreotide</e2> alters bile acid composition and may thus hasten intrahepatic sludge and stone formation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

771	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus <e2>hasten intrahepatic sludge</e2> and stone formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

772	"In addition to its known effect on gallbladder stasis, <e1>octreotide</e1> alters bile acid composition and may thus hasten intrahepatic sludge and <e2>stone formation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

773	"This is the first reported case of <e1>hepatolithiasis</e1> during <e2>octreotide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

774	"We report a case of <e1>hepatolithiasis</e1> (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with <e2>octreotide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

775	"However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between <e1>tamoxifen</e1> therapy in women with breast cancer and the development of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

776	"In this healthy population, the relative risk of developing <e1>endometrial carcinoma</e1> in the <e2>tamoxifen</e2> arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

777	"<e1>INH</e1>, which is a leading cause of <e2>drug eruptions</e2> in the above group of drugs was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

778	"<e1>Isonicotinic acid hydrazide</e1> induced <e2>anagen effluvium</e2> and associated lichenoid eruption."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

779	"<e1>Isonicotinic acid hydrazide</e1> induced anagen effluvium and associated <e2>lichenoid eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

780	"Such <e1>anagen effluvium</e1> with lichenoid eruption following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

781	"Such anagen effluvium with <e1>lichenoid eruption</e1> following <e2>INH</e2> therapy has not been observed previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

782	"<e1>Linear IgA bullous dermatosis</e1> occurring after <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

783	"We report a patient who experienced <e1>LABD</e1> shortly after starting <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

784	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, <e2>agitation</e2>, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

785	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with <e2>confusion</e2>, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

786	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, <e2>diaphoresis</e2>, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

787	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, <e2>fever</e2>, diaphoresis, tachypnea, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

788	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

789	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, <e2>tachycardia</e2>, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

790	"After a second dose of <e1>metoclopramide</e1>, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, <e2>tachypnea</e2>, tachycardia, and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

791	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

792	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

793	"CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious <e1>extrapyramidal reactions</e1> in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

794	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when <e2>metoclopramide</e2> is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

795	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving <e2>sertraline</e2> or venlafaxine when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

796	"CONCLUSIONS: Clinicians should be aware of a risk of <e1>serotonin syndrome</e1> with serious extrapyramidal reactions in patients receiving sertraline or <e2>venlafaxine</e2> when metoclopramide is coadministered even in a single, conventional dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

797	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

798	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

799	"OBJECTIVE: To report 2 cases of serotonin syndrome with serious <e1>extrapyramidal movement disorders</e1> occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

800	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when <e2>metoclopramide</e2> was coadministered with sertraline or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

801	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with <e2>sertraline</e2> or venlafaxine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

802	"OBJECTIVE: To report 2 cases of <e1>serotonin syndrome</e1> with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

803	"<e1>Serotonin syndrome</e1> caused by selective serotonin reuptake-inhibitors-<e2>metoclopramide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

804	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed <e2>agitation</e2>, dysarthria, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

805	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, <e2>diaphoresis</e2>, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

806	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, <e2>dysarthria</e2>, diaphoresis, and a movement disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

807	"She was administered <e1>metoclopramide</e1> because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a <e2>movement disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

808	"She was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed <e2>movement disorder</e2> and a period of unresponsiveness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

809	"She was admitted following a fall and, after being given <e1>metoclopramide</e1>, developed movement disorder and a period of <e2>unresponsiveness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

810	"A patient suffering from a rare enzyme deficiency developed a <e1>malignant neuroleptic syndrome</e1> after having been treated with one single dose of <e2>haloperidol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

811	"BACKGROUND: reports on <e1>delated cutaneous reactions</e1> to <e2>captopril</e2> have been seldom reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

812	"<e1>Captopril</e1> is an angiotensin-converting enzyme (ACE) inhibitor and their <e2>cutaneous side-effects</e2> are documented, but little has been published concerning the usefulness of patch test when they occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

813	"<e1>Dermatitis</e1> to <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

814	"We presented the case of a patient who developed a <e1>cutaneous reaction</e1> induced by <e2>captopril</e2> with positive patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

815	"A 62-year-old Caucasian man with atrial fibrillation who was taking <e1>warfarin</e1> reported an episode of <e2>hematochezia</e2>; his international normalized ratio (INR) was 1.74."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

816	"<e1>Warfarin</e1>-associated <e2>bleeding</e2> complication saved life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

817	"<e1>Warfarin</e1>-associated <e2>bleeding</e2> generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

818	"A case of polymyositis with <e1>dilated cardiomyopathy</e1> associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

819	"A case of <e1>polymyositis</e1> with dilated cardiomyopathy associated with <e2>interferon alpha</e2> treatment for hepatitis B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

820	"In this case, <e1>interferon alpha</e1> induced polymyositis and <e2>cardiomyopathy</e2> is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

821	"In this case, <e1>interferon alpha</e1> induced <e2>polymyositis</e2> and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

822	"<e1>Polymyositis</e1> is a rare complication of <e2>interferon alpha</e2> treatment as a result of immune-modulating role of the drug itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

823	"To treat hepatitis B, <e1>interferon alpha</e1> was administered until the proximal <e2>muscle weakness</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

824	"Long-term follow-up after <e1>neoplastic seeding</e1> complicating percutaneous <e2>ethanol</e2> injection for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

825	"We describe a case of <e1>subcutaneous metastasis</e1> along the needle track after percutaneous <e2>ethanol</e2> injection (PEI) for treatment of hepatocellular carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

826	"<e1>Aggressive endometrial carcinoma</e1> in a breast cancer patient treated with <e2>tamoxifen</e2> with normal transvaginal ultrasonography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

827	"Since <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

828	"Since <e1>tamoxifen</e1> therapy can induce <e2>endometrial disorders</e2>, surveillance schemes of women taking <e1>tamoxifen</e1> have been recommended."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

829	"We described a very atypical case of a high stage, high grade <e1>endometrial cancer</e1> associated with <e2>tamoxifen</e2> in a 64-year-old woman with a past history of breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

830	"Beginning ductopenia was present in two, suggesting that <e1>itraconazole</e1> might be responsible for the occurrence of prolonged drug-induced <e2>cholangiopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

831	"Beginning <e1>ductopenia</e1> was present in two, suggesting that <e2>itraconazole</e2> might be responsible for the occurrence of prolonged drug-induced cholangiopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

832	"CONCLUSIONS: <e1>Itraconazole</e1>-induced liver injury presents with a <e2>cholestatic pattern of injury</e2> with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

833	"CONCLUSIONS: <e1>Itraconazole</e1>-induced liver injury presents with a cholestatic pattern of injury with <e2>damage to the interlobular bile ducts</e2>, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

834	"CONCLUSIONS: <e1>Itraconazole</e1>-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to <e2>ductopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

835	"CONCLUSIONS: <e1>Itraconazole</e1>-induced <e2>liver injury</e2> presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

836	"<e1>Hepatotoxicity</e1> related to <e2>itraconazole</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

837	"METHODS: Three patients with apparent <e1>itraconazole</e1>-induced <e2>liver injury</e2> were studied."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

838	"The occurrence of acute <e1>hepatitis</e1> is best known for <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

839	"We report on three patients who developed acute <e1>liver damage</e1> during therapy with <e2>itraconazole</e2>, and in whom liver biopsy specimens were obtained."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

840	"We suggest that <e1>itraconazole</e1> should be added to the list of drugs that may be responsible for a drug-induced <e2>vanishing bile duct syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

841	"With <e1>itraconazole</e1>, <e2>hepatotoxic</e2> reactions have only very rarely been reported, and histologic data are lacking."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

842	"<e1>Thrombotic stroke</e1> associated with the use of <e2>porcine factor VIII</e2> in a patient with acquired haemophilia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

843	"We have recently encountered a patient with acquired haemophilia who developed a <e1>thrombotic left middle cerebral artery distribution stroke</e1> while being treated with <e2>pFVIII</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

844	"We speculate that platelet activation induced by <e1>pFVIII</e1> may have contributed to <e2>thrombosis</e2> and suggest that <e1>pFVIII</e1> be used with caution in elderly patients with pre-existing cardiovascular risk factors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

845	"<e1>Cutaneous sarcoidosis</e1> during <e2>interferon alfa</e2> and ribavirin treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

846	"<e1>Cutaneous sarcoidosis</e1> during interferon alfa and <e2>ribavirin</e2> treatment of hepatitis C virus infection: two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

847	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

848	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with <e2>interferon alfa</e2> and more recently with the combination of <e2>interferon alfa</e2> plus ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

849	"There have been more than 20 observations of the appearance or aggravation of this <e1>granulomatosis</e1> with interferon alfa and more recently with the combination of interferon alfa plus <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

850	"We report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with <e2>interferon alfa</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

851	"We report two new cases of <e1>sarcoidosis</e1> in two patients with hepatitis C virus infection treated with interferon alfa and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

852	"CONCLUSIONS: Although <e1>mirtazapine</e1> offers clinicians a combination of strong efficacy and good safety, we suggest bearing <e2>SS</e2> in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

853	"DISCU<e1>SS</e1>ION: A review of the cases of <e1>SS</e1> with implication of <e2>mirtazapine</e2> as the cause was performed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

854	"OBJECTIVE: To document a case of <e1>serotonin syndrome</e1> (SS) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

855	"OBJECTIVE: To document a case of serotonin syndrome (<e1>SS</e1>) associated with <e2>mirtazapine</e2> monotherapy, review the previously reported cases of <e1>SS</e1> associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

856	"Severe <e1>serotonin syndrome</e1> induced by <e2>mirtazapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

857	"<e1>Pulmonary toxicity</e1> secondary to <e2>procarbazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

858	"A 64-year-old man presented with <e1>proteinuria</e1> during postoperative <e2>interferon (IFN)-beta</e2> therapy against malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

859	"<e1>Minimal change nephrotic syndrome</e1> developing during postoperative <e2>interferon-beta</e2> therapy for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

860	"To our knowledge this is the first report that demonstrates <e1>histological abnormalities of the glomerulus</e1> associated with postoperative <e2>IFN-beta</e2> therapy for the malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

861	"The authors report two cases of <e1>delayed elimination</e1> of methotrexate in patients receiving <e2>ciprofloxacin</e2>, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

862	"The authors report two cases of <e1>delayed elimination</e1> of <e2>methotrexate</e2> in patients receiving ciprofloxacin, with severe toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

863	"The authors report two cases of delayed elimination of methotrexate in patients receiving <e1>ciprofloxacin</e1>, with severe <e2>toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

864	"CONCLUSIONS: Clinicians should be aware of the possible association of <e1>thrombocytopenia</e1> with <e2>lansoprazole</e2> and discontinue the drug if <e1>thrombocytopenia</e1> becomes apparent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

865	"DISCUSSION: After exclusion of other causes, the onset of <e1>thrombocytopenia</e1> after administration of <e2>lansoprazole</e2>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

866	"DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of <e1>lansoprazole</e1>, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic <e2>thrombocytopenic</e2> response to <e1>lansoprazole</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

867	"He was started on oral <e1>lansoprazole</e1> 60 mg twice daily and, on hospital day 2, his <e2>platelet count decreased</e2> to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

868	"<e1>Lansoprazole</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

869	"OBJECTIVE: To describe a case of <e1>thrombocytopenia</e1> associated with the administration of <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

870	"To date, this is the first reported case of what appears to be isolated <e1>thrombocytopenia</e1> associated with <e2>lansoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

871	"Life-threatening <e1>anaphylactoid reaction</e1> to <e2>amifostine</e2> used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

872	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, hypocalcemia and <e2>allergic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

873	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, hypotension, <e2>hypocalcemia</e2> and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

874	"The most common side effects associated with <e1>amifostine</e1> are nausea, vomiting, <e2>hypotension</e2>, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

875	"The most common side effects associated with <e1>amifostine</e1> are <e2>nausea</e2>, vomiting, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

876	"The most common side effects associated with <e1>amifostine</e1> are nausea, <e2>vomiting</e2>, hypotension, hypocalcemia and allergic reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

877	"The patient suffered a <e1>life-threatening anaphylactoid reaction</e1> to <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

878	"<e1>Agranulocytosis</e1> during <e2>clozapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

879	"Granulocytopenia and <e1>agranulocytosis</e1> are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

880	"<e1>Granulocytopenia</e1> and agranulocytosis are considered among the most dangerous adverse effects of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

881	"The female patient received <e1>clozapine</e1> in a daily dose of 400 mg, which induced <e2>agranulocytosis</e2> after 2 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

882	"The male patient was treated with 225-mg/day <e1>clozapine</e1> and the time to the diagnosis of <e2>agranulocytosis</e2> was 6 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

883	"A 53-year-old man developed <e1>NMS</e1> without rigidity while taking <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

884	"Atypical <e1>neuroleptic malignant syndrome</e1> associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

885	"CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral <e1>zuclopenthixol</e1>, an antipsychotic from the thioxanthene family, who developed an acute, <e2>painful erection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

886	"CONCLUSIONS: <e1>Priapism</e1> is an uncommon but potentially serious adverse effect of <e2>zuclopenthixol</e2> that practitioners, as with many other antipsychotics, should be aware of."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

887	"DISCUSSION: The occurrence of <e1>priapism</e1> in our patient was related to <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

888	"OBJECTIVE: To present a single case of <e1>zuclopenthixol</e1>-induced <e2>priapism</e2> and a literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

889	"<e1>Priapism</e1> associated with <e2>zuclopenthixol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

890	"The capacity of <e1>zuclopenthixol</e1> to induce <e2>priapism</e2> is thought to be due to its antagonist activity on alpha-adrenergic receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

891	"After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming <e1>sepsis</e1> associated with <e2>metamizole</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

892	"<e1>Metamizole</e1>, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of <e2>agranulocytosis</e2> but is widely used in Mexico and other countries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

893	"Erythropoietin is beneficial in <e1>mitomycin</e1>-induced <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

894	"We describe a patient who developed <e1>HUS</e1> after treatment with <e2>mitomycin C</e2> (total dose 144 mg/m2) due to a carcinoma of the ascending colon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

895	"<e1>Levofloxacin</e1>-induced <e2>toxic epidermal necrolysis</e2> in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

896	"To our knowledge, this case is the first published report of <e1>levofloxacin</e1>-induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

897	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, vinblastine and <e2>bleomycin</e2> for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

898	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with <e2>cisplatin</e2>, vinblastine and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

899	"A 31-year-old female developed multiple episodes of <e1>grand mal seizures</e1> after combination chemotherapy with cisplatin, <e2>vinblastine</e2> and bleomycin for germ cell ovarian cancer stage Ic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

900	"<e1>Posterior leukoencephalopathy</e1> following cisplatin, <e2>bleomycin</e2> and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

901	"<e1>Posterior leukoencephalopathy</e1> following <e2>cisplatin</e2>, bleomycin and vinblastine therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

902	"<e1>Posterior leukoencephalopathy</e1> following cisplatin, bleomycin and <e2>vinblastine</e2> therapy for germ cell tumor of the ovary."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

903	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a <e2>hemorrhagic lesion</e2> that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

904	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 <e2>pancytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

905	"After 5 days of treatment with <e1>IL-2</e1>, the patient developed a hemorrhagic lesion that progressed to <e2>toxic epidermal necrolysis</e2>, as well as grade 4 pancytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

906	"OBJECTIVE: To report a case of <e1>cutaneous and hematologic toxicity</e1> in a patient treated with <e2>IL-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

907	"Subcutaneous <e1>IL-2</e1> is safe and well tolerated, with a <e2>mortality rate <3</e2>%."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

908	"<e1>Toxic epidermal necrolysis</e1> associated with <e2>interleukin-2</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

909	"A case of <e1>anaphylactoid reaction</e1> due solely to the use of <e2>Gelofusine</e2> in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

910	"<e2>Gelofusine</e2> allergy--the need for identification jewellery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

911	"The authors describe <e1>valproate</e1>-induced <e2>hyperammonemia</e2> and mental status changes in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

912	"The authors describe <e1>valproate</e1>-induced hyperammonemia and <e2>mental status changes</e2> in an 88-year-old man, the first known reported case in an elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

913	"<e1>Valproate</e1>-induced hyperammonemia as a cause of <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

914	"<e1>Valproate</e1>-induced <e2>hyperammonemia</e2> as a cause of altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

915	"<e1>Leiomyosarcoma</e1> in urinary bladder after <e2>cyclophosphamide</e2> therapy for retinoblastoma and review of bladder sarcomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

916	"The epivodes of <e1>NMS</e1> occured under treatment with clozapine, risperidone, and <e2>amisulpride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

917	"The epivodes of <e1>NMS</e1> occured under treatment with <e2>clozapine</e2>, risperidone, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

918	"The epivodes of <e1>NMS</e1> occured under treatment with clozapine, <e2>risperidone</e2>, and amisulpride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

919	"A 73-year-old woman presented with fever and <e1>cough</e1> 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

920	"A 73-year-old woman presented with <e1>fever</e1> and cough 2 weeks after completing the third cycle of <e2>fludarabine</e2> for chronic lymphocytic leukemia (CLL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

921	"<e1>Fludarabine</e1> induced lung toxicity must be considered in all patients who develop unexplained <e2>lung disease</e2> while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

922	"Fludarabine induced lung toxicity must be considered in all patients who develop unexplained <e1>lung disease</e1> while receiving <e2>fludarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

923	"<e1>Fludarabine</e1> induced <e2>lung toxicity</e2> must be considered in all patients who develop unexplained lung disease while receiving fludarabine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

924	"<e1>Multiple pulmonary nodules</e1>: an unusual presentation of <e2>fludarabine</e2> pulmonary toxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

925	"Multiple pulmonary nodules: an unusual presentation of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

926	"This case extends the spectrum of <e1>fludarabine</e1> pulmonary toxicity to include <e2>pulmonary nodules</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

927	"This case extends the spectrum of <e1>fludarabine</e1> <e2>pulmonary toxicity</e2> to include pulmonary nodules."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

928	"To our knowledge, four cases of <e1>interstitial pneumonitis</e1> associated with <e2>fludarabine</e2> have been reported in medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

929	"<e1>Epoprostenol</e1> may be associated rarely with severe <e2>erythroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

930	"Severe <e1>erythroderma</e1> as a complication of continuous <e2>epoprostenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

931	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and vomiting, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

932	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, <e2>nausea</e2> and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

933	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with <e2>rapidly progressive erythema</e2>, scaling, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

934	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, <e2>scaling</e2>, nausea and vomiting, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

935	"We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with <e1>epoprostenol</e1>, presented with rapidly progressive erythema, scaling, nausea and <e2>vomiting</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

936	"A 50-year-old diabetic and hypertensive male patient is reported who had <e1>ticlopidine</e1>-induced <e2>marrow aplasia</e2> partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

937	"There is no consensus on the treatment of <e1>ticlopidine</e1>-induced <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

938	"<e1>Ticlopidine</e1>-induced <e2>marrow aplasia</e2> treated with cyclosporine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

939	"A 53-year-old man developed <e1>lower leg edema</e1> 4 weeks after <e2>rosiglitazone</e2> was increased from 4 mg once/day to 4 mg twice/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

940	"A 75-year-old man developed <e1>bilateral lower leg edema</e1> 6 months after switching from troglitazone to <e2>pioglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

941	"A 77-year-old man developed <e1>ankle, hand, and facial swelling</e1> 2 weeks after starting <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

942	"Two cases of <e1>polymorphic ventricular tachycardia</e1> induced by the administration of <e2>verapamil</e2> against paroxysmal supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

943	"<e1>Verapamil</e1> is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little <e2>proarrhythmic effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

944	"We describe two cases of PSVT that changed to <e1>non-sustained polymorphic ventricular tachycardia</e1> after administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

945	"<e1>Epsilon-aminocaproic acid</e1> and <e2>renal complications</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

946	"Neonatal <e1>mydriasis</e1>: intravenous <e2>lidocaine</e2> adverse reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

947	"We present a neonate with a seizure disorder who acutely developed <e1>pupillary mydriasis</e1> secondary to <e2>lidocaine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

948	"We suggest adding this side effect to the list of untoward effects of <e1>lidocaine</e1> and to the differential diagnosis of fixed <e2>dilated pupils</e2> in neonates treated with <e1>lidocaine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

949	"Myelodysplasia terminating in <e1>acute myeloid leukemia</e1> in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

950	"<e1>Myelodysplasia</e1> terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with <e2>2-deoxycoformycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

951	"To the best of our knowledge only two previous cases of <e1>AML</e1> have been linked to treatment of HCL with purine analogs, both with <e2>2-chlorodeoxyadenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

952	"CONCLUSIONS: Peripheral administration of low-dose <e1>vasopressin</e1> for septic shock should be discouraged because of the risk of <e2>ischemic skin complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

953	"OBJECTIVE: To describe a case of severe <e1>skin necrosis</e1> resulting from peripheral intravenous administration of low-dose <e2>vasopressin</e2> in a patient with catecholamine-resistant septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

954	"<e1>Skin necrosis</e1> after extravasation of low-dose <e2>vasopressin</e2> administered for septic shock."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

955	"<e1>Mitomycin-C</e1> induced <e2>hemolytic uremic syndrome</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

956	"<e1>Mitomycin-C</e1> is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of <e2>hemolytic uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

957	"Although <e1>vasculitis</e1> has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of <e2>cladribine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

958	"<e1>Systemic vasculitis</e1> complicating hairy cell leukaemia treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

959	"We describe a 73-year-old woman who developed serious <e1>systemic vasculitis</e1> with associated thrombocytopenia in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

960	"We describe a 73-year-old woman who developed serious systemic vasculitis with associated <e1>thrombocytopenia</e1> in the course of treatment with <e2>cladribine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

961	"Drug-induced <e1>mammary hyperplasias</e1> have been reported as rare complications of <e2>D-penicillamine</e2> and Neothetazone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

962	"Drug-induced <e1>mammary hyperplasias</e1> have been reported as rare complications of D-penicillamine and <e2>Neothetazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

963	"<e1>Gigantomastia</e1> induced by <e2>bucillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

964	"Retrospectively, <e1>bucillamine</e1> was believed to be the cause of the <e2>giant hypertrophy</e2> because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

965	"Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to <e1>D-penicillamine</e1>, which was the subject of an abundance of reports of <e2>mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

966	"The authors report the first case of <e1>bucillamine</e1>-induced <e2>giant mammary hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

967	"The authors describe three families in whom the occurrence of <e1>FVS</e1> in all the siblings strongly suggests hereditary susceptibility to <e2>valproic acid</e2>-induced adverse outcome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

968	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and <e2>developmental delay</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

969	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by <e2>distinctive facial appearance</e2>, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

970	"The fetal <e2>valproate</e2> syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

971	"The fetal <e1>valproate</e1> syndrome (<e2>FVS</e2>) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

972	"The fetal <e1>valproate</e1> syndrome (FVS) is characterized by distinctive facial appearance, <e2>major and minor malformations</e2>, and developmental delay."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

973	"<e2>Valproate</e2> embryopathy in three sets of siblings: further proof of hereditary susceptibility."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

974	"<e1>Generalised pustular psoriasis</e1> induced by <e2>cyclosporin a</e2> withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

975	"We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a generalised pustular exacerbation and a <e2>aggravation of the joint condition</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

976	"We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of <e1>cyclosporin A</e1> induced a <e2>generalised pustular exacerbation</e2> and a aggravation of the joint condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

977	"The first case concerns a 70-year-old man who developed severe <e1>aplastic anemia</e1> 7 weeks after treatment with 500 mg of <e2>ticlopidine</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

978	"The second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found neutropenic with <e2>marrow aplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

979	"The second was an 82-year-old man receiving <e1>ticlopidine</e1> for 2 years when, during a febrile episode, he was found <e2>neutropenic</e2> with marrow aplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

980	"<e1>Ticlopidine</e1>-induced <e2>aplastic anemia</e2> (TIAA) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

981	"<e1>Ticlopidine</e1>-induced aplastic anemia (<e2>TIAA</e2>) is considered very uncommon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

982	"<e1>Ticlopidine</e1>-induced <e2>aplastic anemia</e2>: two new case reports, review, and meta-analysis of 55 additional cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

983	"When the data of the 57 patients are evaluated, a reversible direct <e1>cytotoxic effect</e1> of <e2>ticlopidine</e2> on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

984	"<e1>Fixed drug eruption</e1> to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

985	"<e1>Rofecoxib</e1>, used for dysmenorrhea, caused a <e2>herpetiform fixed drug eruption</e2> predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

986	"<e1>Rofecoxib</e1>, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a <e2>red-brown lesion</e2> on the dorsal hand."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

987	"A patient who had been treated with large doses of <e1>thyroid hormone</e1> for several years developed features of secondary <e2>hypothyroidism</e2> after <e1>thyroid hormone</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

988	"BACKGROUND: Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1>-associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

989	"BACKGROUND: <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated <e2>hemolytic-uremic syndrome</e2> (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

990	"BACKGROUND: Gemcitabine has mild renal toxicity, but cases of <e1>gemcitabine</e1>-associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

991	"BACKGROUND: <e1>Gemcitabine</e1> has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (<e2>HUS</e2>) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

992	"BACKGROUND: <e1>Gemcitabine</e1> has mild <e2>renal toxicity</e2>, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

993	"CONCLUSION: There are only a few confirmed cases of <e1>gemcitabine</e1>-associated <e2>HUS</e2> despite the widespread use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

994	"<e1>Gemcitabine</e1>-associated <e2>hemolytic-uremic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

995	"Mean time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

996	"Mean time between initiation of <e1>gemcitabine</e1> therapy and onset of <e2>HUS</e2> was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of <e1>gemcitabine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

997	"METHODS: A case is presented of a 45-year-old woman on prolonged <e1>gemcitabine</e1> treatment for ovarian cancer who developed <e2>HUS</e2> and recovered after drug discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

998	"RESULTS: Including our own patient, a total of 26 cases of <e1>gemcitabine</e1>-associated <e2>HUS</e2> were identified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

999	"An <e1>amiodarone</e1> <e2>optic neuropathy</e2> has been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1000	"Biomicroscopy revealed <e1>amiodarone</e1> <e2>corneal deposits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1001	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, <e2>color vision anomalies</e2>, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1002	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1003	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," <e2>glare</e2>, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1004	"CASE REPORT: Soon after initiation of <e1>amiodarone HCl</e1> (200 mg/day), a 76-year-old man came to us with symptoms of <e2>visual "shining</e2>," glare, color vision anomalies, and gradually decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1005	"<e1>Visual changes</e1> secondary to initiation of <e2>amiodarone</e2>: a case report and review involving ocular management in cardiac polypharmacy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1006	"While both <e1>amiodarone</e1> and digoxin can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1007	"While both amiodarone and <e1>digoxin</e1> can cause permanent visual changes, the <e2>ocular effects</e2> are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1008	"While both <e1>amiodarone</e1> and digoxin can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1009	"While both amiodarone and <e1>digoxin</e1> can cause permanent <e2>visual changes</e2>, the ocular effects are often reversible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1010	"Infant twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of <e2>benzalkonium</e2> (Zephiran) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1011	"Infant twins sustained severe <e1>circumoral and pharyngeal burns</e1> from a concentrated solution of benzalkonium (<e2>Zephiran</e2>) chloride prescribed for treatment of candidiasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1012	"CONCLUSION: Long-term treatment with <e1>rifabutin</e1> may have a reversible and previously undescribed <e2>side-effect on retinal function</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1013	"PURPOSE: To describe the clinical and electrophysiological findings in a young boy with <e1>decreased vision</e1> possibly due to retinal damage by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1014	"PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to <e1>retinal damage</e1> by <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1015	"Retinal dysfunction and <e1>anterior segment deposits</e1> in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1016	"<e1>Retinal dysfunction</e1> and anterior segment deposits in a patient treated with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1017	"We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with <e1>visual disturbance</e1> during treatment with <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1018	"A case is presented of a patient who experienced <e1>benzodiazepine withdrawal symptoms</e1> on discontinuation of <e2>nefazodone</e2>, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1019	"A case of <e1>SIADH</e1> induced by <e2>mizoribin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1020	"<e1>ADH hypersecretion</e1> in relation to plasma osmolality was reversed by <e2>mizoribin</e2> withdrawal, suggesting that bredinin might adversely induce SIADH."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1021	"ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that <e1>bredinin</e1> might adversely induce <e2>SIADH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1022	"In summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1023	"In summary, we report herein the first case of <e1>SIADH</e1> believed to be an adverse effect of <e2>mizoribin</e2>, which may therefore needed to be added to the list of drugs which can induce <e1>SIADH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1024	"We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone (<e1>SIADH</e1>) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1025	"We describe a 74-year-old man with rheumatoid arthritis (RA) who developed <e1>syndrome of inappropriate secretion of antidiuretic hormone</e1> (SIADH) 1.5 months after commencement of <e2>mizoribin</e2> prescription when his arthritis was improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1026	"The disease-modifying drugs he was taking, <e1>cyclosporin</e1> and methotrexate, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1027	"The disease-modifying drugs he was taking, cyclosporin and <e1>methotrexate</e1>, were stopped, and the <e2>lymphoma</e2> resolved spontaneously without the use of chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1028	"Acute onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1029	"We herein report this rare case of acute onset of <e1>nephrotic syndrome</e1> during <e2>interferon-alpha</e2> retreatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1030	"A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced <e1>seizures</e1> after receiving therapy with <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1031	"Seizures and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1032	"Seizures and <e1>extrapyramidal symptoms</e1> in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1033	"<e1>Seizures</e1> and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and <e2>clomipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1034	"<e1>Seizures</e1> and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with <e2>interferon beta-1a</e2> and clomipramine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1035	"A 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a <e2>carboplatin</e2> and cyclophosphamide infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1036	"A 68-year-old female patient with advanced ovarian carcinoma <e1>collapsed</e1> whilst receiving a carboplatin and <e2>cyclophosphamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1037	"<e1>Carboplatin</e1> hypersensitivity presenting as <e2>coronary vasospasm</e2> - a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1038	"Hypersensitivity to <e1>carboplatin</e1> is a rare but real complication of therapy and should be considered in patients presenting with <e2>hyperacute changes on ECG</e2> whilst receiving <e1>carboplatin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1039	"<e1>Hypersensitivity</e1> to <e2>carboplatin</e2> is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving <e2>carboplatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1040	"A 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1041	"A 60-year-old white man with chronic bronchitis was noted to develop <e1>acute respiratory failure</e1> and metabolic acidosis four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1042	"A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on <e2>methazolamide</e2> (Neptazane) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1043	"A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and <e1>metabolic acidosis</e1> four days after being started on methazolamide (<e2>Neptazane</e2>) for an ophthalmologic problem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1044	"<e1>Capecitabine</e1> was discontinued and the <e2>allergic reactions</e2> resolved after the woman took diphenhydramine for 1 week."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1045	"CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1046	"Fluorouracil for <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1047	"It was postulated that the <e1>allergic reaction</e1> was most likely caused by <e2>capecitabine</e2> or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1048	"OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had <e1>allergic reactions</e1> to <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1049	"She developed a generalized rash and itching, sore throat, and <e1>dizziness</e1> approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1050	"She developed a <e1>generalized rash</e1> and itching, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1051	"She developed a generalized rash and <e1>itching</e1>, sore throat, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1052	"She developed a generalized rash and itching, <e1>sore throat</e1>, and dizziness approximately 4 hours after the first dose of <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1053	"After five and six weeks of continuous oral administration of <e1>methylprednisolone</e1>, the boys developed <e2>steroid diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1054	"Reduction of <e1>methylprednisolone</e1> dosage rather than insulin therapy resulted in better control of <e2>glycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1055	"Contrary to previous recommendations, our experience cautions against the further use of high-dose <e1>cytarabine</e1> in patients who develop <e2>PPE</e2>, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1056	"It has been suggested that <e1>PPE</e1> caused by <e2>cytarabine</e2> does not recur with subsequent <e2>cytarabine</e2> re-challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1057	"Recurrent <e1>palmar-plantar erythrodysaesthesia</e1> following high-dose <e2>cytarabine</e2> treatment for acute lymphoblastic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1058	"We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe <e1>bullous eruption</e1>, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1059	"We report a patient with recurrent, increasingly severe episodes of <e1>PPE</e1>, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose <e2>cytarabine</e2> for the treatment of acute lymphoblastic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1060	"Atypical endometriosis may act as a precancerous lesion in the process of <e1>tamoxifen</e1>-induced <e2>malignant transformation of endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1061	"BACKGROUND: <e1>Ovarian cancer</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1062	"CONCLUSION: <e1>Tamoxifen</e1> may cause <e2>malignant transformation of endometriosis</e2> through atypical endometriosis even in the postmenopausal state."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1063	"<e1>Ovarian endometrioid adenocarcinoma</e1> arising from an endometriotic cyst in a postmenopausal woman under <e2>tamoxifen</e2> therapy for breast cancer: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1064	"<e1>Clinical, spectroscopic, and imaging abnormalities</e1> resolved with discontinuation of <e2>metronidazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1065	"Proton MRS examination demonstrated a persistent <e1>lactate elevation</e1> during <e2>metronidazole</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1066	"<e1>Reversible MR imaging and MR spectroscopy abnormalities</e1> in association with <e2>metronidazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1067	"After nine previous uncomplicated cycles she developed severe <e1>anaphylaxis</e1> to <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1068	"<e1>Anaphylaxis</e1> to <e2>cisplatin</e2> following nine previous uncomplicated cycles."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1069	"<e1>Anaphylaxis</e1> to <e2>cisplatin</e2> is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1070	"Although <e1>isradipine</e1> has been associated with <e2>hepatocellular injury</e2>, there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1071	"A second possibility is an interaction between <e1>clarithromycin</e1> and isradipine, potentially <e2>increasing the hepatic toxicity</e2> of isradipine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1072	"A second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1073	"A second possibility is an interaction between clarithromycin and <e1>isradipine</e1>, potentially <e2>increasing the hepatic toxicity</e2> of <e1>isradipine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1074	"CASE SUMMARY: A 58-year-old white woman developed <e1>fulminant liver failure</e1> while being treated with the macrolide antibiotic <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1075	"CONCLUSIONS: <e1>Clarithromycin</e1> may be a cause of <e2>fulminant liver failure</e2> either alone or by inhibiting the metabolism of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1076	"<e1>Fulminant liver failure</e1> associated with <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1077	"OBJECTIVE: To report a patient developing <e1>fulminant liver failure</e1> while being treated with <e2>clarithromycin</e2> for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1078	"The most likely cause of liver failure in this patient was, therefore, <e1>clarithromycin</e1>, which undergoes hepatic metabolism and has been reported to cause <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1079	"The most likely cause of <e1>liver failure</e1> in this patient was, therefore, <e2>clarithromycin</e2>, which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1080	"A <e1>paradoxical ocular effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1081	"CONCLUSION: Under certain circumstances topical <e1>brimonidine</e1> can cause <e2>paradoxical raised IOP</e2> necessitating vigilance in follow-up of patients on topical <e1>brimonidine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1082	"PURPOSE: We report an unusual <e1>paradoxical effect</e1> of <e2>brimonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1083	"RESULTS: <e1>Brimonidine</e1> was observed to cause <e2>IOP elevation</e2>, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1084	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of <e2>anxiety</e2>, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1085	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, <e2>diaphoresis</e2>, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1086	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1087	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with <e2>generalized seizures</e2> and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1088	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and <e2>palpitations</e2>, this is the first reported patient with generalized seizures and status epilepticus secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1089	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1090	"Although <e1>gabapentin</e1> withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and <e2>status epilepticus</e2> secondary to <e1>gabapentin</e1> withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1091	"<e1>Gabapentin</e1> withdrawal presenting as <e2>status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1092	"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and <e1>altered mental status</e1> after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1093	"Although <e1>visual hallucinations</e1> have not been reported as an adverse effect of this agent, we describe three patients who experienced complex <e1>visual hallucinations</e1> and altered mental status after <e2>zonisamide</e2> treatment was begun or its dosage increased."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1094	"<e1>Visual hallucinations</e1> associated with <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1095	"<e1>Doxycycline</e1>-induced <e2>hypoglycemia</e2> in a nondiabetic young man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1096	"We report the first case of <e1>doxycycline</e1>-induced <e2>hypoglycemia</e2> in a young nondiabetic man."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1097	"For patients who suffer from osteogenic sarcoma and have <e1>anaphylactic reactions</e1> to <e2>MTX</e2>, this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1098	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, cough, and <e2>chest tightness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1099	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, facial swelling, <e2>cough</e2>, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1100	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with <e2>diffuse urticaria</e2>, facial swelling, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1101	"He had an immediate hypersensitivity reaction during the initiation of the <e1>MTX</e1> infusion with diffuse urticaria, <e2>facial swelling</e2>, cough, and chest tightness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1102	"He had an immediate <e1>hypersensitivity reaction</e1> during the initiation of the <e2>MTX</e2> infusion with diffuse urticaria, facial swelling, cough, and chest tightness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1103	"He was later skin tested to confirm <e1>allergy</e1> to <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1104	"Successful desensitization to high-dose <e1>methotrexate</e1> after <e2>systemic anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1105	"The successful development and implementation of this protocol will have impact on patients who have <e1>anaphylactic reactions</e1> to <e2>MTX</e2> but require this medication for specific diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1106	"The authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1107	"The authors report a case of <e1>Balint syndrome</e1> with irreversible posterior leukoencephalopathy on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1108	"The authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal methotrexate and <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1109	"The authors report a case of Balint syndrome with irreversible <e1>posterior leukoencephalopathy</e1> on MRI following intrathecal <e2>methotrexate</e2> and cytarabine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1110	"We present a unique case of <e1>GTBM</e1> in a patient with myeloma following treatment with <e2>Melphalan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1111	"Patients with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of <e2>cortical venous thrombosis</e2> and may have this syndrome in addition to a dural puncture headache."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1112	"Patients with lymphoblastic lymphoma who had treatment with <e1>L-asparaginase</e1> and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a <e2>dural puncture headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1113	"<e1>Interstitial pneumonitis</e1> associated with <e2>sirolimus</e2>: a dilemma for lung transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1114	"<e1>Rapamycin</e1>/sirolimus-induced <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1115	"Rapamycin/<e1>sirolimus</e1>-induced <e2>pneumonitis</e2> has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1116	"<e1>Rapamycin</e1>/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1117	"Rapamycin/<e1>sirolimus</e1>-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e2>pulmonary infiltrate</e2> that reversed after ceasing SR therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1118	"Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a <e1>pulmonary infiltrate</e1> that reversed after ceasing <e2>SR</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1119	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1120	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1121	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1122	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, <e2>hyperlipidemia</e2>, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1123	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1124	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1125	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1126	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, <e2>hypertension</e2>, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1127	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1128	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1129	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1130	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1131	"Rapamycin/sirolimus (SR), trade named <e1>Rapammune</e1> (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1132	"<e1>Rapamycin</e1>/sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1133	"Rapamycin/<e1>sirolimus</e1> (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1134	"Rapamycin/sirolimus (<e1>SR</e1>), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with <e2>myelosuppression</e2>, hypertension, hyperlipidemia, and infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1135	"A 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1136	"A 16-year-old boy developed <e1>fever</e1>, generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1137	"A 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1138	"A 16-year-old boy developed fever, <e1>generalized rigidity</e1>, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1139	"A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1140	"A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and <e1>increased serum transaminase and creatine kinase</e1> levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1141	"A 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1142	"A 16-year-old boy developed fever, generalized rigidity, <e1>leukocytosis</e1>, and increased serum transaminase and creatine kinase levels while receiving treatment with <e2>olanzapine</e2> and lithium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1143	"Concomitant administration of <e1>lithium</e1> with olanzapine may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1144	"Concomitant administration of lithium with <e1>olanzapine</e1> may place patients at risk for <e2>NMS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1145	"<e1>Neuroleptic malignant syndrome</e1> in an adolescent receiving olanzapine-<e2>lithium</e2> combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1146	"<e1>Neuroleptic malignant syndrome</e1> in an adolescent receiving <e2>olanzapine</e2>-lithium combination therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1147	"Both <e1>6-MP</e1> and AZA are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1148	"Both 6-MP and <e1>AZA</e1> are widely used and are known to cause <e2>hepatotoxicity</e2> in a proportion of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1149	"<e1>Hepatotoxicity</e1> associated with <e2>6-thioguanine</e2> therapy for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1150	"This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of <e1>thiopurine</e1>-induced <e2>hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1151	"We believe the temporal association of the <e1>abnormal liver enzymes</e1> in this patient, in the absence of other offending agents, argues strongly in favor of <e2>6-TG</e2> as a cause of liver enzyme abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1152	"We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of <e1>6-TG</e1> as a cause of <e2>liver enzyme abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1153	"We describe a case of significant <e1>elevation of serum transaminases</e1> in a patient treated with <e2>6-TG</e2> for a flare of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1154	"Early peritoneal dialysis has not previously been reported for <e1>lisinopril</e1> induced <e2>multiorgan failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1155	"We observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with prednisolone and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1156	"We observed transient <e1>panhypogammaglobulinaemia</e1> in a patient with neuropsychiatric SLE after treatment with <e2>prednisolone</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1157	"<e1>Fulminant hepatic failure</e1> developed in a 24-year-old black woman who had been treated with propylthiouracil and <e2>propranolol</e2> for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1158	"<e1>Fulminant hepatic failure</e1> developed in a 24-year-old black woman who had been treated with <e2>propylthiouracil</e2> and propranolol for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1159	"<e1>Fulminant hepatitis</e1> and lymphocyte sensitization due to <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1160	"These observations indicate that submassive hepatic necrosis may result from treatment with <e1>propylthiouracil</e1> and are consistent with the notion that sensitization mechanisms may be responsible for the <e2>hepatic injury</e2> induced by this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1161	"These observations indicate that <e1>submassive hepatic necrosis</e1> may result from treatment with <e2>propylthiouracil</e2> and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1162	"The diagnosis of <e1>hypothermia</e1> was delayed until it was apparent for several days but resolved with the discontinuation of <e2>risperidone</e2> and continuation of clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1163	"This is a case report of subtle, mild <e1>hypothermia</e1> in a 54-year old female patient receiving <e2>risperidone</e2> for schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1164	"<e1>Akathisia</e1> is a relatively rare side effect with the newer atypical antipsychotic agents, particularly <e2>clozapine</e2>, and is easily misdiagnosed in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1165	"<e1>Clozapine</e1>-induced <e2>akathisia</e2> in children with schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1166	"Two cases of childhood-onset schizophrenia associated with <e1>clozapine</e1>-induced <e2>akathisia</e2> responsive to beta-blocker treatment are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1167	"After reviewing the literature we suggest the CPM was a complication of <e1>lithium</e1> toxicity which affected the lateral geniculate nucleus which produced <e2>blindness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1168	"After reviewing the literature we suggest the <e1>CPM</e1> was a complication of <e2>lithium</e2> toxicity which affected the lateral geniculate nucleus which produced blindness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1169	"<e1>Central pontine myelinolysis</e1> manifested by temporary blindness: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1170	"Central pontine myelinolysis manifested by <e1>temporary blindness</e1>: a possible complication of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1171	"Antithyroid treatment with <e1>propylthiouracil</e1> (PTU) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1172	"Antithyroid treatment with propylthiouracil (<e1>PTU</e1>) resulted in <e2>elevated hepatic enzymes</e2> and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1173	"Successful treatment with carbimazole of a hyperthyroid pregnancy with <e1>hepatic impairment</e1> after <e2>propylthiouracil</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1174	"Interferon-alpha (<e1>IFN-alpha</e1>) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1175	"<e1>Interferon-alpha</e1> (IFN-alpha) may precipitate or exacerbate the occurrence of <e2>MPGN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1176	"<e1>Minimal change disease</e1> in a patient receiving <e2>IFN-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1177	"A 58-yr-old male patient with essential thrombocythaemia (ET) developed <e1>chronic myeloid leukaemia</e1> (CML) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1178	"A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (<e1>CML</e1>) after continuous uneventful treatment with <e2>hydroxyurea</e2> for 18 yr."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1179	"Emergence of <e1>Philadelphia positive chronic myeloid leukaemia</e1> during treatment with <e2>hydroxyurea</e2> for Philadelphia negative essential thrombocythaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1180	"There are no previous reports in the literature about the emergence of <e1>CML</e1> during treatment with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1181	"His fever resolved, but he developed symptoms consistent with those of <e2>chloroquine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1182	"OBJECTIVE: To report a case of severe <e2>chloroquine</e2> toxicity in the presence of high-grade <e2>chloroquine</e2>-resistant Plasmodium vivax."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1183	"<e1>Toxicity</e1> related to <e2>chloroquine</e2> treatment of resistant vivax malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1184	"A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and <e1>fever</e1> two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1185	"A 72-year-old woman with a history of thyrotoxicosis presented with <e1>sore throat</e1> and fever two weeks after starting <e2>carbimazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1186	"Treatment of <e1>carbimazole</e1>-induced <e2>agranulocytosis</e2> and sepsis with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1187	"Treatment of <e1>carbimazole</e1>-induced agranulocytosis and <e2>sepsis</e2> with granulocyte colony stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1188	"We present the management of <e1>agranulocytosis</e1> and neutropenic sepsis secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1189	"We present the management of agranulocytosis and <e1>neutropenic sepsis</e1> secondary to <e2>carbimazole</e2> with recombinant human granulocyte colony stimulating factor (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1190	"<e1>Comeoscleral perforation</e1> after pterygium excision and intraoperative <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1191	"To the best of our knowledge, <e1>corneoscleral melting</e1> in the first postoperative week after a single intraoperative application of <e2>mitomycin C</e2> has not been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1192	"A 71-year-old man, who had a history of a previous <e1>bullous drug reaction</e1> to a <e2>sulfonamide</e2>, began receiving an ophthalmic preparation that contained sulfacetamide sodium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1193	"The patient received only the ophthalmic <e1>sulfonamide</e1>, and it was used for one day, but he developed <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1194	"The <e1>sulfonamides</e1> are the best verified drug-trigger for <e2>erythema multiforme</e2> and Stevens-Johnson syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1195	"The <e1>sulfonamides</e1> are the best verified drug-trigger for erythema multiforme and <e2>Stevens-Johnson syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1196	"Based on these findings, the patient was diagnosed with <e1>diabetes insipidus</e1> secondary to <e2>lithium</e2> therapy and was treated successfully with amiloride."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1197	"Clinicians have been aware of <e2>lithium</e2> toxicity for many years and traditionally have administered thiazide diuretics for <e2>lithium</e2>-induced polyuria and nephrogenic diabetes insipidus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1198	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1>-induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1199	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1>-induced polyuria and <e2>nephrogenic diabetes insipidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1200	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1>-induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1201	"Clinicians have been aware of <e1>lithium</e1> toxicity for many years and traditionally have administered thiazide diuretics for <e1>lithium</e1>-induced <e2>polyuria</e2> and nephrogenic diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1202	"Treatment of <e1>lithium</e1>-induced <e2>diabetes insipidus</e2> with amiloride."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1203	"<e1>Systemic capillary leak syndrome</e1> after granulocyte colony-stimulating factor (<e2>G-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1204	"<e1>Systemic capillary leak syndrome</e1> after <e2>granulocyte colony-stimulating factor</e2> (G-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1205	"We present two cases in which both patients suffered with <e1>CLS</e1>, which we believe was caused following administration of <e2>granulocyte colony-stimulating factor</e2>, to our knowledge not described in the intensive care patient previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1206	"<e1>FK506</e1>, which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before <e2>neurologic abnormalities</e2> began."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1207	"Rapid identification of <e1>speech loss</e1> linked to <e2>FK506</e2> may be important because reduction or cessation of the drug may be associated with reverse of <e1>speech loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1208	"Tacrolimus (<e1>FK506</e1>), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1209	"<e1>Tacrolimus</e1> (FK506), an immunosuppressant, has been associated with <e2>mutism</e2> in adults after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1210	"Tacrolimus (<e1>FK506</e1>)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1211	"<e1>Tacrolimus</e1> (FK506)-induced <e2>mutism</e2> after liver transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1212	"Does the use of <e1>insulin</e1> in a patient with liver dysfunction increase water retention in the body, i.e. cause <e1>insulin</e1> <e2>oedema</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1213	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, <e2>ascites</e2> and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1214	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked <e2>peripheral oedema</e2>, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1215	"Soon after introduction of <e1>insulin</e1> therapy, she developed severe anasarca, including marked peripheral oedema, ascites and <e2>pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1216	"Soon after introduction of <e1>insulin</e1> therapy, she developed <e2>severe anasarca</e2>, including marked peripheral oedema, ascites and pleural effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1217	"The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1218	"The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of <e1>insulin</e1> (> 110 units/day), suggesting the existence of <e1>insulin</e1> insensitivity and hyper<e1>insulin</e1>aemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1219	"We conjectured that the side effects of <e1>insulin</e1>, such as <e2>anti-natriuresis</e2> and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1220	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1221	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and <e2>hypoalbuminaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1222	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and <e2>increased vascular permeability</e2>, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1223	"We conjectured that the side effects of <e1>insulin</e1>, such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies <e1>insulin</e1> insensitivity, hyper<e1>insulin</e1>aemia and hypoalbuminaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1224	"While 40 mg/day of <e1>prednisolone</e1> improved hepatic dysfunction dramatically, her <e2>diabetic milieu deteriorated</e2> seriously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1225	"Intrathecal <e1>methotrexate</e1>-induced <e2>acute cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1226	"We describe a patient who developed <e1>acute cerebellar syndrome</e1> after prophylactic intrathecal <e2>methotrexate</e2> administration and recovered spontaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1227	"<e1>Angioimmunoblastic lymphadenopathy with dysproteinemia</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1228	"We report a case of <e1>AILD</e1> in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1229	"We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and <e1>fever</e1> following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1230	"We report a case of AILD in an 80-year-old male who presented with a <e1>generalized pruritic maculopapular eruption</e1> and fever following <e2>doxycycline</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1231	"<e1>Anaphylaxis</e1> from <e2>isoniazid</e2> is a possible side effect to this commonly prescribed antibiotic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1232	"<e1>Isoniazid</e1>-induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1233	"A case is reported in which severe hypocalcemia, with a <e1>low plasma parathyroid hormone</e1> (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1234	"A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (<e1>PTH</e1>) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1235	"A case is reported in which <e1>severe hypocalcemia</e1>, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of <e2>magnesium sulfate</e2> for toxemia of pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1236	"<e1>Carbamazepine</e1>-related <e2>hyponatremia</e2> following cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1237	"We discuss the association between <e1>carbamazepine</e1> and <e2>hyponatremia</e2> and the causes of <e2>hyponatremia</e2> after cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1238	"After <e1>5-ASA</e1> was discontinued, the <e2>polyneuropathy</e2> symptoms recovered gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1239	"<e1>Sensorimotor polyneuropathy</e1> with <e2>5-aminosalicylic acid</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1240	"This clinical course suggests that the <e1>sensorimotor polyneuropathy</e1> may have been caused by <e2>5-ASA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1241	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1242	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and <e2>atrophy</e2> in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1243	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1244	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and <e2>gait disturbance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1245	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1246	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed <e2>weakness</e2> and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1247	"When SASP was changed to <e1>5-aminosalicylic acid</e1> (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1248	"When SASP was changed to 5-aminosalicylic acid (<e1>5-ASA</e1>), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive <e2>worsening of the dysesthesia</e2> in his legs and gait disturbance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1249	"<e1>Disseminated cellulitic cryptococcosis</e1> in the setting of <e2>prednisone</e2> monotherapy for pemphigus vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1250	"In both cases, high fever, skin rash, liver dysfunction and <e1>atypical lymphocytosis</e1> developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1251	"In both cases, <e1>high fever</e1>, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1252	"In both cases, high fever, skin rash, <e1>liver dysfunction</e1> and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1253	"In both cases, high fever, <e1>skin rash</e1>, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with <e2>SASP</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1254	"Slow acetylator genotypes as a possible risk factor for <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1255	"We report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by <e2>salazosulfapyridine</e2> (SASP)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1256	"We report two patients with <e1>infectious mononucleosis-like syndrome</e1> induced by salazosulfapyridine (<e2>SASP</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1257	"A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance <e1>infliximab</e1> infusions and methotrexate, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1258	"A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and <e1>methotrexate</e1>, developed a <e2>lupus-like syndrome</e2> eight months after her initial infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1259	"A <e1>lupus-like syndrome</e1> associated with <e2>infliximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1260	"<e1>Infliximab</e1> therapy may cause a <e2>lupus-like syndrome</e2> that is reversible upon discontinuing this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1261	"We report in detail an unusual adverse reaction to <e1>infliximab</e1> therapy, a drug-induced <e2>lupus-like clinical syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1262	"Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha (<e1>IFNalpha</e1>) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1263	"Chronic myelogenous leukemia (CML), hepatitis C, and <e1>interferon alpha</e1> (IFNalpha) have all been associated with <e2>renal dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1264	"Despite the underlying hepatitis C, this case represents <e1>renal abnormalities</e1> consistent with <e2>IFNalpha</e2> therapy for CML."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1265	"<e1>Interferon-alpha</e1>-induced <e2>focal segmental glomerulosclerosis</e2> in chronic myelogenous leukemia: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1266	"The renal biopsy showed <e1>focal segmental glomerulosclerosis</e1>, which has only been previously reported in two cases of CML treated with <e2>IFNalpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1267	"Severe <e1>autoimmune hemolytic anemia</e1> following <e2>rituximab</e2> therapy in a patient with a lymphoproliferative disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1268	"The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after <e1>destruction of CD20 positive cells</e1> by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1269	"The pathophysiological mechanisms remain unknown, although the drug could act through <e1>massive cytokines liberation</e1> after destruction of CD20 positive cells by <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1270	"We report the first case, to our knowledge, of <e1>rituximab</e1>-related <e2>autoimmune hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1271	"Early-onset <e1>acute transverse myelitis</e1> following <e2>hepatitis B vaccination</e2> and respiratory infection: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1272	"In this paper, we report a case of 3 years-old boy who developed <e1>acute onset tetraparesia</e1> following a viral respiratory infecction and <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1273	"Although it would be expected that, like other type IA toxicities, <e1>diphenhydramine</e1>-induced <e2>cardiotoxicity</e2> could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1274	"<e1>Diphenhydramine</e1>-induced wide complex <e2>dysrhythmia</e2> responds to treatment with sodium bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1275	"However, because <e1>diphenhydramine</e1> also exhibits type IA sodium channel blockade, <e2>cardiac toxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1276	"We describe 3 cases of <e1>diphenhydramine</e1>-induced <e2>cardiac toxicity</e2> that were responsive to bicarbonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1277	"We describe a patient with extranodal non-Hodgkin lymphoma who developed <e1>systemic candidiasis</e1> after treatment with a <e2>cyclophosphamide</e2>-based chemotherapy regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1278	"<e1>Stevens-Johnson syndrome</e1> in a boy with nephrotic syndrome during <e2>prednisolone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1279	"We report a case of <e1>SJS</e1> in a 14-year-old male with nephrotic syndrome, who was treated with oral <e2>prednisolone</e2> for 6 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1280	"A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting <e2>dapsone</e2> and rifampin therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1281	"A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a <e1>reversal reaction</e1> after starting dapsone and <e2>rifampin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1282	"However, in order to avoid <e1>neuropathic side effects</e1>, patients under <e2>thalidomide</e2> therapy should be monitored every 6 months with nerve conduction studies while taking the drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1283	"After a two-month interruption of interferon administration, natural <e1>interferon alpha</e1> was given but followed by another episode of the same <e2>neurological manifestations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1284	"Case 1, a 62-year-old woman, developed <e1>bilateral optic neuritis</e1> with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1285	"Case 1, a 62-year-old woman, developed bilateral optic neuritis with <e1>decreased sensation of vibration</e1> and increased deep tendon reflex in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1286	"Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and <e1>increased deep tendon reflex</e1> in the lower extremities after a seven-month use of <e2>recombinant interferon alpha-2a</e2> for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1287	"Case 2, a 29-year-old woman, developed <e1>bilateral optic neuritis</e1> combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1288	"Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as <e1>bowel and bladder dysfunction</e1> after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1289	"Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with <e1>numbness of the lower extremities</e1> as well as bowel and bladder dysfunction after a 22-month use of <e2>recombinant interferon alpha-2b</e2> for chronic myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1290	"CONCLUSIONS: Optic neuritis in combination with other <e1>neurological signs</e1>, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1291	"CONCLUSIONS: <e1>Optic neuritis</e1> in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1292	"<e1>Multiple sclerosis-like disease</e1> secondary to <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1293	"PURPOSE: To describe <e1>bilateral optic neuritis</e1> that occurred as an adverse effect of recombinant and natural <e2>interferon alpha</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1294	"<e1>Acute abdomen</e1> due to endometriosis in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1295	"Acute abdomen due to <e1>endometriosis</e1> in a premenopausal woman taking <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1296	"We describe a premenopausal woman who, while having <e1>tamoxifen</e1> due to a diagnosis of in situ ductal carcinoma, developed <e2>endometriosis</e2> requiring surgery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1297	"A case report of fatal <e1>dapsone</e1>-induced <e2>agranulocytosis</e2> in an Indian mid-borderline leprosy patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1298	"<e1>Fatal agranulocytosis</e1> in an Indian male receiving 100mg of <e2>dapsone</e2> daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1299	"Various case reports concerning <e1>dapsone</e1>-induced <e2>agranulocytosis</e2> are reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1300	"<e1>Massive pulmonary embolism</e1> due to late-onset <e2>heparin</e2>-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1301	"Massive pulmonary embolism due to late-onset <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> following coronary artery bypass graft surgery: successful treatment with lepirudin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1302	"Most cardiac surgical patients have had previous exposure to <e1>heparin</e1> for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> (HIT) postoperatively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1303	"<e1>Acute psychosis</e1> associated with <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1304	"A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed <e1>acute psychosis</e1> 10 days after the administration of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1305	"The <e1>psychotic behavior</e1> resolved completely soon after the discontinuation of <e2>levetiracetam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1306	"CASES: "A" was an 8-year-old boy with attention deficit and chronic tic disorder who developed <e1>obsessive-compulsive symptoms</e1> within 2 weeks of starting <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1307	"<e1>Obsessive-compulsive symptoms</e1> suddenly emerged 10 days after starting <e2>risperidone</e2> and resolved within 3 days of discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1308	"<e1>Risperidone</e1>-induced <e2>obsessive-compulsive symptoms</e2> in two children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1309	"<e1>Proliferation of abnormal bone marrow histiocytes</e1>, an undesired effect of <e2>granulocyte macrophage-colony-stimulating factor</e2> therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1310	"Possible <e1>heart failure exacerbation</e1> associated with <e2>rosiglitazone</e2>: case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1311	"<e1>Enoxaparin</e1>-induced <e2>generalized exanthem</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1312	"Only one case of a <e1>generalized maculopapular rash</e1> with <e2>enoxaparin</e2> has been reported in Europe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1313	"To our knowledge, this is the first case reported in the English literature of a <e1>generalized exanthem</e1> due to subcutaneous injection of <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1314	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, <e2>aggression</e2>, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1315	"Behavioral side effects associated with <e1>clonazepam</e1> may include <e2>agitation</e2>, aggression, hyperactivity, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1316	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, <e2>hyperactivity</e2>, irritability, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1317	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, <e2>irritability</e2>, property destruction, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1318	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, <e2>property destruction</e2>, and temper tantrums."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1319	"Behavioral side effects associated with <e1>clonazepam</e1> may include agitation, aggression, hyperactivity, irritability, property destruction, and <e2>temper tantrums</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1320	"This report describes an individual with mental retardation who experienced <e1>behavioral exacerbation</e1> associated with <e2>clonazepam</e2> prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1321	"<e1>Cefuroxime</e1>-induced <e2>immune hemolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1322	"We report the first case of <e1>IHA</e1> associated with <e2>cefuroxime</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1323	"After 39 hours on <e1>argatroban</e1>, the infusion was stopped when minor <e2>bleeding</e2> was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1324	"Argatroban for <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> in hepato-renal failure and CVVHD."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1325	"<e1>Argatroban</e1> is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in <e2>hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1326	"OBJECTIVE: To report a case of significant <e1>hepatic and renal failure</e1> with the use of <e2>argatroban</e2> in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1327	"OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> (HIT) requiring continuous veno-veno hemodialysis (CVVHD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1328	"<e1>Schneiderian first-rank symptoms</e1> associated with <e2>fluvoxamine</e2> treatment: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1329	"The patient, a 28-year-old man suffering from panic disorder, developed several <e1>first-rank symptoms</e1> during <e2>fluvoxamine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1330	"This communication describes a patient who developed <e1>Schneiderian first-rank symptoms</e1> in the course of treatment with <e2>fluvoxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1331	"This finding suggests that <e1>fluvoxamine</e1> can precipitate <e2>Schneiderian first-rank symptoms</e2> in some susceptible patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1332	"We present a surprising case of a woman schizophrenic patient treated with <e1>clozapine</e1> suffering from <e2>EPS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1333	"<e1>Hyperpigmentation</e1> during <e2>interferon-alpha</e2> therapy for chronic hepatitis C virus infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1334	"These <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with interferon-alpha (<e2>IFN</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1335	"These <e1>skin lesions</e1> may be induced or worsened during antiviral therapy with <e2>interferon-alpha</e2> (IFN)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1336	"We describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1337	"We describe two dark-skinned patients who developed <e1>hyperpigmented skin</e1> and tongue lesions during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1338	"We describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with <e2>IFN</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1339	"We describe two dark-skinned patients who developed hyperpigmented skin and <e1>tongue lesions</e1> during combination therapy with IFN and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1340	"It is concluded that simultaneous administration of <e1>ciprofloxacin</e1> and tazobactam/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1341	"It is concluded that simultaneous administration of ciprofloxacin and tazobactam/<e1>piperacillin</e1> may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1342	"It is concluded that simultaneous administration of ciprofloxacin and <e1>tazobactam</e1>/piperacillin may cause marked <e2>thrombocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1343	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of <e2>ciprofloxacin</e2> and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1344	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam/<e2>piperacillin</e2> and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1345	"Since the <e1>thrombocyte count started to increase</e1> immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and <e2>tazobactam</e2>/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1346	"<e1>Thrombocytosis</e1> under <e2>ciprofloxacin</e2> and tazobactam/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1347	"<e1>Thrombocytosis</e1> under ciprofloxacin and tazobactam/<e2>piperacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1348	"<e1>Thrombocytosis</e1> under ciprofloxacin and <e2>tazobactam</e2>/piperacillin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1349	"<e1>Anaphylaxis</e1> after the injection of <e2>chymopapain</e2> occurs in about 1% of such cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1350	"Both patients suddenly became <e1>hypotensive</e1> after injection of <e2>chymopapain</e2> into a disk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1351	"<e1>Lethargy</e1> in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1352	"Lethargy in a newborn: <e2>lithium</e2> toxicity or lab error?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1353	"The newborn manifested a four day course of <e1>lethargy</e1> with unexplained high <e2>lithium</e2> levels in the adult toxic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1354	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1355	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1356	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, <e1>fever</e1>, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1357	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1358	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1359	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, <e1>leukopenia</e1> and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1360	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1361	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1362	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and <e1>positive anti-nuclear antibody</e1> (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1363	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1364	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1365	"A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, <e1>rash</e1>, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1366	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of <e2>carbamazepine</e2> (CBZ; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1367	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (<e2>CBZ</e2>; Tegretol) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1368	"A 14-year-old female developed <e1>systemic lupus erythematosus (SLE)-like symptoms</e1>, rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; <e2>Tegretol</e2>) used against benign Rolandic epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1369	"<e1>Carbamazepine</e1>-induced <e2>systemic lupus erythematosus-like disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1370	"The cases of <e1>CBZ</e1>-induced <e2>SLE</e2> reported in the literature were reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1371	"After four months, while receiving <e1>RH</e1>, he developed painful <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1372	"<e1>Gynaecomastia</e1> is a rarely reported adverse drug reaction due to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1373	"<e1>Isoniazid</e1> associated, painful, <e2>bilateral gynaecomastia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1374	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1375	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (HAT), recurrent arteriothromboses, and <e2>acute renal failure</e2> after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1376	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1377	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (<e2>HAT</e2>), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1378	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1379	"A patient suffering from <e1>heparin</e1>-associated thrombocytopenia (HAT), <e2>recurrent arteriothromboses</e2>, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1380	"A patient suffering from <e1>heparin</e1>-associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1381	"A patient suffering from <e1>heparin</e1>-associated <e2>thrombocytopenia</e2> (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard <e1>heparin</e1> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1382	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine <e2>Clexane</e2> (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1383	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins <e2>Fragmin</e2> and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1384	"By means of the in vitro heparin-induced <e1>platelet activation</e1> (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and <e2>Fraxiparin</e2> (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e1>platelet activation</e1> with the patient's serum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1385	"By means of the in vitro <e1>heparin</e1>-induced <e2>platelet activation</e2> (HIPA) assay it was shown that standard <e1>heparin</e1> and the LMW <e1>heparin</e1>s Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced <e2>platelet activation</e2> with the patient's serum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1386	"<e1>Heparin</e1>-associated <e2>thrombocytopenia</e2>: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1387	"<e1>Hemodynamic collapse</e1> following <e2>labetalol</e2> administration in preeclampsia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1388	"A patient with Parkinson's disease, initially treated with <e1>bromocriptine</e1> and subsequently with cabergoline, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1389	"A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with <e1>cabergoline</e1>, developed progressive <e2>pleuropulmonary abnormalities</e2> during the latter therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1390	"<e1>Pleuropulmonary changes</e1> during treatment of Parkinson's disease with a long-acting ergot derivative, <e2>cabergoline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1391	"Thus cabergoline may cause similar <e1>pleuropulmonary abnormalities</e1> to <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1392	"Thus <e1>cabergoline</e1> may cause similar <e2>pleuropulmonary abnormalities</e2> to bromocriptine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1393	"<e1>Acute myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1394	"<e1>Acute myopathy</e1> with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1395	"Acute myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with <e2>methylprednisolone</e2> and vecuronium."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1396	"Acute myopathy with selective <e1>degeneration of myosin filaments</e1> following status asthmaticus treated with methylprednisolone and <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1397	"<e1>Flaccid quadriparesis</e1> was noted after discontinuation of <e2>vecuronium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1398	"This entity is probably related to a combination of high doses of corticosteroids, <e1>vecuronium</e1> administration and metabolic abnormalities associated with <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1399	"A patient with ulcerative colitis developed skin pigmentation and <e1>diffuse pulmonary shadowing</e1> without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1400	"A patient with ulcerative colitis developed <e1>skin pigmentation</e1> and diffuse pulmonary shadowing without respiratory symptomatology, while taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1401	"<e1>Pulmonary infiltrates</e1> and skin pigmentation associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1402	"Pulmonary infiltrates and <e1>skin pigmentation</e1> associated with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1403	"<e1>Sulfasalazine</e1>-induced <e2>lung disorder</e2> is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1404	"<e1>Sulfasalazine</e1>-induced lung disorder is an extremely rare entity which must be considered in all <e2>ulcerative colitis</e2> patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1405	"Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all <e1>ulcerative colitis</e1> patients while on <e2>sulfasalazine</e2> therapy, despite the absence of pulmonary symptomatology."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1406	"Reversible <e1>sclerotic changes of lumbar spine and femur</e1> due to long-term oral <e2>isotretinoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1407	"Although an association between exposure to <e1>bleomycin</e1> and the development of <e2>scleroderma</e2> has been suspected, few cases are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1408	"Our series of 3 patients supports a causal connection between <e1>bleomycin</e1> and <e2>scleroderma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1409	"<e1>Scleroderma</e1> in association with the use of <e2>bleomycin</e2>: a report of 3 cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1410	"We describe the development of <e1>cutaneous scleroderma</e1> in 3 patients coincident with the use of <e2>bleomycin</e2> in low cumulative doses of less than 100 U."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1411	"A patient presented with <e1>dilated cardiomyopathy</e1> after many years of overusing an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1412	"<e1>Dilated cardiomyopathy</e1> associated with chronic overuse of an <e2>adrenaline</e2> inhaler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1413	"A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus (<e1>SLE</e1>) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1414	"A 21-year-old woman suffering from bipolar affective disorder developed <e1>systemic lupus erythematosus</e1> (SLE) with characteristic laboratory findings, 18 months after starting <e2>carbamazepine</e2> maintenance treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1415	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1416	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1417	"Although both the spontaneous occurrence of <e1>SLE</e1> and the psychosis as a sign of CNS involvement of <e1>SLE</e1> cannot be excluded, <e1>SLE</e1> could be considered as an adverse effect of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1418	"<e1>Carbamazepine</e1>-induced <e2>systemic lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1419	"<e1>SLE</e1> receded after withdrawal of <e2>carbamazepine</e2> and treatment with anti-inflammatory drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1420	"We report a case of <e1>acne fulminans</e1> occurring during treatment with <e2>13-cis-retinoic acid</e2> for cystic acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1421	"Carbamyl phosphate synthetase-1 deficiency discovered after <e1>valproic acid</e1>-induced <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1422	"<e1>Valproic acid</e1> induced <e2>coma</e2> is presented in an adult patient without a history of metabolic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1423	"<e1>Asterixis</e1> induced by <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1424	"In this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding <e2>carbamazepine</e2> (CBZ) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1425	"In this report we present four patients treated with a combination of different psychotropic drugs, in whom <e1>asterixis</e1> was triggered either by adding carbamazepine (<e2>CBZ</e2>) to a treatment regimen, or by increasing its dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1426	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1427	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1428	"We consider <e1>asterixis</e1> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1429	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e2>CBZ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1430	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e2>clozapine</e2> are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1431	"We consider asterixis to be an easily overlooked sign of <e1>neurotoxicity</e1>, which may occur even at low or moderate dosage levels, if certain drugs as <e2>lithium</e2> or clozapine are used in combination with CBZ."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1432	"<e1>Encephalopathy</e1> and seizures induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1433	"Encephalopathy and <e1>seizures</e1> induced by intravesical <e2>alum</e2> irrigations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1434	"<e1>Hemorrhagic cystitis</e1> is a significant toxic effect of <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1435	"We report four cases of encephalopathy coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1436	"We report four cases of <e1>encephalopathy</e1> coincident with elevated <e2>alum</e2>inum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with <e2>alum</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1437	"We report four cases of encephalopathy coincident with elevated <e1>alum</e1>inum levels as well as one patient who developed <e2>seizures</e2> while receiving continuous bladder irrigations with <e1>alum</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1438	"Seizure with <e1>hyponatremia</e1> in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1439	"<e1>Seizure</e1> with hyponatremia in a child prescribed <e2>desmopressin</e2> for nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1440	"We report a case of hyponatremia associated with a <e1>grand mal seizure</e1> in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1441	"We report a case of <e1>hyponatremia</e1> associated with a grand mal seizure in a 28 month-old child after intra-nasal <e2>desmopressin</e2> administration for high fluid intake with nocturnal enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1442	"This case report describes a 38-year-old male in whom <e1>SIADH</e1> was strongly suspected secondary to <e2>Tegretol</e2> therapy to control a seizure disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1443	"<e1>Gestational diabetes</e1> was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with <e2>norethisterone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1444	"However, follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging <e2>diabetes mellitus</e2> and impaired glucose tolerance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1445	"However, follow-up revealed that <e1>gestational diabetes</e1> when associated with <e2>norethisterone</e2> had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1446	"However, follow-up revealed that gestational diabetes when associated with <e1>norethisterone</e1> had a lesser risk of emerging diabetes mellitus and <e2>impaired glucose tolerance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1447	"In a single practice during the 21 years 1971-1991, the incidence of <e1>gestational diabetes</e1> in pregnancies in which <e2>norethisterone</e2> was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take <e2>norethisterone</e2> (137 of 1,684) (p < 0.001)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1448	"Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to <e1>norethisterone</e1>; all were cases of <e2>clitoral hypertrophy</e2> not requiring surgical treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1449	"<e1>Masculinization of a female fetus</e1> occurred in 5 of 39 (12.8%) exposed to <e2>norethisterone</e2>; all were cases of clitoral hypertrophy not requiring surgical treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1450	"<e1>Norethisterone</e1> in these 69 pregnancies accounted for 33.3% (5 of 15) cases of <e2>clitoral hypertrophy</e2> diagnosed in 100,756 consecutive births."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1451	"An adverse reaction to <e1>IFN</e1> was strongly suspected as the cause of <e2>CHF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1452	"Multiple myeloma complicated by <e1>congestive heart failure</e1> following first administration of <e2>recombinant alpha-interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1453	"Sixteen hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of congestive heart failure (<e2>CHF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1454	"Sixteen hours after the first administration of <e1>IFN</e1>, <e1>IFN</e1> was suspended by the symptoms of <e2>congestive heart failure</e2> (CHF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1455	"<e1>Neutrophilic eccrine hidradenitis</e1> mimicking cutaneous vasculitis in a lupus patient: a complication of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1456	"We report a case of <e1>NEH</e1> masquerading as cutaneous vasculitis in a woman receiving <e2>cyclophosphamide</e2> for lupus nephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1457	"<e1>Generalised cutaneous rash</e1> associated with <e2>ganciclovir</e2> therapy has rarely been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1458	"<e1>Skin rash</e1> and splinter hemorrhages from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1459	"Skin rash and <e1>splinter hemorrhages</e1> from <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1460	"Can roxithromycin and <e1>betamethasone</e1> induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1461	"Can <e1>roxithromycin</e1> and betamethasone induce <e2>acute pancreatitis</e2>? A case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1462	"CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and <e1>betamethasone</e1>, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1463	"CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with <e1>roxithromycin</e1> and betamethasone, manifested <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1464	"<e1>Renal tubular acidosis</e1> secondary to <e2>FK506</e2> in living donor liver transplantation: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1465	"RTA is one type of <e1>nephrotoxicity</e1> induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1466	"<e1>RTA</e1> is one type of nephrotoxicity induced by <e2>FK506</e2>, and it is reversible in mild cases when appropriately treated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1467	"Surgeons and physicians should therefore be aware of the potential for <e1>RTA</e1> to occur with <e2>FK506</e2> after any organ transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1468	"The mechanism of <e1>RTA</e1> induced by <e2>FK506</e2> has not yet been clearly elucidated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1469	"The treatment for acidosis and hyperkalaemia should be started as soon as <e1>RTA</e1> is diagnosed, and the dosage of <e2>FK506</e2> should also be reduced if possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1470	"We report a case of <e1>RTA</e1> secondary to <e2>FK506</e2> administration in liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1471	"A 74-year-old patient with idiopathic Parkinson's disease was evaluated for <e1>unintended sleep episodes</e1> that occurred after long-term treatment with 400 mg/day of <e2>L-dopa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1472	"<e1>L-DOPA</e1>-induced excessive <e2>daytime sleepiness</e2> in PD: a placebo-controlled case with MSLT assessment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1473	"The authors' results suggest that <e1>L-dopa</e1> may cause <e2>daytime somnolence</e2> in some patients with Parkinson's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1474	"<e1>Neurotoxicity</e1> of intrathecal <e2>methotrexate</e2>: MR imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1475	"We attribute the clinical and radiographic findings to <e1>cytotoxic edema</e1> secondary to intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1476	"We report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as left arm weakness and <e2>aphasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1477	"We report a case of intrathecal <e1>methotrexate</e1> neurotoxicity manifesting as <e2>left arm weakness</e2> and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1478	"We report a case of intrathecal <e1>methotrexate</e1> <e2>neurotoxicity</e2> manifesting as left arm weakness and aphasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1479	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1480	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential teratogenicity, and it has been implicated in <e2>Epstein's anomaly</e2>, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1481	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1482	"In this article <e1>lithium</e1> is not discussed, although there are a number of concerns about <e1>lithium</e1>'s potential <e2>teratogenicity</e2>, and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking <e1>lithium</e1>; as with other medications, however, the data have specific limitations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1483	"We present a case of a 20-year-old woman who ingested 900 mg of <e1>glyburide</e1> causing refractory <e2>hypoglycemia</e2> resistant to treatment with intravenous dextrose, glucagon, and diazoxide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1484	"Ocular <e2>ethambutol</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1485	"The most commonly recognized toxic effect of <e1>ethambutol</e1> is <e2>optic neuropathy</e2>, which generally is considered uncommon and reversible in medical literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1486	"This case and a review of the literature show the severe and unpredictable nature of <e2>ethambutol</e2> toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1487	"This case and a review of the literature show the severe and unpredictable nature of <e1>ethambutol</e1> toxicity and its potential for irreversible <e2>vision loss</e2> despite careful ophthalmologic monitoring."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1488	"We describe a 43-year-old man who developed signs and symptoms of <e1>bilateral optic neuropathy</e1> during treatment with <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1489	"The case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, <e2>brompheniramine</e2>, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1490	"The case history and toxicological findings of an infant <e1>fatality</e1> involving pseudoephedrine, brompheniramine, and <e2>dextromethorphan</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1491	"The case history and toxicological findings of an infant <e1>fatality</e1> involving <e2>pseudoephedrine</e2>, brompheniramine, and dextromethorphan are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1492	"Early <e1>overanticoagulation</e1> with <e2>acenocoumarol</e2> due to a genetic polymorphism of cytochrome P450 CYP2C9."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1493	"We report the case of a young healthy woman who presented an early <e1>overanticoagulation</e1> when receiving <e2>acenocoumarol</e2> for a first thromboembolic episode."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1494	"<e1>Colchicine</e1>-induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1495	"CONCLUSIONS: <e1>Colchicine</e1>-induced <e2>myopathy</e2> should be excluded in patients with FMF who present with generalized muscle weakness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1496	"DISCUSSION: <e1>Colchicine</e1>, the most important drug in treatment of FMF, can cause <e2>myopathy</e2> in patients with impaired renal and hepatic function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1497	"In our patient, an objective causality scale showed that therapeutic doses of <e1>colchicine</e1> for FMF were the definite cause of <e2>myopathy</e2>, even though his renal and hepatic function were normal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1498	"OBJECTIVE: To report a case of <e1>colchicine</e1>-induced <e2>myopathy</e2> in a teenager with familial Mediterranean fever (FMF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1499	"<e1>Angioedema</e1> and dysphagia caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1500	"Angioedema and <e1>dysphagia</e1> caused by contact allergy to inhaled <e2>budesonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1501	"We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1502	"We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and <e1>dysphagia</e1>, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1503	"We report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1504	"We report a 43-year-old woman who developed <e1>sore throat</e1>, swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1505	"We report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of budesonide spray (<e2>Budefat</e2>) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1506	"We report a 43-year-old woman who developed sore throat, <e1>swelling of the lips and oral cavity</e1> and dysphagia, 2 weeks after the use of <e2>budesonide</e2> spray (Budefat) for treatment of bronchial asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1507	"<e1>Infectious toxicity</e1> of <e2>dexamethasone</e2> during all remission-induction chemotherapy: report of two cases and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1508	"We describe the infectious toxicities experienced by the first two patients in our institution treated with <e1>dexamethasone</e1> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e1>dexamethasone</e1> arm of BFM 2000 and review the relevant literature that suggests an increased risk of <e2>infectious complications</e2> with <e1>dexamethasone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1509	"We describe the <e1>infectious toxicities</e1> experienced by the first two patients in our institution treated with <e2>dexamethasone</e2> (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the <e2>dexamethasone</e2> arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with <e2>dexamethasone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1510	"We describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--<e2>cytarabine</e2> and mitoxantrone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1511	"We describe a patient who developed <e1>NEH</e1> on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and <e2>mitoxantrone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1512	"A diagnosis of <e1>infliximab</e1>-induced <e2>lupus</e2> was made and the drug treatment was withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1513	"<e1>Infliximab</e1>-induced <e2>lupus</e2> in Crohn's disease: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1514	"This is the first case, to our knowledge, of onset of prolonged <e1>infliximab</e1>-induced <e2>lupus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1515	"Treatment with <e1>infliximab</e1> is known to produce an increase of autoantibodies (antinuclear antibodies, <e2>anti-double-stranded DNA</e2>), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1516	"Treatment with <e1>infliximab</e1> is known to produce an increase of autoantibodies (<e2>antinuclear antibodies</e2>, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1517	"Treatment with <e1>infliximab</e1> is known to produce an <e2>increase of autoantibodies</e2> (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1518	"<e1>Severe Raynaud's phenomenon</e1> with <e2>yohimbine</e2> therapy for erectile dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1519	"We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced <e1>worsening of Raynaud's phenomenon</e1> when using <e2>yohimbine</e2> for ED."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1520	"After initiation of topical <e1>vitamin D3</e1> ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the <e2>serum level of calcium and urinary excretion of calcium increased</e2> gradually."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1521	"Iatrogenic <e1>hypercalcemia</e1> due to vitamin D3 ointment (<e2>1,24(OH)2D3</e2>) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1522	"Iatrogenic <e1>hypercalcemia</e1> due to vitamin D3 ointment (1,24(OH)2D3) combined with <e2>thiazide</e2> diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1523	"Iatrogenic <e1>hypercalcemia</e1> due to <e2>vitamin D3</e2> ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1524	"The present case is the first report of <e1>hypercalcemia</e1> induced by vitamin D3 ointment and <e2>thiazide</e2> simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1525	"The present case is the first report of <e1>hypercalcemia</e1> induced by <e2>vitamin D3</e2> ointment and thiazide simultaneously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1526	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1527	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in hypercalciuria and <e2>hypercalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1528	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with <e1>tacalcitol</e1> ointment and thiazide, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1529	"We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and <e1>thiazide</e1>, respectively, resulting in <e2>hypercalciuria</e2> and hypercalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1530	"<e1>2-CdA</e1> typically causes a long-lasting state of <e2>immunodeficiency</e2> and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1531	"<e1>2-CdA</e1> typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of <e2>secondary neoplasms</e2> after its use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1532	"<e1>2-Chloro-deoxyadenosine</e1> induces durable complete remission in Castleman's disease but may accelerate its transformation to <e2>non-Hodgkin's lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1533	"Therefore, it is reasonable to conclude that: 1) <e1>2-CdA</e1> can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that <e1>2-CdA</e1> may accelerate the <e2>transformation of MCD to NHL</e2> cannot be ruled out."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1534	"Since this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (total AV-block) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1535	"Since this amount of FAB was insufficient to bind all <e1>DGTX</e1> present in the serum, cardiac <e1>DGTX</e1> toxicity (<e2>total AV-block</e2>) persisted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1536	"All patients had taken <e1>phenytoin</e1> for variable time periods (range 16-80 days; mean: 40) and were on the medication when the <e2>skin lesions</e2> first appeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1537	"<e1>Erythema multiforme</e1> associated with <e2>phenytoin</e2> and cranial radiation therapy: a report of three patients and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1538	"In conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (<e2>CyA</e2> or tacrolimus), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1539	"In conclusion, <e1>RSDS</e1> is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or <e2>tacrolimus</e2>), even under monotherapy or with a low steroid dose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1540	"<e1>Reflex sympathetic dystrophy syndrome</e1> in renal transplanted patients under immunosuppression with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1541	"We now present four cases of <e1>RSDS</e1> in kidney transplant recipients treated with <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1542	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in <e2>acute myopia</e2> and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1543	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and <e2>angle-closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1544	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and <e2>anterior chamber shallowing</e2>, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1545	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with <e2>ciliochoroidal effusion</e2> with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1546	"CONCLUSIONS: <e1>Topiramate</e1> may be associated with ciliochoroidal effusion with forward <e2>displacement of the lens-iris diaphragm</e2> and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1547	"Mechanism of <e1>topiramate</e1>-induced <e2>acute-onset myopia</e2> and angle closure glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1548	"Mechanism of <e1>topiramate</e1>-induced acute-onset myopia and <e2>angle closure glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1549	"METHODS: In an institutional practice setting, two women, aged 25 and 45, developed <e1>acute myopia</e1> after starting <e2>topiramate</e2> for epilepsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1550	"<e1>Doxycycline</e1>-induced <e2>photo-onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1551	"We present a case of <e1>photo-onycholysis</e1> in a patient treated with <e2>doxycycline</e2> for acne vulgaris."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1552	"A new type of <e1>minocycline</e1>-induced <e2>cutaneous hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1553	"<e1>Pigmentary disorders</e1> are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1554	"This fourth type of cutaneous <e1>minocycline</e1> <e2>hyperpigmentation</e2> may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1555	"Three distinct types of <e1>minocycline</e1>-induced <e2>cutaneous pigmentation</e2> have been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1556	"We report two patients with acne vulgaris with a fourth type of <e1>minocycline</e1>-induced <e2>cutaneous pigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1557	"<e1>Ciprofloxacin</e1>-induced <e2>toxic epidermal necrolysis</e2> in a patient with systemic lupus erythematosus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1558	"We report here a case of <e1>TEN</e1> after administration of <e2>ciprofloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1559	"A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed <e1>fever</e1> concurrent with the administration of <e2>amifostine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1560	"<e1>Amifostine</e1>-induced <e2>fever</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1561	"Patients receiving <e1>amifostine</e1> who develop only <e2>fever</e2> should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fever</e2>s of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1562	"Patients receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and <e2>fevers of neutropenia</e2>, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1563	"Patients receiving <e1>amifostine</e1> who develop only fever should be evaluated for an adverse drug reaction, as well as for <e2>sepsis</e2> and fevers of neutropenia, and it may be necessary to discontinue the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1564	"To our knowledge, this is the first case report that demonstrates the occurrence of <e1>fever</e1> with low-dose <e2>amifostine</e2> therapy without the manifestation of accompanying rash or hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1565	"<e1>Acute interstitial nephritis</e1> due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1566	"After 5 weeks of therapy, she stopped taking <e1>pantoprazole</e1> due to <e2>general malaise</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1567	"OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of <e1>acute interstitial nephritis</e1> (AIN) due to <e2>pantoprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1568	"The Naranjo probability scale suggests a highly probable relationship between <e1>AIN</e1> and <e2>pantoprazole</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1569	"There have been several reported cases of <e1>omeprazole</e1>-induced <e2>AIN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1570	"It was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1571	"It was highly suspected that <e1>finasteride</e1> was associated with the <e2>anterior subcapsular opacity on the lens</e2>, and the patient therefore discontinued use of <e1>finasteride</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1572	"<e1>Propecia</e1>-associated <e2>bilateral cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1573	"To the best of the authors' knowledge, this is the first reported case of <e1>Propecia</e1>-associated <e2>cataract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1574	"<e1>Scleromyxedema</e1> in a patient with multiple sclerosis and monoclonal gammopathy on <e2>interferon beta-1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1575	"CASE SUMMARY: Two children with attention deficit disorder treated with <e1>methylphenidate</e1> as a simple drug developed <e2>fixed drug eruption of the scrotum</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1576	"CONCLUSIONS: <e1>Fixed drug rash</e1> induced by <e2>methylphenidate</e2> is a possible but rare phenomenon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1577	"<e1>Fixed drug eruption of the scrotum</e1> due to <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1578	"OBJECTIVE: To report two cases of <e1>fixed drug eruption</e1> induced by <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1579	"<e1>Methotrexate</e1> <e2>pneumonitis</e2> in nonsurgical treatment of ectopic pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1580	"We describe a case of <e1>pneumonitis</e1> following local administration of <e2>methotrexate</e2> for nonsurgical termination of an ectopic pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1581	"BACKGROUND: The risk/benefit ratio of <e1>warfarin</e1> therapy changes in the over 75s, when <e2>haemorrhagic side-effects</e2> become more common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1582	"CASE REPORT: A woman of 80 years, on long-term <e1>warfarin</e1> therapy presented with an <e2>acute dissecting thoracic aortic aneurysm</e2>; on investigation the only precipitating factor found was an international normalised ratio of 4.8."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1583	"<e1>Warfarin</e1>-associated <e2>thoracic aortic dissection</e2> in an elderly woman."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1584	"<e1>Cutaneous vasculitis</e1> secondary to <e2>ramipril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1585	"Here we report <e1>ramipril</e1>-induced <e2>cutaneous vasculitis</e2> in a patient who required steroid therapy to control it."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1586	"<e1>Ramipril</e1>-induced <e2>cutaneous vasculitis</e2> is particularly rare and our case was atypical because the patient had tolerated lisinopril before."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1587	"CONCLUSION: This is, to our knowledge, the first report of <e1>severe myelopathy</e1> following accidental intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1588	"Neurological improvement and rehabilitation potential following <e1>toxic myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1589	"RESULTS: Evidence of neurological improvement and rehabilitation potential after <e1>severe myelopathy</e1> due to intrathecal injection of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1590	"STUDY DESIGN: Case report of a 31-year-old woman who presented with <e1>toxic myelopathy</e1> due to intrathecal administration of <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1591	"After <e1>infliximab</e1> treatment, additional sleep studies revealed an <e2>increase in the number of apneic events</e2> and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1592	"After <e1>infliximab</e1> treatment, additional sleep studies revealed an increase in the number of apneic events and <e2>SaO2 dips</e2> suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1593	"Thus, clinical recognition of <e1>sleep disordered breathing</e1> should be taken into account when rheumatoid arthritis patients are to be treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1594	"<e1>Hypernatraemia</e1> induced by sodium polystyrene sulphonate (<e2>Kayexalate</e2>) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1595	"<e1>Hypernatraemia</e1> induced by <e2>sodium polystyrene sulphonate</e2> (Kayexalate) in two extremely low birth weight newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1596	"We describe two ELBW infants affected by hyperkalaemia, treated with <e1>Kayexalate</e1>, who developed serious <e2>hypernatraemia</e2>, that has never been reported before in preterm infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1597	"<e1>Bull's-eye maculopathy</e1> associated with <e2>quinacrine</e2> therapy for malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1598	"CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe <e1>maculopathy</e1> indistinguishable from <e2>chloroquine</e2> <e1>maculopathy</e1> in certain patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1599	"CONCLUSIONS: Low dosages of <e1>quinacrine</e1> used for malaria prophylaxis can be associated with a delayed, <e2>severe maculopathy</e2> indistinguishable from chloroquine maculopathy in certain patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1600	"RESULTS: A patient developed a <e1>bilaterally symmetric bull's-eye maculopathy</e1> 45 years after taking <e2>quinacrine</e2> for 18 months as prophylaxis against malaria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1601	"The clinical picture was identical to that of <e1>chloroquine</e1> and hydroxy<e1>chloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1602	"The clinical picture was identical to that of chloroquine and <e1>hydroxychloroquine</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1603	"<e1>Cerebral infarcts</e1> in a pediatric patient secondary to <e2>phenylpropanolamine</e2>, a recalled medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1604	"<e1>Phenylpropanolamine</e1> (PPA) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1605	"Phenylpropanolamine (<e1>PPA</e1>) recently has been publicly implicated as a cause of stroke and other <e2>neurologic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1606	"<e1>Phenylpropanolamine</e1> (PPA) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1607	"Phenylpropanolamine (<e1>PPA</e1>) recently has been publicly implicated as a cause of <e2>stroke</e2> and other neurologic events."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1608	"The patient developed occipital infarcts and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1609	"The patient developed <e1>occipital infarcts</e1> and was found to have extremely elevated levels of <e2>PPA</e2> in his blood and dialysis fluid."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1610	"We present a case of <e1>stroke</e1> after <e2>PPA</e2> ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1611	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and <e2>hallucinations</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1612	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or <e2>mild headache</e2>, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1613	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of <e2>minor dizziness</e2> or mild headache, although rare occurrences of seizures and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1614	"Central nervous system effects secondary to <e1>ciprofloxacin</e1> treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of <e2>seizures</e2> and hallucinations have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1615	"<e1>Ciprofloxacin</e1>-induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1616	"DATA SYNTHESIS: A 49-year-old man developed symptoms of <e1>severe psychosis</e1> concomitant with <e2>ciprofloxacin</e2> (250 mg bid) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1617	"OBJECTIVE: To report a case of <e1>ciprofloxacin</e1>-induced <e2>psychosis</e2> and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1618	"<e1>Agranulocytosis</e1> induced by <e2>vancomycin</e2> in an ESRD patient on CAPD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1619	"<e1>Agranulocytosis</e1> is a rare adverse effect associated with prolonged <e2>vancomycin</e2> therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1620	"We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed <e1>vancomycin</e1>-induced <e2>agranulocytosis</e2> during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1621	"It is very likely that the <e1>dexamethasone</e1> used in the antiemetic drug regimen contributed to the development of <e2>osteonecrosis</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1622	"<e1>Osteonecrosis</e1> is a serious side effect of antiemetic treatment with <e2>dexamethasone</e2> and this serious complication should be incorporated in the current guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1623	"Patients should be informed about the risk of <e1>osteonecrosis</e1> when taking <e2>dexamethasone</e2> as an antiemetic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1624	"Development of <e1>Peyronie's disease</e1> during long-term <e2>colchicine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1625	"However here we reported two patients, presenting with <e1>PD</e1> during high dose <e2>colchicine</e2> treatment for familiar mediterranean fever (FMF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1626	"A patient developed <e1>cholestatic hepatitis</e1> while being treated with <e2>nitrofurantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1627	"A second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of <e2>furazolidone</e2> and nifuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1628	"A second episode of <e1>jaundice</e1> followed the intravaginal administration of a mixture of furazolidone and <e2>nifuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1629	"A case of <e1>phenobarbital</e1> <e2>exacerbation of a preexisting maladaptive behavior</e2> partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1630	"Ten years of behavioral data are presented to support the hypothesis that <e1>phenobarbital</e1> was exacerbating <e2>maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1631	"This profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> <e2>behavioral side effects</e2> or exacerbation of preexisting maladaptive behaviors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1632	"This profile should trigger a "red flag" as to the possibility of <e1>phenobarbital</e1> behavioral side effects or <e2>exacerbation of preexisting maladaptive behaviors</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1633	"<e2>Pilocarpine</e2> toxicity and the treatment of xerostomia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1634	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in <e2>bradycardia</e2>, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1635	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, <e2>mild hypotension</e2>, and muscarinic symptoms in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1636	"We report a case of unintentional overdose of oral <e1>pilocarpine</e1> tablets that resulted in bradycardia, mild hypotension, and <e2>muscarinic symptoms</e2> in a patient with Sjogren's syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1637	"Although combinations of <e1>belladonna</e1>, ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1638	"Although combinations of belladonna, <e1>ergotamine</e1>, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1639	"Although combinations of belladonna, ergotamine, and <e1>phenobarbital</e1> have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with <e2>anticonvulsant hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1640	"<e1>Anticonvulsant hypersensitivity syndrome</e1> associated with <e2>Bellamine S</e2>, a therapy for menopausal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1641	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (<e2>belladonna alkaloids</e2>; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1642	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking <e2>Bellamine S</e2> (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1643	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; <e2>ergotamine</e2>; phenobarbital) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1644	"We report a case of a previously healthy, postmenopausal woman who developed <e1>anticonvulsant hypersensitivity syndrome</e1> while taking Bellamine S (belladonna alkaloids; ergotamine; <e2>phenobarbital</e2>) for hot flashes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1645	"A case of <e1>heatstroke</e1> is reported in a 32-year-old man diagnosed with schizophrenia and on <e2>clozapine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1646	"<e1>Heat stroke</e1> in schizophrenia during <e2>clozapine</e2> treatment: rapid recognition and management."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1647	"<e1>Gemcitabine</e1>-related <e2>radiation recall</e2> preferentially involves internal tissue and organs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1648	"The authors also determined that their case of <e1>myositis</e1> developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1649	"The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1650	"The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of <e1>radiation recall</e1>, thereby bringing the number of patients who developed <e1>radiation recall</e1> to <e2>gemcitabine</e2> and were discussed in the current study to 13."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1651	"The literature search found 12 cases of <e1>radiation recall</e1> caused by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1652	"The majority of <e1>radiation recall reactions</e1> attributed to <e2>gemcitabine</e2> are reported to affect internal tissue or organs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1653	"<e1>Cystoid macular edema</e1> in a low-risk patient after switching from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1654	"<e1>Cystoid macular edema</e1> in a low-risk patient after switching from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1655	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1656	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and <e1>cystoid macula edema</e1> after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1657	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to <e1>bimatoprost</e1> 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1658	"METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from <e1>latanoprost</e1> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this <e2>cystoid macular edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1659	"METHODS: A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from latanoprost to <e2>bimatoprost</e2> 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1660	"METHODS: A 68-year-old man developed <e1>intense conjunctival hyperemia</e1> and cystoid macula edema after switching from <e2>latanoprost</e2> to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1661	"PURPOSE: To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from latanoprost to <e2>bimatoprost</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1662	"PURPOSE: To report a case of angiographically documented <e1>cystoid macula edema</e1> occurring after switching a pseudophakic patient from <e2>latanoprost</e2> to bimatoprost."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1663	"An immediate <e1>hemolytic reaction</e1> induced by repeated administration of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1664	"CASE REPORT: We report a patient who developed a <e1>DAT-positive hemolytic episode</e1> after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of <e2>oxaliplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1665	"Although neurotoxicity is a frequent complication of <e1>methotrexate</e1> therapy, <e2>fatal acute neurotoxicity</e2> is extremely uncommon, especially in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1666	"Although <e1>neurotoxicity</e1> is a frequent complication of <e2>methotrexate</e2> therapy, fatal acute <e1>neurotoxicity</e1> is extremely uncommon, especially in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1667	"Clinicians should be aware of the signs and symptoms of <e1>neurotoxicity</e1> during treatment, as well as predisposing factors that put patients receiving <e2>methotrexate</e2> at risk for neurotoxic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1668	"<e1>Fatal acute encephalomyelitis</e1> after a single dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1669	"The day after <e1>methotrexate</e1> administration, the patient complained of <e2>severe back pain</e2> and urinary retention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1670	"The day after <e1>methotrexate</e1> administration, the patient complained of severe back pain and <e2>urinary retention</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1671	"This patient rapidly progressed from mild neurotoxicity to <e1>fatal encephalopathy</e1> after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1672	"This patient rapidly progressed from <e1>mild neurotoxicity</e1> to fatal encephalopathy after one dose of intrathecal <e2>methotrexate</e2> during his third cycle of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1673	"We report a third case of a 6-week-old infant with Escherichia coli sepsis who received <e1>ampicillin</e1> and other antibiotics and subsequently developed <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1674	"One patient developed <e1>large intramural esophageal hematoma</e1> as a complication of <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1675	"<e1>Eosinophilic cystitis</e1> after bladder instillation with <e2>dimethyl sulfoxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1676	"We report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with <e2>dimethyl sulfoxide</e2> (DMSO) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1677	"We report the first case of an acute flare of <e1>eosinophilic cystitis</e1> in a 51-year-old woman after bladder instillation with dimethyl sulfoxide (<e2>DMSO</e2>) for presumed interstitial cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1678	"<e1>Acute dystonia</e1> during <e2>pegylated interferon alpha</e2> therapy in a case with chronic hepatitis B infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1679	"In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed <e1>acute dystonia</e1> soon after the first dose of <e2>pegylated interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1680	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, <e2>akathisia</e2>, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1681	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and <e2>depressive disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1682	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of <e2>neuropsychiatric symptoms</e2>, such as Parkinsonism, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1683	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as <e2>Parkinsonism</e2>, akathisia, seizure, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1684	"Therapy with <e1>IFN-alpha</e1> may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, <e2>seizure</e2>, and depressive disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1685	"A patient developed <e1>restless legs symptoms</e1> paralleling the course of interferon-alpha (<e2>IFN alpha</e2>) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1686	"A patient developed <e1>restless legs symptoms</e1> paralleling the course of <e2>interferon-alpha</e2> (IFN alpha) therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1687	"<e1>Restless legs syndrome</e1> due to <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1688	"<e1>Restless legs syndrome</e1> may thus be an adverse effect of <e2>IFN alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1689	"Many clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist <e2>naltrexone</e2> (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1690	"Many clinicians appear to be concerned about the potential <e1>hepatotoxicity</e1> of the opiate antagonist naltrexone (<e2>NTX</e2>) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1691	"We describe a heroin abuser in whom clinical and laboratory manifestations of <e1>acute hepatitis B and C</e1> appeared a few days after the insertion of a subcutaneous <e2>naltrexone</e2> implant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1692	"<e1>Sweet's syndrome</e1> associated with <e2>sargramostim</e2> (granulocyte-macrophage colony stimulating factor) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1693	"Sweet's syndrome is an <e1>acute febrile neutrophilic dermatosis</e1> that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1694	"<e1>Sweet's syndrome</e1> is an acute febrile neutrophilic dermatosis that is a known complication of the administration of <e2>filgrastim</e2>, a drug that causes increased neutrophil proliferation and differentiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1695	"We report a case of <e1>Sweet's syndrome</e1> in association with <e2>sargramostim</e2> treatment following chemotherapy for acute myelogenous leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1696	"Sudden cardiac death due to <e1>hypersensitivity myocarditis</e1> during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1697	"<e1>Sudden cardiac death</e1> due to hypersensitivity myocarditis during <e2>clozapine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1698	"The autopsy findings and a detailed medical history supported the conclusion that <e1>clozapine</e1>-induced <e2>hypersensitivity myocarditis</e2> was the most likely cause of death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1699	"The case concerns the <e1>sudden death</e1> of a 29-year-old male during <e2>clozapine</e2> therapy started 2 weeks before."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1700	"Purple glove syndrome, named for its distinctive <e1>purple discoloration</e1> and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1701	"<e1>Purple glove syndrome</e1>, named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1702	"Purple glove syndrome, named for its distinctive purple discoloration and <e1>swelling of the hands</e1> in the distribution of a glove, is an uncommon complication of intravenous <e2>phenytoin</e2> administration through small dorsal veins of the hands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1703	"The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of <e1>phenytoin</e1>, also termed <e2>purple glove syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1704	"The findings were judged to be consistent with <e1>soft-tissue injury</e1> associated with intravenous administration of <e2>phenytoin</e2>, also termed purple glove syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1705	"Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received <e1>levodopa</e1> and anti-cholinergic drugs and whose head had become almost <e2>completely bald</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1706	"A patient with monocular open-angle glaucoma had <e1>trichiasis</e1>, a condition associated with the use of a <e2>prostaglandin</e2> analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1707	"<e1>Increased lash length</e1>, thickness, and pigmentation are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1708	"Increased lash length, thickness, and <e1>pigmentation</e1> are well-documented side effects of <e2>prostaglandin</e2> analog glaucoma drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1709	"<e1>Trichiasis</e1> associated with <e2>prostaglandin</e2> analog use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1710	"<e1>Fatal pulmonary fibrosis</e1> associated with <e2>BCNU</e2>: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1711	"<e1>Pulmonary fibrosis</e1> is a severe complication associated with bis-chloronitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1712	"<e1>Pulmonary fibrosis</e1> is a severe complication associated with <e2>bis-chloronitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1713	"These novel findings may offer specific therapeutic targets in the treatment of <e1>BCNU</e1>-associated <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1714	"We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of <e1>BCNU</e1>-related <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1715	"We report here a 26-year-old female with diffuse large B-cell lymphoma who died of <e1>severe pulmonary fibrosis</e1> 81 days after the administration of high-dose <e2>BCNU</e2> (600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1716	"<e1>Dorzolamide</e1>-induced <e2>choroidal detachment</e2> in a surgically untreated eye."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1717	"METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a <e1>choroidal detachment</e1> 12 hours after initiation of therapy with <e2>dorzolamide</e2> eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1718	"We document the abrupt development of an extensive <e1>choroidal detachment</e1> after initiation of <e2>dorzolamide</e2> therapy in a surgically untreated eye with primary open-angle glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1719	"<e1>Deepening of lid sulcus</e1> from topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1720	"In each of the three reported patients, <e1>alteration of eyelid appearance</e1> with deepening of the lid sulcus was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1721	"In each of the three reported patients, alteration of eyelid appearance with <e1>deepening of the lid sulcus</e1> was evident as the result of topical <e2>bimatoprost</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1722	"<e1>Lichen planus</e1> induced by <e2>hepatitis B vaccination</e2>: a new case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1723	"Case report: <e1>life-threatening hypoglycaemia</e1> associated with <e2>sulfadoxine-pyrimethamine</e2>, a commonly used antimalarial drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1724	"In this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1725	"In this report, we present a case of <e1>hypoglycaemic coma</e1> associated with <e2>SP</e2>, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of <e2>SP</e2> increases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1726	"Initial treatment with <e1>heparin</e1> was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by <e2>fatal intracerebral haemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1727	"<e1>Extensive forearm deep venous thrombosis</e1> following a severe <e2>infliximab</e2> infusion reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1728	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1729	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (<e2>IIR</e2>), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1730	"Here we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1731	"Here we describe a patient with Crohn's disease who developed a severe <e2>infliximab</e2> infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of <e2>infliximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1732	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1733	"Here we describe a patient with Crohn's disease who developed a severe <e1>infliximab</e1> infusion reaction (IIR), complicated 1 day later by <e2>severe swelling of the forearm and hand ipsilateral</e2> to the site of <e1>infliximab</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1734	"The site of thrombosis and the chronological relationship with the IIR implicates a <e1>hypersensitivity</e1> to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1735	"The site of thrombosis and the chronological relationship with the <e1>IIR</e1> implicates a hypersensitivity to <e2>infliximab</e2> in the causation of the venous thrombosis in this case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1736	"The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to <e1>infliximab</e1> in the causation of the <e2>venous thrombosis</e2> in this case."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1737	"After 3- to 13-month period of therapy without <e1>indapamide</e1>, glucose levels of all patients decreased and <e2>diabetes</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1738	"After stopping <e1>indapamide</e1>, <e2>glucose tolerance impairing</e2> may be reversed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1739	"CONCLUSION: Therapy with <e1>indapamide</e1> may induce <e2>diabetes</e2> in essential hypertension patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1740	"OBJECTIVE: To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1741	"OBJECTIVE: To study therapy with <e1>indapamide</e1> impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of <e2>diabetes</e2> induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1742	"OBJECTIVE: To study therapy with <e1>indapamide</e1> <e2>impairing carbohydrate metabolism</e2> in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by <e1>indapamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1743	"Possible induction of <e1>diabetes</e1> by treatment of hypertension with <e2>indapamide</e2> (with four case reports)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1744	"RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and <e1>fosinopril</e1> (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1745	"RESULTS: After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1746	"RESULTS: After 4- to 14-month period of therapy with the combination of <e1>indapamide</e1> (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with <e1>indapamide</e1> (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of <e2>diabetes</e2> diagnoses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1747	"CONTEXT: Previous investigators have reported <e1>discrepancies between hematologic, marrow morphologic, and cytogenetic responses</e1> to <e2>imatinib mesylate</e2> among patients with chronic myeloid leukemia (CML)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1748	"Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to <e1>blast crisis</e1> at 7 to 10 months of <e2>imatinib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1749	"In addition to disease refractoriness, rare instances of disease progression from chronic phase to <e1>blast crisis</e1> during <e2>imatinib</e2> therapy have recently been anecdotally reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1750	"OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to <e1>blast crisis</e1> while taking <e2>imatinib</e2> and to perform a review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1751	"Our findings suggest that significant <e1>progression of marrow reticulin fibrosis</e1> during <e2>imatinib</e2> therapy can be an indicator for a return or progression of CML and, in some patients with CML, <e2>imatinib</e2> may promote cytogenetic clonal evolution, resulting in a poor response to treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1752	"Progression of chronic myeloid leukemia to <e1>blast crisis</e1> during treatment with <e2>imatinib mesylate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1753	"Easily reversible hypoxemia and <e1>hypotension</e1> induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1754	"Easily reversible <e1>hypoxemia</e1> and hypotension induced by <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1755	"In this paper we report a case of <e1>nimodipine</e1> overdosage resulting in prolonged hypotension and <e2>hypoxemia</e2>, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1756	"In this paper we report a case of <e1>nimodipine</e1> overdosage resulting in <e2>prolonged hypotension</e2> and hypoxemia, which was successfully treated with calcium gluconate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1757	"<e1>Refractory hypoglycemia</e1> from <e2>ciprofloxacin</e2> and glyburide interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1758	"<e1>Refractory hypoglycemia</e1> from ciprofloxacin and <e2>glyburide</e2> interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1759	"We present a case of a diabetic patient taking glyburide who was prescribed <e1>ciprofloxacin</e1> and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1760	"We present a case of a diabetic patient taking <e1>glyburide</e1> who was prescribed ciprofloxacin and developed <e2>prolonged hypoglycemia</e2>, which persisted for over 24 hours."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1761	"<e2>Aminophylline</e2> hypersensitivity apparently due to ethylenediamine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1762	"<e1>Aminophylline hypersensitivity</e1> apparently due to <e2>ethylenediamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1763	"We present a case of ethylenediamine-induced <e1>delayed hypersensitivity reaction</e1> in a 46-year-old woman who received parenteral <e2>aminophylline</e2> for an acute asthma exacerbation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1764	"We present a case of <e1>ethylenediamine</e1>-induced <e2>delayed hypersensitivity reaction</e2> in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1765	"<e1>L-asparaginase</e1>-induced pancreatitis is an uncommon but potential <e2>lethal complication</e2> of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1766	"<e1>L-asparaginase</e1>-induced <e2>pancreatitis</e2> is an uncommon but potential lethal complication of the treatment of leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1767	"<e1>L-asparaginase</e1>-induced <e2>severe necrotizing pancreatitis</e2> successfully treated with percutaneous drainage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1768	"Most cases of <e1>pancreatitis</e1> associated with <e2>L-asparaginase</e2> toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1769	"<e1>Pancreatitis</e1> has been noted to be a complication in 2-16% of patients undergoing treatment with <e2>L-asparaginase</e2> for a variety of pediatric neoplasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1770	"We present a pediatric patient with leukemia and a severe, <e1>L-asparaginase</e1>-induced <e2>necrotizing pancreatitis</e2>, treated successfully with percutaneous drainage used to flush the infected necrotic parts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1771	"<e1>Disulfiram</e1>-induced <e2>fulminant hepatic failure</e2> in an active duty soldier."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1772	"<e1>Fulminant hepatic failure</e1> is a rare complication of <e2>disulfiram</e2> treatment for alcoholism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1773	"This case describes <e1>fulminant hepatic failure</e1> in a patient taking <e2>disulfiram</e2> with no previous liver disease and report of being compliant with alcohol abstinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1774	"<e1>Tiagabine</e1> overdose causes an <e2>unusual array of neurological symptoms</e2>, many similar to reported adverse effects during therapeutic use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1775	"A case of <e1>sideroblastic anemia</e1> is presented in a patient with a left ventricular assist device drive-line infection who was receiving <e2>linezolid</e2>, an antibiotic used for serious infections with gram-positive organisms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1776	"As <e1>linezolid</e1> has been shown to have <e2>hematologic side effects</e2>, blood count monitoring is recommended in patients receiving this drug for long-term therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1777	"<e1>Sideroblastic anemia</e1> due to <e2>linezolid</e2> in a patient with a left ventricular assist device."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1778	"In this report, two newborns with congenital heart anomalies demonstrated the <e1>harlequin color change</e1>, one whose skin findings showed a course related to the dose of systemic <e2>prostaglandin E1</e2>, suggesting a possible association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1779	"The <e1>harlequin color change</e1> and association with <e2>prostaglandin E1</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1780	"<e1>Acute renal insufficiency</e1> is known to occur in patients who are taking <e2>ciprofloxacin</e2>, particularly the elderly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1781	"<e1>Ciprofloxacin</e1>-induced <e2>renal insufficiency</e2> in cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1782	"Multiple mechanisms for <e1>ciprofloxacin</e1>-induced <e2>nephrotoxicity</e2> have been proposed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1783	"We report two young patients with cystic fibrosis who presented with <e1>acute renal insufficiency</e1> after 2-3 weeks of oral <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1784	"Sensory neuropathy revealing <e1>necrotizing vasculitis</e1> during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1785	"<e1>Sensory neuropathy</e1> revealing necrotizing vasculitis during <e2>infliximab</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1786	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to <e2>necrotizing vasculitis</e2> in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1787	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with <e2>peripheral neuropathy</e2> due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1788	"We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom <e1>infliximab</e1> therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to <e2>progression of preexisting mononeuritis multiplex</e2> in the other."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1789	"<e1>Progressive anemia</e1> following combination therapy with <e2>interferon-alpha</e2> and interleukin-2 in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1790	"<e1>Progressive anemia</e1> following combination therapy with interferon-alpha and <e2>interleukin-2</e2> in a patient with metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1791	"We report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving IL-2 plus <e2>IFN-alpha</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1792	"We report a case of <e1>severe anemia</e1>, which responded well to steroid therapy, in a patient receiving <e2>IL-2</e2> plus IFN-alpha for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1793	"An objective causality assessment indicated a probable relationship between <e1>clotting abnormality</e1> and <e2>warfarin</e2> administration, although the degree of elevation of the INR was unusual in the light of the daily <e2>warfarin</e2> dose and duration of its exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1794	"Based on the clinical status of the patient, it was suspected that several conditions contributed to the <e1>abnormal hypersensitivity</e1> to <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1795	"Despite the low dosage of <e1>warfarin</e1>, international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and <e2>bleeding symptoms</e2> concurrently developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1796	"In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid <e1>fatal haemorrhage</e1> after initiating <e2>warfarin</e2> therapy regardless of the dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1797	"Unusual <e1>hypersensitivity</e1> to <e2>warfarin</e2> in a critically ill patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1798	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, foscarnet, and <e2>cidofovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1799	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with ganciclovir, <e2>foscarnet</e2>, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1800	"We report an allogeneic bone marrow transplant recipient who developed <e1>CMV infection</e1> refractory to sequential therapy with <e2>ganciclovir</e2>, foscarnet, and cidofovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1801	"<e1>5-fluorouracil</e1> (5-FU)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1802	"5-fluorouracil (<e1>5-FU</e1>)-associated <e2>peripheral neuropathy</e2> is an uncommon event."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1803	"During analysis of 28 patients receiving <e1>CAP</e1> with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with <e2>peripheral neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1804	"Knowledge regarding potential adverse effects of <e1>CAP</e1> is paramount and dose modification is indicated with development of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1805	"<e1>Neurologic symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1806	"<e1>Neurologic symptoms</e1> resolved after stopping <e2>CAP</e2> for 4 weeks in Patient A, with no recurrence after reinitiating <e2>CAP</e2> alone at 2000 mg/m2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1807	"Patient A reported right leg weakness (<e1>foot drop</e1>) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1808	"Patient A reported <e1>right leg weakness</e1> (foot drop) during week 4 of <e2>CAP-XRT</e2> (1600 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1809	"Patient B developed <e1>perioral and upper extremity paresthesias</e1> during the fourth cycle of <e2>CAP</e2> alone (2500 mg/m2)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1810	"<e1>Peripheral neuropathy</e1> associated with <e2>capecitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1811	"We conclude <e1>peripheral neuropathy</e1> with <e2>5-FU</e2> is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1812	"<e1>Severe hypo-alpha-lipoproteinemia</e1> during treatment with <e2>rosiglitazone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1813	"We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound <e1>reduction in plasma HDL cholesterol and apolipoprotein AI levels</e1> soon after the initiation of <e2>rosiglitazone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1814	"Severe leukopenia associated with <e1>mild hepatotoxicity</e1> in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1815	"<e1>Severe leukopenia</e1> associated with mild hepatotoxicity in an HIV carrier treated with <e2>nevirapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1816	"We report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2>-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1817	"We report an HIV-infected woman who developed mild <e1>leukopenia</e1> as the first sign of a <e2>nevirapine</e2>-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe <e1>leukopenia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1818	"We report an HIV-infected woman who developed mild leukopenia as the first sign of a <e1>nevirapine</e1>-related adverse event, which was followed by <e2>skin and hepatic toxicity</e2> associated with a more severe leukopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1819	"In all cases, drugs in addition to <e1>quetiapine</e1> were detected, but in cases #1 and #2, the cause of <e2>death</e2> was considered to be a <e1>quetiapine</e1> overdose and the other drugs were not considered to be contributory."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1820	"These cases were chosen for study because they were all <e1>deaths</e1> as a result of suicidal ingestion of drugs in which <e2>quetiapine</e2> was considered a significant factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1821	"We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which <e1>suicidal overdose deaths</e1> were associated with <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1822	"After approximately two weeks of <e1>sertraline</e1> treatment he noted an <e2>intense itching sensation</e2> in his scalp after eating a piece of chocolate cake."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1823	"<e1>Itch</e1> and skin rash from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1824	"<e1>Itch</e1> and skin rash from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1825	"Itch and <e1>skin rash</e1> from chocolate during <e2>fluoxetine</e2> and sertraline treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1826	"Itch and <e1>skin rash</e1> from chocolate during fluoxetine and <e2>sertraline</e2> treatment: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1827	"<e1>Pulmonary lymphohistiocytic reactions</e1> temporally related to <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1828	"This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of <e1>pulmonary signs and symptoms with alveolar infiltrates</e1> temporally related to the institution of <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1829	"<e1>Paradoxical cerebral cortical hyperexcitability</e1> following <e2>flupirtine</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1830	"We report the case of a patient with <e1>increased cerebral cortical excitability</e1> following intoxication with <e2>flupirtine</e2>, a centrally acting analgesic and antispastic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1831	"AIM: Report of a case of a woman patient who developed <e1>celiac disease</e1> after <e2>pegylated interferon alpha-2a</e2> and ribavirin use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1832	"AIM: Report of a case of a woman patient who developed <e1>celiac disease</e1> after pegylated interferon alpha-2a and <e2>ribavirin</e2> use for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1833	"<e1>Celiac disease</e1> onset after <e2>pegylated interferon</e2> and ribavirin treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1834	"<e1>Celiac disease</e1> onset after pegylated interferon and <e2>ribavirin</e2> treatment of chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1835	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1836	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed progressive malaise and <e2>anemia</e2> 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1837	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving <e1>pegylated interferon alpha-2a</e1> and ribavirin for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1838	"PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and <e1>ribavirin</e1> for 6 months, developed <e2>progressive malaise</e2> and anemia 6 months after the end of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1839	"We present two cases of <e1>anaphylaxis</e1> under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist <e2>metaraminol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1840	"In this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1841	"In this article, we describe another case of subcutaneous changes following repeated <e1>glatiramer acetate</e1> injection, presented as <e2>localized panniculitis</e2> in the area around the injection sites, in a 46-year-old female patient who was treated with <e1>glatiramer acetate</e1> for 18 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1842	"In this article, we describe another case of <e1>subcutaneous changes</e1> following repeated <e2>glatiramer acetate</e2> injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with <e2>glatiramer acetate</e2> for 18 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1843	"Localized panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1844	"Localized panniculitis and subsequent <e1>lipoatrophy</e1> with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1845	"<e1>Localized panniculitis</e1> and subsequent lipoatrophy with subcutaneous glatiramer acetate (<e2>Copaxone</e2>) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1846	"<e1>Localized panniculitis</e1> and subsequent lipoatrophy with subcutaneous <e2>glatiramer acetate</e2> (Copaxone) injection for the treatment of multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1847	"In a postoperative patient with pre-existent myasthenia gravis, oral <e1>verapamil</e1> caused a marked <e2>exacerbation in myasthenic weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1848	"In four patients, thrombosis occurred 2-45 days after severe <e1>hepatic veno-occlusive disease</e1> (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1849	"In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (<e1>HVOD</e1>) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1850	"In four patients, <e1>thrombosis</e1> occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1851	"PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e1>busulfan</e1> and to be associated with <e2>HVOD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1852	"<e1>PVT</e1> during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing <e2>busulfan</e2> and to be associated with HVOD."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1853	"Here, we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon</e2> alpha treatment, probably induced by the immunomodulatory effects of <e2>interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1854	"Here, we describe a case of <e1>Vogt-Koyanagi-Harada disease</e1> occurring 4 months after the start of <e2>interferon alpha</e2> treatment, probably induced by the immunomodulatory effects of interferon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1855	"Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1856	"<e1>Retinal abnormalities</e1>, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1857	"Retinal abnormalities, including <e1>retinal hemorrhage</e1> and "cotton-wool" spots, often occur within the first 8 weeks in the course of <e2>interferon</e2> therapy in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1858	"<e1>Vogt-Koyanagi-Harada disease</e1> occurring during <e2>interferon alpha</e2> therapy for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1859	"<e1>Acute hepatic failure</e1> is a rare and potentially lethal complication of <e2>propylthiouracil</e2> (PTU) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1860	"<e1>Acute hepatic failure</e1> is a rare and potentially lethal complication of propylthiouracil (<e2>PTU</e2>) use for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1861	"After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with <e1>PTU</e1>-induced <e2>fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1862	"Successful treatment of hyperthyroidism with amiodarone in a patient with <e1>propylthiouracil</e1>-induced <e2>acute hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1863	"We present a 20-year-old woman with Basedow-Graves' disease who developed <e1>PTU</e1>-induced <e2>fulminant hepatitis</e2>, which progressed to acute hepatic failure with grade III hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1864	"<e1>Epstein-Barr virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on <e2>methotrexate</e2> and rofecoxib: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1865	"<e1>Epstein-Barr virus-associated lymphoproliferative disorder</e1> in a patient with rheumatoid arthritis on methotrexate and <e2>rofecoxib</e2>: idiosyncratic reaction or pharmacogenetics?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1866	"<e1>Methotrexate</e1> (MTX) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in MTX-treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1867	"Methotrexate (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1>-treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1868	"Methotrexate (<e1>MTX</e1>) is a commonly used second line agent for RA, and there have been several recent reports of <e2>Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder</e2> in <e1>MTX</e1>-treated RA patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1869	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including <e2>acute renal failure</e2>, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1870	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, <e2>diarrhea</e2>, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1871	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, <e2>elevated liver transaminases</e2>, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1872	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, <e2>jaundice</e2>, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1873	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, <e2>mucosal ulcerations</e2>, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1874	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, <e2>pancytopenia</e2>, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1875	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and <e2>pyrexia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1876	"Previous studies have demonstrated the interaction of <e1>MTX</e1> and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, <e2>vomiting</e2>, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1877	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the <e2>EBV-associated lymphoproliferative disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1878	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced <e2>hematopoietic toxicity</e2> and immunosuppression causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1879	"We hypothesize that decreased renal elimination of <e1>MTX</e1> induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and <e2>immunosuppression</e2> causing the EBV-associated lymphoproliferative disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1880	"OBSERVATIONS: We observed <e1>aggravation and spreading of a psoriatic plaque</e1> when treated topically with the toll-like receptor (TLR) 7 agonist <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1881	"<e1>Psoriasis</e1> triggered by toll-like receptor 7 agonist <e2>imiquimod</e2> in the presence of dermal plasmacytoid dendritic cell precursors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1882	"Since <e1>imiquimod</e1> induces <e2>large amounts of type I interferon production</e2> from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1883	"The <e1>exacerbation of psoriasis</e1> was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1884	"<e1>Vision declined</e1> after treatment with <e2>methylprednisolone</e2>, after which fundus examination became consistent with progressive outer retinal necrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1885	"Allergic side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1886	"Allergic side effects of <e1>AZA</e1> are rare, and reported <e2>allergic skin eruptions</e2> from <e1>AZA</e1> are very limited in Japan."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1887	"DLST is a good diagnostic tool for <e1>AZA</e1> <e2>allergy</e2>, especially for severe drug <e2>allergy</e2> cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1888	"<e1>Drug eruption</e1> caused by <e2>azathioprine</e2>: value of using the drug-induced lymphocytes stimulation test for diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1889	"We report <e1>AZA</e1>-induced <e2>drug eruption</e2> that developed in two cases of systemic scleroderma with polymyositis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1890	"<e1>Tardive dyskinesia</e1> in 2 patients treated with <e2>ziprasidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1891	"Two of our patients developed <e1>TD</e1> after 23 months and 34 months of <e2>ziprasidone</e2> monotherapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1892	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing <e2>extrapyramidal symptoms</e2>, including tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1893	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1894	"<e1>Ziprasidone</e1> is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1895	"<e1>Asthenozoospermia</e1>: possible association with long-term exposure to an anti-epileptic drug of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1896	"The patient was found to have <e1>no motile sperm</e1> with a normal sperm count, while taking a dose of 400 mg/day of <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1897	"<e1>Scrotal ulceration</e1> induced by all-trans <e2>retinoic acid</e2> in a patient with acute promyelocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1898	"The <e1>ulcer</e1> did not respond to antibiotic treatment and healed shortly after withholding <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1899	"We report the development of <e1>scrotal ulcer</e1> in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with <e2>ATRA</e2> at a dose of 40 mg orally twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1900	"A case of <e1>clozapine</e1>-induced <e2>tonic-clonic seizures</e2> managed with valproate: implications for clinical care."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1901	"Following discontinuation of <e1>clozapine</e1>, she was rechallenged and again was observed to have <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1902	"These findings suggest that <e1>clozapine</e1>-induced <e2>seizures</e2> can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of <e2>seizures</e2> and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1903	"We describe a case of <e1>clozapine</e1>-induced <e2>seizures</e2> in a patient with treatment-resistant schizophrenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1904	"CONCLUSIONS: Symptoms and pathologic changes of <e1>colitis</e1> are associated with exposure to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1905	"OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop <e1>lower gastrointestinal symptoms</e1> when exposed to <e2>rofecoxib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1906	"RESULTS: Three patients who developed symptoms of inflammatory bowel disease (<e1>IBD</e1>) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1907	"RESULTS: Three patients who developed symptoms of <e1>inflammatory bowel disease</e1> (IBD) during <e2>rofecoxib</e2> exposure are described along with pathology findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1908	"After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1909	"After administration of Oxybutynin concomitantly with an increase in the dose of <e1>Dantrolene</e1>, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1910	"After administration of <e1>Oxybutynin</e1> concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of <e2>Carbamazepine intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1911	"<e2>Carbamazepine</e2> toxicity following Oxybutynin and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1912	"<e1>Carbamazepine toxicity</e1> following Oxybutynin and <e2>Dantrolene</e2> administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1913	"<e1>Carbamazepine toxicity</e1> following <e2>Oxybutynin</e2> and Dantrolene administration: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1914	"OBJECTIVE: To report a case of <e2>Carbamazepine</e2> toxicity following the administration of Oxybutynin and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1915	"OBJECTIVE: To report a case of <e1>Carbamazepine toxicity</e1> following the administration of Oxybutynin and <e2>Dantrolene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1916	"OBJECTIVE: To report a case of <e1>Carbamazepine toxicity</e1> following the administration of <e2>Oxybutynin</e2> and Dantrolene."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1917	"To the best of our knowledge, this is the first reported patient with <e1>captopril</e1>-induced <e2>pemphigus</e2> in whom no new lesions developed after subsequent treatment with enalapril."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1918	"We report a case of drug-induced <e1>pemphigus</e1> caused by an angiotensin-converting enzyme inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1919	"<e1>Neuropathy</e1> is a significant side effect of <e2>thalidomide</e2> therapy, which may limit its clinical use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1920	"<e1>Thalidomide</e1> <e2>neuropathy</e2> in childhood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1921	"<e1>Thalidomide</e1> <e2>neuropathy</e2> is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1922	"<e1>Thalidomide</e1> neuropathy is often associated with <e2>proximal weakness</e2> and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1923	"<e1>Thalidomide</e1> was withdrawn from world markets in 1961 following recognition of its <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1924	"We report four cases of <e1>sensorimotor axonal neuropathy</e1> in children aged 10-15 years, treated with <e2>thalidomide</e2> for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1925	"<e1>Cerebral edema</e1> associated with <e2>Gliadel</e2> wafers: two case studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1926	"Following are two clinical case reports demonstrating profound <e1>cerebral edema</e1> associated with implantation of <e2>Gliadel</e2> wafers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1927	"While the introduction of <e1>carmustine</e1> wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1928	"While the introduction of carmustine wafers (<e1>Gliadel</e1> wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant <e2>cerebral edema</e2> is a potential adverse effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1929	"<e1>Cis-retinoic acid</e1> (RA) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1930	"Cis-retinoic acid (<e1>RA</e1>) may further increase the risk of developing <e2>BMTN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1931	"It is likely that <e1>RA</e1> contributed to the <e2>deterioration in renal function</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1932	"<e1>Retinoic acid</e1> may increase the risk of <e2>bone marrow transplant nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1933	"The occurrence of <e1>BMTN</e1> in two children treated with <e2>RA</e2> in our unit is unlikely to be coincidental."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1934	"He developed a late <e1>secondary infection</e1> in some sites treated with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1935	"A 64-year-old man with schizophrenia developed <e1>myoclonic jerks</e1> when given higher doses of <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1936	"<e1>Quetiapine</e1>-induced <e2>myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1937	"We report a case of <e1>myoclonus</e1> induced by <e2>quetiapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1938	"Treatment-related <e1>myelodysplastic syndrome</e1> after <e2>temozolomide</e2> for recurrent high-grade glioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1939	"We report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with <e2>temozolomide</e2> (TMZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1940	"We report a 44-year-old woman with t-MDS (<e1>refractory anemia with excess blasts</e1>) following treatment of recurrent anaplastic astrocytoma with temozolomide (<e2>TMZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1941	"Typically, drug-induced <e1>neutropenia</e1> occurs in a patient receiving a semisynthetic <e2>penicillin</e2> for two weeks or more."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1942	"<e1>Livedo reticularis</e1> associated with <e2>interferon alpha</e2> therapy in two melanoma patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1943	"These cases highlight the occurrence of <e1>livedo reticularis</e1> as an uncommon side-effect of <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1944	"We report two patients who developed intense <e1>livedo reticularis</e1> clearly related to the administration of <e2>interferon alpha 2b</e2> as an adjuvant therapy for melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1945	"CONCLUSION: This rare case of <e1>PTU</e1>-induced <e2>ANCA-associated vasculitis</e2> manifested with ototoxicity in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1946	"CONCLUSION: This rare case of <e1>PTU</e1>-induced ANCA-associated vasculitis manifested with <e2>ototoxicity</e2> in combination with systemic involvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1947	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of <e1>propylthiouracil</e1> (PTU)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1948	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil (<e1>PTU</e1>)-induced <e2>antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1949	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of <e2>propylthiouracil</e2> (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1950	"OBJECTIVE: To report the case of a young woman with Graves' disease in whom <e1>ototoxicity</e1> developed because of propylthiouracil (<e2>PTU</e2>)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1951	"<e1>Propylthiouracil</e1>-induced sensorineural hearing loss associated with <e2>antineutrophil cytoplasmic antibodies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1952	"<e1>Propylthiouracil</e1>-induced <e2>sensorineural hearing loss</e2> associated with antineutrophil cytoplasmic antibodies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1953	"RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, <e1>hearing impairment in the left ear (with progression to the right ear)</e1>, and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1954	"RESULTS: In a 22-year-old Thai woman with Graves' disease, <e1>tinnitus</e1>, hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1955	"RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and <e1>vertigo</e1> developed after 3 years of therapy with <e2>PTU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1956	"The <e1>hearing impairment</e1> and tinnitus were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1957	"The hearing impairment and <e1>tinnitus</e1> were gradually reduced after <e2>PTU</e2> withdrawal and corticosteroid and azathioprine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1958	"Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of <e1>optic neuritis</e1> secondary to <e2>ethambutol</e2> administration at another hospital."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1959	"During the anti-tuberculous therapy, <e1>visual loss</e1> can be related to <e2>ethambutol</e2> toxicity or the tuberculosis infection itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1960	"In addition, <e1>ethambutol</e1> rarely causes <e2>visual loss</e2> during the early period or when given at lower doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1961	"<e1>Flucloxacillin</e1>-induced <e2>aplastic anaemia</e2> and liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1962	"<e1>Flucloxacillin</e1>-induced aplastic anaemia and <e2>liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1963	"It is well-recognized that <e1>flucloxacillin</e1> may occasionally result in <e2>fatal hepatic injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1964	"We report the case of a 40-year-old woman who developed fulminant hepatic failure and <e1>aplastic anaemia</e1> following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1965	"We report the case of a 40-year-old woman who developed <e1>fulminant hepatic failure</e1> and aplastic anaemia following a course of oral <e2>flucloxacillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1966	"Four days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of carpopedal spasm and <e2>bronchospasm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1967	"Four days after intravenous <e1>Zoledronic acid</e1>, the patient presented to emergency room with complaints of <e2>carpopedal spasm</e2> and bronchospasm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1968	"<e1>Zoledronic acid</e1>-induced <e2>severe hypocalcaemia</e2> in a prostate cancer patient with extensive osteoblastic bone metastases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1969	"This case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received cyclophosphamide (<e2>CY</e2>) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1970	"This case report describes an adolescent with <e1>severe lupus erythematosus</e1> who received <e2>cyclophosphamide</e2> (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1971	"<e1>Mucosal pigmentation</e1> after oral lichen planus treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1972	"The relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1973	"The relation between <e1>tacrolimus</e1> treatment and staining was suggested by the appearance of <e2>pigmentation</e2> during topical <e1>tacrolimus</e1> treatment and its clinical disappearance when treatment was stopped."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1974	"We report the first histopathologically documented case of <e1>oral mucosa pigmentation</e1> after OLP treatment with topical <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1975	"Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with <e1>Methotrexate</e1> (MTX) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1976	"Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate (<e1>MTX</e1>) and <e2>malignant lymphoma</e2> developing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1977	"<e1>Risperidone</e1> is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including <e2>tardive dyskinesia</e2> (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1978	"<e1>Risperidone</e1> is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia (<e2>TD</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1979	"<e1>Risperidone</e1> withdrawal-related <e2>respiratory dyskinesia</e2>: a case diagnosed by spirography and fibroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1980	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], <e1>limb dyskinesia</e1>, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1981	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and <e1>orofacial dyskinesia</e1>) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1982	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [<e1>RD</e1>], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1983	"The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including <e1>respiratory dyskinesia</e1> [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1984	"The authors present an elderly patient with mixed dementia who developed <e1>TD</e1> at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of <e2>risperidone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1985	"Therefore, clinicians should pay close attention to possible onset of <e1>RD</e1> in patients with multiple risk factors for TD, even when <e2>SDA</e2> therapy is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1986	"In this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1987	"In this study, we report on three individual patients who received <e1>BTX-B</e1> and who subsequently developed <e2>parasympathetic dysfunction of the visual system</e2> after injections of <e1>BTX-B</e1> at remote sites."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1988	"To date, there have been few reports of <e1>visual disturbances</e1> associated with <e2>BTX-B</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1989	"Visual system side effects caused by <e1>parasympathetic dysfunction</e1> after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1990	"<e1>Visual system side effects</e1> caused by parasympathetic dysfunction after <e2>botulinum toxin type B</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1991	"<e1>Enalapril</e1>-induced <e2>anemia</e2> in two kidney transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1992	"Two renal transplant patients developed <e1>anemia</e1> during treatment of hypertension with <e2>enalapril</e2> medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1993	"A 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general muscle weakness and <e2>muscle pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1994	"A 74-year-old hypercholestrerolaemic woman taking <e1>cerivastatin</e1> (0.15 mg/day) for 22 days complained of general <e2>muscle weakness</e2> and muscle pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1995	"Clearance rates of <e1>cerivastatin</e1> metabolites in a patient with <e1>cerivastatin</e1>-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1996	"We report on a patient who developed <e1>acute rhabdomyolysis</e1> after taking <e2>cerivastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1997	"<e1>Carboplatin</e1> <e2>hypersensitivity</e2> induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

1998	"Carboplatin <e1>hypersensitivity</e1> induced by low-dose paclitaxel/<e2>carboplatin</e2> in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

1999	"Carboplatin <e1>hypersensitivity</e1> induced by low-dose <e2>paclitaxel</e2>/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2000	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and <e1>apnea</e1>, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2001	"However, one patient exhibited severe hypersensitivity reactions including <e1>cardiac arrest</e1> and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2002	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed <e1>eruptions</e1>, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2003	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, <e1>hypotension</e1>, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2004	"However, one patient exhibited <e1>severe hypersensitivity reactions</e1> including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2005	"However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and <e1>tachycardia</e1> soon after administration of <e2>CBDCA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2006	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2007	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2008	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2009	"Our report suggested that <e1>CBDCA</e1> <e2>hypersensitivity</e2> was correlated with the total dose of previously administered platinum agents and that <e1>CBDCA</e1> should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because <e1>CBDCA</e1> <e2>hypersensitivity</e2> can occur even with low-dose <e1>CBDCA</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2010	"We report five cases of <e1>carboplatin</e1> (CBDCA) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2011	"We report five cases of carboplatin (<e1>CBDCA</e1>) <e2>hypersensitivity</e2> after weekly low-dose paclitaxel (60 mg/m2)/<e1>CBDCA</e1> (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2012	"We report five cases of carboplatin (CBDCA) <e1>hypersensitivity</e1> after weekly low-dose <e2>paclitaxel</e2> (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2013	"TREATMENT/OUTCOME: Standard anti-tuberculosis therapy was administered but was complicated by interaction with <e1>cyclosporine</e1> and drug-induced <e2>cholestasis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2014	"Chronic <e1>fentanyl</e1> application induces <e2>adrenocortical insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2015	"We report a case of a 64-year-old man with secondary <e1>adrenocortical insufficiency</e1> who has been on a chronic transdermal <e2>fentanyl</e2> treatment because of sciatic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2016	"<e1>Fluphenazine</e1>-induced <e2>neuroleptic malignant syndrome</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2017	"OBJECTIVE: To report a case of <e1>neuroleptic malignant syndrome</e1> (NMS) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2018	"OBJECTIVE: To report a case of neuroleptic malignant syndrome (<e1>NMS</e1>) associated with <e2>fluphenazine</e2> in a schizophrenic patient and review the literature related to this condition."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2019	"Intraventricular <e1>vancomycin</e1>-induced <e2>cerebrospinal fluid eosinophilia</e2>: report of two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2020	"We propose a mechanism of <e1>vancomycin</e1>-induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of <e2>CSFE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2021	"We report two cases of <e1>cerebrospinal fluid eosinophilia</e1> (CSFE) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2022	"We report two cases of cerebrospinal fluid eosinophilia (<e1>CSFE</e1>) secondary to the intraventricular administration of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2023	"Successful recovery from <e1>interstitial pneumonitis</e1>, induced by <e2>bicalutamide</e2> and leuprorelin acetate given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2024	"Successful recovery from <e1>interstitial pneumonitis</e1>, induced by bicalutamide and <e2>leuprorelin acetate</e2> given as treatment for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2025	"We report a case of <e1>interstitial pneumonitis</e1> induced by <e2>bicalutamide</e2> and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2026	"We report a case of <e1>interstitial pneumonitis</e1> induced by bicalutamide and/or <e2>leuprorelin acetate</e2> given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2027	"CONCLUSIONS: In these 3 cases, the unique positive ocular finding was <e1>corneal endothelial deposits</e1>, which may be related to the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2028	"<e1>Corneal endothelial deposits</e1> associated with <e2>rifabutin</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2029	"PURPOSE: The aim of this study was to report on the possible development of <e1>corneal endothelial deposits</e1> resulting from the use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2030	"RESULTS: All cases developed <e1>corneal endothelial deposits</e1> after previous use of <e2>rifabutin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2031	"CASE: A <e1>malignant mixed mesodermal tumor</e1> was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking <e2>raloxifene</e2> for osteoporosis prevention."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2032	"CONCLUSION: There may be an association between <e1>raloxifene</e1> and the development of <e2>malignant mixed mesodermal tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2033	"<e1>Malignant mixed mullerian tumor of the uterus</e1> in a patient taking <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2034	"We report a case of a women in whom a <e1>malignant mixed mesodermal tumor</e1> was diagnosed while she was taking <e2>raloxifene</e2>, which is also a selective estrogen receptor modulator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2035	"Herein we report four patients who underwent liver transplantation and developed <e1>neutropenia</e1> while receiving <e2>MMF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2036	"<e1>Mycophenolate mofetil</e1>-induced <e2>neutropenia</e2> in liver transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2037	"The mean time from starting <e1>MMF</e1> to the development of <e2>neutropenia</e2> was 4 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2038	"The side effects of <e1>MMF</e1>, such as <e2>bone marrow toxicity</e2>, have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2039	"A previous review described data on 15 patients who experienced <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2040	"A previous review described data on 15 patients who experienced acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP or secondary thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2041	"Disseminated intravascular coagulation associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2042	"<e1>Disseminated intravascular coagulation</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2043	"Disseminated intravascular coagulation associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>Rh(0)(D) immune globulin</e2> intravenous administration for immune thrombocytopenic purpura."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2044	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation (<e2>DIC</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2045	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of hemoglobinemia, particularly <e2>disseminated intravascular coagulation</e2> (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2046	"That review suggested that patients receiving <e1>anti-D IGIV</e1> be monitored for those and other potential complications of <e2>hemoglobinemia</e2>, particularly disseminated intravascular coagulation (DIC)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2047	"The purpose of this review is to increase awareness among physicians and other health care professionals that <e1>DIC</e1> may be a rare but potentially severe complication of <e2>anti-D IGIV</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2048	"This review presents the first case series of DIC associated with <e1>acute hemoglobinemia</e1> or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2049	"This review presents the first case series of <e1>DIC</e1> associated with acute hemoglobinemia or hemoglobinuria following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2050	"This review presents the first case series of DIC associated with acute hemoglobinemia or <e1>hemoglobinuria</e1> following <e2>anti-D IGIV</e2> administration for ITP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2051	"After the second <e1>infliximab</e1> infusion, he was found to have a <e2>severe transient neutropenia</e2> (0.5 x 10(9)/L)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2052	"Drug-induced <e1>agranulocytosis</e1> during treatment with <e2>infliximab</e2> in enteropathic spondyloarthropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2053	"These data indicated that <e1>infliximab</e1> possibly triggered production of granulocyte and neutrophil autoantibodies with resultant <e2>autoimmune agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2054	"These data indicated that <e1>infliximab</e1> possibly triggered <e2>production of granulocyte and neutrophil autoantibodies</e2> with resultant autoimmune agranulocytosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2055	"However, peripheral neuropathy and <e1>bone marrow depression</e1> led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2056	"However, peripheral <e1>neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and <e1>neuropathy</e1> may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2057	"However, <e1>peripheral neuropathy</e1> and bone marrow depression led to <e2>linezolid</e2> withdrawal in seven patients, and neuropathy may not be fully reversible in all patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2058	"Six patients developed peripheral neuropathy and five patients <e1>bone marrow depression</e1>, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2059	"Six patients developed <e1>peripheral neuropathy</e1> and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of <e2>linezolid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2060	"A case of <e1>high-grade endometrial stromal sarcoma</e1>, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2061	"A case of high-grade endometrial stromal sarcoma, confined into an <e1>intrauterine polypoid growth</e1>, in a woman with a history of breast cancer who was treated with adjuvant <e2>tamoxifen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2062	"<e1>High-grade endometrial stromal sarcoma</e1> after <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2063	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2064	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including <e2>endometrial adenocarcinoma</e2> or uterine sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2065	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2066	"In deciding if <e1>tamoxifen</e1> therapy is warranted, all potentially life-threatening adverse events associated with <e1>tamoxifen</e1> should be considered, including endometrial adenocarcinoma or <e2>uterine sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2067	"After only the third dose of <e1>pentamidine</e1>, it was noted that the patient's <e2>heart rate had decreased</e2> to 48 beats/minute."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2068	"Although various manifestations of <e1>pentamidine</e1>-induced <e2>cardiotoxicity</e2> have been reported, to our knowledge, second-degree heart block associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2069	"Although various manifestations of <e1>pentamidine</e1>-induced cardiotoxicity have been reported, to our knowledge, <e2>second-degree heart block</e2> associated with this agent has not been described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2070	"Clinicians should be vigilant when monitoring for <e1>cardiotoxicity</e1> in patients receiving <e2>pentamidine</e2> throughout the duration of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2071	"Early-onset <e1>pentamidine</e1>-associated <e2>second-degree heart block</e2> and sinus bradycardia: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2072	"Early-onset <e1>pentamidine</e1>-associated second-degree heart block and <e2>sinus bradycardia</e2>: case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2073	"<e1>Falling backward</e1> in two elderly patients taking <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2074	"RESULTS: Both patients experienced a previously unreported side effect--<e1>falling backward</e1>--associated with <e2>bupropion</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2075	"<e1>Ophthalmologic and neurologic findings</e1> in two children exposed to <e2>vigabatrin</e2> in utero."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2076	"The knowledge concerning <e1>VGB</e1>-associated <e2>visual dysfunction</e2> in pediatric patients, particularly in those who have been exposed to <e1>VGB</e1> in utero is limited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2077	"<e1>Vigabatrin</e1>-induced <e2>visual field defects</e2> are at present the most important safety issue in the use of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2078	"We explored <e1>ophthalmic and neurologic findings</e1> in two children who have been exposed prenatally to <e2>VGB</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2079	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2080	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and <e2>cotton wool spots</e2> at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2081	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2082	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated retinopathy is typically characterized by <e2>retinal hemorrhages</e2> and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2083	"BACKGROUND: Interferon (<e1>IFN</e1>)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2084	"BACKGROUND: <e1>Interferon</e1> (IFN)-associated <e2>retinopathy</e2> is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2085	"Clinical course of <e1>macular edema</e1> in two cases of <e2>interferon</e2>-associated retinopathy observed by optical coherence tomography."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2086	"Clinical course of macular edema in two cases of <e1>interferon</e1>-associated <e2>retinopathy</e2> observed by optical coherence tomography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2087	"CONCLUSION: During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing macular edema in patients who have <e2>decreased vision</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2088	"CONCLUSION: During and after <e1>IFN</e1> therapy, OCT is a useful examination technique for revealing <e2>macular edema</e2> in patients who have decreased vision."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2089	"Ophthalmologists should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of <e2>hypoalbuminemia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2090	"Ophthalmologists should be aware of the <e1>ocular side effects</e1> of <e2>IFN</e2> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2091	"Ophthalmologists should be aware of the ocular side effects of <e1>IFN</e1> therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2092	"The former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2093	"The former patient had complained once that his <e1>visual acuity had decreased</e1> after the termination of <e2>IFN</e2> therapy, and the latter patient complained twice during <e2>IFN</e2> therapy that his <e1>visual acuity had decreased</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2094	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2095	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated retinopathy who had developed <e2>macular edema</e2> and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2096	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2097	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated retinopathy who had developed macular edema and <e2>reduced visual acuity</e2> during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2098	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2099	"With the use of optical coherence tomography (OCT), two patients with <e1>IFN</e1>-associated <e2>retinopathy</e2> who had developed macular edema and reduced visual acuity during the clinical course of <e1>IFN</e1> therapy were observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2100	"Late development of <e1>diabetes mellitus</e1> after <e2>interferon-alfa</e2> and ribavirin therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2101	"Late development of <e1>diabetes mellitus</e1> after interferon-alfa and <e2>ribavirin</e2> therapy for chronic hepatitis C: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2102	"OBJECTIVE: To report the late development of <e1>immune-mediated diabetes mellitus</e1> after completion of <e2>alfa-interferon</e2> therapy for hepatitis C in an Asian patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2103	"<e1>Cutaneous necrosis</e1> after injection of polyethylene glycol-modified <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2104	"<e1>Cutaneous necrosis</e1> as a result of <e2>interferon alfa</e2> is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2105	"We report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2106	"We report 5 patients (3 patients with chronic hepatitis C treated with <e1>pegylated interferon alfa-2b</e1> in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of <e1>pegylated interferon alfa-2b</e1> at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2107	"We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral <e1>ribavirin</e1> and two patients with chronic myelocytic leukemia) who developed <e2>local cutaneous reactions</e2> at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2108	"We review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard <e2>interferon alfa</e2> or pegylated <e2>interferon alfa</e2>-2b and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2109	"We review the literature on previously reported cases of <e1>cutaneous necrosis</e1> after injection of standard interferon alfa or <e2>pegylated interferon alfa-2b</e2> and discuss the different pathophysiologic mechanisms that might be involved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2110	"Potential mechanisms involved in the occurrence of <e1>ischemic colitis</e1> in patients receiving <e2>tegaserod</e2> are also discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2111	"<e1>Tegaserod</e1>-associated <e2>ischemic colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2112	"We describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2113	"We describe the development of ischemic colitis in a woman who was treated with <e1>tegaserod</e1> and review the relationship among ischemic colitis, <e1>tegaserod</e1> use, and <e2>irritable bowel syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2114	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2115	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2116	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2117	"We describe the development of <e1>ischemic colitis</e1> in a woman who was treated with <e2>tegaserod</e2> and review the relationship among <e1>ischemic colitis</e1>, <e2>tegaserod</e2> use, and irritable bowel syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2118	"A 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2119	"A 57-year-old man developed <e1>chronic, watery diarrhea</e1> four weeks after Helicobacter pylori eradication therapy including <e2>lansoprazole</e2> followed by <e2>lansoprazole</e2> monotherapy for gastroesophageal reflux disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2120	"<e1>Lansoprazole</e1>-associated <e2>collagenous colitis</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2121	"The reported case represents an unusual association between medication with the proton pump inhibitor <e1>lansoprazole</e1> and the development of <e2>collagenous colitis</e2> suggesting the importance of evaluation of drug use in patients with microscopic colitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2122	"46-year-old woman developed <e1>painful ulcers</e1> over her lower abdomen in the form of reticulate erythema after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2123	"46-year-old woman developed painful ulcers over her lower abdomen in the form of <e1>reticulate erythema</e1> after injecting <e2>interferon beta-1b</e2> subcutaneously for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2124	"<e1>Abdominal wall ulceration</e1> and mucinosis secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2125	"Abdominal wall ulceration and <e1>mucinosis</e1> secondary to <e2>recombinant human interferon-beta-1b</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2126	"<e1>Itraconazole</e1>-related increased <e2>vincristine neurotoxicity</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2127	"Itraconazole-related increased <e2>vincristine</e2> neurotoxicity: case report and review of literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2128	"Nineteen cases of unusual enhanced vincristine <e1>neurotoxicity</e1> related to <e2>itraconazole</e2> have been reported in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2129	"Nineteen cases of unusual enhanced <e1>vincristine</e1> <e2>neurotoxicity</e2> related to itraconazole have been reported in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2130	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and <e2>absence of deep reflexes</e2>, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2131	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, <e2>mild left ptosis</e2>, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2132	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and <e2>mild weakness of the upper extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2133	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, <e2>neurogenic bladder</e2>, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2134	"Ten days after <e1>itraconazole</e1> was started, he developed <e2>paralytic ileus</e2>, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2135	"Ten days after <e1>itraconazole</e1> was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with <e2>severe paralysis of the lower extremities</e2> and mild weakness of the upper extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2136	"The authors suggest that in the absence of any proven benefit of <e1>itraconazole</e1> prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2137	"The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with <e1>vincristine</e1> leading to severe and even potentially <e2>fatal toxicities</e2>, the combination use of these drugs should be avoided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2138	"CASE REPORT: We report a case of <e1>intracerebral hemorrhage</e1> occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting <e2>pseudoephedrine</e2> daily for one year."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2139	"Only one report links <e1>phenylpropanolamine</e1> consumption to an <e2>intracerebral hemorrhage</e2> in a patient with an AVM."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2140	"<e1>Pseudoephedrine</e1>-induced hemorrhage associated with a <e2>cerebral vascular malformation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2141	"<e1>Pseudoephedrine</e1>-induced <e2>hemorrhage</e2> associated with a cerebral vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2142	"Since 1979, over 30 published case reports have documented the relationship between <e1>phenylpropanolamine</e1> and <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2143	"This is a case of <e1>pseudoephedrine</e1>-induced <e2>intracerebral hemorrhage</e2> in a patient with an underlying vascular malformation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2144	"Rapid onset of <e1>quetiapine</e1>-induced <e2>diabetic ketoacidosis</e2> in an elderly patient: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2145	"We report a case of reversible <e1>DKA</e1> and new-onset DM that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2146	"We report a case of reversible DKA and new-onset <e1>DM</e1> that developed in a demented patient who was treated with <e2>quetiapine</e2> for 14 days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2147	"<e1>Pulmonary leukostasis</e1> secondary to <e2>all-trans retinoic acid</e2> in the treatment of acute promyelocytic leukemia in first relapse."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2148	"<e1>Eruptive epidermoid cysts</e1> resulting from treatment with <e2>imiquimod</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2149	"METHODS: A 79-year-old woman being treated with <e1>imiquimod</e1> 5 days per week for a nodular basal cell developed a <e2>verrucous plaque</e2> over the treatment area after 7 weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2150	"The <e1>multiple comedones</e1> and ruptured epidermoid cysts are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2151	"The multiple comedones and <e1>ruptured epidermoid cysts</e1> are newly reported adverse effects of <e2>imiquimod</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2152	"We report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in neurological and cardiovascular toxicity resulting in <e2>death</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2153	"We report an unusual case of massive <e1>fluoxetine</e1> ingestion resulting in <e2>neurological and cardiovascular toxicity</e2> resulting in death."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2154	"<e1>Hepatocellular damage</e1> following therapeutic intravenous <e2>iron sucrose</e2> infusion in a child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2155	"The case reported here is of a child given a large dose of intravenous <e1>iron sucrose</e1> (16 mg/kg) over 3 hours, who subsequently developed features of <e2>systemic iron toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2156	"Five personal observations of an <e1>acute amnestic episode</e1> in younger individuals after intake of <e2>clioquinol</e2> are described together with three observations from the medical literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2157	"The clinical aspect closely resembled classical transient global amnesia but the episode after <e1>clioquinol</e1> lasted longer (24 hours to three days) and a more or less extensive <e2>retrograde amnesia</e2> persisted permanently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2158	"The clinical aspect closely resembled classical <e1>transient global amnesia</e1> but the episode after <e2>clioquinol</e2> lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2159	"<e1>Transient global amnesia</e1> after <e2>clioquinol</e2>: five personal observations from outside Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2160	"In the other patient, a 78-year-old woman, <e1>Neisseria mucosa knee arthritis</e1> occurred after a single <e2>sodium hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2161	"One patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of sodium hyaluronate and <e2>corticosteroids</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2162	"One patient was an 80-year-old woman who was admitted for <e1>Staphylococcus aureus knee arthritis</e1> after several intraarticular injections of <e2>sodium hyaluronate</e2> and corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2163	"<e1>Septic knee arthritis</e1> after intra-articular <e2>hyaluronate</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2164	"<e1>Acute dystonia</e1> induced by <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2165	"<e1>ADR</e1> induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of <e2>lamivudine</e2>-induced <e1>ADR</e1> in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2166	"The authors report two cases of <e1>acute dystonic reactions</e1> (ADRs) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2167	"The authors report two cases of acute dystonic reactions (<e1>ADRs</e1>) as a side effect of <e2>lamivudine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2168	"The authors think that although <e1>lamivudine</e1> is widely used and well tolerated, it can cause <e2>ADRs</e2>, which are reversible after drug withdrawal."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2169	"<e1>Pleuropulmonary fibrosis</e1> after long-term treatment with the dopamine agonist <e2>pergolide</e2> for Parkinson Disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2170	"CONCLUSIONS: This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2171	"CONCLUSIONS: This observation of "on-off" <e1>risperidone</e1> treatment suggests that <e1>risperidone</e1> may have worsened both <e2>psychiatric and physical manifestations</e2> of the mitochondrial disorder in this adolescent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2172	"OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and <e1>increased mood symptoms</e1> during treatment with <e2>risperidone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2173	"<e1>Risperidone</e1>-induced psychosis and <e2>depression</e2> in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2174	"<e1>Risperidone</e1>-induced <e2>psychosis</e2> and depression in a child with a mitochondrial disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2175	"<e1>Fatal radiation myelopathy</e1> after high-dose <e2>busulfan</e2> and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2176	"<e1>Fatal radiation myelopathy</e1> after high-dose busulfan and <e2>melphalan</e2> chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2177	"<e1>Gemcitabine</e1>-induced <e2>pericardial effusion</e2> and tamponade after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2178	"<e1>Gemcitabine</e1>-induced pericardial effusion and <e2>tamponade</e2> after unblocked cardiac irradiation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2179	"<e1>Gemcitabine</e1> therapy has been associated with <e2>radiation recall reactions</e2> when used in the treatment of carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2180	"Physicians should be aware of the potential for developing a <e1>gemcitabine</e1>-induced radiation recall reaction resulting in hemodynamically significant <e2>pericardial effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2181	"Physicians should be aware of the potential for developing a <e1>gemcitabine</e1>-induced <e2>radiation recall reaction</e2> resulting in hemodynamically significant pericardial effusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2182	"We report four cases of hemodynamically significant <e1>pericardial effusion</e1> in patients with refractory lymphoma who were receiving <e2>gemcitabine</e2>, all of whom had a history of mediastinal radiation without subcarinal blocking."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2183	"A patient with generalized MG was effectively managed with <e1>MM</e1> but developed <e2>CNS lymphoma</e2> after 3 years of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2184	"Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with <e1>MM</e1> may be associated with increased risk of <e2>lymphoproliferative disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2185	"Primary <e1>CNS lymphoma</e1> complicating treatment of myasthenia gravis with <e2>mycophenolate mofetil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2186	"Primary <e1>CNS lymphoma</e1> regressed on withdrawal of <e2>MM</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2187	"<e1>Baclofen</e1> withdrawal: a cause of prolonged <e2>fever</e2> in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2188	"<e1>Baclofen</e1> <e2>withdrawal syndrome</e2> resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2189	"Baclofen <e1>withdrawal syndrome</e1> resulting from underdosing of oral <e2>baclofen</e2> should be considered as a potential source of prolonged fever in the intensive care unit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2190	"The patient continued to have fever and <e1>autonomic instability</e1> without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2191	"The patient continued to have <e1>fever</e1> and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral <e2>baclofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2192	"We report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2193	"We report a case of <e1>baclofen</e1> <e2>withdrawal syndrome</e2> resulting from oral <e1>baclofen</e1> underdosing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2194	"After discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her <e2>eosinophilia</e2> and radiographic abnormalities both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2195	"After discontinuing <e1>captopril</e1> and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and <e2>radiographic abnormalities</e2> both resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2196	"<e1>Captopril</e1>-induced <e2>pulmonary infiltrates with eosinophilia</e2> in an infant with congenital heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2197	"We report a case of an infant with complex congenital heart disease who was placed on <e1>captopril</e1> for afterload reduction following cardiac surgery and subsequently developed <e2>pulmonary infiltrates with eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2198	"Can <e1>propofol</e1> precipitate <e2>pancreatitis</e2> in patients with Cushing's syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2199	"Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to <e1>acute pancreatitis</e1> following <e2>propofol</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2200	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a <e1>focal seizure</e1>) of severe <e2>lithium</e2>-induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2201	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a <e1>prolonged seizure</e1>, a serotonin syndrome and a focal seizure) of severe <e2>lithium</e2>-induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2202	"Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a <e1>serotonin syndrome</e1> and a focal seizure) of severe <e2>lithium</e2>-induced side effects while patients underwent ECT without complications and <e2>lithium</e2> serum levels were still subtherapeutic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2203	"<e1>CD20-negative T-cell-rich B-cell lymphoma</e1> as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with <e2>rituximab</e2>: a molecular analysis using laser capture microdissection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2204	"Recently, <e1>CD20-negative tumors</e1> have been described after <e2>Rituximab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2205	"A 51-year old physically fit woman experienced <e1>angio-oedema</e1> and hypotensive shock after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2206	"A 51-year old physically fit woman experienced angio-oedema and <e1>hypotensive shock</e1> after <e2>irbesartan</e2> ingestion requiring noradrenaline infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2207	"To our knowledge, our report is one of the first on shock and <e1>angio-oedema</e1> from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2208	"To our knowledge, our report is one of the first on <e1>shock</e1> and angio-oedema from <e2>irbesartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2209	"She died within six weeks of developing <e1>congestive heart failure</e1> coupled with liver failure due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2210	"She died within six weeks of developing congestive heart failure coupled with liver failure due to <e1>haemosiderosis</e1> despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2211	"She died within six weeks of developing congestive heart failure coupled with <e1>liver failure</e1> due to haemosiderosis despite regular use of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2212	"<e1>Transfusion haemosiderosis</e1> inspite of regular use of <e2>desferrioxamine</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2213	"One of the side-effects of intravitreal <e1>triamcinolone</e1> is the development of <e2>cataract</e2>, and it is known that <e2>cataract</e2> extraction can exacerbate macular degeneration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2214	"Severe loss of vision after removal of <e1>cataract</e1> caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2215	"<e1>Severe loss of vision</e1> after removal of cataract caused by intravitreal <e2>triamcinolone</e2> in combination with photodynamic therapy for exudative age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2216	"<e1>Rhabdomyolysis</e1> caused by tocolysis with oral <e2>ritodrine hydrochloride</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2217	"<e1>Rhabdomyolysis</e1> has been recognized as a complication of tocolytic therapy with <e2>ritodrine hydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2218	"We report here a rare case of <e1>ritodrine-hydrochloride</e1>-induced <e2>rhabdomyolysis</e2> in a pregnant patient with myotonic dystrophy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2219	"<e1>Acute myocardial ischemia</e1> following accidental intravenous administration of <e2>epinephrine</e2> in high concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2220	"Inadvertent and accidental <e1>epinephrine</e1> overdose might result in potentially <e2>lethal complications</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2221	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in <e2>acute myocardial ischemia</e2> in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2222	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2223	"We present a case of acute <e1>epinephrine</e1> toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed <e2>severe allergic reaction</e2> to intravenous immunoglobulin, and was subsequently given <e1>epinephrine</e1> by mistake intravenously rather than subcutaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2224	"Polysomnographic and pharmacokinetic findings in <e1>levodopa</e1>-induced augmentation of <e2>restless legs syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2225	"Symptoms and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2226	"Symptoms and signs of <e1>augmentation</e1> were related to low plasma <e2>levodopa</e2> levels, abating 75 minutes after oral <e2>levodopa</e2> administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma <e2>levodopa</e2> concentration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2227	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with <e2>anarchic discharges of motor unit potentials</e2>, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2228	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and <e2>flexor spasms</e2>, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2229	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated <e2>marked motor hyperactivity</e2> during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2230	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with <e2>painful dysesthesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2231	"Videopolysomnographic and pharmacokinetic studies with monitoring of plasma <e1>levodopa</e1> levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, <e2>tonic grouped discharges</e2> and flexor spasms, associated with painful dysesthesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2232	"We describe a patient with idiopathic RLS who developed <e1>augmentation</e1> after 8 months of <e2>levodopa</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2233	"The major side effect of <e1>infliximab</e1> is <e2>infection</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2234	"This report describes a probable case of <e1>infliximab</e1>-induced <e2>membranous nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2235	"<e1>Linezolid</e1>-induced <e2>dyserythropoiesis</e2>: chloramphenicol toxicity revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2236	"We report here two cases of <e1>dyserythropoietic anaemia</e1> associated with long-term <e2>linezolid</e2> use that share striking similarities to chloramphenicol-associated myelotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2237	"We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to <e1>chloramphenicol</e1>-associated <e2>myelotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2238	"A selective association between <e1>fluoxetine</e1> and extensive, prominent <e2>eye movements in nonrapid eye movement (NREM) sleep</e2> was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2239	"In addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2240	"In addition, a 31-year-old man with obsessive-compulsive disorder developed <e1>RBD</e1> soon after starting <e2>fluoxetine</e2> therapy, which persisted at PSG study 19 months after <e2>fluoxetine</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2241	"<e1>Prominent eye movements during NREM sleep</e1> and REM sleep behavior disorder associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2242	"Prominent eye movements during NREM sleep and <e1>REM sleep behavior disorder</e1> associated with <e2>fluoxetine</e2> treatment of depression and obsessive-compulsive disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2243	"Because of serious side effects of an <e1>increase in the QT interval</e1> causing torsades de pointes, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2244	"Because of serious side effects of an increase in the QT interval causing <e1>torsades de pointes</e1>, <e2>dofetilide</e2> must be initiated with close monitoring of the QT interval in an inpatient setting."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2245	"Marked QT prolongation and torsades de pointes secondary to <e1>acute ischemia</e1> in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2246	"<e1>Marked QT prolongation</e1> and torsades de pointes secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2247	"Marked QT prolongation and <e1>torsades de pointes</e1> secondary to acute ischemia in an elderly man taking <e2>dofetilide</e2> for atrial fibrillation: a cautionary tale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2248	"We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from <e1>acute myocardial ischemia</e1> in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2249	"We report marked QT prolongation and torsades de pointes in a setting of <e1>flash pulmonary edema</e1> resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2250	"We report marked <e1>QT prolongation</e1> and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2251	"We report marked QT prolongation and <e1>torsades de pointes</e1> in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with <e2>dofetilide</e2> for atrial fibrillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2252	"Prominent <e1>positive U waves</e1> appearing with high-dose intravenous <e2>phenylephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2253	"While on a maximal dose of <e1>phenylephrine</e1> she developed prominent <e2>positive U waves</e2>, which disappeared with the cessation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2254	"<e1>Hepatoxicity</e1> is a rare complication of <e2>SRL</e2> therapy and may be connected with some diagnostic and/or therapeutic problems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2255	"<e1>Sirolimus</e1>-associated <e2>hepatotoxicity</e2> in the kidney graft recipient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2256	"The aim of our paper was to describe <e1>hepatotoxicity</e1> of <e2>sirolimus</e2> (SRL) in a kidney graft recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2257	"CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of <e1>nephrotic syndrome</e1> while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2258	"<e1>Nephrotic syndrome</e1> in a multiple sclerosis patient treated with <e2>interferon beta 1a</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2259	"SUBSEQUENT COURSE: The <e1>nephrosis</e1> resolved almost completely once the <e2>interferon</e2> was stopped and after immunosuppressive treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2260	"This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential <e1>renal toxicity</e1> of <e2>interferons</e2> in MS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2261	"<e1>Capecitabine</e1>-induced <e2>multifocal leukoencephalopathy</e2>: a report of five cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2262	"The authors report five additional cases of <e1>capecitabine</e1>-induced <e2>multifocal leukoencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2263	"A 56-year-old white woman with a diagnosis of reactive depression developed severe <e1>UI</e1> after a 30 days' treatment with <e2>venlafaxine</e2> 75 mg/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2264	"The authors report a case of urinary incontinence (<e1>UI</e1>) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2265	"The authors report a case of <e1>urinary incontinence</e1> (UI) that occurred in a woman after administration of <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2266	"<e1>Venlafaxine</e1>-induced <e2>urinary incontinence</e2> resolved after switching to sertraline."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2267	"Diagnosis of <e1>hypothyroidism</e1> during treatment can be difficult because of the common side effects of <e2>alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2268	"<e1>Sustained hypothyroidism</e1> induced by <e2>recombinant alpha interferon</e2> in patients with chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2269	"<e1>Thyroid dysfunction</e1> has been reported in patients with malignant disease treated with <e2>recombinant alpha interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2270	"Two cases of <e1>hypothyroidism</e1> in patients with chronic hepatitis C treated with <e2>recombinant alpha interferon</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2271	"<e1>Atrial fibrillation</e1> after <e2>vardenafil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2272	"We report a case admitted with a first-detected, <e1>symptomatic paroxysmal atrial fibrillation</e1> in a healthy patient after self-medication with <e2>vardenafil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2273	"We describe a case of infection with <e1>Mycobacterium abscessus</e1> in a 67-year-old woman receiving <e2>infliximab</e2> as a component of her therapy for RA."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2274	"DIAGNOSIS: <e1>Interferon alpha-2b</e1>-induced <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2275	"<e1>Reversible cardiomyopathy</e1> caused by administration of <e2>interferon alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2276	"In this case <e1>senna</e1> was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2277	"In this case <e1>senna</e1> was likely the cause of a <e2>subacute cholestatic hepatitis</e2> exemplifying again the potential role of herbal related liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2278	"<e1>Subacute cholestatic hepatitis</e1> likely related to the use of <e2>senna</e2> for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2279	"We report a case of <e1>senna</e1>-induced <e2>cholestatic hepatitis</e2> which was not diagnosed at presentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2280	"Based on the history and clinical features, a diagnosis of <e1>insulin</e1>-induced <e2>lipohypertrophy</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2281	"<e1>Insulin</e1>-induced <e2>lipohypertrophy</e2>: report of a case with histopathology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2282	"Thus, the possible in vivo effects of <e1>insulin</e1> on adipocytes were clearly observed in this case of <e1>insulin</e1>-induced <e2>lipohypertrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2283	"To our knowledge, this is the first report of <e1>insulin</e1>-induced <e2>lipohypertrophy</e2> with detailed histological examinations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2284	"A 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2285	"A 7-year-old girl developed <e1>diabetes mellitus</e1> and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2286	"A 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with <e2>azathioprine</e2> and/or prednisone for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2287	"A 7-year-old girl developed diabetes mellitus and <e1>exocrine pancreatic insufficiency</e1> after 3.5 years of almost continuous treatment with azathioprine and/or <e2>prednisone</e2> for idiopathic auto-immune haemolytic anaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2288	"An objective causality assessment suggests that the <e1>JHR</e1> in our patient was probably related to <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2289	"CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with <e1>JHR</e1> after an initial intravenous dose of <e2>penicillin G</e2> for presumed neurosyphilis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2290	"<e1>Penicillin</e1>-induced <e2>Jarisch-Herxheimer reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2291	"The patient described feeling cold with worsening headache and <e1>chills</e1> approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2292	"The patient described <e1>feeling cold</e1> with worsening headache and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2293	"The patient described feeling cold with <e1>worsening headache</e1> and chills approximately one hour after infusion of the first dose of <e2>penicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2294	"<e1>Acute respiratory distress syndrome</e1> after <e2>rituximab</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2295	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as infliximab, <e2>gemtuzumab ozogamicin</e2>, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2296	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as <e2>infliximab</e2>, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2297	"<e1>ARDS</e1> has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and <e2>OKT3</e2> and is believed to be directly mediated by release of proinflammatory cytokines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2298	"<e1>ARDS</e1> is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2299	"<e1>ARDS</e1> is rarely associated with <e2>rituximab</e2> infusion for lympho-proliferative disorders, but it should be considered by those administering <e2>rituximab</e2>, especially when a patient develops severe pulmonary symptoms soon after infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2300	"ARDS is rarely associated with <e1>rituximab</e1> infusion for lympho-proliferative disorders, but it should be considered by those administering <e1>rituximab</e1>, especially when a patient develops <e2>severe pulmonary symptoms</e2> soon after infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2301	"<e1>Dyspnea</e1>, hypoxemia, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2302	"Dyspnea, <e1>hypoxemia</e1>, and pleuritic chest pain occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2303	"Dyspnea, hypoxemia, and <e1>pleuritic chest pain</e1> occurred within 24 hours of <e2>rituximab</e2> administration, and there was no other apparent explanation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2304	"<e1>Progressive hypoxemia</e1> mandated endotracheal intubation 1 week after <e2>rituximab</e2> administration and led to death 4 weeks after admission."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2305	"We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed <e1>acute respiratory distress syndrome</e1> (ARDS) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2306	"We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (<e1>ARDS</e1>) after a single infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2307	"Symptomatic hypocalcaemia and <e1>renal impairment</e1> associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2308	"<e1>Symptomatic hypocalcaemia</e1> and renal impairment associated with <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2309	"We report three cases of <e1>severe hypocalcaemia</e1> associated with i.v. <e2>bisphosphonate</e2> treatment in patients with multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2310	"<e1>Gemcitabine</e1>-related <e2>radiation recall</e2> in a patient with pancreatic cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2311	"<e1>Gemcitabine</e1> should be added to the list of drugs known to cause <e2>radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2312	"<e1>Radiation recall</e1> from <e2>gemcitabine</e2> is rare, but can potentially arise in any site that has been previously irradiated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2313	"<e1>Radiation recall</e1> related to <e2>gemcitabine</e2> has been reported in lung and breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2314	"We report a patient with inoperable pancreatic cancer who developed <e1>gastrointestinal bleeding</e1> secondary to radiation-recall related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2315	"We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to <e1>radiation-recall</e1> related to <e2>gemcitabine</e2> and review literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2316	"We suggest discontinuing <e1>gemcitabine</e1> if <e2>radiation recall</e2> is observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2317	"A 17-year-old boy with acute lymphoblastic leukemia developed <e1>acute renal failure</e1> within 48 h of an intravenous high-dose <e2>methotrexate</e2> (5 g/m2) infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2318	"High-dose <e1>methotrexate</e1>-associated <e2>acute renal failure</e2> may be an avoidable complication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2319	"<e1>Methotrexate</e1>-associated <e2>nephropathy</e2> is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2320	"Massive <e1>prolapse of the urethral mucosa</e1> following periurethral injection of <e2>calcium hydroxylapatite</e2> for stress urinary incontinence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2321	"The authors present a case report of a <e1>granulomatous reaction</e1> leading to urethral prolapse, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2322	"The authors present a case report of a granulomatous reaction leading to <e1>urethral prolapse</e1>, 3 months after the transurethral injection of <e2>calcium hydroxylapatite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2323	"To our knowledge, this is the first <e1>granulomatous reaction</e1> described after <e2>calcium hydroxylapatite</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2324	"CASE SUMMARY: A 57-year-old female with cardiomyopathy and "sulfa" (trimethoprim/sulfamethoxazole) allergy documented as <e1>pancreatitis</e1> presented with symptoms consistent with <e1>pancreatitis</e1> after use of <e2>furosemide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2325	"In addition, while cases of loop diuretic-induced <e1>pancreatitis</e1>, including <e2>furosemide</e2>, have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2326	"<e1>Torsemide</e1> appears to also be a part of a long list of agents that can cause <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2327	"<e1>Heparin</e1>-induced thrombocytopenia complicated with <e2>massive thrombosis of the inferior vena cava</e2> after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2328	"<e1>Heparin</e1>-induced <e2>thrombocytopenia</e2> complicated with massive thrombosis of the inferior vena cava after filter placement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2329	"On the 3rd day, an inferior vena cava (IVC) filter was placed with a <e1>heparin</e1> flush, after which massive <e2>IVC thrombosis</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2330	"The patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> with thrombosis syndrome (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2331	"The patient was positive for antibody against complexes of <e1>heparin</e1> and platelet factor 4, and was diagnosed as <e1>heparin</e1>-induced thrombocytopenia with <e2>thrombosis syndrome</e2> (HITTS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2332	"When <e1>thrombosis</e1> develops during <e2>heparin</e2> treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2333	"After <e1>gastric-outlet obstruction</e1> was recognized in several infants who received <e2>prostaglandin E1</e2>, we studied the association between the drug and this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2334	"CONCLUSIONS: The administration of <e1>prostaglandin E1</e1> to neonates can cause gastric-outlet obstruction due to <e2>antral hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2335	"CONCLUSIONS: The administration of <e1>prostaglandin E1</e1> to neonates can cause <e2>gastric-outlet obstruction</e2> due to antral hyperplasia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2336	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, <e1>cisplatin</e1>, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2337	"Moreover, treatment with immunosuppressive drugs such as <e1>cyclosporine</e1>, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2338	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and <e1>interferon-alpha</e1> can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2339	"Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, <e1>tacrolimus</e1>, and interferon-alpha can induce a condition resembling <e2>RPLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2340	"<e1>Reversible posterior leukoencephalopathy syndrome</e1> in systemic lupus erythematosus with thrombocytopenia treated with <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2341	"We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, <e1>headache</e1>, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2342	"We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and <e1>seizure</e1> after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2343	"We report a case of a young woman with SLE and thrombocytopenia, who developed <e1>severe perspiration</e1>, headache, and seizure after receiving <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2344	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between <e2>lopinavir</e2>/ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2345	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/<e2>ritonavir</e2> and valproic acid (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2346	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and <e2>valproic acid</e2> (VPA) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2347	"OBJECTIVE: To describe a case of exacerbated <e1>mania</e1> potentially related to an interaction between lopinavir/ritonavir and valproic acid (<e2>VPA</e2>) and propose a mechanism of action for this interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2348	"Possible interaction between <e1>lopinavir</e1>/ritonavir and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2349	"Possible interaction between lopinavir/<e1>ritonavir</e1> and valproic Acid exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2350	"Possible interaction between lopinavir/ritonavir and <e1>valproic Acid</e1> exacerbates <e2>bipolar disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2351	"After intravitreal injection of <e1>triamcinolone acetonide</e1>, <e2>cataract</e2> may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2352	"<e1>Arthritis</e1> and bursitis in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2353	"Arthritis and <e1>bursitis</e1> in multiple sclerosis patients treated with <e2>interferon-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2354	"Our literature review revealed an additional six cases of onset of <e1>inflammatory arthritis</e1> in MS patients receiving <e2>IFN-beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2355	"The first patient developed a <e1>monoarthritis</e1> 2 weeks after initiation of <e2>IFN-beta</e2>, which persisted during the 14 months of therapy and resolved with discontinuation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2356	"Therapy with <e1>IFN-beta</e1> has rarely been associated with the development of <e2>autoimmune disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2357	"The second patient developed both <e1>autoimmune thyroid disease</e1> and a refractory pre-patellar bursitis after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2358	"The second patient developed both autoimmune thyroid disease and a <e1>refractory pre-patellar bursitis</e1> after 50 months of <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2359	"We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed <e1>inflammatory musculoskeletal manifestations</e1>, following <e2>IFN-beta</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2360	"<e1>Trimethoprim-sulfamethoxazole</e1>-induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2361	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2362	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2363	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2364	"We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of <e1>meningitis</e1> after using <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2365	"We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/<e1>SMX</e1>-induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2366	"We reviewed the literature in an attempt to characterize the pattern and predictors of <e1>TMP</e1>/SMX-induced <e2>aseptic meningitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2367	"In this paper, we report a patient with primary anti-phospholipid syndrome treated by <e1>corticosteroid</e1>, who developed <e2>disseminated nocardiosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2368	"<e1>Chloroquine</e1>-induced <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2369	"<e1>Ptosis</e1> occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2370	"<e1>Ptosis</e1> occurring 24 h after <e2>chloroquine</e2> therapy, with full recovery 48 h after cessation of <e2>chloroquine</e2>, has not been described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2371	"This report describes a case of <e1>bilateral ptosis</e1> induced by <e2>chloroquine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2372	"DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a <e1>central neurological syndrome</e1> within days of intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2373	"Diffusion-weighted MRI correlates of subacute <e1>methotrexate</e1>-related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2374	"OBJECTIVES: A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving <e2>methotrexate</e2> (MTX) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2375	"OBJECTIVES: A delayed <e1>stroke-like leukoencephalopathy</e1> has been observed in patients receiving methotrexate (<e2>MTX</e2>) for childhood leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2376	"Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered <e1>subacute neurotoxicity</e1> after intrathecal <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2377	"This is a rare case of <e1>ARDS</e1> associated with <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2378	"CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the "indirect" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced <e1>dyskinesias</e1> may differ from those involved in <e2>L-dopa</e2> induced <e1>dyskinesias</e1>; (iii) <e1>dyskinesias</e1> induced by STN surgery resolve spontaneously as compensatory mechanisms develop."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2379	"Prior to surgery, <e1>levodopa</e1> induced <e2>dyskinesia</e2> had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2380	"A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent <e1>triazolam</e1>-induced <e2>eating disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2381	"<e1>Triazolam</e1>-induced nocturnal bingeing with <e2>amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2382	"<e1>Triazolam</e1>-induced <e2>nocturnal bingeing</e2> with amnesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2383	"Although interferon gamma has been implicated in the pathogenesis of <e1>sarcoidosis</e1>, only a few cases of <e1>sarcoidosis</e1> associated with <e2>interferon alpha</e2> therapy have been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2384	"Development of <e1>sarcoidosis</e1> during <e2>interferon alpha 2b</e2> and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2385	"Development of <e1>sarcoidosis</e1> during interferon alpha 2b and <e2>ribavirin</e2> combination therapy for chronic hepatitis C--a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2386	"We report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2387	"We report a case with chronic hepatitis C (CHC) who developed <e1>sarcoidosis</e1> after the treatment by interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2388	"We suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during <e2>interferon alpha</e2> and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2389	"We suggest that <e1>sarcoidosis</e1> may develop in chronic hepatitis C patients during interferon alpha and/or <e2>ribavirin</e2> treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2390	"<e1>Neutropenic colitis</e1> during standard dose combination chemotherapy with nedaplatin and <e2>irinotecan</e2> for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2391	"<e1>Neutropenic colitis</e1> during standard dose combination chemotherapy with <e2>nedaplatin</e2> and irinotecan for testicular cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2392	"In this paper, we report a case of <e1>severe hypercalcemia</e1> of immobilization in a 40-year-old hemodialyzed woman treated by <e2>cinacalcet HCl</e2> for a severe HPTH-II (PTH>1,000 pg/mL)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2393	"Here, we present a case of <e1>sirolimus</e1>-associated <e2>interstitial pneumonitis</e2> in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2394	"Reversible <e1>sirolimus</e1>-associated <e2>pneumonitis</e2> after heart transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2395	"Two cases of <e1>sirolimus</e1>-associated <e2>pneumonitis</e2> have been reported after cardiac transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2396	"An objective causality assessment by use of the Naranjo probability scale revealed that <e1>NCSE</e1> due to <e2>ifosfamide</e2> was probable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2397	"CASE SUMMARIES: Two patients who received <e1>ifosfamide</e1>-containing chemotherapy developed <e2>NCSE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2398	"CONCLUSIONS: Among the many presentations of <e1>ifosfamide</e1> <e2>neurotoxicity</e2>, clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2399	"<e1>NCSE</e1>, an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2400	"<e1>Nonconvulsive status epilepticus</e1> due to <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2401	"OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus (<e1>NCSE</e1>) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2402	"OBJECTIVE: To report 2 cases of <e1>nonconvulsive status epilepticus</e1> (NCSE) following infusion of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2403	"We describe a case of intraoperative <e1>gelatine</e1>-induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2404	"We describe a case of intraoperative <e1>gelatine</e1>-induced <e2>anaphylaxis</e2> whose diagnosis was delayed as the use of <e1>gelatine</e1> during surgical procedures was omitted for two times in patient's medical records."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2405	"<e1>Cutaneous mycobacterial infection</e1> post intravesical <e2>BCG</e2> installation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2406	"<e1>Disseminated tuberculous lesions</e1> post intravesical <e2>BCG</e2> therapy are rare but need to be identified and treated quickly."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2407	"Some patients develop <e1>hypersensitivity rash</e1> in response to <e2>HCQ</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2408	"Administration of <e1>sumatriptan</e1> in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce <e2>symptomatic cerebral vasospasm</e2> with potentially dangerous consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2409	"METHOD: We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with <e2>quetiapine</e2> and risperidone, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2410	"METHOD: We describe two patients who presented with <e1>diabetic ketoacidosis</e1> after treatment with quetiapine and <e2>risperidone</e2>, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2411	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2412	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2413	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2414	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, <e1>atypical lymphocytosis</e1>, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2415	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2416	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2417	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2418	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, <e1>cervical lymphadenopathy</e1>, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2419	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2420	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2421	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2422	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and <e1>eosinophilia</e1> two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2423	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2424	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2425	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2426	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with <e1>fever</e1>, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2427	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2428	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2429	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2430	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, <e1>hepatosplenomegaly</e1>, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2431	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole (<e2>SMX</e2>) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2432	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-<e2>sulfamethoxazole</e2> (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2433	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (<e2>TMP</e2>)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2434	"A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, <e1>skin eruptions</e1>, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving <e2>trimethoprim</e2> (TMP)-sulfamethoxazole (SMX) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2435	"This is the first case of <e1>TMP-SMX</e1>-induced <e2>hypersensitivity syndrome</e2> associated with the reactivation of a latent viral infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2436	"<e1>Trimethoprim-sulfamethoxazole</e1>-induced <e2>hypersensitivity syndrome</e2> associated with reactivation of human herpesvirus-6."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2437	"PURPOSE: To report a case of severe <e1>corticosteroid</e1>-induced <e2>glaucoma</e2> after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2438	"PURPOSE: To report a case of severe corticosteroid-induced <e1>glaucoma</e1> after intravitreal injection of <e2>triamcinolone acetate</e2> in a 34-year-old man without a history of <e1>glaucoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2439	"RESULTS: A 34-year-old man acquired visual field defects and <e1>severe vision loss</e1> in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2440	"RESULTS: A 34-year-old man acquired <e1>visual field defects</e1> and severe vision loss in both eyes after intravitreal injection of <e2>triamcinolone</e2> for diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2441	"Severe <e1>steroid</e1>-induced <e2>glaucoma</e2> following intravitreal injection of triamcinolone acetonide."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2442	"Severe steroid-induced <e1>glaucoma</e1> following intravitreal injection of <e2>triamcinolone acetonide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2443	"This treatment has the potential to cause severe vision loss as a result of intractable <e1>corticosteroid</e1>-induced <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2444	"This treatment has the potential to cause <e1>severe vision loss</e1> as a result of intractable <e2>corticosteroid</e2>-induced glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2445	"<e1>Autoimmune thyroid disease</e1> is a common side-effect of interferon-alpha (<e2>IFN-alpha</e2>) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2446	"<e1>Autoimmune thyroid disease</e1> is a common side-effect of <e2>interferon-alpha</e2> (IFN-alpha) treatment of viral hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2447	"Destructive thyrotoxicosis appeared 4-6 months after starting <e1>IFN-alpha</e1>, followed by <e2>Graves' hyperthyroidism</e2> within 8 to 11 months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2448	"Destructive <e1>thyrotoxicosis</e1> appeared 4-6 months after starting <e2>IFN-alpha</e2>, followed by Graves' hyperthyroidism within 8 to 11 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2449	"Hence, <e1>hyperthyroidism</e1> induced by <e2>IFN-alpha</e2> could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2450	"<e1>Interferon-alpha</e1>-induced <e2>hyperthyroidism</e2>: a three-stage evolution from silent thyroiditis towards Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2451	"We have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2452	"We have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent thyroiditis followed by <e2>hyperthryroidism</e2> relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2453	"We have described three patients with hepatitis C for whom <e1>IFN-alpha</e1> and ribavirin were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2454	"We have described three patients with hepatitis C for whom IFN-alpha and <e1>ribavirin</e1> were prescribed and who developed two successive phases of silent <e2>thyroiditis</e2> followed by hyperthryroidism relapse due to Graves' disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2455	"<e1>Dipyrone</e1>, also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2456	"Dipyrone, also known as <e1>metamizole</e1>, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2457	"<e1>Dipyrone</e1>-induced <e2>granulocytopenia</e2>: a case for awareness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2458	"We describe a patient who developed <e1>granulocytopenia</e1> and fever after taking <e2>dipyrone</e2> and discuss the available literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2459	"Herein, we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with <e2>efalizumab</e2> and infliximab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2460	"Herein, we describe 2 patients who developed unusual <e1>CD8+ cutaneous lymphoproliferative disorders</e1> after treatment with efalizumab and <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2461	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2462	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, <e2>abdominal pain</e2> and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2463	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2464	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed <e2>fever</e2>, severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2465	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2466	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, <e2>severe cutaneous involvement</e2>, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2467	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2468	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, <e2>swelling</e2>, abdominal pain and transaminitis, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2469	"A 7-year-old with congenital toxoplasmosis who took <e1>pyrimethamine</e1> and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2470	"A 7-year-old with congenital toxoplasmosis who took pyrimethamine and <e1>sulfadiazine</e1> for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and <e2>transaminitis</e2>, persisting weeks after withholding medicines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2471	"Severe <e1>sulfadiazine</e1> <e2>hypersensitivity</e2> in a child with reactivated congenital toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2472	"This case underscores problems in clinical management with <e1>sulfadiazine</e1> <e2>hypersensitivity</e2>, potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2473	"<e1>Fatal lung fibrosis</e1> caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and <e2>carboplatin</e2> as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2474	"<e1>Fatal lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2475	"<e1>Fatal lung fibrosis</e1> caused by <e2>paclitaxel</e2> toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of <e2>paclitaxel</e2> and carboplatin as combination chemotherapy for advanced ovarian cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2476	"<e1>Fatal pulmonary fibrosis</e1> induced by <e2>paclitaxel</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2477	"Physicians should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause pneumonitis and <e2>lung fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2478	"Physicians should keep in mind that taxanes such as <e1>paclitaxel</e1> have the potential to cause <e2>pneumonitis</e2> and lung fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2479	"<e1>Pulmonary fibrosis</e1> is a complication of <e2>paclitaxel</e2> therapy that may occur despite treatments with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2480	"<e1>Infections</e1> are a major adverse effect during the treatment with <e2>anti-TNF-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2481	"In this case report, we have described a patient with Crohn's disease who developed <e1>subfulminant hepatitis B</e1> after the fourth infusion of <e2>infliximab</e2> due to an unrecognized HBs-antigen carrier state."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2482	"<e1>Subfulminant hepatitis B</e1> after <e2>infliximab</e2> in Crohn's disease: need for HBV-screening?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2483	"<e1>Acute unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2484	"The visual loss in this patient seems to result from <e1>phenol</e1> <e2>neurotoxicity</e2> rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2485	"The <e1>visual loss</e1> in this patient seems to result from <e2>phenol</e2> neurotoxicity rather than mechanical compression of the intraorbital optic nerve."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2486	"We report a 78-year-old man who had <e1>acute unilateral total visual loss</e1> after retrogasserian <e2>phenol</e2> injection for the treatment of trigeminal neuralgia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2487	"Drug induced <e1>liver injury</e1> secondary to interferon-beta (<e2>IFN-beta</e2>) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2488	"Drug induced <e1>liver injury</e1> secondary to <e2>interferon-beta</e2> (IFN-beta) in multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2489	"<e1>Grade 3 hepatotoxicity</e1> (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on <e2>IFN beta</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2490	"Post marketing studies of Interferon-beta (<e1>IFN beta</e1>) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2491	"Post marketing studies of <e1>Interferon-beta</e1> (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2492	"We report three cases of <e1>IFN beta</e1> induced <e2>hepatitis</e2> in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2493	"We report three cases of <e1>IFN beta</e1> induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2494	"A 55-year-old woman presented an episode of <e1>acute urticaria</e1> and labial angioedema 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2495	"A 55-year-old woman presented an episode of acute urticaria and <e1>labial angioedema</e1> 60 minutes after ingesting 500 mg of <e2>cloxacillin</e2> for a skin abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2496	"<e1>Allergy</e1> to <e2>cloxacillin</e2> with normal tolerance to amoxicillin and cefuroxime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2497	"Several <e1>hypersensitivity</e1> reactions to <e2>cloxacillin</e2> have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e2>cloxacillin</e2> allergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2498	"Several hypersensitivity reactions to <e1>cloxacillin</e1> have been reported, although <e2>IgE-mediated allergic reactions</e2> to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with <e1>cloxacillin</e1> allergy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2499	"<e1>Cardiac toxicity</e1> related to <e2>BCNU</e2> has not been described well."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2500	"<e1>Myocardial ischemia</e1> associated with high-dose <e2>carmustine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2501	"Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of <e1>myocardial ischemia</e1> during and immediately after <e2>BCNU</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2502	"Adverse reaction in a patient with <e1>aspirin</e1>-induced <e2>asthma</e2> treated with zafirlukast."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2503	"We present a case of <e1>hypereosinophilia</e1> related to <e2>zafirlukast</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2504	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, <e2>edema</e2>, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2505	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, rapidly progressive erythema, edema, and <e2>pain in his right forearm</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2506	"Shortly after chemotherapy and an injection of <e1>pegfilgrastim</e1>, the patient developed poorly defined, <e2>rapidly progressive erythema</e2>, edema, and pain in his right forearm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2507	"A few recent individual case reports have suggested that a <e1>myasthenic syndrome</e1> may be associated with <e2>statin</e2> treatment, but this association is not well described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2508	"<e1>Statin</e1>-associated <e2>myasthenia gravis</e2>: report of 4 cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2509	"We report 4 patients who developed symptoms of <e1>myasthenia gravis</e1> within 2 weeks of starting treatment with a <e2>statin</e2> drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2510	"<e1>Reactivation of cytomegalovirus</e1> probably followed the treatment of Wegener's granulomatosis with corticosteroids and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2511	"After excluding other causes of long QT syndrome, the <e1>HCQ</e1> was suspected as the cause of her <e2>ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2512	"Chronic <e1>hydroxychloroquine</e1> use associated with <e2>QT prolongation</e2> and refractory ventricular arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2513	"Chronic <e1>hydroxychloroquine</e1> use associated with QT prolongation and <e2>refractory ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2514	"CONCLUSION: The chronic use of <e1>HCQ</e1> for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal <e2>cardiac arrhythmias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2515	"We report a case of chronic use of <e1>HCQ</e1> associated with <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2516	"CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with <e1>metformin</e1> might result in more cases of <e2>lactic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2517	"<e1>Severe acidosis</e1> in patients taking <e2>metformin</e2>--rapid reversal and survival despite high APACHE score."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2518	"Case report: lack of control of <e1>diabetes</e1> and weight gain in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2519	"Case report: lack of control of diabetes and <e1>weight gain</e1> in a patient on initiation and rechallenge of therapy with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2520	"The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as <e2>uncontrolled diabetes mellitus</e2> and weight gain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2521	"The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of <e1>olanzapine</e1> to metabolic changes manifested as uncontrolled diabetes mellitus and <e2>weight gain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2522	"The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of weight gain and <e2>uncontrolled diabetes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2523	"The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, <e1>olanzapine</e1> was discontinued because of <e2>weight gain</e2> and uncontrolled diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2524	"PURPOSE: To report a case of traumatic flap dehiscence and <e1>Enterobacter keratitis</e1> 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2525	"PURPOSE: To report a case of <e1>traumatic flap dehiscence</e1> and Enterobacter keratitis 34 months after <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2526	"Traumatic late flap dehiscence and <e1>Enterobacter keratitis</e1> following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2527	"<e1>Traumatic late flap dehiscence</e1> and Enterobacter keratitis following <e2>LASIK</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2528	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with <e2>docetaxel</e2> and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2529	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with <e1>BOOP</e1> after chemotherapy with docetaxel and <e2>gemcitabine</e2> producing severe respiratory insufficiency, and simulating a progression of the tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2530	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2531	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing severe respiratory insufficiency, and simulating a <e2>progression of the tumor</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2532	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with <e1>docetaxel</e1> and gemcitabine producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2533	"We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and <e1>gemcitabine</e1> producing <e2>severe respiratory insufficiency</e2>, and simulating a progression of the tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2534	"A 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with <e2>bloody tears</e2> was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2535	"A 65-year-old man on <e1>warfarin</e1> therapy with a sudden spontaneous onset of <e2>sub-conjunctival haematoma</e2> associated with bloody tears was assessed in the clinic following a referral from an optometrist."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2536	"An unusual presentation of spontaneous <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2537	"Due to discomfort, <e1>diplopia</e1> and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2538	"Due to <e1>discomfort</e1>, diplopia and lagophthalmos, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2539	"Due to discomfort, diplopia and lagophthalmos, the <e1>haematoma</e1> necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2540	"Due to discomfort, diplopia and <e1>lagophthalmos</e1>, the haematoma necessitated suspension of <e2>warfarin</e2> therapy and a surgical evacuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2541	"The <e1>sub-conjunctival haematoma</e1> in a patient receiving <e2>warfarin</e2> can pose a significant management challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2542	"<e1>Angioedema</e1> and maculopapular eruptions associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2543	"Angioedema and <e1>maculopapular eruptions</e1> associated with <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2544	"<e1>Angioedema</e1>, a rare side effect of <e2>carbamazepine</e2>, involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2545	"<e1>Cutaneous eruptions</e1> occur in 3% of individuals administered <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2546	"<e1>Cutaneous rashes</e1> and eruptions can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2547	"Cutaneous rashes and <e1>eruptions</e1> can be caused by many medications, including <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2548	"We report the case of a 27-year-old Indian woman who developed maculopapular rash and <e1>angioedema</e1> secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2549	"We report the case of a 27-year-old Indian woman who developed <e1>maculopapular rash</e1> and angioedema secondary to <e2>carbamazepine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2550	"Severe adenovirus pneumonia (<e1>AVP</e1>) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2551	"<e1>Severe adenovirus pneumonia</e1> (AVP) following <e2>infliximab</e2> infusion for the treatment of Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2552	"We report a case of <e1>severe AVP</e1> three weeks following the administration of <e2>infliximab</e2> for the treatment of Crohn's disease (CD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2553	"First case of <e1>ivermectin</e1>-induced <e2>severe hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2554	"To our knowledge, this is the first case of <e1>ivermectin</e1>-induced <e2>severe liver disease</e2> published in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2555	"We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed <e1>severe hepatitis</e1>, identified 1 month after a single dose of <e2>ivermectin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2556	"CASE REPORT: We hereby report a case of radiation recall dermatitis and <e1>myositis</e1> occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2557	"CASE REPORT: We hereby report a case of <e1>radiation recall dermatitis</e1> and myositis occurring on <e2>gemcitabine</e2> monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2558	"CONCLUSIONS: This is the second case report that describes <e1>gemcitabine</e1>-induced <e2>radiation recall</e2> in rectus abdominus muscles after <e1>gemcitabine</e1>-based radiation therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2559	"<e1>Gemcitabine</e1>-induced <e2>rectus abdominus radiation recall</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2560	"<e1>Sporadic rippling muscle disease</e1> unmasked by <e2>simvastatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2561	"We report a 53-year-old-man who developed <e1>rippling muscle disease</e1> (RMD) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2562	"We report a 53-year-old-man who developed rippling muscle disease (<e1>RMD</e1>) 2 months after starting <e2>simvastatin</e2> therapy for hypercholesterolemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2563	"<e1>Acute coronary syndrome</e1> induced by <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2564	"This case highlights the possible development of <e1>acute coronary syndrome</e1> as a side effect of <e2>Capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2565	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with seizures, <e2>coma</e2> and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2566	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with seizures, coma and <e2>respiratory depression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2567	"Acute severe intoxication with <e1>carbamazepine</e1> is associated with <e2>seizures</e2>, coma and respiratory depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2568	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2569	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the <e2>hepatic enzyme disturbances</e2> reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2570	"After rechallenge with monotherapy <e1>pegvisomant</e1>, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely <e1>pegvisomant</e1> alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2571	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with pegvisomant and <e2>octreotide</e2> long-acting repeatable attributed to the use of pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2572	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2573	"Drug-induced <e1>hepatitis</e1> in an acromegalic patient during combined treatment with <e2>pegvisomant</e2> and octreotide long-acting repeatable attributed to the use of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2574	"The <e1>hepatic enzyme disturbances</e1> normalized after discontinuation of <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2575	"We report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog <e2>octreotide</e2> and the GH receptor antagonist pegvisomant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2576	"We report on a patient with acromegaly who developed severe drug-induced <e1>hepatitis</e1> during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist <e2>pegvisomant</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2577	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2578	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, <e2>anaemia</e2>, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2579	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2580	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, <e2>fever</e2>, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2581	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2582	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and <e2>hypokalaemia</e2> are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2583	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2584	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, <e2>malaise</e2>, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2585	"Amphotericin B (<e1>AmB</e1>) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2586	"<e1>Amphotericin B</e1> (AmB) is effective, but its use is limited by toxicity: <e2>renal impairment</e2>, anaemia, fever, malaise, and hypokalaemia are common."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2587	"DIAGNOSIS: Severe <e1>temozolomide</e1>-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, <e2>brain abscess with Listeria monocytogenes</e2>, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2588	"DIAGNOSIS: Severe <e1>temozolomide</e1>-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and <e2>cutaneous Kaposi's sarcoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2589	"DIAGNOSIS: Severe <e1>temozolomide</e1>-induced <e2>immunosuppression</e2>, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2590	"DIAGNOSIS: Severe <e1>temozolomide</e1>-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic <e2>infections with Pneumocystis jiroveci pneumonia</e2>, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2591	"DIAGNOSIS: Severe <e1>temozolomide</e1>-induced immunosuppression, exacerbated by corticosteroids, with profound <e2>T-cell lymphocytopenia</e2> and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2592	"Listeria brain abscess, Pneumocystis pneumonia and <e1>Kaposi's sarcoma</e1> after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2593	"<e1>Listeria brain abscess</e1>, Pneumocystis pneumonia and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2594	"Listeria brain abscess, <e1>Pneumocystis pneumonia</e1> and Kaposi's sarcoma after <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2595	"PURPOSE: <e1>Topiramate</e1>-induced <e2>angle-closure glaucoma</e2> (TiACG) is believed to be related to its sulfonamide moiety."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2596	"Rapid resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with methylprednisolone and <e2>mannitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2597	"Rapid resolution of topiramate-induced <e1>angle-closure glaucoma</e1> with <e2>methylprednisolone</e2> and mannitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2598	"Rapid resolution of <e1>topiramate</e1>-induced <e2>angle-closure glaucoma</e2> with methylprednisolone and mannitol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2599	"<e1>Spontaneous splenic infarction</e1> associated with <e2>sumatriptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2600	"Though they are generally considered safe, there have been a few reports of <e1>myocardial infarction</e1> and stroke associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2601	"Though they are generally considered safe, there have been a few reports of myocardial infarction and <e1>stroke</e1> associated with <e2>triptan</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2602	"We report a patient who developed <e1>spontaneous splenic infarction</e1> after the use of <e2>sumatriptan</e2> for the treatment of migraine headache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2603	"<e1>Acute myocardial infarction</e1> during high-dose <e2>methylprednisolone</e2> therapy for Graves' ophthalmopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2604	"Except <e1>hypothyroidism</e1> after <e2>radioiodine</e2> treatment (euthyroid under substitutional therapy), she suffered from no other diseases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2605	"Here we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by <e2>myocardial infarction</e2> on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2606	"Here we present the case of a woman who received high doses of <e1>methylprednisolone</e1> (1 g iv daily) for active Graves' ophthalmopathy, and developed <e2>severe hypertension</e2> followed by myocardial infarction on the fifth day of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2607	"We conclude that <e1>myocardial infarction</e1> may develop in patients treated with high-dose <e2>glucocorticoids</e2> for Graves' ophthalmopathy, and increased blood pressure may herald this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2608	"Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (<e1>SASP</e1>) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2609	"Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of <e1>sulphasalazine</e1> (SASP) therapy developed a severe and lasting <e2>psoriasis-like skin reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2610	"<e1>Psoriasis-like skin reaction</e1> in a patient with rheumatoid arthritis after <e2>sulphasalazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2611	"Five days after the fourth dose of <e1>vincristine</e1>, she presented with <e2>bilateral ptosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2612	"<e1>Vincristine</e1> induced <e2>cranial polyneuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2613	"We describe a 5-year-old girl showed recovery of <e1>vincristine</e1> induced <e2>cranial polyneuropathy</e2> with pyridoxine and pyridostigmine treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2614	"<e1>Acute generalized exanthematous pustulosis</e1> caused by <e2>morphine</e2>, confirmed by positive patch test and lymphocyte transformation test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2615	"<e1>Morphine</e1>, an opium alkaloid, frequently causes side effects such as hyperhidrosis and <e2>facial flushing</e2>, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2616	"<e1>Morphine</e1>, an opium alkaloid, frequently causes side effects such as <e2>hyperhidrosis</e2> and facial flushing, but serious cutaneous adverse drug reactions are seldom observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2617	"We describe a case of a man treated with an EGFR-inhibitor (<e1>erlotinib</e1>) for a cell lung cancer who developed <e2>skin manifestations</e2> localized in an uncommon area and with an atypical evolution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2618	"<e1>Olanzapine</e1>-associated <e2>neuroleptic malignant syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2619	"<e1>Allergic contact angioedema</e1> to <e2>benzoyl peroxide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2620	"Factors that suggested an association between the <e1>severe angioedematous reaction</e1> and <e2>BP</e2> topical application include the strong reaction to <e2>BP</e2> in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2621	"A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of <e1>5-fluorouracil</e1> as episodes of <e2>acute confusional state</e2> and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2622	"A 35-year-old woman presented with <e1>neurotoxicity</e1> correlated to an i.v. regimen of <e2>5-fluorouracil</e2> as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2623	"Reversible findings of restricted diffusion in <e1>5-fluorouracil</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2624	"We present the case of a 58-year-old woman who ingested more than 35 g of <e1>caffeine</e1> in a <e2>suicide attempt</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2625	"It may cause a severe adverse drug reaction with multiorgan involvement known as <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2626	"Severe <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2627	"We report the case of a 21-year-old female patient with <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2628	"<e1>Anaphylaxis</e1> to intrathecal <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2629	"We believe this is the first report of intrathecal <e1>diamorphine</e1> causing <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2630	"We highlight two instances of <e1>systemic allergic reaction</e1>, and discuss the potential side effects of local <e2>aprotinin</e2> injections in the orthopaedic setting as well as the evidence base for its use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2631	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2632	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2633	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2634	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2635	"METHOD: Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS/<e2>NMS</e2> features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/<e2>NMS</e2> in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2636	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and <e1>carbamazepine</e1>) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2637	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, <e1>divalproex sodium</e1>, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2638	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, <e1>risperidone</e1>, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2639	"METHOD: Case analysis of a poly-drug overdose (venlafaxine, <e1>topiramate</e1>, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2640	"METHOD: Case analysis of a poly-drug overdose (<e1>venlafaxine</e1>, topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed <e2>SS</e2>/NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated <e2>SS</e2>/NMS in critical care settings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2641	"<e1>Fever</e1> and maculopapular rashes appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2642	"Fever and <e1>maculopapular rashes</e1> appeared at 10 days after <e2>phenytoin</e2> initiation, and then the drug was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2643	"<e1>Localized purpura</e1> associated with <e2>lamotrigine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2644	"This case study is the second report of <e1>localized purpura</e1> after prolonged <e2>lamotrigine</e2> treatment suggesting this may be an atypical <e2>lamotrigine</e2>-induced drug reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2645	"This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed <e1>localized purpura</e1> after 23 months of <e2>lamotrigine</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2646	"<e1>Acute renal failure</e1> during <e2>lisinopril</e2> and losartan therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2647	"<e1>Acute renal failure</e1> during lisinopril and <e2>losartan</e2> therapy for proteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2648	"This report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor <e2>lisinopril</e2> and the ARB losartan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2649	"This report describes a case of acute compromise of renal function associated with <e1>hypotension</e1> in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB <e2>losartan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2650	"<e1>Reversible corneal keratinization</e1> following trabeculectomy and treatment with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2651	"<e1>Bronchiolitis obliterans with organizing pneumonia</e1> after <e2>rituximab</e2> therapy for non-Hodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2652	"Moreover, these findings suggest that the incidence of <e1>BOOP</e1> following <e2>rituximab</e2> therapy may be higher than has been previously appreciated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2653	"This is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2>-based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2654	"This is the first reported case of <e1>BOOP</e1> associated with single-agent <e2>rituximab</e2>, and along with two other patients we describe, as well as two prior reports of <e1>BOOP</e1> in NHL patients receiving <e2>rituximab</e2>-based combinations, strengthens the possibility of a causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2655	"We describe a case of an NHL patient who received <e1>rituximab</e1> and developed symptomatic, biopsy-proven multinodular <e2>bronchiolitis obliterans with organizing pneumonia</e2> (BOOP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2656	"Despite a very low complication rate, several <e1>severe arterial thrombotic events</e1> have been reported following <e2>thrombin</e2> injection of pseudoaneurysms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2657	"Lower extremity <e1>arterial thrombosis</e1> following sonographically guided <e2>thrombin</e2> injection of a femoral pseudoaneurysm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2658	"Native <e1>arterial thrombosis</e1>, though recognized as a severe complication of <e2>thrombin</e2> injection, has not been well described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2659	"We report a case of successful surgical management of <e1>arterial thrombosis</e1> after percutaneous <e2>thrombin</e2> injection of a femoral artery pseudoaneurysm in a 69-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2660	"A small number of <e1>oxaliplatin</e1>-related <e2>hemolytic and/or thrombocytopenic reactions</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2661	"<e1>Hemolytic uremic syndrome</e1> following the infusion of <e2>oxaliplatin</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2662	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, <e2>5-fluorouracil</e2> and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2663	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and <e2>leucovorin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2664	"We present a case of <e1>hemolytic-uremic syndrome</e1> that developed during the 4th cycle of combination chemotherapy with <e2>oxaliplatin</e2>, 5-fluorouracil and leucovorin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2665	"First, a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2666	"First, a review of the literature produced 41 anecdotic cases of neutropenia or <e1>agranulocytosis</e1> during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2667	"First, a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with <e2>olanzapine</e2> (Zyprexa) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2668	"First, a review of the literature produced 41 anecdotic cases of <e1>neutropenia</e1> or agranulocytosis during treatment with olanzapine (<e2>Zyprexa</e2>) reported in a total of 24 publications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2669	"Neutropenia and <e1>agranulocytosis</e1> are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2670	"Neutropenia and <e1>agranulocytosis</e1> are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2671	"<e1>Neutropenia</e1> and agranulocytosis are risks known to occur with phenothiazines and <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2672	"<e1>Neutropenia</e1> and agranulocytosis are risks known to occur with <e2>phenothiazines</e2> and clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2673	"Second, we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving <e2>olanzapine</e2> and thiazide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2674	"Second, we report a case of <e1>neutropenia</e1>, which proved to be fatal in a schizophrenia patient receiving olanzapine and <e2>thiazide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2675	"Thus any case of <e1>severe neutropenia</e1> occurring in a patient receiving <e2>olanzapine</e2> is alarming to clinicians."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2676	"We present a depressive patient who developed mild parkinsonian signs and <e1>camptocormia</e1> after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2677	"We present a depressive patient who developed <e1>mild parkinsonian signs</e1> and camptocormia after the introduction of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2678	"Five months after initiating <e1>mirtazapine</e1> therapy, she developed <e2>symptomatic hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2679	"In this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from <e2>citalopram</e2> to mirtazapine, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2680	"In this case, unlike those previously reported, <e1>hyponatremia</e1> recurred 5 months after switching from citalopram to <e2>mirtazapine</e2>, which is believed to be a safe antidepressant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2681	"<e1>Recurrent hyponatremia</e1> associated with <e2>citalopram</e2> and mirtazapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2682	"<e1>Recurrent hyponatremia</e1> associated with citalopram and <e2>mirtazapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2683	"A 43-year-old woman with multiple sclerosis (MS) had <e1>nephrotic syndrome</e1> 21 months after starting treatment with <e2>interferon (IFN)-beta-1b</e2> (subcutaneous administration)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2684	"Because <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2685	"Because <e1>nephrotic syndrome</e1> may be induced by <e2>IFN</e2> therapy, the <e2>IFN</e2> was stopped."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2686	"<e1>Nephrotic syndrome</e1> associated with <e2>interferon-beta-1b</e2> therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2687	"Though proteinuria and <e1>nephrotic syndrome</e1> is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2688	"Though <e1>proteinuria</e1> and nephrotic syndrome is a rare adverse effect of <e2>IFN-beta-1b</e2> therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2689	"A 70-year-old man was admitted to our hospital because of <e1>dyspnea</e1> after taking an antihistaminic agent (<e2>homochlorcyclizine hydrochloride</e2>) for itching."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2690	"<e1>Acute eosinophilic pneumonia</e1> caused by <e2>calcium stearate</e2>, an additive agent for an oral antihistaminic medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2691	"Therefore, we concluded that this patient's <e1>pulmonary disease</e1> was caused by <e2>calcium stearate</e2>, an additive for an antihistaminic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2692	"<e1>Scleritis</e1> complicating <e2>zoledronic acid</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2693	"We present a case of <e1>severe unilateral posterior scleritis</e1> associated with <e2>zoledronic acid</e2> administration that was recognized and treated in a timely manner."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2694	"Late lethal <e1>hepatitis B virus reactivation</e1> after <e2>rituximab</e2> treatment of low-grade cutaneous B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2695	"Several such <e1>HBV reactivations</e1> were reported after combined <e2>rituximab</e2> and multiagent chemotherapy for B-cell lymphomas."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2696	"This is the first case of <e1>HBV reactivation</e1> occurring during the year following <e2>rituximab</e2> monotherapy in the absence of any other immunosuppressive factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2697	"This is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with prednisolone and <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2698	"This is a case report of fatal <e1>cryptococcal meningitis</e1> in a child with systemic lupus erythematosus being treated with <e2>prednisolone</e2> and azathioprine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2699	"An <e1>intertrigo-like eruption</e1> from pegylated liposomal <e2>doxorubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2700	"This <e1>eruption</e1> appears to be a distinct cutaneous toxicity of <e2>PLD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2701	"We report the case of a 60-year-old woman who developed erythema and <e1>erosions in the axilla and groin</e1> while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2702	"We report the case of a 60-year-old woman who developed <e1>erythema</e1> and erosions in the axilla and groin while on <e2>PLD</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2703	"Herein is reported an unusual case of coexistent <e1>warfarin</e1>-induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2704	"Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2705	"<e1>Warfarin</e1>-induced <e2>skin necrosis</e2> and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2706	"Warfarin-induced skin necrosis and <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> following mitral valve replacement for marantic endocarditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2707	"Exposure of the fetus to <e1>indomethacin</e1> by administration of the drug to the mother may cause many side effects, including <e2>premature closure of the ductus arteriosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2708	"<e1>Hypoxia</e1> is a predisposing factor for premature ductal closure and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2709	"Hypoxia is a predisposing factor for <e1>premature ductal closure</e1> and often occurs after maternal <e2>indomethacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2710	"<e1>Premature closure of the ductus arteriosus</e1>: variable response among monozygotic twins after in utero exposure to <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2711	"This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to <e1>ductal closure</e1> in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2712	"This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to <e1>hypoxia</e1> and thus was more susceptible to ductal closure in response to <e2>indomethacin</e2> exposure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2713	"CONCLUSION: These cases suggest that <e1>moxifloxacin</e1> may interfere with the healing of <e2>corneal ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2714	"RESULTS: Both cases presented here describe <e1>corneal ulcers</e1> that persisted and showed signs of worsening during weeks of frequent topical dosing with <e2>moxifloxacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2715	"<e1>Severe corneal toxicity</e1> after topical <e2>fluoroquinolone</e2> therapy: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2716	"<e1>Acute generalized exanthematous pustulosis</e1> induced by <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2717	"We report a case of <e1>acute generalized exanthematous pustulosis</e1> (AGEP) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2718	"We report a case of acute generalized exanthematous pustulosis (<e1>AGEP</e1>) in a 50-year-old woman that was attributed to the ingestion of <e2>nimesulide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2719	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and <e2>bradycardia</e2> reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2720	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant <e2>cardiac toxicity</e2>, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2721	"DISCUSSION: <e1>Amphotericin B deoxycholate</e1> has been reported to produce significant cardiac toxicity, with <e2>ventricular arrhythmias</e2> and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2722	"OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a <e1>fatal cardiac arrhythmia</e1> after an acute overdose of <e2>amphotericin B</e2> and to review its toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2723	"Use of the Naranjo probability scale indicated a highly probable relationship between the observed <e1>cardiac toxicity</e1> and <e2>amphotericin B deoxycholate</e2> therapy in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2724	"The authors describe a case of <e1>valvular heart disease</e1> in a 48-year-old woman receiving <e2>benfluorex</e2> (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2725	"<e1>Valvular heart disease</e1> in a patient taking <e2>benfluorex</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2726	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, myelo-suppression and <e2>liver dysfunction</e2>, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2727	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, <e2>localized pain</e2>, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2728	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were <e2>low-grade fever</e2>, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2729	"The main side-effects of <e1>Lp-TAE</e1> combined with HT were low-grade fever, localized pain, <e2>myelo-suppression</e2> and liver dysfunction, but these were transient and eventually disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2730	"<e1>Tacrolimus</e1>-induced HUS: an unusual cause of <e2>acute renal failure</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2731	"<e1>Tacrolimus</e1>-induced <e2>HUS</e2>: an unusual cause of acute renal failure in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2732	"Thus, <e1>tacrolimus</e1>-induced HUS is a rare cause of <e2>ARF</e2> in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2733	"Thus, <e1>tacrolimus</e1>-induced <e2>HUS</e2> is a rare cause of ARF in nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2734	"Liver transplantation for <e1>fulminant hepatitis</e1> related to <e2>nevirapine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2735	"We describe a detailed case of <e1>fulminant hepatitis</e1> induced by <e2>nevirapine</e2> (Viramune) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2736	"We describe a detailed case of <e1>fulminant hepatitis</e1> induced by nevirapine (<e2>Viramune</e2>) and treated by liver transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2737	"<e1>Cholelithiasis</e1> and thrombosis of the central retinal vein in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2738	"Cholelithiasis and <e1>thrombosis of the central retinal vein</e1> in a renal transplant recipient treated with <e2>cyclosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2739	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and <e1>azathioprine</e1>, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2740	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of <e1>cyclosporin</e1>, prednisone and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2741	"In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, <e1>prednisone</e1> and azathioprine, developed <e2>thrombosis</e2> of the central retinal vein 5 years following the transplantation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2742	"The use of <e1>cyclosporin</e1> has been associated with the development of <e2>cholelithiasis</e2> in transplant recipients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2743	"<e1>Hepatotoxicity</e1> induced by <e2>cyproterone acetate</e2>: a report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2744	"Three male patients aged 78-83 years are presented, in whom <e1>severe hepatotoxic reactions</e1> emerged after <e2>CPA</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2745	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after <e2>cutaneous leishmaniasis</e2> in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2746	"CASE PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in <e2>corticosteroid</e2> (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2747	"CASE PRESENTATION: Three cases of <e1>Leishmania infantum leishmaniasis</e1> in corticosteroid (<e2>CS</e2>)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with <e2>CS</e2> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e2>CS</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2748	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in <e1>corticosteroid</e1> (CS)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2749	"CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid (<e1>CS</e1>)-treated patients are reported: an isolated <e2>lingual leishmaniasis</e2> in a farmer treated with <e1>CS</e1> for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving <e1>CS</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2750	"<e1>Leishmania infantum leishmaniasis</e1> in <e2>corticosteroid</e2>--treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2751	"However, an association of <e1>Ritalin</e1> with <e2>glaucoma</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2752	"Large dose of <e1>methylphenidate</e1> may cause <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2753	"Large dose of <e1>methylphenidate</e1> may cause cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2754	"<e1>Methylphenidate</e1> (Ritalin)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2755	"Methylphenidate (<e1>Ritalin</e1>)-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2756	"<e1>Methylphenidate</e1> (Ritalin)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2757	"Methylphenidate (<e1>Ritalin</e1>)-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2758	"We report a case of <e1>Ritalin</e1>-associated <e2>cataract</e2> and glaucoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2759	"We report a case of <e1>Ritalin</e1>-associated cataract and <e2>glaucoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2760	"CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome (<e1>CBS</e1>) in patients with severe AMD after intravitreal <e2>Avastin</e2>-injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2761	"CONCLUSIONS: We report a typical symptoms of <e1>Charles-Bonnet syndrome</e1> (CBS) in patients with severe AMD after intravitreal <e2>Avastin</e2>-injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2762	"PURPOSE: To describe <e1>transient structured visual hallucinations</e1> in a patient with vascular age-related macular degeneration (AMD), following an intravitreal <e2>Avastin</e2>-injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2763	"<e1>Visual hallucinations</e1> after intravitreal injection of <e2>bevacizumab</e2> in vascular age-related macular degeneration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2764	"A case of <e1>metoclopramide</e1>-induced <e2>oculogyric crisis</e2> in a 16-year-old girl with cystic fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2765	"A case of <e1>oculogyric crisis</e1> induced by <e2>metoclopramide</e2> is described in this paper."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2766	"However, <e1>cyclosporine</e1> dependency is associated with the risk of <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2767	"<e1>Quinapril</e1> is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to <e2>prolonged hypotension</e2> and, less frequently, transient renal impairment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2768	"<e1>Quinapril</e1> is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, <e2>transient renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2769	"<e1>Cardiomyopathy</e1> after widely separated courses of adriamycin exacerbated by <e2>actinomycin-D</e2> and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2770	"<e1>Cardiomyopathy</e1> after widely separated courses of <e2>adriamycin</e2> exacerbated by actinomycin-D and mithramycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2771	"<e1>Cardiomyopathy</e1> after widely separated courses of adriamycin exacerbated by actinomycin-D and <e2>mithramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2772	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics <e2>actinomycin-D</e2> (NSC-3053) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2773	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and <e2>mithramycin</e2> (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2774	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (<e2>NSC-24559</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2775	"<e1>Exacerbations of the heart failure</e1> were temporally related to the administration of the antitumor antibiotics actinomycin-D (<e2>NSC-3053</e2>) and mithramycin (NSC-24559)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2776	"The pathogenic mechanisms involved in the development of <e1>adriamycin</e1> <e2>cardiomyopathy</e2> are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2777	"<e1>Cardiac hypersensitivity</e1> and myopericarditis have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2778	"Cardiac hypersensitivity and <e1>myopericarditis</e1> have been reported during long-term treatment with <e2>mesalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2779	"We report the case of a man, treated with <e1>mesalazine</e1> for Crohn's disease who developed drug-induced <e2>pericarditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2780	"Acute drug induced <e1>hepatitis</e1> due to <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2781	"CASE REPORT: We report a case of <e1>acute severe hepatitis</e1> resulting from <e2>erlotinib</e2> monotherapy in a patient with locally advanced pancreatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2782	"CONCLUSIONS: <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors gefitinib or <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2783	"CONCLUSIONS: <e1>Acute severe hepatitis</e1> though rare is occasionally observed with EGFR inhibitors <e2>gefitinib</e2> or erlotinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2784	"<e1>Hepatotoxicity</e1> resolved once <e2>erlotinib</e2> was discontinued and serum transaminases returned to baseline normal values."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2785	"<e1>Heparin</e1>-associated <e2>thrombocytopenia</e2> and thrombosis is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2786	"Heparin-associated <e1>thrombocytopenia</e1> and thrombosis is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2787	"<e1>Heparin</e1>-associated thrombocytopenia and <e2>thrombosis</e2> is a severe complication of systemic heparin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2788	"Heparin-associated thrombocytopenia and <e1>thrombosis</e1> is a severe complication of systemic <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2789	"This experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1>-associated <e2>thrombocytopenia</e2> and thrombosis, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2790	"This experience supports the hypothesis that <e1>heparin</e1> can be readministered early to patients with <e1>heparin</e1>-associated thrombocytopenia and <e2>thrombosis</e2>, provided antiplatelet therapy is given."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2791	"Usefulness of antiplatelet drugs in the management of <e1>heparin</e1>-associated <e2>thrombocytopenia</e2> and thrombosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2792	"Usefulness of antiplatelet drugs in the management of <e1>heparin</e1>-associated thrombocytopenia and <e2>thrombosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2793	"RESULTS: A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor tadalafil (<e2>Cialis</e2>) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2794	"RESULTS: A clinical diagnosis of <e1>fixed drug eruption</e1> owing to use of the PDE5 inhibitor <e2>tadalafil</e2> (Cialis) was made."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2795	"Even though only a few cases of this adverse event have been reported in the literature, severe <e1>docetaxel</e1>-induced <e2>pulmonary toxicity</e2> needs to be considered in the differential diagnosis when such patients present with respiratory symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2796	"<e1>Fatal interstitial pneumonitis</e1> associated with <e2>docetaxel</e2> administration in a patient with hormone-refractory prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2797	"The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 <e1>docetaxel</e1> who developed <e2>subacute interstitial pneumonitis-related pulmonary fibrosis</e2> after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2798	"The patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2799	"The patient presented with <e1>fulminant microangiopathic hemolytic anemia</e1> and thrombocytopenia within 48 hr of initiating therapy with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2800	"The patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2801	"The patient presented with fulminant microangiopathic hemolytic anemia and <e1>thrombocytopenia</e1> within 48 hr of initiating therapy with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2802	"<e1>Thrombotic thrombocytopenic purpura</e1> induced by trimethoprim-<e2>sulfamethoxazole</e2> in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2803	"<e1>Thrombotic thrombocytopenic purpura</e1> induced by <e2>trimethoprim</e2>-sulfamethoxazole in a Jehovah's Witness."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2804	"We report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to trimethoprim-<e2>sulfamethoxazole</e2> therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2805	"We report a case of <e1>Thrombotic Thrombocytopenic Purpura</e1> occurring as an allergic response to <e2>trimethoprim</e2>-sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2806	"<e1>Juvenile absence epilepsy</e1> exacerbated by <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2807	"This report describes a case of <e1>paradoxical</e1>, intravenous valproic acid-induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2808	"This report describes a case of paradoxical, intravenous <e1>valproic acid</e1>-induced <e2>seizure exacerbation</e2> in a child with juvenile absence epilepsy, documented by video-electroencephalography."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2809	"<e1>Acute endophthalmitis</e1> following intravitreal bevacizumab (<e2>Avastin</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2810	"<e1>Acute endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> (Avastin) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2811	"CONCLUSIONS: <e1>Infectious endophthalmitis</e1> is a potential complication of intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2812	"METHODS: Two patients with exudative <e1>age-related macular degeneration</e1> were treated sequentially with an intravitreal injection of <e2>bevacizumab</e2> and developed signs of severe but painless infectious endophthalmitis 2 days later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2813	"METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of <e1>bevacizumab</e1> and developed signs of severe but <e2>painless infectious endophthalmitis</e2> 2 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2814	"PURPOSE: To report two cases of <e1>acute endophthalmitis</e1> following intravitreal <e2>bevacizumab</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2815	"<e1>Pulmonary hypertension</e1> during <e2>lithium</e2> therapy: clinical case study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2816	"The authors presented a case of <e1>pulmonary hypertension</e1> during <e2>lithium</e2> therapy, while she has been on <e2>lithium</e2> for 6 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2817	"This is the first report of <e1>pulmonary hypertension</e1> in an adult patient during <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2818	"The patient's <e1>arthritis</e1> flared after the second infusion of <e2>infliximab</e2>, which was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2819	"A 32-year-old man with a family history of type 2 diabetes mellitus presented with <e1>circulatory collapse</e1> and deep coma after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2820	"A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and <e1>deep coma</e1> after 9 days of treatment with <e2>perospirone hydrochloride</e2>, a recently developed atypical antipsychotic agent available only in Japan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2821	"The risk of new-onset <e1>diabetic ketoacidosis</e1> in patients with diabetic risk factors who are taking <e2>perospirone hydrochloride</e2> or other atypical antipsychotics should be kept in mind."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2822	"<e1>Fatal venous thrombembolism</e1> complicating <e2>imatinib</e2> therapy in a patient with metastatic gastrointestinal stromal tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2823	"The possibility of <e1>deep vein thrombosis</e1> caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2824	"We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving <e2>cisplatin</e2> and gemcitabine chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2825	"We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed <e1>status epilepticus</e1> shortly after receiving cisplatin and <e2>gemcitabine</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2826	"Of particular interest in this patient is the <e1>fluctuation of the QT interval</e1> at a stable dose of <e2>methadone</e2>, suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2827	"We present a case report of a patient who developed a <e1>prolonged QT</e1> while being treated with oral <e2>methadone</e2> for a chronic pain syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2828	"AIMS: To present a case of <e1>piloerection</e1> after replacing <e2>fluvoxamine maleate</e2> with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2829	"AIMS: To present a case of <e1>piloerection</e1> after replacing fluvoxamine maleate with <e2>milnacipran hydrochloride</e2>, and to analyse this effect based on receptor occupancy theory."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2830	"CONCLUSIONS: The <e1>piloerection</e1> observed after the replacement of <e2>fluvoxamine</e2> with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2831	"CONCLUSIONS: The <e1>piloerection</e1> observed after the replacement of fluvoxamine with <e2>milnacipran</e2> in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2832	"<e1>Piloerection</e1> induced by replacing <e2>fluvoxamine</e2> with milnacipran."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2833	"<e1>Piloerection</e1> induced by replacing fluvoxamine with <e2>milnacipran</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2834	"CASE PRESENTATION: We report a patient with CF who developed <e1>recurrent eosinophilia</e1> and severe persistent bronchospasm following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2835	"CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and <e1>severe persistent bronchospasm</e1> following repeated administration of preservative-free <e2>tobramycin</e2> by inhalation, beginning at 16 months of age."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2836	"CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and <e1>deterioration of pulmonary function</e1> following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2837	"CONCLUSION: Hypersensitivity reaction should be considered in patients who develop <e1>recurrent eosinophilia</e1> and deterioration of pulmonary function following the use of <e2>tobramycin</e2> by inhalation or by intravenous administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2838	"Inhaled <e1>tobramycin</e1> solution-associated <e2>recurrent eosinophilia</e2> and severe persistent bronchospasm in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2839	"Inhaled <e1>tobramycin</e1> solution-associated recurrent eosinophilia and <e2>severe persistent bronchospasm</e2> in a patient with cystic fibrosis: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2840	"The most serious dental side effect of <e1>bisphosphonate</e1> treatment (particularly when it is administered intravenously) is, paradoxically, <e2>osteonecrosis of the mandible</e2> or the maxilla represented by exposed nonhealing bone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2841	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, <e2>aggravation of arrhythmia</e2>, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2842	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, <e2>hepatotoxicity</e2>, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2843	"Adverse effects of <e1>amiodarone</e1> including <e2>pulmonary toxicity</e2>, hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2844	"Adverse effects of <e1>amiodarone</e1> including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and <e2>thyroid diseases</e2> are well understood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2845	"<e1>Pancreatitis</e1> is a very rare adverse effect associated with the use of <e2>amiodarone</e2>, and only four cases of <e2>amiodarone</e2>-induced pancreatitis have been reported in literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2846	"Pancreatitis is a very rare adverse effect associated with the use of <e1>amiodarone</e1>, and only four cases of <e1>amiodarone</e1>-induced <e2>pancreatitis</e2> have been reported in literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2847	"Under the suspicion of <e1>amiodarone</e1>-induced <e2>acute pancreatitis</e2>, <e1>amiodarone</e1> was substituted by propafenone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2848	"We report a patient who developed <e1>acute pancreatitis</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2849	"DISCUSSION: To our knowledge this is the first reported case of <e1>tuberculous uveitis</e1> following treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2850	"<e1>Tuberculous uveitis</e1> after treatment with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2851	"We report the first case of <e1>tuberculous uveitis</e1> due to <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2852	"A complex pattern of <e1>melanonychia</e1> and onycholysis after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2853	"A complex pattern of melanonychia and <e1>onycholysis</e1> after treatment with <e2>pemetrexed</e2> for lung cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2854	"<e1>Infliximab</e1> and its serious adverse effects are discussed, and other cases of <e2>osteomyelitis</e2> with infliximab use are also reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2855	"Infliximab and its serious adverse effects are discussed, and other cases of <e1>osteomyelitis</e1> with <e2>infliximab</e2> use are also reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2856	"<e1>Osteomyelitis</e1> occurring during <e2>infliximab</e2> treatment of severe psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2857	"Based on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2858	"Based on the Naranjo probability scale, <e1>serotonin syndrome</e1> was a probable adverse reaction associated with co-administration of citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2859	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, <e2>agitation</e2>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2860	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2861	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, <e1>agitation</e1>, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2862	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed <e2>confusion</e2>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2863	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2864	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed <e1>confusion</e1>, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2865	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, <e2>myoclonic jerks</e2> and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2866	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2867	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, <e1>myoclonic jerks</e1> and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2868	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e2>serotonin syndrome</e2>, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2869	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2870	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with <e1>serotonin syndrome</e1>, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2871	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, <e2>tachycardia</e2>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2872	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2873	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, <e1>tachycardia</e1>, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2874	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, <e2>tremors</e2>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2875	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2876	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, <e1>tremors</e1>, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2877	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) <e1>citalopram</e1> developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e2>unsteady gait</e2>, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2878	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2879	"CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and <e1>unsteady gait</e1>, consistent with serotonin syndrome, following initiation of <e2>fentanyl</e2>, and all symptoms and signs resolved following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2880	"CONCLUSION: Healthcare professionals should be aware of the possible development of <e1>serotonin syndrome</e1> as a complication of initiation of <e2>fentanyl</e2> and other phenylpiperidine opioids in patients treated with SSRIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2881	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between fentanyl and <e2>citalopram</e2>, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2882	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2883	"OBJECTIVE: To report a case of <e1>serotonin syndrome</e1> associated with interaction between <e2>fentanyl</e2> and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2884	"<e1>Serotonin syndrome</e1> caused by interaction between <e2>citalopram</e2> and fentanyl."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2885	"<e1>Serotonin syndrome</e1> caused by interaction between citalopram and <e2>fentanyl</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2886	"<e1>Renal failure</e1> after high-dose <e2>methotrexate</e2> in a child homozygous for MTHFR C677T polymorphism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2887	"We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose methotrexate (<e2>HDMTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2888	"We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented <e1>renal failure</e1> following the second cycle of high-dose <e2>methotrexate</e2> (HDMTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2889	"<e1>Docetaxel</e1> induced <e2>Meibomian duct inflammation and blockage</e2> is the likely cause of this presentation in a patient with no history of eyelid masses in the past."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2890	"<e1>Docetaxel</e1>-induced Meibomian duct inflammation and blockage leading to <e2>chalazion</e2> formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2891	"<e1>Docetaxel</e1>-induced <e2>Meibomian duct inflammation and blockage</e2> leading to chalazion formation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2892	"We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly <e1>docetaxel</e1> for 12 weeks and developed significant <e2>eye irritation and dryness</e2> during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2893	"A case of <e1>recall pneumonitis</e1> induced by <e2>gemcitabine</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2894	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed <e2>dry cough</e2>, subfebrile temperatures and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2895	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and <e2>dyspnea</e2> within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2896	"After having received <e1>gemcitabine</e1> on day 1 of the second course, the patient developed dry cough, <e2>subfebrile temperatures</e2> and dyspnea within 48 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2897	"CONCLUSION: <e1>Gemcitabine</e1>-induced <e2>recall pneumonitis</e2> is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2898	"<e1>Radiation recall pneumonitis</e1> induced by <e2>gemcitabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2899	"CONCLUSIONS: For all patients with <e1>vancomycin</e1>-induced <e2>neutropenia</e2>, possible cross-reactivity of teicoplanin should be monitored."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2900	"However, a new episode of <e1>neutropenia</e1>, with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after <e2>teicoplanin</e2> initiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2901	"OBJECTIVE: To report <e1>teicoplanin</e1>-related <e2>neutropenia</e2> that developed after an episode of <e2>neutropenia</e2> induced by vancomycin therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2902	"OBJECTIVE: To report teicoplanin-related <e1>neutropenia</e1> that developed after an episode of <e1>neutropenia</e1> induced by <e2>vancomycin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2903	"<e1>Teicoplanin</e1>-induced <e2>agranulocytosis</e2> that followed vancomycin-induced <e2>agranulocytosis</e2> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2904	"Teicoplanin-induced <e1>agranulocytosis</e1> that followed <e2>vancomycin</e2>-induced <e1>agranulocytosis</e1> suggests a possible cross-reactivity between the 2 drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2905	"<e1>Cutaneous ulceration</e1>: an unusual complication of intravenous <e2>pentamidine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2906	"This is a report of a renal transplant patient with Pneumocystis pneumonia who developed <e1>chemical cellulitis</e1> and ulceration following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2907	"This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and <e1>ulceration</e1> following the extravasation of intravenous <e2>pentamidine</e2> into the soft tissues of the left hand and forearm."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2908	"OBSERVATIONS: A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with <e2>peginterferon alfa-2a</e2> and ribavirin for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2909	"OBSERVATIONS: A 48-year-old woman presented with <e1>disfiguring facial edema</e1> 10 weeks after she began antiviral therapy with peginterferon alfa-2a and <e2>ribavirin</e2> for chronic hepatitis C infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2910	"<e1>Tumor-volume increase</e1> at beginning of primary treatment with topical <e2>interferon alpha 2-beta</e2> in a case of conjunctiva-cornea intraepithelial neoplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2911	"<e1>Flecainide</e1> overdose can rapidly result in profound <e2>cardiovascular collapse</e2>, and is associated with a relatively high mortality."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2912	"Managing <e1>cardiovascular collapse</e1> in severe <e2>flecainide</e2> overdose without recourse to extracorporeal therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2913	"<e1>Ezetimibe</e1>-induced <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2914	"Since its FDA approval in 2002, there are no known citations of <e1>ezetimibe</e1>-induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2915	"Selective estrogen receptor modulator <e1>raloxifene</e1>-associated <e2>aggravation of nonalcoholic steatohepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2916	"This is the first histologically confirmed case of <e1>NASH</e1> that was aggravated by <e2>raloxifene</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2917	"A case of <e1>liver damage</e1> following treatment with <e2>Danazol</e2> for fibrocystic breast disease is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2918	"<e1>Hepatic damage</e1> after <e2>danazol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2919	"<e1>Hypersensitivity pneumonitis-like syndrome</e1> associated with the use of <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2920	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, hypoxia, and <e2>diffuse pulmonary infiltrates</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2921	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom <e2>dyspnea</e2>, fever, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2922	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, <e2>fever</e2>, hypoxia, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2923	"In this report, we describe a patient receiving <e1>lenalidomide</e1> in whom dyspnea, fever, <e2>hypoxia</e2>, and diffuse pulmonary infiltrates developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2924	"Physicians should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1>-like drugs who present with <e2>fever</e2> and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2925	"Physicians should be cognizant of this potential complication in patients receiving <e1>thalidomide</e1> or <e1>thalidomide</e1>-like drugs who present with fever and <e2>pulmonary infiltrates</e2> and fail to improve despite treatment with broad-spectrum antibiotics."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2926	"Thus, the patient's clinical course and workup strongly support a diagnosis of <e1>lenalidomide</e1>-induced <e2>hypersensitivity pneumonitis-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2927	"Intravitreal <e1>triamcinolone</e1> may have had an influence on the <e2>exacerbation of retinochoroiditis</e2> in the posterior pole of the patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2928	"A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced <e1>rapid cognitive decline</e1> after commencement of <e2>ethambutol</e2>, and symptoms fully resolved with cessation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2929	"<e1>Ethambutol</e1> toxicity manifesting as <e2>acute onset psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2930	"<e1>Psoriasis</e1> induced by <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2931	"<e1>Recombinant human interferon-alpha</e1> has been used in the treatment of several cancers, but there have been several reports that it may <e2>exacerbate psoriasis or trigger off its onset</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2932	"We report four patients, three of whom first developed <e1>psoriasis</e1> and one who had an aggravation of the condition during treatment with <e2>interferon-alpha</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2933	"A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking <e2>sulfamethoxazole</e2>/trimethoprim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2934	"A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed <e1>generalized erythema</e1> with high fever 3 weeks after taking sulfamethoxazole/<e2>trimethoprim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2935	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2936	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and <e1>raised intracranial pressure</e1> (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2937	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe <e2>sodium valproic acid</e2> (VPA) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2938	"INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with <e1>severe cerebral swelling</e1> and raised intracranial pressure (ICP) after severe sodium valproic acid (<e2>VPA</e2>) intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2939	"Neurointensive care management of <e1>raised intracranial pressure</e1> caused by severe <e2>valproic acid</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2940	"<e1>Bleomycin</e1> induced <e2>hyperpigmentation</e2> with yolk sac tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2941	"The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the <e1>skin toxicity</e1> of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2942	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, etoposide and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2943	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included <e2>cisplatin</e2>, etoposide and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2944	"We report a child with yolk sac tumor who developed <e1>localized pigmentation</e1> after the first course of chemotherapy regimen that included cisplatin, <e2>etoposide</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2945	"A cause-effect relationship to <e1>capecitabine</e1> was suggested due to resolution of <e2>headache</e2> with <e1>capecitabine</e1> withdrawal and reappearance with <e1>capecitabine</e1> rechallenge."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2946	"BACKGROUND: <e1>Headaches</e1> have been reported as a potential side effect of <e2>capecitabine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2947	"<e1>Capecitabine</e1>-induced <e2>headache</e2> responding to diltiazem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2948	"CCBs should be considered in the treatment of <e1>5-FU</e1> or capecitabine-induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2949	"CCBs should be considered in the treatment of 5-FU or <e1>capecitabine</e1>-induced <e2>headaches</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2950	"The patient developed grade 3 <e1>capecitabine</e1>-induced <e2>headache</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2951	"We hypothesize that <e1>capecitabine</e1>-induced <e2>headache</e2> is vascular in nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2952	"<e1>Brugada type electrocardiographic changes</e1> induced by concomitant use of <e2>lithium</e2> and propafenone in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2953	"<e1>Brugada type electrocardiographic changes</e1> induced by concomitant use of lithium and <e2>propafenone</e2> in patient with Wolff-Parkinson-White syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2954	"We report a case of <e1>ST elevation in right precordial leads</e1> compatible with type 1 Brugada syndrome following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2955	"We report a case of ST elevation in right precordial leads compatible with <e1>type 1 Brugada syndrome</e1> following administration of <e2>propafenone</e2> in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2956	"We postulate that <e1>gastritis</e1> caused by <e2>dexamethasone</e2>, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2957	"We postulate that gastritis caused by dexamethasone, <e1>mucositis</e1> caused by <e2>doxorubicin</e2>, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2958	"<e1>Bortezomib</e1>-induced paralytic ileus is a potential <e2>gastrointestinal side effect</e2> of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2959	"<e1>Bortezomib</e1>-induced <e2>paralytic ileus</e2> is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2960	"<e1>Paralytic ileus</e1> in patients undergoing <e2>bortezomib</e2> treatment has been reported, although a definite attribution to <e2>bortezomib</e2> administration has not been established."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2961	"We report a myeloma patient who developed <e1>severe paralytic ileus</e1> during <e2>bortezomib</e2> therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2962	"A woman developed <e1>delusional parasitosis</e1> when taking <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2963	"<e1>Delusional parasitosis</e1> associated with <e2>phenelzine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2964	"Interstitial pneumonitis and <e1>alveolar hemorrhage</e1> complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2965	"<e1>Interstitial pneumonitis</e1> and alveolar hemorrhage complicating use of <e2>rituximab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2966	"The use of <e1>rituximab</e1> has been uncommonly associated with <e2>delayed pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2967	"Fulminant <e1>metoclopramide</e1> induced <e2>neuroleptic malignant syndrome</e2> rapidly responsive to intravenous dantrolene."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2968	"We report a case of fulminant <e1>neuroleptic malignant syndrome</e1> in a man aged 70 developing within 12 hours of starting six-hourly intravenous <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2969	"The clinical symptoms of <e1>gastric mucosa foveolar hyperplasia</e1> due to long-term <e2>PGE1</e2> therapy simulate hypertrophic pyloric stenosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2970	"The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of <e1>gastric mucosa foveolar hyperplasia</e1> due to prolonged <e2>PGE1</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2971	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of <e1>fatigue</e1>, myalgia, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2972	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and <e1>leg weakness</e1>, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2973	"A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, <e1>myalgia</e1>, and leg weakness, shortly after starting treatment with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2974	"A case of <e1>colchicine</e1>-induced <e2>rhabdomyolysis</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2975	"<e1>Colchicine</e1>-induced <e2>rhabdomyolysis</e2> is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2976	"<e1>Colchicine</e1>-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2977	"Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of <e1>colchicine</e1> resulted in resolution of clinical and biochemical features of <e2>rhabdomylysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2978	"<e1>5-Fluorouracil</e1> <e2>cardiotoxicity</e2> complicating treatment of stage IIB cervical cancer--case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2979	"CONCLUSION: <e1>Acetic acid</e1> is corrosive and may cause <e2>vagina bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2980	"Induction of <e1>systemic lupus erythematosus</e1> by <e2>interferon-gamma</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2981	"The development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2982	"The development of systemic lupus erythematosus (<e1>SLE</e1>) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2983	"The development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with <e2>recombinant human interferon gamma</e2> (rIFN-gamma) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2984	"The development of <e1>systemic lupus erythematosus</e1> (SLE) after 38 months of therapy with recombinant human interferon gamma (<e2>rIFN-gamma</e2>) was observed in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2985	"We assume that <e1>rIFN-gamma</e1> induced the de novo development of <e2>SLE</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2986	"<e1>Bisphosphonate</e1> induced <e2>osteochemonecrosis of the jaw</e2> mimicking a tumour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2987	"<e1>Clozapine</e1>-induced <e2>eosinophilia</e2> and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2988	"Drug-induced <e1>eosinophilia</e1> is a non-dose-dependent side effect of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2989	"Occasionally, despite good therapeutic response, <e1>clozapine</e1> must be stopped due to dangerous side effects such as <e2>agranulocytosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2990	"Metformin-associated <e1>lactic acidosis</e1> (MALA) is a serious metabolic complication that occurs because of <e2>metformin</e2> accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2991	"<e1>Metformin</e1>-associated <e2>lactic acidosis</e2> (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2992	"<e1>Metformin</e1>-associated <e2>lactic acidosis</e2> precipitated by diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2993	"An apparent link is described between the use of <e1>MMF</e1> with prednisone to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2994	"An apparent link is described between the use of MMF with <e1>prednisone</e1> to treat pemphigus vulgaris and the development of <e2>red blood cell anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

2995	"<e1>Red blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of <e2>mycophenolate mofetil</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2996	"<e1>Red blood cell anemia</e1> in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2997	"The dermatology literature heretofore has not noted that <e1>anemia</e1> is a side effect of patients taking <e2>MMF</e2> to treat pemphigus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2998	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, <e2>cyclosporine</e2> and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

2999	"This report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3000	"This report suggests that <e1>anemia</e1> can occur due to <e2>MMF</e2>, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of <e2>MMF</e2>, cyclosporine and prednisone is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3001	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3002	"This report suggests that <e1>anemia</e1> can occur due to MMF, in particular when it is given with <e2>prednisone</e2>, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and <e2>prednisone</e2> is used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3003	"A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of <e1>oxcarbazepine</e1>-associated <e2>angioedema</e2> in pediatric patients aged 16 years and younger."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3004	"Clinical profile of <e1>oxcarbazepine</e1>-related <e2>angioneurotic edema</e2>: case report and review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3005	"<e1>Oxcarbazepine</e1>-associated <e2>angioedema</e2> manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3006	"We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced <e1>angioedema</e1> during treatment with <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3007	"Here we describe another case of <e1>VOD</e1> occurring after LT, but in which the causative role was played by <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3008	"One case of <e1>tacrolimus</e1>-induced <e2>hepatic VOD</e2> developing after lung transplantation (LT) has been recently reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3009	"<e1>Carbamazepine</e1> <e2>hypersensitivity syndrome</e2> is a rare, life-threatening condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3010	"A patient with chronic myelomonocytic leukemia developed drug-induced <e1>pulmonary toxicity</e1> after using low dose oral <e2>etoposide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3011	"Because <e1>etoposide</e1>-induced <e2>pulmonary toxicity</e2> is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3012	"PET scintigraphy of <e1>etoposide</e1>-induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3013	"Detection of antineutrophil cytoplasmic antibody in a patient with <e1>L-tryptophan</e1> induced <e2>eosinophilia-myalgia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3014	"The Center for Disease Control has received numerous reports of an <e1>eosinophilia-myalgia syndrome</e1> related to products containing <e2>L-tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3015	"Here, we report a case of <e1>RFP</e1>-induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3016	"<e1>Rifampin</e1>-induced <e2>hypothyroidism</e2> without underlying thyroid disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3017	"Rifampin (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1>-induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3018	"<e1>Rifampin</e1> (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with <e2>Hashimoto's thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3019	"Rifampin (<e1>RFP</e1>) increases hepatic microsomal enzyme activity, and there are case reports of <e1>RFP</e1>-induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3020	"<e1>Rifampin</e1> (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced <e2>hypothyroidism</e2>, all associated with Hashimoto's thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3021	"A patient is described who developed a rapid onset of <e1>pulmonary fibrosis</e1> following treatment with a new non-steroidal anti-inflammatory drug, <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3022	"<e1>Pulmonary fibrosis</e1> associated with <e2>nabumetone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3023	"<e1>Cyclosporine</e1> is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3024	"Cyclosporine is a potent inhibitor of <e1>simvastatin</e1> metabolism, and may therefore facilitate <e1>simvastatin</e1>-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3025	"Discontinuation of simvastatin and <e1>cyclosporine</e1> resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3026	"Discontinuation of <e1>simvastatin</e1> and cyclosporine resulted in resolution of <e2>rhabdomyolysis</e2> and normalization of renal function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3027	"Simvastatin-induced <e1>rhabdomyolysis</e1> following <e2>cyclosporine</e2> treatment for uveitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3028	"<e1>Simvastatin</e1>-induced <e2>rhabdomyolysis</e2> following cyclosporine treatment for uveitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3029	"<e1>Generalized lichen nitidus</e1> with involvement of the palms following <e2>interferon alpha</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3030	"Here we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with <e2>interferon alpha</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3031	"Here we present the case of a <e1>generalized lichen nitidus</e1> with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3032	"It is tempting to speculate that <e1>interferon alpha</e1> may be involved in the pathogenesis of <e2>lichen nitidus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3033	"<e1>Sirolimus-eluting stent thrombosis</e1> several years after <e2>clopidogrel</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3034	"Treatment of APL in pregnancy is controversial as the use of <e1>ATRA</e1> has been questioned due to the <e2>teratogenic effect</e2> of retinoids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3035	"Interstitial lung disease (<e1>ILD</e1>) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3036	"<e1>Interstitial lung disease</e1> (ILD) related to therapy with the drug <e2>gefitinib</e2> has been well reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3037	"<e1>Pulmonary toxicity</e1> associated with <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3038	"Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known <e1>pulmonary fibrosis</e1> may be at particular risk for <e2>erlotinib</e2> pulmonary toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3039	"Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for <e1>erlotinib</e1> <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3040	"This case and other published evidence should alert physicians to the possibility of fatal <e1>erlotinib</e1>-induced <e2>ILD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3041	"We report a case of <e1>fatal pulmonary toxicity</e1> in a patient with advanced non-small cell lung cancer who received <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3042	"It has been reported that <e1>fluoroquinolone</e1> antimicrobials prolong the corrected QT interval but rarely cause <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3043	"<e1>Torsade de pointes</e1> associated with <e2>moxifloxacin</e2>: a rare but potentially fatal adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3044	"AIM: To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent terlipressin (<e2>Glypressin</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3045	"AIM: To report three cases of extensive <e1>skin necrosis</e1> in cirrhotic patients treated with the vasoconstrictor agent <e2>terlipressin</e2> (Glypressin)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3046	"Both <e1>colchicine</e1> and statin therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3047	"Both colchicine and <e1>statin</e1> therapy may be associated with <e2>myopathy</e2>, which usually occurs after several months of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3048	"Rapid onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3049	"Rapid onset of <e1>muscle weakness</e1> (rhabdomyolysis) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3050	"Rapid onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of simvastatin and <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3051	"Rapid onset of muscle weakness (<e1>rhabdomyolysis</e1>) associated with the combined use of <e2>simvastatin</e2> and colchicine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3052	"The concomitant use, however, of <e1>colchicine</e1> and statin has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3053	"The concomitant use, however, of colchicine and <e1>statin</e1> has been associated with the rapid onset of <e2>muscle weakness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3054	"We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed <e1>acute weakness</e1> within 3 weeks after the start of treatment with <e2>colchicine</e2> for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3055	"We report a case of a patient with mild chronic renal insufficiency who had been taking <e1>simvastatin</e1> for over a year and developed <e2>acute weakness</e2> within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3056	"We report a case of a patient with <e1>mild chronic renal insufficiency</e1> who had been taking <e2>simvastatin</e2> for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3057	"<e1>Pneumocystis carinii pneumonia</e1> as a complication of <e2>methotrexate</e2> treatment of asthma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3058	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with <e2>fever</e2>, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3059	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, pulmonary infiltrates, and <e2>hypoxia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3060	"<e1>Pneumocystis pneumonia</e1> should be considered in asthmatic patients taking <e2>methotrexate</e2> who present with fever, pulmonary infiltrates, and hypoxia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3061	"Pneumocystis pneumonia should be considered in asthmatic patients taking <e1>methotrexate</e1> who present with fever, <e2>pulmonary infiltrates</e2>, and hypoxia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3062	"CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a <e1>unilateral hearing loss</e1> shortly after commencing <e2>desferrioxamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3063	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), <e2>abdominal sepsis</e2> (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3064	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), <e2>cellulitis</e2> (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3065	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), <e2>disseminated herpes zoster</e2> (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3066	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and <e2>gastroenteritis</e2> (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3067	"Eleven patients developed <e1>infection</e1> requiring hospitalization while taking <e2>leflunomide</e2> including: lower respiratory tract <e1>infection</e1>s (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3068	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: <e2>lower respiratory tract infections</e2> (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3069	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), <e2>mycotic aneurysm</e2> (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3070	"Eleven patients developed infection requiring hospitalization while taking <e1>leflunomide</e1> including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable <e2>TB liver</e2> (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3071	"<e1>Leflunomide</e1>-associated <e2>infections</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3072	"The NZ Pharmacovigilance Centre has received 7 additional reports of <e1>severe infections</e1> in patients with RA taking <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3073	"A 58-year-old woman with rheumatoid arthritis (RA) developed <e1>fever</e1>, skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3074	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, <e1>leukocytopenia</e1>, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3075	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, <e1>skin eruptions</e1>, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3076	"A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and <e1>thrombocytopenia</e1>, 3 weeks after treatment with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3077	"<e1>Sulfasalazine</e1>-induced hypersensitivity syndrome and <e2>hemophagocytic syndrome</e2> associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3078	"<e1>Sulfasalazine</e1>-induced <e2>hypersensitivity syndrome</e2> and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3079	"This case illustrates that the <e1>hemophagocytic syndrome</e1> associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3080	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from <e2>carbamazepine</e2> (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3081	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine (<e2>CBZ</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3082	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of oxcarbazepine (<e2>OXC</e2>), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3083	"The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into <e1>status migrainosus</e1> after the introduction of <e2>oxcarbazepine</e2> (OXC), as part of a switch off from carbamazepine (CBZ)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3084	"Uncontrolled <e1>headache</e1> induced by <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3085	"CONCLUSION: A patient with CHF and ESRD developed <e1>myoclonic muscle spasms</e1> after receiving <e2>dobutamine</e2> by continuous i.v. infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3086	"<e1>Myoclonus</e1> associated with continuous <e2>dobutamine</e2> infusion in a patient with end-stage renal disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3087	"PURPOSE: The occurrence of <e1>myoclonus</e1> associated with continuous i.v. infusion of <e2>dobutamine</e2> in a patient with end-stage renal disease (ESRD) is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3088	"Reports of <e1>colonic perforation</e1> as a result of the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3089	"Reports of <e1>colonic perforation</e1> as a result of the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3090	"We concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3091	"We concluded that the <e1>colonic ulcer</e1> and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3092	"We concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of <e2>calcium polystyrene sulfonate</e2> and sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3093	"We concluded that the colonic ulcer and the <e1>sigmoidovesical fistula</e1> had been caused by the administration of calcium polystyrene sulfonate and <e2>sorbitol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3094	"<e1>Psychosis</e1> in a 12-year-old HIV-positive girl with an increased serum concentration of <e2>efavirenz</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3095	"We report (to our knowledge, for the first time in a child) the emergence of <e1>psychosis</e1> in a 12-year old white girl with an increased <e2>efavirenz</e2> concentration and heterozygous gene polymorphism of the CYP2B6-G516T."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3096	"<e1>Mycobacterium marinum infection</e1> complicating Crohn's disease, treated with <e2>infliximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3097	"<e1>Sustained monomorphic ventricular tachycardia</e1> after <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3098	"We present a case of a <e1>sustained monomorphic ventricular tachycardia</e1> following <e2>adenosine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3099	"Surprisingly, we found that three patients appeared to develop <e1>tardive OGC</e1> while taking <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3100	"<e1>Tardive oculogyric crisis</e1> during treatment with <e2>clozapine</e2>: report of three cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3101	"<e1>Metronidazole</e1> <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3102	"Two patients are described who developed <e1>sensory neuropathy</e1> after the ingestion of 30.6 and 114 g <e2>metronidazole</e2> respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3103	"We report a case of a patient with rheumatoid arthritis treated with low-dose <e1>methotrexate</e1> (15 mg/week) who developed <e2>infection with both M. tuberculosis and M. chelonae</e2> after the revision of a prosthetic hip."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3104	"DIAGNOSIS: <e1>Sustained ventricular tachycardia</e1> possibly owing to <e2>thalidomide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3105	"<e1>Multiple syncopal episodes</e1> started to occur during <e2>thalidomide</e2> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3106	"Multiple syncopal episodes started to occur during <e1>thalidomide</e1> treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of <e2>sustained ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3107	"<e1>Sustained ventricular tachycardia</e1> in a <e2>thalidomide</e2>-treated patient with primary plasma-cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3108	"A patient developed typical <e1>ECM</e1> after subcutaneous selfinjection of <e2>glatiramer acetate</e2> for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3109	"<e1>Embolia cutis medicamentosa</e1> following subcutaneous injection of <e2>glatiramer acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3110	"This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) <e1>glatiramer acetate</e1> can induce <e2>skin necrosis</e2> as a side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3111	"Although it is difficult to be certain of the direct link of <e1>amiodarone</e1> on the basis of a single case, it is reasonable to presume that this histopathology is associated with <e1>amiodarone</e1>-induced <e2>hypothyroidism</e2> and that involution changes represent the hypofunctional status of this drug-induced disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3112	"<e1>Amiodarone</e1> is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause <e2>thyroid dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3113	"Histopathology of the thyroid in <e1>amiodarone</e1>-induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3114	"This is the first report on the histopathological findings of thyroid tissue from a patient with <e1>amiodarone</e1>-induced <e2>hypothyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3115	"Although adverse effects are usually mild, the author reports here a case of <e1>leucocytopenia</e1> and thrombocytopenia with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3116	"Although adverse effects are usually mild, the author reports here a case of leucocytopenia and <e1>thrombocytopenia</e1> with <e2>quetiapine</e2> treatment that required its discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3117	"<e1>Quetiapine</e1>-induced <e2>leucopenia</e2> and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3118	"<e1>Quetiapine</e1>-induced leucopenia and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3119	"<e1>Amphotericin B</e1>-induced <e2>cutaneous leucocytoclastic vasculitis</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3120	"<e1>Palpable purpuric skin lesions</e1> on the anterior surface of both legs appeared on the 55th day of <e2>amphotericin B</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3121	"We present a case of <e1>cutaneous leucocytoclastic vasculitis</e1> in which <e2>amphotericin B</e2> might presumably be the aetiological factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3122	"The incidence of <e1>5-fluorouracil</e1> (5-FU)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3123	"The incidence of 5-fluorouracil (<e1>5-FU</e1>)-related <e2>cardiotoxicity</e2> seems to be dosage and schedule dependent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3124	"<e1>Transient asymptomatic bradycardia</e1> in patients on infusional <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3125	"We report such a series of patients who had <e1>transient asymptomatic bradycardia</e1> after being treated with continuous infusion <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3126	"According to the Naranjo probability scale, the <e1>papular eruption</e1> was probably caused by <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3127	"CONCLUSIONS: The pathogenesis of <e1>methotrexate</e1>-induced <e2>papular eruption</e2> in collagen vascular diseases may suggest cutaneous small-vessel vasculitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3128	"DISCUSSION: <e1>Methotrexate</e1>-induced <e2>papular eruption</e2> is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3129	"<e1>Methotrexate</e1>-induced <e2>papular eruption</e2> following treatment of psoriasis has not been previously reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3130	"<e1>Methotrexate</e1>-induced <e2>papular eruption</e2> following treatment of psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3131	"OBJECTIVE: To report a case of a <e1>diffuse papular eruption</e1> following treatment of psoriasis with <e2>methotrexate</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3132	"Pathogenesis of <e1>methotrexate</e1>-induced papular eruption in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1>-induced <e2>cutaneous vasculitis</e2> in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3133	"Pathogenesis of <e1>methotrexate</e1>-induced <e2>papular eruption</e2> in psoriasis may involve immune mechanisms other than those of <e1>methotrexate</e1>-induced cutaneous vasculitis in collagen vascular disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3134	"Ten hours after the second <e1>methotrexate</e1> injection, the patient experienced a <e2>diffuse pruritic papular eruption</e2> located mainly on the limbs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3135	"<e1>Metabolic acidosis</e1> induced by <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3136	"<e1>Pericardial hemorrhage</e1> due to <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3137	"The authors describe <e1>pericardial hemorrhage</e1>, which is related to the use of low-dose <e2>acetylsalicylic acid</e2> in a patient with essential thrombocythemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3138	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), <e1>nelfinavir</e1> (<e2>cutaneous rash</e2>), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3139	"From 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (renal colic and <e2>fever</e2>), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3140	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (<e2>nausea</e2> and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3141	"From 1996 to 2002 several medications were changed due to their adverse effects: <e1>indinavir</e1> (<e2>renal colic</e2> and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3142	"From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and <e1>efavirenz</e1> (nausea and <e2>temporary memory loss</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3143	"Conventional and diffusion-weighted MRI findings of <e1>methotrexate</e1> related <e2>sub-acute neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3144	"This case demonstrates the value of DWI in evaluation and diagnosis of <e1>sub-acute toxic leukoencephalopathy</e1> in patients being treated with <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3145	"We describe longitudinal diffusion-weighted MRI findings of <e1>sub-acute leukoencephalopathy</e1> following <e2>methotrexate</e2> therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3146	"New onset of <e1>CD</e1> may be considered as an immune-mediated injury induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3147	"New onset of CD may be considered as an <e1>immune-mediated injury</e1> induced by <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3148	"New onset of <e1>Crohn's disease</e1> during treatment of active ankylosing spondylitis with <e2>etanercept</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3149	"Typical symptoms of active <e1>CD</e1> occurred 11, 12, and 26 months after start of <e2>etanercept</e2> therapy, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3150	"We describe 3 AS patients treated with <e1>etanercept</e1> for active AS who developed new onset of <e2>CD</e2> while AS related symptoms responded well to <e1>etanercept</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3151	"<e1>Upper gastrointestinal haemorrhage</e1> is a serious complication of <e2>aspirin</e2> and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3152	"<e1>Upper gastrointestinal haemorrhage</e1> is a serious complication of aspirin and <e2>clopidogrel</e2> (dual) anti-platelet therapy with a high morbidity and mortality."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3153	"While <e1>doxorubicin</e1> was administered, the patient presented thoracic pain and <e2>breathing distress</e2> due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3154	"While <e1>doxorubicin</e1> was administered, the patient presented <e2>thoracic pain</e2> and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3155	"<e1>Severe hepatocellular dysfunction</e1> following <e2>cyproterone acetate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3156	"We report 3 patients with severe hepatocellular damage due to <e1>CPA</e1> therapy, 2 with <e2>fatal fulminant hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3157	"We report 3 patients with <e1>severe hepatocellular damage</e1> due to <e2>CPA</e2> therapy, 2 with fatal fulminant hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3158	"She was treated with <e1>acyclovir</e1> and subsequently developed <e2>VZV antigen-positive zoster</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3159	"According to the Naranjo adverse drug reaction probability scale, the likelihood that <e1>temozolomide</e1> was responsible for the adverse drug reaction of <e2>fever</e2> was probable (score of 6)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3160	"Clinicians should be aware that an erythematous and <e1>exfoliative rash</e1> may be induced by <e2>temozolomide</e2>, and be familiar with the pharmacologic and supportive measures necessary for its treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3161	"Due to the severity of the <e1>rash</e1>, <e2>temozolomide</e2> was permanently discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3162	"<e1>Temozolomide</e1>-induced <e2>desquamative skin rash</e2> in a patient with metastatic melanoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3163	"<e1>Temozolomide</e1> was restarted 2 months later; the patient again developed a <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3164	"<e1>Exfoliative dermatitis</e1> secondary to <e2>tobramycin sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3165	"We report a case of <e1>exfoliative dermatitis</e1> clearly linked to intravenous and intraperitoneal administration of <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3166	"<e1>Rituximab-CHOP</e1> induced <e2>interstitial pneumonitis</e2> in patients with disseminated extranodal marginal zone B cell lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3167	"<e1>Phenytoin</e1> toxicity: an easily missed cause of <e2>cerebellar syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3168	"A diagnosis of <e1>trastuzumab</e1>-induced <e2>pneumonitis</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3169	"A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a <e1>plural effusion dyspnoea</e1> after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3170	"A female patient with HER2 positive, metastatic breast cancer presented with <e1>pulmonary infiltrates</e1>, and a plural effusion dyspnoea after several months of <e2>trastuzumab</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3171	"Life-threatening <e1>interstitial lung disease</e1> associated with <e2>trastuzumab</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3172	"A 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to <e2>4-chloro-7-nitrobenzofurazan</e2> (NBD-Cl)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3173	"A 30-year-old pharmacist suffered from <e1>acute allergic contact dermatitis</e1> due to 4-chloro-7-nitrobenzofurazan (<e2>NBD-Cl</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3174	"<e1>Allergic contact dermatitis</e1> from <e2>4-chloro-7-nitrobenzofurazan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3175	"<e1>Photo-onycholysis</e1> caused by olanzapine and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3176	"<e1>Photo-onycholysis</e1> caused by <e2>olanzapine</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3177	"We report the case of a woman who developed <e1>photo-onycholysis</e1> on multiple nails after uptake of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3178	"<e1>Diffuse alveolar hemorrhage</e1> after <e2>leflunomide</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3179	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, <e1>hemoptysis</e1>, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3180	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and <e1>severe weakness</e1>, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3181	"We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset <e1>short-of-breath</e1>, hemoptysis, and severe weakness, about 2 weeks after the administration of <e2>leflunomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3182	"<e1>Hyponatraemia</e1> developed after rechallenge with controlled release <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3183	"<e1>Hyponatraemia</e1> during low-dose <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3184	"We report the syndrome of inappropriate <e1>antidiuresis</e1> as a much earlier side-effect of <e2>carbamazepine</e2> administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3185	"In the present paper, we describe two patients with active UC who developed a <e1>severe systemic CMV infection</e1> during a treatment with an oral microemulsion form of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3186	"A short review on <e1>imatinib</e1>-related <e2>hepatotoxicity</e2> is also presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3187	"<e1>Imatinib mesylate</e1>-related <e2>fatal acute hepatic failure</e2> in a patient with chronic myeloid leukaemia and chronic hepatitis B infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3188	"Up to four percent of patients treated with <e1>imatinib</e1> may develop <e2>hepatotoxicity</e2>, which usually resolves with discontinuation of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3189	"We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with herpetic rash and <e2>acute liver failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3190	"We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on <e1>imatinib</e1> treatment, presenting with <e2>herpetic rash</e2> and acute liver failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3191	"CONCLUSIONS: Clinicians treating elderly patients with <e1>olanzapine</e1> should be aware of the potential for rapidly developing <e2>hyperglycemia</e2> and monitor such patients accordingly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3192	"OBJECTIVE: To report a case of rapidly occurring <e1>hyperglycemia</e1> that occurred in a geriatric patient 3 days after treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3193	"Rapidly developing <e1>hyperglycemia</e1> during treatment with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3194	"Subsequently, he developed <e1>hyperglycemia</e1> (fasting blood glucose 138 mg/dL) that resolved when <e2>olanzapine</e2> was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with <e2>olanzapine</e2> 2.5 mg twice daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3195	"There have been numerous case reports of <e1>hyperglycemia</e1> with <e2>olanzapine</e2> in the literature, but none reported <e1>hyperglycemia</e1> within days of initiation of the medication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3196	"<e1>Adult respiratory distress syndrome</e1> after treatment with <e2>pegylated interferon alpha-2a</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3197	"<e1>Adult respiratory distress syndrome</e1> after treatment with pegylated interferon alpha-2a and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3198	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3199	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3200	"We report the first case of fulminant <e1>adult respiratory distress syndrome</e1> (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3201	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (<e2>pegIFNalpha-2a</e2>) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3202	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with <e2>pegylated interferon alpha-2a</e2> (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3203	"We report the first case of fulminant adult respiratory distress syndrome (<e1>ARDS</e1>) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and <e2>ribavirin</e2> use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3204	"<e1>Bilateral anterior uveitis</e1> associated with <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3205	"PURPOSE: To report a case of <e1>bilateral anterior uveitis</e1> associated with ovulation induction therapy using <e2>clomiphene citrate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3206	"Development of <e1>tics</e1> in a thirteen-year-old male following <e2>atomoxetine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3207	"There are, however, case studies describing patients experiencing recurrences of <e1>tics</e1> following treatment with <e2>atomoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3208	"A 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant <e2>alpha-2b peginterferon</e2> plus ribavirin for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3209	"A 51-year-old man developed <e1>type 1 diabetes mellitus</e1> following 24 weeks of treatment with recombinant alpha-2b peginterferon plus <e2>ribavirin</e2> for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3210	"The clinical course suggested that <e1>recombinant alpha-2b peginterferon</e1> plus ribavirin provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3211	"The clinical course suggested that recombinant alpha-2b peginterferon plus <e1>ribavirin</e1> provoked <e2>type 1 diabetes mellitus</e2>, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3212	"<e1>Type 1 diabetes mellitus</e1> provoked by <e2>peginterferon alpha-2b</e2> plus ribavirin treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3213	"<e1>Type 1 diabetes mellitus</e1> provoked by peginterferon alpha-2b plus <e2>ribavirin</e2> treatment for chronic hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3214	"BACKGROUND: To describe the occurrence of <e1>ocular hypertension</e1> in four patients following injection of <e2>ranibizumab</e2> intravitreally."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3215	"CONCLUSION: Severe and <e1>sustained ocular hypertension</e1> may occur after intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3216	"<e1>Ocular hypertension</e1> occurred 1 month after the second <e2>ranibizumab</e2> injection in patients 1 and 3, and 1 month after the first <e2>ranibizumab</e2> in patient 2."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3217	"<e1>Persisent ocular hypertension</e1> following intravitreal <e2>ranibizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3218	"Methylphenidate and <e1>dextroamphetamine</e1>-induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3219	"<e1>Methylphenidate</e1> and dextroamphetamine-induced <e2>peripheral vasculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3220	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3221	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with <e2>acral cyanosis</e2>, livedo reticularis, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3222	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3223	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, <e2>livedo reticularis</e2>, or Raynaud phenomenon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3224	"We report 4 patients, 2 on methylphenidate and 2 on <e1>dextroamphetamine</e1> who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3225	"We report 4 patients, 2 on <e1>methylphenidate</e1> and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or <e2>Raynaud phenomenon</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3226	"<e1>Disseminated eruptive giant mollusca contagiosa</e1> in an adult psoriasis patient during <e2>efalizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3227	"We report a 45-year-old psoriasis patient who developed <e1>eruptive mollusca contagiosa</e1> during an antipsoriatic treatment with <e2>efalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3228	"Gastric tumor, endometrial carcinoma and <e1>cervical adenocarcinoma</e1> in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3229	"Gastric tumor, <e1>endometrial carcinoma</e1> and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3230	"<e1>Gastric tumor</e1>, endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3231	"<e1>Incomplete posterior hyaloid detachment</e1> after intravitreal <e2>pegaptanib</e2> injection in diabetic macular edema."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3232	"The authors report one case of <e1>incomplete posterior hyaloid detachment</e1> (PHD) following intravitreal <e2>pegaptanib</e2> to treat DME."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3233	"<e1>Enalaprilat</e1> induced <e2>acute parotitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3234	"We present here a female patient who developed <e1>acute bilateral parotitis</e1> within minutes of i.v. <e2>enalaprilat</e2> injection and recovered within 24 hours of stopping the drug and with symptomatic treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3235	"We report a 4-year-old girl who presented with <e1>acute bilateral blindness</e1>, a focal seizure and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3236	"We report a 4-year-old girl who presented with acute bilateral blindness, a <e1>focal seizure</e1> and hypertension 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3237	"We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and <e1>hypertension</e1> 10 days after commencing <e2>oxybutynin</e2> to treat enuresis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3238	"<e1>Severe symptomatic hyponatremia</e1> during <e2>sibutramine</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3239	"The known side effects of <e1>sibutramine</e1>, ie, <e2>hypertension</e2> and tachycardia, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3240	"The known side effects of <e1>sibutramine</e1>, ie, hypertension and <e2>tachycardia</e2>, depend on its adrenergic and serotoninergic effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3241	"We describe a case of life-threatening <e1>hyponatremia</e1> associated with <e2>sibutramine</e2> use in an obese woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3242	"Our findings reveal that even in patients without a history of seizures, <e1>pregabalin</e1> can cause a <e2>cortical negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3243	"<e1>Pregabalin</e1>-induced <e2>cortical negative myoclonus</e2> in a patient with neuropathic pain."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3244	"We describe a patient who, after receiving his first dose of <e1>pregabalin</e1> to relieve neuropathic pain, presented with a <e2>negative myoclonus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3245	"<e1>Muzolimine</e1>-induced <e2>severe neuromyeloencephalopathy</e2>: report of seven cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3246	"We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic <e1>muzolimine</e1> (range 240 to 1440 mg per day) <e2>fatal neuromyeloencephalopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3247	"<e1>L-asparaginase</e1>-induced <e2>posterior reversible encephalopathy</e2> syndrome during acute lymphoblastic leukemia treatment in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3248	"The purpose of this article is to present the first case-series of <e1>posterior reversible encephalopathy syndrome</e1> (PRES) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3249	"The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome (<e1>PRES</e1>) associated with <e2>L-asparaginase</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3250	"We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and <e1>altered sensorium</e1> after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3251	"We report 3 cases of children with acute lymphoblastic leukemia who developed <e1>seizures</e1> and altered sensorium after <e2>L-asparaginase</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3252	"<e1>Anastrozole</e1>-associated <e2>sclerosing glomerulonephritis</e2> in a patient with breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3253	"CONCLUSIONS: <e1>Anastrozole</e1> may be the causative factor in patients with <e2>sclerosing glomerulonephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3254	"Diagnosis of <e1>sclerosing glomerulonephritis</e1> occurred in this patient during <e2>anastrozole</e2> use, suggesting a newly defined side effect of <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3255	"<e1>Renal injury</e1> due to <e2>anastrozole</e2> has not been published in the English literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3256	"There are major side effects of <e1>anastrozole</e1> including <e2>decrease in both lumbar spine</e2> and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3257	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and <e2>increase in the cholesterol level</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3258	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, <e2>increase in the incidence of all bone fractures</e2> (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3259	"There are major side effects of <e1>anastrozole</e1> including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), <e2>joint disorders</e2> and increase in the cholesterol level."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3260	"We believe that the <e1>acute renal failure</e1> in our patient was associated with <e2>anastrozole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3261	"CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed <e1>acute hepatitis</e1> one week after the final dose of a long-term course of pulse <e2>itraconazole</e2> therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3262	"CONCLUSIONS: Prolonged exposure to <e1>itraconazole</e1>, administered either continuously or intermittently, may precipitate <e2>severe and irreversible hepatotoxic events</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3263	"<e1>Fatal hepatitis</e1> after long-term pulse <e2>itraconazole</e2> treatment for onychomycosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3264	"OBJECTIVE: To report the occurrence of <e1>acute cytolytic hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2>-induced hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3265	"OBJECTIVE: To report the occurrence of acute cytolytic <e1>hepatitis</e1> in a patient exposed to pulse <e2>itraconazole</e2> therapy for 24 weeks and provide a concise review of the literature on cases of <e2>itraconazole</e2>-induced <e1>hepatitis</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3266	"Only one case of <e1>severe symptomatic hepatitis</e1> occurring after pulse therapy with <e2>itraconazole</e2> for onychomycosis and requiring transplantation has been reported previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3267	"CONCLUSIONS: Intrathecal <e1>baclofen</e1> can <e2>impair sexual function</e2> and ejaculation in some patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3268	"RESULTS: A male and a female patient with spasticity treated with intrathecal <e1>baclofen</e1> were recognized to have <e2>sexual dysfunction</e2> side effects from treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3269	"<e1>Sexual dysfunction</e1> associated with intrathecal <e2>baclofen</e2> use: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3270	"<e1>Anaphylactic reaction</e1> to <e2>recombinant insulin-like growth factor-I</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3271	"We report a 13 year-old male who developed life-threatening <e1>anaphylaxis</e1> early in the course of <e2>Increlex</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3272	"Increasing the <e1>olanzapine</e1> dosage severely aggravated the symptoms of <e2>RLS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3273	"Restless legs syndrome and <e1>periodic limb movements during sleep</e1> probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3274	"<e1>Restless legs syndrome</e1> and periodic limb movements during sleep probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3275	"The fifth patient exhibited paraesthesia and <e1>agitation</e1> caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic <e1>agitation</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3276	"The fifth patient exhibited <e1>paraesthesia</e1> and agitation caused by <e2>olanzapine</e2> that was misdiagnosed as psychotic agitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3277	"The fourth patient showed <e1>RLS symptoms</e1> that were initially caused by a 20-mg daily <e2>olanzapine</e2> dosage and were later mitigated when <e2>olanzapine</e2> was reduced and ropinirole was administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3278	"The second patient exhibited sudden <e1>PLMS</e1> following <e2>olanzapine</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3279	"The third patient had been suffering from serious <e1>akathisia</e1> while on risperidone, and was cured after switching to <e2>olanzapine</e2>, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3280	"The third patient had been suffering from serious <e1>akathisia</e1> while on <e2>risperidone</e2>, and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3281	"The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to <e1>olanzapine</e1>, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3282	"The third patient had been suffering from serious akathisia while on <e1>risperidone</e1>, and was cured after switching to olanzapine, but thereafter the patient suffered from <e2>RLS</e2> at nighttime."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3283	"We report five cases of restless legs syndrome (RLS) and <e1>periodic limb movements during sleep</e1> (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3284	"We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep (<e1>PLMS</e1>) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3285	"We report five cases of <e1>restless legs syndrome</e1> (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3286	"We report five cases of restless legs syndrome (<e1>RLS</e1>) and periodic limb movements during sleep (PLMS) that were probably associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3287	"CONCLUSION: <e1>Alendronate</e1> led to <e2>nodular scleritis</e2> and rechallenge caused recurrence of scleritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3288	"CONCLUSION: <e1>Alendronate</e1> led to nodular <e2>scleritis</e2> and rechallenge caused recurrence of <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3289	"<e1>Nodular scleritis</e1> following <e2>alendronate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3290	"PURPOSE: To report a case of <e1>nodular scleritis</e1> following <e2>alendronate sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3291	"Two weeks following rechallenge with <e1>alendronate sodium</e1> resulted in recurrence of his <e2>scleritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3292	"In addition, there is a report on <e1>prolonged ECT seizure</e1> related to <e2>ciprofloxacin</e2>, which has an epileptogenic property with a similar action to beta-lactam antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3293	"Thus, <e1>tardive seizures</e1> in our cases are thought to be related to piperacillin and <e2>cefotiam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3294	"Thus, <e1>tardive seizures</e1> in our cases are thought to be related to <e2>piperacillin</e2> and cefotiam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3295	"<e1>Acute delirium</e1> resulting from <e2>levofloxacin</e2> therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3296	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3297	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3298	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3299	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3300	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3301	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, <e2>dizziness</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3302	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3303	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3304	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3305	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3306	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3307	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including <e2>headache</e2>, dizziness and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3308	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, <e1>gatifloxacin</e1> and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3309	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, <e1>grepafloxacin</e1>, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3310	"CONCLUSION: The new quinolone derivatives (<e1>levofloxacin</e1>, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3311	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and <e1>moxifloxacin</e1>), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3312	"CONCLUSION: The new quinolone derivatives (levofloxacin, <e1>sparfloxacin</e1>, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3313	"CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, <e1>trovafloxacin</e1>, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3314	"Here, we describe <e1>levofloxacin</e1>-induced <e2>delirium with psychotic features</e2> in a relatively young, otherwise healthy female."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3315	"<e1>Levofloxacin</e1>-induced <e2>delirium with psychotic features</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3316	"RESULTS: A previously healthy 42-year-old woman presented with <e1>acute-onset delirium with psychotic features</e1> as a consequence of <e2>levofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3317	"CONCLUSIONS: Clinicians should be aware that <e1>Crohn's disease</e1> is a potential novel adverse drug effect of <e2>Copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3318	"Development of <e1>Crohn's disease</e1> in a patient with multiple sclerosis treated with <e2>copaxone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3319	"RESULTS: Our patient developed <e1>Crohn's disease</e1> while on <e2>Copaxone</e2> treatment as a consequence of long-term immunosuppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3320	"RESULTS: Our patient developed Crohn's disease while on <e1>Copaxone</e1> treatment as a consequence of <e2>long-term immunosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3321	"She had been on <e1>Copaxone</e1> 20 mg/day treatment for 2 years when she first exhibited <e2>gastrointestinal symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3322	"The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, <e1>obsessional-like suicidal ideas and images</e1> after ingestion of the anti-fungal drug <e2>ketoconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3323	"During intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly <e2>prolonged QT interval</e2> and torsade de pointes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3324	"During intravenous treatment with <e1>terlipressin</e1> for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and <e2>torsade de pointes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3325	"<e1>Terlipressin</e1>-induced <e2>ventricular arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3326	"<e1>Spontaneous nasal septal perforation</e1> with antiangiogenic <e2>bevacizumab</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3327	"This case describes a 52-year-old white woman who developed a <e1>spontaneous nasal septal perforation</e1> after given the antiangiogenic drug, <e2>bevacizumab</e2>, for metastatic ovarian cancer treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3328	"A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous <e1>VRC</e1> and developed <e2>angio-oedema</e2> 10 days after starting therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3329	"<e1>Angio-oedema</e1> as an unusual tolerable side effect of <e2>voriconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3330	"Here, we report a case of <e1>angio-oedema</e1> associated with <e2>VRC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3331	"To our knowledge, this is the first report of an <e1>angio-oedema</e1> associated with <e2>VRC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3332	"<e1>Voriconazole</e1> (VRC) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3333	"Voriconazole (<e1>VRC</e1>) has not previously been reported to cause <e2>angio-oedema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3334	"<e1>Multiple seizures</e1> after <e2>bupropion</e2> overdose in a small child."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3335	"The patient experienced hallucinations, <e1>agitation</e1>, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3336	"The patient experienced <e1>hallucinations</e1>, agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3337	"The patient experienced hallucinations, agitation, vomiting, tachycardia and <e1>seizures</e1> after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3338	"The patient experienced hallucinations, agitation, vomiting, <e1>tachycardia</e1> and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3339	"The patient experienced hallucinations, agitation, <e1>vomiting</e1>, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release <e2>bupropion</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3340	"We report a case of pediatric <e1>bupropion</e1> ingestion resulting in <e2>multiple seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3341	"<e1>Methylphenidate</e1>-associated <e2>enuresis</e2> in attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3342	"This is a case report of possible association of <e1>methylphenidate</e1> and <e2>enuresis</e2> in an 11-year-old boy with attention deficit hyperactivity disorder."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3343	"<e1>Cephalosporin</e1>-induced <e2>leukopenia</e2> following rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3344	"CONCLUSIONS: <e1>Cefazolin</e1> was a probable cause of this patient's <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3345	"OBJECTIVE: To describe a case of <e1>cefazolin</e1>-induced <e2>leukopenia</e2> in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3346	"Use of the Naranjo probability scale determined the association between <e1>cephalosporin</e1> use and <e2>leukopenia</e2> to be probable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3347	"Posterior reversible encephalopathy syndrome (<e1>PRES</e1>) induced by <e2>cyclosporine</e2> use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3348	"<e1>Posterior reversible encephalopathy syndrome</e1> (<e2>PRES</e2>) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3349	"We describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (<e2>CSA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3350	"We describe a case of <e1>PRES</e1> in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of <e2>cyclosporine</e2> (CSA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3351	"<e1>Stuttering priapism</e1> complicating <e2>warfarin</e2> therapy in a patient with protein C deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3352	"This therapy was also complicated by <e1>Warfarin</e1>-induced <e2>skin necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3353	"We report a rare case of recurrent (stuttering) <e1>priapism</e1> in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3354	"We report a rare case of recurrent (<e1>stuttering</e1>) priapism in a patient with protein C deficiency while maintained on <e2>Warfarin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3355	"The patient expired after seven cycles of treatment had been completed because of <e1>pulmonary fibrosis</e1> and the drug toxicity of <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3356	"CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for <e1>mild cognitive impairment</e1>, had been taking <e2>propafenone</e2> 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3357	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3358	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, falls) and mimicked <e2>coronary artery disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3359	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3360	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, <e2>dizziness</e2>, falls) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3361	"CONCLUSIONS: This is the first report of a possible interaction between propafenone and <e1>citalopram</e1>, which caused propafenone adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3362	"CONCLUSIONS: This is the first report of a possible interaction between <e1>propafenone</e1> and citalopram, which caused <e1>propafenone</e1> adverse effects (eg, dizziness, <e2>falls</e2>) and mimicked coronary artery disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3363	"Three months after starting <e1>citalopram</e1>, she experienced episodes of <e2>chest tightness</e2> and dizziness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3364	"Three months after starting <e1>citalopram</e1>, she experienced episodes of chest tightness and <e2>dizziness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3365	"CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex <e1>neurologic symptoms</e1> in patients who are receiving the antibiotic treatment described here, especially <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3366	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and <e2>piperacillin</e2>/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3367	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin/<e2>tazobactam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3368	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics vancomycin, <e2>tobramycin</e2>, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3369	"DISCUSSION: To our knowledge, this is the first case report illustrating <e1>neuralgic amyotrophy</e1> triggered by exposure to the antibiotics <e2>vancomycin</e2>, tobramycin, and piperacillin/tazobactam."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3370	"<e1>Seizures</e1> and transient blindness following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3371	"Seizures and <e1>transient blindness</e1> following intravenous pulse <e2>methylprednisolone</e2> in children with primary glomerulonephritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3372	"Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of <e1>seizures</e1> and transient blindness at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3373	"Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and <e1>transient blindness</e1> at different times after i.v. pulse <e2>methylprednisolone</e2> (IVPMP) treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3374	"BACKGROUND: <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with <e2>mucocutaneous adverse events</e2> and nail hyperpigmentation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3375	"BACKGROUND: <e1>Hydroxyurea</e1> is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and <e2>nail hyperpigmentation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3376	"Based on the Naranjo algorithm, the adverse reaction observed was probably related to the <e1>hydroxyurea</e1> treatment (score = 6); however, the <e1>hydroxyurea</e1> chemotherapy could not be discontinued because of the <e2>myeloproliferative disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3377	"Both the <e1>longitudinal melanonychia</e1> and the multiple skin cancers first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3378	"Both the longitudinal melanonychia and the <e1>multiple skin cancers</e1> first appeared after approximately 6 months of <e2>hydroxyurea</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3379	"CONCLUSIONS: We report this case of the concomitant appearance of <e1>multiple skin cancers</e1> and nail changes associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3380	"CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and <e1>nail changes</e1> associated with <e2>hydroxyurea</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3381	"<e1>Hydroxyurea</e1> associated with concomitant occurrence of <e2>diffuse longitudinal melanonychia</e2> and multiple squamous cell carcinomas in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3382	"<e1>Hydroxyurea</e1> associated with concomitant occurrence of diffuse longitudinal melanonychia and <e2>multiple squamous cell carcinomas</e2> in an elderly subject."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3383	"OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and <e1>diffuse nail hyperpigmentation</e1> associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3384	"OBJECTIVE: The purpose of this study was to report the concomitant occurrence of <e1>multiple squamous cell carcinomas</e1> and diffuse nail hyperpigmentation associated with <e2>hydroxyurea</e2> treatment, and to describe a successful therapeutic approach using imiquimod 5%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3385	"The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a <e1>painful hand ulcer</e1>, possibly associated with the <e2>hydroxyurea</e2>, and new skin cancers were observed at the last follow-up visit."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3386	"The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the <e1>hydroxyurea</e1>, and new <e2>skin cancers</e2> were observed at the last follow-up visit."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3387	"It is the first case of <e1>ciprofloxacin</e1>-induced <e2>VBDS</e2> successfully treated with tacrolimus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3388	"Vanishing bile duct and <e1>Stevens-Johnson syndrome</e1> associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3389	"<e1>Vanishing bile duct</e1> and Stevens-Johnson syndrome associated with <e2>ciprofloxacin</e2> treated with tacrolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3390	"We report a case of a patient with <e1>ciprofloxacin</e1>-induced <e2>SJS</e2> and acute onset of VBDS, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3391	"We report a case of a patient with <e1>ciprofloxacin</e1>-induced SJS and acute onset of <e2>VBDS</e2>, and reviewed the related literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3392	"A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving <e2>aspirin</e2> and clopidogrel."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3393	"A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for <e1>intracranial bleeding</e1> while receiving aspirin and <e2>clopidogrel</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3394	"<e1>Disseminated salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3395	"We describe the first case of <e1>disseminated salmonellosis</e1> in a patient treated with <e2>temozolomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3396	"<e1>Ceftriaxone</e1>-induced <e2>fixed drug eruption</e2>: first report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3397	"<e1>FDE</e1> from <e2>cephalosporins</e2> has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3398	"<e1>FDE</e1> from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of <e2>ceftriaxone</e2>-induced <e1>FDE</e1> in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3399	"We report the first case of a 54-year-old Turkish woman who presented with <e1>ceftriaxone</e1>-induced <e2>FDE</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3400	"CONCLUSION: All doctors need to be aware of the need to review the indications for <e1>gabapentin</e1> use during periods of acute illness, especially with regard to <e2>renal impairment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3401	"<e1>Gabapentin</e1> toxicity in <e2>renal failure</e2>: the importance of dose adjustment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3402	"OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of <e1>gabapentin</e1> during an episode of <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3403	"<e1>Acute syphilitic posterior placoid chorioretinitis</e1> following intravitreal <e2>triamcinolone acetonide</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3404	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3405	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of <e1>acute syphilitic posterior placoid chorioretinitis</e1> (ASPPC) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3406	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal triamcinolone acetonide (<e2>IVTA</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3407	"BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (<e1>ASPPC</e1>) that developed after intravitreal <e2>triamcinolone acetonide</e2> (IVTA) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3408	"CONCLUSIONS: The fundus picture shown in these cases may be typical of <e1>ASPPC</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3409	"RESULTS: Two patients with ocular inflammation of unknown origin developed <e1>severe chorioretinitis</e1> after <e2>IVTA</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3410	"Although it is difficult to solely attribute <e1>intratumoral hemorrhage</e1> to <e2>aspirin</e2>, we have to be careful when prescribing <e2>aspirin</e2> for patients who have asymptomatic meningioma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3411	"<e1>Hemorrhage</e1> from a falx meningioma after internal use of low-dose <e2>aspirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3412	"On the other hand, <e1>aspirin</e1> may have promoted the <e2>enlargement of spontaneous hemorrhage</e2> from meningioma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3413	"Our case is the second one in which <e1>hemorrhage</e1> from a meningioma may have been induced by <e2>aspirin</e2> prophylaxis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3414	"We report a case in which <e1>hemorrhage</e1> occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose <e2>aspirin</e2> for 16 months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3415	"<e1>Acute coronary syndromes</e1> can be associated with the infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3416	"<e1>Acute coronary syndromes</e1> complicating the first infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3417	"The aim of this study was to describe the occurrence of <e1>acute coronary syndromes</e1> in 3 cases of <e2>rituximab</e2> infusions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3418	"The occurrence of symptoms that could be ascribed to an <e1>acute coronary syndrome</e1> should always be taken seriously during the first <e2>rituximab</e2> infusion and investigated aggressively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3419	"We reviewed the records of 3 patients with lymphoproliferative disorders who experienced <e1>acute coronary syndromes</e1> associated with their initial infusion of <e2>rituximab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3420	"CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and <e1>acenocoumarol</e1> that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3421	"CONCLUSION: This report describes a case of a probable interaction between topical <e1>econazole</e1> lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening <e2>laryngeal hematoma</e2> in this elderly patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3422	"<e1>Laryngeal dyspnea</e1> in relation to an interaction between <e2>acenocoumarol</e2> and topical econazole lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3423	"<e1>Laryngeal dyspnea</e1> in relation to an interaction between acenocoumarol and topical <e2>econazole</e2> lotion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3424	"<e1>Adrenal suppression in a fetus</e1> due to administration of <e2>methylprednisolone</e2> has hitherto been rarely published."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3425	"CONCLUSIONS: Life-threatening <e1>adrenal suppression</e1>, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose <e2>methylprednisolone</e2> in late pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3426	"High-dose <e1>methylprednisolone</e1> in a pregnant woman with Crohn's disease and <e2>adrenal suppression</e2> in her newborn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3427	"A 10-year-old asthmatic boy began to suffer from urticarial rash and <e1>moderately severe bronchospasm</e1> after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3428	"A 10-year-old asthmatic boy began to suffer from <e1>urticarial rash</e1> and moderately severe bronchospasm after 8 weeks' treatment with <e2>disodium cromoglycate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3429	"<e1>Asthma</e1> and urticaria during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3430	"Asthma and <e1>urticaria</e1> during <e2>disodium cromoglycate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3431	"When <e1>DSCG</e1> was withdrawn, <e2>urticaria</e2> vanished and the child remained symptom-free."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3432	"After the first oral dose of <e1>propranolol</e1>, syncope developed together with <e2>atrioventricular block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3433	"After the first oral dose of <e1>propranolol</e1>, <e2>syncope</e2> developed together with atrioventricular block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3434	"<e1>Syncope</e1> induced by <e2>propranolol</e2> in hypertrophic cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3435	"<e1>Olanzapine</e1>-induced <e2>hyperglycaemic coma</e2> and neuroleptic malignant syndrome: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3436	"<e1>Olanzapine</e1>-induced hyperglycaemic coma and <e2>neuroleptic malignant syndrome</e2>: case report and review of literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3437	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and <e2>allergic skin reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3438	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, hypertension, <e2>alopecia</e2>, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3439	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of <e2>diarrhea</e2>, nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3440	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, liver enzyme elevation, <e2>hypertension</e2>, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3441	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, nausea, <e2>liver enzyme elevation</e2>, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3442	"DISCUSSION: The main adverse effects of <e1>leflunomide</e1> consist of diarrhea, <e2>nausea</e2>, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3443	"<e1>Leflunomide</e1>-induced <e2>toxic epidermal necrolysis</e2> in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3444	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), <e1>mediastinal lymphadenopathy</e1> and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3445	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and <e1>pleurisy</e1> associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3446	"In this report we described a case of juvenile idiopathic arthritis patient who developed <e1>thymic enlargement</e1> (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3447	"In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true <e1>thymic hyperplasia</e1>), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under <e2>Etanercept</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3448	"<e1>Thymic enlargement</e1> in a patient with juvenile idiopathic arthritis during <e2>etanercept</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3449	"<e1>Oxcarbazepine</e1>-induced Drug Reaction with Eosinophilia and Systemic Symptoms (<e2>DRESS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3450	"<e1>Oxcarbazepine</e1>-induced <e2>Drug Reaction with Eosinophilia and Systemic Symptoms</e2> (DRESS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3451	"This is an image and brief case report of a 13-year-old boy who presented with <e1>severe rash</e1> and systemic symptoms after starting <e2>oxcarbazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3452	"After treatment with a beta-sympathomimetic drug (<e1>Partusisten</e1>) one fetus developed <e2>supraventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3453	"<e1>Rosaceiform eruption</e1> induced by <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3454	"The aim of this paper is to report the case of <e1>rosaceiform eruption</e1> induced by <e2>erlotinib</e2> in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3455	"In patients with <e1>methotrexate</e1>-induced <e2>anaphylaxis</e2>, discontinuation of treatment may increase the risk of death due to cancer progression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3456	"Management and successful desensitization in <e1>methotrexate</e1>-induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3457	"Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience <e1>methotrexate</e1>-induced <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3458	"We report the case of a child with metastatic osteosarcoma, who experienced an <e1>anaphylactic/anaphylactoid reaction</e1> to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3459	"Drug-induced <e1>fever</e1> due to <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3460	"Drug-induced <e1>fever</e1> should be considered in patients who have unexplained high temperatures during <e2>diltiazem</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3461	"To our knowledge, drug-induced <e1>fever</e1> has not been reported with the use of <e2>diltiazem hydrochloride</e2>, a commonly prescribed calcium channel blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3462	"A case of <e1>congestive heart failure</e1> in a child with Wilms' tumor treated <e2>Adriamycin</e2> is presented and discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3463	"Radiologic recognition of <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3464	"The role of <e1>Adriamycin</e1> in the production of <e2>cardiotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3465	"<e1>Carbamazepine</e1>-induced <e2>Diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3466	"<e1>Diabetes Mellitus</e1> was observed in a patient given <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3467	"The present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as mianserin and <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3468	"The present study describes a patient who had <e1>unusual weight fluctuation</e1> under corticosteroid and psychotropic treatment such as <e2>mianserin</e2> and aripiprazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3469	"Although <e1>heparin</e1>-dependent antibodies (HDAs) typically manifest with <e2>thrombocytopenia</e2> as in <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> (HIT), they may also manifest with preserved platelet counts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3470	"Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing <e1>thrombosis</e1> who are receiving <e2>heparin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3471	"Heparin-dependent antibodies and thrombosis without <e1>heparin</e1>-induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3472	"Despite these antithrombotic effects, the patient developed repeated <e1>venous thromboembolism</e1> during treatment with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3473	"Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for <e1>progressive liver failure</e1> and severe hepatocellular necrosis thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3474	"Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and <e1>severe hepatocellular necrosis</e1> thought to be due to <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3475	"Initiation of <e1>posaconazole</e1> led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant <e2>enterococcal peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3476	"<e1>Iatrogenic Cushing syndrome</e1> after epidural <e2>triamcinolone</e2> injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3477	"We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed <e1>Cushing syndrome</e1> with profound complications after epidural <e2>triamcinolone</e2> injections."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3478	"A 22-year-old drug-abuser injected <e1>flunitrazepam</e1> tablets dissolved in tap water into her left femoral artery and presented with clinical signs of <e2>acute ischaemia of the left leg</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3479	"<e1>Acute ischaemia of the leg</e1> following accidental intra-arterial injection of dissolved <e2>flunitrazepam</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3480	"A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with <e2>infliximab</e2> and leflunomide is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3481	"A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a <e1>syringotropic hypersensitivity reaction</e1> after 9 months of therapy with infliximab and <e2>leflunomide</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3482	"<e1>Syringotropic hypersensitivity reaction</e1> associated with <e2>infliximab</e2> and leflunomide combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3483	"<e1>Syringotropic hypersensitivity reaction</e1> associated with infliximab and <e2>leflunomide</e2> combination therapy in a child with psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3484	"A case of <e1>severe aplastic anemia</e1> secondary to treatment with <e2>lenalidomide</e2> for multiple myeloma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3485	"Although moderate myelosuppression is not uncommonly seen in patients treated with <e1>lenalidomide</e1>, <e2>aplastic anemia</e2> has not previously been reported to be associated with this agent."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3486	"We describe a case of severe aplastic anemia (<e1>AA</e1>) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3487	"We describe a case of <e1>severe aplastic anemia</e1> (AA) that was probably induced by <e2>lenalidomide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3488	"After cessation of <e1>amantadine</e1>, the <e2>edema</e2> resolved, and the endothelial cell densities were <or=600/mm."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3489	"CONCLUSIONS: <e1>Amantadine</e1> can cause <e2>reversible corneal edema</e2> but can irreversibly reduce the density of endothelial cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3490	"<e1>Corneal edema</e1> recurred when the administration of <e2>amantadine</e2> was resumed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3491	"<e1>Corneal endothelial dysfunction</e1> associated with <e2>amantadine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3492	"PURPOSE: To describe <e1>bilateral corneal endothelial dysfunction</e1> in a patient with Parkinson disease who was treated with long-term <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3493	"RESULTS: A 52-year-old woman with Parkinson disease who had taken <e1>amantadine</e1> for 6 years had <e2>bilateral corneal edema</e2> for 2 months at baseline."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3494	"Therefore, <e1>amantadine</e1> was permanently discontinued and the <e2>cornea</e2> cleared again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3495	"Biopsy-proven <e1>acute interstitial nephritis</e1> associated with the tyrosine kinase inhibitor <e2>sunitinib</e2>: a class effect?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3496	"We report the first biopsy confirmed occurrence of <e1>acute interstitial nephritis</e1> in a patient receiving treatment with <e2>Sunitinib</e2> for metastatic renal cell cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3497	"<e1>Extrapyramidal symptoms</e1> are well-documented complications of therapy with <e2>haloperidol</e2>, even when small doses are used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3498	"This report highlights a case of drug-induced <e1>dysphagia</e1> in a patient receiving <e2>haloperidol</e2> for obsessive nocturnal thoughts and auditory disturbances."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3499	"A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an <e1>iron deficiency anemia</e1> after a ten-month treatment of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3500	"<e1>Methotrexate</e1> induced <e2>sprue-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3501	"Only 3 cases of <e1>imatinib</e1>-induced <e2>tumor lysis syndrome</e2> have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3502	"We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed <e1>tumor lysis syndrome</e1> after 10-day treatment with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3503	"<e1>IFNalpha</e1>-induced recurrence of <e2>Graves' disease</e2> ten years after thyroidectomy in chronic viral hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3504	"In contrast to chronic or subacute thyroiditis, <e1>Graves' disease</e1> rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3505	"In contrast to chronic or <e1>subacute thyroiditis</e1>, Graves' disease rarely complicates <e2>IFN-alpha</e2> therapy for chronic viral C hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3506	"We report the case of a 51-year-old man in whom <e1>IFN-alpha</e1> treatment was followed by recurrence of <e2>Graves' disease</e2> 10 years after thyroidectomy was performed and the patient was declared cured."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3507	"<e1>Interstitial granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3508	"The authors describe a case of <e1>interstitial granulomatous dermatitis</e1> associated with <e2>darifenacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3509	"<e1>Gemcitabine</e1> is a known risk factor for <e2>hemolytic uremic syndrome</e2> (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3510	"<e1>Gemcitabine</e1> is a known risk factor for hemolytic uremic syndrome (<e2>HUS</e2>), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3511	"METHODS: A retrospective report of the first case of <e1>gemcitabine</e1>-related <e2>HUS</e2>, in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3512	"Rituximab-based therapy for <e1>gemcitabine</e1>-induced <e2>hemolytic uremic syndrome</e2> in a patient with metastatic pancreatic adenocarcinoma: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3513	"<e1>Drug rash with eosinophilia and systemic symptoms</e1> after <e2>chlorambucil</e2> treatment in chronic lymphocytic leukaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3514	"He developed recurrent skin rash, fever, hypereosinophilia, and <e1>acute renal failure</e1> after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3515	"He developed recurrent skin rash, <e1>fever</e1>, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3516	"He developed recurrent skin rash, fever, <e1>hypereosinophilia</e1>, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3517	"He developed recurrent <e1>skin rash</e1>, fever, hypereosinophilia, and acute renal failure after rechallenge with <e2>chlorambucil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3518	"We report the first case of <e1>chlorambucil</e1>-induced <e2>DRESS syndrome</e2> in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3519	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e1>methotrexate</e1> (MTX) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3520	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e1>MTX</e1>) (12 g/m2), and went on to develop <e2>acute renal failure</e2> with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3521	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3522	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme <e1>elevation of aspartate aminotrasferase</e1> and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3523	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose <e2>methotrexate</e2> (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3524	"A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending <e1>renal toxicity</e1> and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (<e2>MTX</e2>) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3525	"Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of <e1>renal toxicity</e1> may be present as early as 2 hours after the completion of a 4-hour <e2>MTX</e2> infusion, and to suggest that monitoring for <e2>MTX</e2> toxicity should perhaps begin within a few hours after the completion of 4-hour <e2>MTX</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3526	"Early recognition of <e1>renal toxicity</e1> of high-dose <e2>methotrexate</e2> therapy: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3527	"Multifocal electroretinographic abnormalities in <e1>ethambutol</e1>-induced <e2>visual loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3528	"These are the first reported patients to show mfERG abnormalities that correspond to <e1>bitemporal visual field defects</e1> and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3529	"These are the first reported patients to show <e1>mfERG abnormalities</e1> that correspond to bitemporal visual field defects and add to the growing evidence that <e2>ethambutol</e2> damages the retina."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3530	"Two patients who developed decreased visual acuity after several months of <e1>ethambutol</e1> treatment for Mycobacterium avium-intracellulare infection had <e2>bitemporal visual field defects</e2> that suggested optic chiasm damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3531	"Two patients who developed <e1>decreased visual acuity</e1> after several months of <e2>ethambutol</e2> treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3532	"<e1>Tenofovir</e1>-associated <e2>nephrotoxicity</e2> in two HIV-infected adolescent males."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3533	"To our knowledge, these cases represent the first reports of <e1>TDF</e1>-associated <e2>irreversible renal failure</e2> and rickets in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3534	"To our knowledge, these cases represent the first reports of <e1>TDF</e1>-associated irreversible renal failure and <e2>rickets</e2> in pediatric patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3535	"We report two cases of tenofovir (<e1>TDF</e1>)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3536	"We report two cases of <e1>tenofovir</e1> (TDF)-associated <e2>nephrotoxicity</e2> in perinatally HIV-infected adolescents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3537	"In this case, discontinuing <e1>piroxicam</e1>, a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's <e2>ulcers</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3538	"<e1>Acute renal failure</e1> following intravenous <e2>immunoglobulin</e2> therapy in a HIV-infected patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3539	"<e1>Acute renal failure</e1> is a rare complication following the administration of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3540	"The exact mechanism of <e1>IVIG</e1>-associated <e2>acute renal failure</e2> remains unclear."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3541	"A 58-year-old man with advanced renal cell carcinoma developed grade 3 <e1>proteinuria</e1> (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after <e2>temsirolimus</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3542	"<e1>Temsirolimus</e1>-induced <e2>glomerulopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3543	"<e1>Hypoglycemia</e1> can be a serious side effect of <e2>etanercept</e2> in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3544	"Hypoglycemia can be a serious side effect of <e1>etanercept</e1> in patients already on antidiabetic medications known to cause <e2>hypoglycemia</e2>, such as sulfonylureas, meglitinides, and insulin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3545	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, meglitinides, and <e2>insulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3546	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as sulfonylureas, <e2>meglitinides</e2>, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3547	"Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause <e1>hypoglycemia</e1>, such as <e2>sulfonylureas</e2>, meglitinides, and insulin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3548	"<e1>Persistent hypoglycemia</e1> in a patient with diabetes taking <e2>etanercept</e2> for the treatment of psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3549	"We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent <e1>etanercept</e1> for severe plaque psoriasis, experienced <e2>persistent hypoglycemia</e2> requiring the lowering and eventual elimination of his previous insulin regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3550	"We report on three cases wherein treatment of <e1>dexmedetomidine</e1>-induced <e2>bradycardia</e2> with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of <e2>bradycardia</e2> but also resulting in an exaggerated increase of arterial blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3551	"We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. <e1>glycopyrrolate</e1> (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an <e2>exaggerated increase of arterial blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3552	"<e1>Bisphosphonate</e1>-related <e2>osteonecrosis of the jaw</e2> (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3553	"<e1>Bisphosphonate</e1>-related <e2>osteonecrosis of the skull base</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3554	"A previous study of patients with "<e1>quinine</e1>-associated <e2>TTP/HUS</e2>" found that ADAMTS13 activities were not abnormal in 12/12 patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3555	"A retrospective review of TTP patients with <e1>quinine</e1>-associated <e2>thrombotic microangiopathy</e2> (TMA) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3556	"A retrospective review of TTP patients with <e1>quinine</e1>-associated thrombotic microangiopathy (<e2>TMA</e2>) for whom ADAMTS13 was measured before plasma exchange was performed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3557	"<e1>Thrombocytopenia</e1> with or without microangiopathy following <e2>quinine</e2> is often referred to as <e2>quinine</e2> "hypersensitivity." When schistocytes are present it is frequently termed "<e2>quinine</e2>-associated TTP/HUS." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3558	"Thrombocytopenia with or without microangiopathy following <e1>quinine</e1> is often referred to as <e1>quinine</e1> "hypersensitivity." When schistocytes are present it is frequently termed "<e1>quinine</e1>-associated <e2>TTP/HUS</e2>." A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3559	"We conclude that while thrombocytopenia and <e1>schistocytosis</e1> can be seen in <e2>quinine</e2>-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3560	"We conclude that while <e1>thrombocytopenia</e1> and schistocytosis can be seen in <e2>quinine</e2>-associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3561	"We conclude that while thrombocytopenia and schistocytosis can be seen in <e1>quinine</e1>-associated <e2>TTP/HUS</e2>, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3562	"We recommend that a TMA in association with <e1>quinine</e1> be consistently referred to as <e1>quinine</e1>-associated <e2>thrombotic microangiopathy</e2> (<e1>quinine</e1>-TMA) to better distinguish this entity from idiopathic TTP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3563	"Complications associated with <e1>primary and secondary perforation of the bladder</e1> following immediate instillations of <e2>epirubicin</e2> after transurethral resection of superficial urothelial tumours."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3564	"MATERIALS AND METHODS: We present two cases of significant morbidity related to <e1>primary and secondary perforation of the bladder</e1> following two instillations of <e2>epirubicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3565	"<e1>Aliskiren</e1>-associated <e2>acute renal failure</e2> with hyperkalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3566	"We report the first case of <e1>acute renal failure</e1> with hyperkalemia associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3567	"We report the first case of acute renal failure with <e1>hyperkalemia</e1> associated with the recently marketed direct renin inhibitor <e2>aliskiren</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3568	"A case of <e1>acute cardiomyopathy</e1> and pericarditis associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3569	"A case of acute cardiomyopathy and <e1>pericarditis</e1> associated with <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3570	"However, <e1>acute cardiomyopathy</e1> and pericarditis secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3571	"However, acute cardiomyopathy and <e1>pericarditis</e1> secondary to <e2>methylphenidate</e2> use has been rarely reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3572	"We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and <e1>acute left ventricular dysfunction</e1> following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3573	"We report the case of a 17-year-old male who developed <e1>chest pain</e1>, elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3574	"We report the case of a 17-year-old male who developed chest pain, <e1>elevated cardiac biomarkers</e1>, and acute left ventricular dysfunction following a single dose of <e2>methylphenidate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3575	"According to the Naranjo et al. adverse-reaction probability scale, <e1>enoxaparin</e1> was the probable cause of <e2>hepatotoxicity</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3576	"CONCLUSION: A woman receiving <e1>enoxaparin</e1> every 12 hours developed signs and symptoms of <e2>hepatotoxicity</e2> after the second dose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3577	"Probable <e1>enoxaparin</e1>-induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3578	"PURPOSE: A case of probable <e1>enoxaparin</e1>-induced <e2>hepatotoxicity</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3579	"<e1>Posterior reversible encephalopathy syndrome</e1> associated with <e2>methotrexate</e2> neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3580	"The addition of intrathecal <e1>methotrexate</e1> to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3581	"We describe a 15-year-old female patient diagnosed with <e1>acute lymphoblastic leukemia</e1> presenting with status epilepticus after receiving intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3582	"<e1>Cyclosporine</e1>-induced <e2>pain syndrome</e2> in a child undergoing hematopoietic stem cell transplant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3583	"In this case, <e1>CIPS</e1> was considered to be probably associated with <e2>cyclosporine</e2> according to the Naranjo probability scale."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3584	"OBJECTIVE: To report a case of <e1>calcineurin</e1>-induced <e2>pain syndrome</e2> (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3585	"With the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3586	"With the first <e1>cyclosporine</e1> dose, the patient complained of <e2>leg pain</e2> that was most severe during the <e1>cyclosporine</e1> infusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3587	"<e1>Neuroleptic malignant syndrome</e1> due to <e2>risperidone</e2> treatment in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3588	"This report describes a case of <e1>neuroleptic malignant syndrome</e1> due to <e2>risperidone</e2> in a child with Joubert syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3589	"A case of <e1>tuberculosis</e1> in a patient on <e2>Efalizumab</e2> and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3590	"A case of <e1>tuberculosis</e1> in a patient on Efalizumab and <e2>Etanercept</e2> for treatment of refractory palmopustular psoriasis and psoriatic arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3591	"The most common complication of <e1>warfarin</e1> use is adverse <e2>bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3592	"CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from <e2>stavudine</e2> to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3593	"CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of <e1>symptomatic hyperlactatemia</e1> after being switched from stavudine to <e2>zidovudine</e2> and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3594	"DISCUSSION: This case shows that switching to <e1>zidovudine</e1> potentially can lead to a <e2>hyperlactatemia relapse</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3595	"INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop <e1>stavudine</e1> induced <e2>hyperlactatemia</e2> are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3596	"<e1>Anaphylactic reaction</e1> to <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3597	"We report a case of an 11-year-old boy who experienced an <e1>anaphylactic reaction</e1> after administration of <e2>bacitracin</e2> ointment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3598	"Herein, we present a patient with severe and <e1>prolonged hypoglycemia</e1> after long-acting <e2>octreotide</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3599	"<e1>Hypoglycemia</e1> induced by long-acting <e2>somatostatin</e2> analogues in a patient with nonfunctional neuroendocrine tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3600	"In these patients, long-acting <e1>octreotide</e1> may trigger <e2>serious hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3601	"<e1>Leukopenia</e1> due to parvovirus B19 in a Crohn's disease patient using <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3602	"The uncomplicated long-term use of adequately-dosed <e1>AZA</e1> and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3603	"We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and <e1>leukopenia</e1> during long-term <e2>AZA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3604	"<e1>Isoniazid</e1> causing <e2>breast tissue enlargement</e2> has been very rarely reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3605	"<e1>Isoniazid</e1> induced <e2>gynaecomastia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3606	"<e1>Cryptococcus neoformans fatal sepsis</e1> in a chronic lymphocytic leukemia patient treated with <e2>alemtuzumab</e2>: case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3607	"The international literature regarding opportunistic infections after immunosuppressive therapy with <e1>alemtuzumab</e1> with particular attention on <e2>fungal infections</e2> has also been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3608	"The international literature regarding <e1>opportunistic infections</e1> after immunosuppressive therapy with <e2>alemtuzumab</e2> with particular attention on fungal infections has also been reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3609	"Secondary <e1>acute myeloid leukemia</e1> after <e2>etoposide</e2> therapy for haemophagocytic lymphohistiocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3610	"The risk of developing <e1>sAML</e1> is estimated to be between 1% and 5%, 2-20 years after exposure to <e2>etoposide</e2> but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3611	"Two patients with HLH developed <e1>etoposide</e1>-related secondary acute myeloid leukemia (<e2>sAML</e2>) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3612	"Two patients with HLH developed <e1>etoposide</e1>-related <e2>secondary acute myeloid leukemia</e2> (sAML) following therapy for HLH."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3613	"<e1>Polymyoclonus seizure</e1> resulting from accidental injection of <e2>tranexamic acid</e2> in spinal anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3614	"<e1>Rhabdomyolysis</e1> following <e2>clarithromycin</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3615	"We report the first case of <e1>rhabdomyolysis</e1> related to the administration of <e2>clarithromycin</e2> without concurrent use of other medications."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3616	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the <e2>development of abnormally large mammary glands</e2> associated with pain and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3617	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with <e2>pain</e2> and peri-areolar erythema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3618	"At the end of his fifth cycle of <e1>sunitinib</e1> therapy, the patient complained of the development of abnormally large mammary glands associated with pain and <e2>peri-areolar erythema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3619	"However, re-initiation of <e1>sunitinib</e1> treatment was followed by <e2>bilateral breast enlargement</e2> again."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3620	"Onset of male <e1>gynaecomastia</e1> in a patient treated with <e2>sunitinib</e2> for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3621	"The mechanism by which <e1>sunitinib</e1> induces <e2>gynaecomastia</e2> is thought to be associated with an unknown direct action on breast hormonal receptors."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3622	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, <e2>elevated lipase</e2> and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3623	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, <e2>fatigue</e2>, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3624	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, <e2>hand-foot syndrome</e2>, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3625	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include <e2>hypertension</e2>, fatigue, hand-foot syndrome, elevated lipase and lymphopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3626	"The more common grade 3 or 4 adverse effects of <e1>sunitinib</e1> include hypertension, fatigue, hand-foot syndrome, elevated lipase and <e2>lymphopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3627	"<e1>Divalproex sodium</e1>-induced <e2>eosinophilic pleural effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3628	"We report a case of 48-year-old woman with seizure disorder on divalproex sodium (<e1>Depakote</e1>) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3629	"We report a case of 48-year-old woman with seizure disorder on <e1>divalproex sodium</e1> (Depakote) who presented with <e2>dyspnea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3630	"Withdrawal of <e1>Depakote</e1> resulted in resolution of the <e2>effusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3631	"<e1>Flurbiprofen</e1>-associated <e2>acute tubulointerstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3632	"We report a case of biopsy-proven <e1>acute tubulointerstitial nephritis</e1> associated with a second course of <e2>flurbiprofen</e2>, a nonsteroidal anti-inflammatory drug of the propionic acid class."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3633	"<e1>Stupor</e1> and fast activity on electroencephalography in a child treated with <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3634	"The case of a 4-year-old girl with <e1>valproate</e1>-induced <e2>stupor</e2> and electroencephalographic pattern of increased fast activity is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3635	"<e1>Localized dyskeratotic plaque</e1> with milia associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3636	"Localized dyskeratotic plaque with <e1>milia</e1> associated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3637	"This article presents a case of an <e1>atypical localized cutaneous eruption</e1> with an unusual course and protracted resolution time associated with <e2>sorafenib</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3638	"According to the Naranjo adverse drug reaction probability scale, <e1>tigecycline</e1> was the probable cause of her <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3639	"Following 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and elevated pancreatic enzymes suggesting <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3640	"Following 7 days of <e1>tigecycline</e1> she developed severe abdominal pain and <e2>elevated pancreatic enzymes</e2> suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3641	"Following 7 days of <e1>tigecycline</e1> she developed <e2>severe abdominal pain</e2> and elevated pancreatic enzymes suggesting acute pancreatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3642	"Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about <e1>tigecycline</e1>-induced <e2>acute pancreatitis</e2> have recently been raised."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3643	"<e1>Tigecycline</e1>-induced <e2>acute pancreatitis</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3644	"We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including <e1>abdominal pain</e1>, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3645	"We recommend that clinicians monitor patients for signs and symptoms of <e1>pancreatitis</e1>, including abdominal pain, during treatment with <e2>tigecycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3646	"Drug induced <e1>polymyositis</e1> secondary to <e2>leuprolide acetate</e2> (Lupron) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3647	"Drug induced <e1>polymyositis</e1> secondary to leuprolide acetate (<e2>Lupron</e2>) therapy for prostate carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3648	"We report a case of biopsy proven <e1>myositis</e1> whose symptoms began within 10 days of receiving <e2>leuprolide acetate</e2> therapy for prostate cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3649	"<e1>Aripiprazole</e1>-induced <e2>hiccups</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3650	"We report a patient of organic bipolar affective disorder who developed <e1>hiccups</e1> with the atypical antipsychotic <e2>aripiprazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3651	"CONCLUSIONS: This patient's <e1>rhabdomyolysis</e1> was probably induced by <e2>sertraline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3652	"DISCUSSION: The Naranjo probability scale indicated a probable relationship between <e1>sertraline</e1> treatment and the onset of <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3653	"OBJECTIVE: To describe a case of <e1>sertraline</e1>-induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3654	"<e1>Sertraline</e1>-induced <e2>rhabdomyolysis</e2> in an elderly patient with dementia and comorbidities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3655	"The patient's other comorbidities and medications have not been suggested as possible interactions with <e1>sertraline</e1> that can cause <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3656	"<e1>Tumor lysis syndrome</e1> after transcatheter arterial infusion of <e2>cisplatin</e2> and embolization therapy for liver metastases of melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3657	"He had <e1>priapism</e1> following the use of <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3658	"<e1>Priapism</e1> associated with <e2>olanzapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3659	"Can <e1>ketamine</e1> prescribed for pain cause <e2>damage to the urinary tract</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3660	"Possible mechanisms for <e1>damage to the urothelium</e1> by <e2>ketamine</e2> are suggested."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3661	"Presentation of three palliative care patients who were given <e1>ketamine</e1> as an analgesic and subsequently developed significant and debilitating <e2>urological symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3662	"These two cases highlight the importance of considering <e1>lopinavir</e1>/ritonavir induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3663	"These two cases highlight the importance of considering lopinavir/<e1>ritonavir</e1> induced <e2>arrhythmias</e2> when dealing with HIV-positive individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3664	"<e1>Transient cardiac arrhythmias</e1> related to <e2>lopinavir</e2>/ritonavir in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3665	"<e1>Transient cardiac arrhythmias</e1> related to lopinavir/<e2>ritonavir</e2> in two patients with HIV infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3666	"<e1>Colitis</e1> as a manifestation of <e2>infliximab</e2>-associated disseminated cryptococcosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3667	"Colitis as a manifestation of <e1>infliximab</e1>-associated <e2>disseminated cryptococcosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3668	"After three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with severe agitation and <e2>aggressive behavior</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3669	"After three weeks of <e1>carbamazepine</e1> therapy, the patient arrived at the emergency department (ED) with <e2>severe agitation</e2> and aggressive behavior."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3670	"<e1>Carbamazepine</e1>-induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3671	"CONCLUSION: A 26-year-old man with bipolar disorder developed <e1>hyperammonemia</e1> three weeks after initiating <e2>carbamazepine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3672	"He had also developed <e1>elevated serum ammonia levels</e1> while on <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3673	"PURPOSE: A case of <e1>carbamazepine</e1>-induced <e2>hyperammonemia</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3674	"<e1>Adriamycin</e1>-induced <e2>cardiomyopathy</e2> aggravated by cis-platinum nephrotoxicity requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3675	"Adriamycin-induced cardiomyopathy aggravated by <e1>cis-platinum</e1> <e2>nephrotoxicity</e2> requiring dialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3676	"Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and <e1>adriamycin</e1> <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3677	"Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included <e1>cisplatinum</e1> <e2>nephrotoxicity</e2> and adriamycin cardiotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3678	"A 65-year-old female patient presented with <e1>jaundice</e1> followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3679	"A 65-year-old female patient presented with jaundice followed 2 days later by <e1>severe dyspnea</e1> and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3680	"A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and <e1>tachypnea</e1> which worsened when patient was lying flat, 1 week after the fourth dose of <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3681	"A case of <e1>acute respiratory failure</e1> due to diaphragmatic weakness following <e2>adalimumab</e2> therapy for psoriasis is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3682	"<e1>Acute bilateral phrenic neuropathy</e1> following treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3683	"The potential development of <e1>SJS</e1>/TEN, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3684	"The potential development of SJS/<e1>TEN</e1>, a severe life-threatening illness, emphasizes the need for judicious use of <e2>TMP-Sx</e2> and close monitoring and follow-up for patients who were given <e2>TMP-Sx</e2> for SSTIs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3685	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3686	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (<e1>SJS</e1>/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3687	"We report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3688	"We report a case of <e1>Stevens-Johnson syndrome</e1>/toxic epidermal necrolysis (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3689	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3690	"We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/<e1>TEN</e1>) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3691	"We report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to trimethoprim-sulfamethoxazole (<e2>TMP-Sx</e2>) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3692	"We report a case of Stevens-Johnson syndrome/<e1>toxic epidermal necrolysis</e1> (SJS/TEN) secondary to <e2>trimethoprim-sulfamethoxazole</e2> (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3693	"CONCLUSIONS: <e1>Spontaneous hemothorax</e1> is a rare phenomenon in conjunction with <e2>LMWH</e2> but should be considered in cases of acute respiratory distress following commencement of <e2>LMWH</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3694	"On day 4, following 3 doses of <e1>dalteparin</e1>, the patient developed <e2>acute respiratory distress</e2> attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3695	"<e1>Spontaneous hemothorax</e1> following anticoagulation with low-molecular-weight <e2>heparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3696	"<e1>Acute ocular ischemic change</e1> may be associated with intravitreal injection of <e2>bevacizumab</e2> in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3697	"<e1>Acute vision loss</e1> after intravitreal injection of bevacizumab (<e2>avastin</e2>) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3698	"<e1>Acute vision loss</e1> after intravitreal injection of <e2>bevacizumab</e2> (avastin) associated with ocular ischemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3699	"Acute vision loss after intravitreal injection of bevacizumab (<e1>avastin</e1>) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3700	"Acute vision loss after intravitreal injection of <e1>bevacizumab</e1> (avastin) associated with <e2>ocular ischemic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3701	"AIM: To report a patient with diabetic rubeosis who suffered from <e1>acute retinal ischemic change</e1> and stroke after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3702	"AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and <e1>stroke</e1> after intravitreal injection of <e2>bevacizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3703	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as <e2>carotid insufficiency</e2>, coagulopathy and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3704	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, <e2>coagulopathy</e2> and poorly controlled diabetes mellitus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3705	"CONCLUSIONS: Patients receiving intravitreal injections of <e1>bevacizumab</e1> should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and <e2>poorly controlled diabetes mellitus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3706	"Three days after intravitreal injection of <e1>bevacizumab</e1>, <e2>acute ocular ischemic syndrome</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3707	"Three days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed <e2>acute vision loss</e2> and change of consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3708	"Three days after receiving intravitreal injection of <e1>bevacizumab</e1> (1.25 mg in 0.1 ml), he developed acute vision loss and <e2>change of consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3709	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, <e2>cyclophosphamide</e2>, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3710	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, <e2>doxorubicin</e2>, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3711	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with <e2>etoposide</e2>, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3712	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, <e2>prednisone</e2>, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3713	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and <e2>rituximab</e2> (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3714	"Herein, we describe a patient with AIDS who presented to medical attention with <e1>pancytopenia</e1> 48 months postchemotherapy with etoposide, prednisone, <e2>vincristine</e2>, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3715	"Favorable outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with lamivudine and <e2>adefovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3716	"Favorable outcome of de novo <e1>hepatitis B infection</e1> after liver transplantation with <e2>lamivudine</e2> and adefovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3717	"<e1>Linezolid</e1>-associated <e2>acute interstitial nephritis</e2> and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3718	"<e1>Linezolid</e1>-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3719	"<e1>Linezolid</e1>-associated acute interstitial nephritis and <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3720	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, <e2>eosinophilia</e2>, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3721	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, <e2>facial edema</e2>, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3722	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, <e2>macular rash</e2>, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3723	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, <e2>marked increase in serum creatinine level</e2>, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3724	"On day 7 of <e1>linezolid</e1> treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and <e2>mild hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3725	"On day 7 of <e1>linezolid</e1> treatment, the patient developed <e2>severe pruritus</e2>, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3726	"This case of <e1>linezolid</e1>-associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3727	"This case of <e1>linezolid</e1>-associated <e2>acute interstitial nephritis</e2> within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3728	"This case of <e1>linezolid</e1>-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3729	"This case of <e1>linezolid</e1>-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms (<e2>DRESS</e2>) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3730	"This case of <e1>linezolid</e1>-associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3731	"This case of <e1>linezolid</e1>-associated acute interstitial nephritis within the context of a <e2>drug rash with eosinophilia and systemic symptoms</e2> (DRESS) syndrome in a patient treated with <e1>linezolid</e1> raises concerns about the presumed renal safety of this drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3732	"Increased awareness is needed on the possible occurrence of <e1>LPD</e1> resembling gastric cancer in rheumatoid arthritis patients treated with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3733	"Reversible <e1>methotrexate</e1>-associated <e2>lymphoproliferative disorder</e2> resembling advanced gastric cancer in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3734	"She was diagnosed with <e1>Epstein-Barr virus-associated polymorphic lymphoproliferative disorder</e1> (LPD) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3735	"She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to <e1>immunodeficiency</e1> caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3736	"She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (<e1>LPD</e1>) due to immunodeficiency caused by <e2>MTX</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3737	"To our knowledge, this is the first case of spontaneous remission of <e1>MTX</e1>-associated <e2>gastric LPD</e2> after discontinuation of <e1>MTX</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3738	"However, he developed <e1>acute renal failure</e1>, hyperkalemia, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3739	"However, he developed acute renal failure, <e1>hyperkalemia</e1>, and hyperuricemia 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3740	"However, he developed acute renal failure, hyperkalemia, and <e1>hyperuricemia</e1> 30 d after receiving the <e2>sorafenib</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3741	"<e1>Sorafenib</e1> induced <e2>tumor lysis syndrome</e2> in an advanced hepatocellular carcinoma patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3742	"Are nasal decongestants safer than rhinitis? A case of <e1>oxymetazoline</e1>-induced <e2>syncope</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3743	"We report here a case of cardiovascular and <e1>neurological depression</e1> induced by <e2>oxymetalzoline</e2> in a toddler."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3744	"Given that discontinuation of <e1>nitrofurantoin</e1> and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of <e2>toxic liver damage</e2> caused by <e1>nitrofurantoin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3745	"<e1>Nitrofurantoin</e1>-induced <e2>acute liver damage</e2> in pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3746	"A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (<e1>PCNSL</e1>) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3747	"A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed <e1>primary central nervous system lymphoma</e1> (PCNSL) after having received 21 doses of <e2>natalizumab</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3748	"<e1>Primary central nervous system lymphoma</e1> in a patient treated with <e2>natalizumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3749	"The first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant <e2>fatigue</e2> and hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3750	"The first patient is undergoing hemodialysis and, though responding to <e1>sunitinib</e1>, is having significant fatigue and <e2>hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3751	"OBJECTIVE: To report a case of <e1>severe apnea</e1> in an infant exposed to <e2>lamotrigine</e2> through breast-feeding."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3752	"<e1>Severe apnea</e1> in an infant exposed to <e2>lamotrigine</e2> in breast milk."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3753	"The Naranjo probability scale indicated a probable relationship between <e1>apnea</e1> and exposure to <e2>lamotrigine</e2> through breast-feeding in this infant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3754	"Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with <e1>dasatinib</e1>-induced <e2>pleural effusion</e2> with complete pleural fluid analysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3755	"<e1>Dasatinib</e1>-induced <e2>pleural effusions</e2>: a lymphatic network disorder?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3756	"RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a <e1>carboplatin</e1>-based regimen, developed a <e2>platinum hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3757	"One week after the initial-dose of <e1>adalimumab</e1> (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a <e2>fulminant cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3758	"<e1>Severe cardiomyopathy</e1> following treatment with the tumour necrosis factor-alpha inhibitor <e2>adalimumab</e2> for Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3759	"<e1>Amikacin</e1>-induced type 5 Bartter-like syndrome with <e2>severe hypocalcemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3760	"<e1>Amikacin</e1>-induced <e2>type 5 Bartter-like syndrome</e2> with severe hypocalcemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3761	"Recovery of the <e1>tubular dysfunction</e1> took 15 days following cessation of the offending drug, <e2>Amikacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3762	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, <e2>hypocalcemia</e2>, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3763	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, <e2>hypomagnesemia</e2>, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3764	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, <e2>metabolic alkalosis</e2>, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3765	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3766	"We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with <e1>Amikacin</e1>, resulting in <e2>refractory hypokalemia</e2>, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3767	"We discuss a patient who developed <e1>severe renal tubular dysfunction</e1> secondary to short-term therapy with <e2>Amikacin</e2>, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3768	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and <e2>multiple infarcts</e2> on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3769	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were <e2>slow to awaken</e2>; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3770	"Postoperatively, the first two patients treated with 1 to 2 cc of <e1>thrombin</e1> were slow to awaken; one had evidence of <e2>vasospasm</e2> by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3771	"<e1>Thrombin</e1> is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the <e2>cerebral infarctions</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3772	"<e1>Ciprofloxacin</e1>-induced <e2>hemorrhagic vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3773	"<e1>Ciprofloxacin</e1>-induced <e2>hemorrhagic vasculitis</e2> is a rare side effect."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3774	"Ciprofloxacin is among the standard treatments for infected ischemic ulcers; in the rare case of <e1>ciprofloxacin</e1>-induced <e2>hemorrhagic vasculitis</e2>, it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3775	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1>-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a <e2>below-knee amputation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3776	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1>-induced <e2>hemorrhagic vasculitis</e2> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3777	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1>-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to <e2>progressive gangrene</e2> and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3778	"In one patient the vasculitis resolved after termination of the <e1>ciprofloxacin</e1> therapy; in the other patient the <e1>ciprofloxacin</e1>-induced hemorrhagic vasculitis was superimposed on a <e2>severe forefoot infection</e2>, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3779	"In one patient the <e1>vasculitis</e1> resolved after termination of the <e2>ciprofloxacin</e2> therapy; in the other patient the <e2>ciprofloxacin</e2>-induced hemorrhagic <e1>vasculitis</e1> was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3780	"However, a recent post-marketing survey in Japan revealed that <e1>interstitial pneumonia</e1> occurred in 4 among approximately 2 000 Japanese patients treated with <e2>sorafenib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3781	"<e1>Interstitial pneumonia</e1> probably associated with <e2>sorafenib</e2> treatment: An alert of an adverse event."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3782	"In this article, we describe a Japanese patient with <e1>severe interstitial pneumonia</e1> probably caused by <e2>sorafenib</e2> treatment for metastatic renal cell carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3783	"Oncologists supervising future clinical trials for lung cancer should be alert to the fact that <e1>sorafenib</e1> can potentially induce serious <e2>interstitial lung disease</e2>, although this might depend on racial differences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3784	"Fatal <e1>gemcitabine</e1>-induced <e2>pulmonary toxicity</e2> in metastatic   gallbladder adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3785	"<e1>Gemcitabine</e1>-induced <e2>pulmonary toxicity</e2> is usually a dramatic condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3786	"In this report, we describe a fatal <e1>gemcitabine</e1>-induced <e2>pulmonary toxicity</e2> in a patient with gallbladder metastatic adenocarcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3787	"He had <e1>hypokalemia</e1> (K 2.3 mmol/L) induced by <e2>licorice</e2> and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3788	"Therefore, although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for <e2>cardiac rhythms</e2> than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3789	"Therefore, although <e1>garenoxacin</e1> reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during <e2>hypokalemia</e2> in order to prevent TdP."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3790	"<e1>Torsades de Pointes</e1> induced by a combination of garenoxacin and <e2>disopyramide</e2> and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3791	"<e1>Torsades de Pointes</e1> induced by a combination of <e2>garenoxacin</e2> and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3792	"We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes (<e1>TdP</e1>) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3793	"We report an 82-year-old man who developed ventricular tachycardia and <e1>Torsades de Pointes</e1> (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3794	"We report an 82-year-old man who developed <e1>ventricular tachycardia</e1> and Torsades de Pointes (TdP) after oral administration of <e2>garenoxacin</e2>, a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3795	"Of 371 patients treated with <e1>8MOP</e1>, three (0.8%) developed an <e2>acute dermatitis</e2> in the PUVA-treated areas."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3796	"<e1>Hepatotoxicity</e1> after high-dose <e2>methylprednisolone</e2> for demyelinating disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3797	"We observed 2 cases of <e1>hepatotoxicity</e1> after a high-dose <e2>methylprednisolone</e2> treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3798	"<e1>Colonic mucosal necrosis</e1> following administration of <e2>calcium polystryrene sulfonate</e2> (Kalimate) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3799	"<e1>Colonic mucosal necrosis</e1> following administration of calcium polystryrene sulfonate (<e2>Kalimate</e2>) in a uremic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3800	"<e1>Colonic necrosis</e1> is known as a rare complication following the administration of <e2>Kayexalate</e2> (sodium polystryrene sulfonate) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3801	"<e1>Colonic necrosis</e1> is known as a rare complication following the administration of Kayexalate (<e2>sodium polystryrene sulfonate</e2>) in sorbitol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3802	"Two days after administration of <e1>Kalimate</e1> enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse <e2>colonic mucosal necrosis in the rectum</e2> and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3803	"Two days after administration of <e1>Kalimate</e1> enema, he had <e2>profuse hematochezia</e2>, and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3804	"We report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (<e2>calcium polystryrene sulfonate</e2>), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3805	"We report a rare case of <e1>colonic mucosal necrosis</e1> following <e2>Kalimate</e2> (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3806	"We report a rare case of <e1>colonic mucosal necrosis</e1> following Kalimate (calcium polystryrene sulfonate), an analogue of <e2>Kayexalate</e2> without sorbitol in a 34-yr-old man."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3807	"<e1>Clozapine</e1>-induced <e2>tardive dyskinesia</e2> in schizophrenic patients taking clozapine as a first-line antipsychotic drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3808	"CONCLUSIONS: These results suggest that <e1>clozapine</e1> may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported <e2>discomfort</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3809	"CONCLUSIONS: These results suggest that <e1>clozapine</e1> may cause <e2>TD</e2>; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3810	"However, several case reports have suggested that <e1>clozapine</e1> could also cause <e2>TD</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3811	"OBJECTIVE: <e1>Clozapine</e1> causes few <e2>extrapyramidal symptoms</e2> and is recommended as a treatment drug for severe tardive dyskinesia (TD)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3812	"<e1>All-trans retinoic acid</e1>-induced <e2>focal myositis</e2>, synovitis, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3813	"<e1>All-trans retinoic acid</e1>-induced focal myositis, synovitis, and <e2>mononeuritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3814	"<e1>All-trans retinoic acid</e1>-induced focal myositis, <e2>synovitis</e2>, and mononeuritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3815	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed <e1>acute focal myositis</e1>, synovitis, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3816	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and <e1>possible vasculitis</e1>, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3817	"Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, <e1>synovitis</e1>, and possible vasculitis, after receiving <e2>all-trans retinoic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3818	"BACKGROUND: To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with <e2>pegylated interferon</e2> and ribavirin combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3819	"BACKGROUND: To assess the nature, incidence, and risk factors of <e1>retinopathy</e1> associated with pegylated interferon and <e2>ribavirin</e2> combination therapy in chronic hepatitis C patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3820	"CONCLUSION: Significant ocular complications such as an <e1>irreversible decrease of visual acuity</e1> may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3821	"CONCLUSION: Significant <e1>ocular complications</e1> such as an irreversible decrease of visual acuity may develop in patients treated with <e2>pegylated interferon</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3822	"<e1>Retinopathy</e1> in hepatitis C patients due to combination therapy with <e2>pegylated interferon</e2> and ribavirin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3823	"<e1>Retinopathy</e1> in hepatitis C patients due to combination therapy with pegylated interferon and <e2>ribavirin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3824	"Administration of cisplatin in three patients with <e1>carboplatin</e1> <e2>hypersensitivity</e2>: is skin testing useful?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3825	"<e1>Hypersensitivity</e1> to <e2>carboplatin</e2> has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3826	"Prick tests and intradermal tests with a series of dilutions of <e1>carboplatin</e1> and cisplatin were performed on three patients who had exhibited medium and <e2>severe hypersensitivity</e2> reactions to <e1>carboplatin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3827	"<e1>Aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3828	"<e1>Aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3829	"Aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3830	"Aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3831	"Aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3832	"Aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension in a patient treated with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3833	"Aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3834	"Aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> in a patient treated with <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3835	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3836	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and <e1>aseptic meningitis</e1> simultaneously after using <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3837	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3838	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed <e1>hemolytic anemia</e1>, hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3839	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3840	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, <e1>hepatitis</e1>, orthostatic hypotension, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3841	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3842	"CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, <e1>orthostatic hypotension</e1>, and aseptic meningitis simultaneously after using <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3843	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3844	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, <e2>difficulty with speech</e2>, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3845	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3846	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, <e2>dizziness</e2>, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3847	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3848	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of <e2>headaches</e2>, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3849	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3850	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and <e2>itching on the trunk</e2> of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3851	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3852	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a <e2>maculopapular rash</e2> was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3853	"He had been taking trimethoprim-<e1>sulfamethoxazole</e1> for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3854	"He had been taking <e1>trimethoprim</e1>-sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, <e2>weakness</e2>, and itching on the trunk of his body and legs, where a maculopapular rash was noted."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3855	"PURPOSE: The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3856	"PURPOSE: The case of a patient who developed <e1>aseptic meningitis</e1>, hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2>-sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3857	"PURPOSE: The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3858	"PURPOSE: The case of a patient who developed aseptic meningitis, <e1>hemolytic anemia</e1>, hepatitis, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2>-sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3859	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3860	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, <e1>hepatitis</e1>, and orthostatic hypotension simultaneously during treatment with <e2>trimethoprim</e2>-sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3861	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with trimethoprim-<e2>sulfamethoxazole</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3862	"PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and <e1>orthostatic hypotension</e1> simultaneously during treatment with <e2>trimethoprim</e2>-sulfamethoxazole is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3863	"A patient, while on intravenous <e1>ritodrine</e1> therapy for preterm labor, experienced an episode of <e2>acute chest pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3864	"The electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3865	"The electrocardiogram (ECG), which was read as normal prior to <e1>ritodrine</e1> infusion, demonstrated a <e2>type I second-degree AV block</e2> which disappeared upon discontinuation of <e1>ritodrine</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3866	"Type I second-degree AV block (<e1>Mobitz type I</e1>, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3867	"<e1>Type I second-degree AV block</e1> (Mobitz type I, Wenckebach AV block) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3868	"Type I second-degree AV block (Mobitz type I, <e1>Wenckebach AV block</e1>) during <e2>ritodrine</e2> therapy for preterm labor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3869	"Exacerbation of <e1>anthracycline</e1>-induced <e2>early chronic cardiomyopathy</e2> with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3870	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and <e2>all-trans retinoic acid</e2> (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3871	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (<e2>ATRA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3872	"We report the case of a 14-year-old female with acute promyelocytic leukemia who developed <e1>symptomatic cardiomyopathy</e1> only 4 months into treatment with a combination of <e2>daunomycin</e2> and all-trans retinoic acid (ATRA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3873	"CONCLUSIONS: We present a case of a patient with CML who developed <e1>KS</e1> 12 months after starting treatment with <e2>imatinib</e2> 400 mg/d."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3874	"Flare of <e1>Kaposi's sarcoma</e1> (KS) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3875	"Flare of Kaposi's sarcoma (<e1>KS</e1>) is well described in immunosuppressed patients treated with corticosteroids and <e2>rituximab</e2>, but has not yet been reported during treatment with imatinib."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3876	"<e1>Kaposi's sarcoma</e1> in a patient treated with <e2>imatinib mesylate</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3877	"OBJECTIVE: We report a case of <e1>cutaneous KS lesions</e1> in a patient affected by CML treated with <e2>imatinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3878	"<e1>Bulbar</e1> and pseudobulbar palsy complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3879	"Bulbar and <e1>pseudobulbar palsy</e1> complicating therapy with high-dose <e2>cytosine arabinoside</e2> in children with leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3880	"<e1>Interferon</e1>-based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including <e2>neuropsychiatric symptoms</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3881	"<e1>Interferon</e1>-induced <e2>psychosis</e2> as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3882	"METHOD: The authors followed a patient with chronic HCV who received <e1>interferon</e1> and ribavirin and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3883	"METHOD: The authors followed a patient with chronic HCV who received interferon and <e1>ribavirin</e1> and who developed <e2>hallucinations</e2> ultimately requiring psychiatric hospitalization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3884	"OBJECTIVE: The authors described a case of <e1>interferon</e1>-induced <e2>psychosis</e2> as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3885	"CONCLUSION: <e1>Zidovudine</e1> is well a known cause of <e2>anaemia</e2> and thus should be used with caution in the initiation of antiretroviral therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3886	"We report a case of <e1>Zidovudine</e1> induced <e2>anaemia</e2> and bone marrow aplasia in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3887	"We report a case of <e1>Zidovudine</e1> induced anaemia and <e2>bone marrow aplasia</e2> in a patient infected with HIV."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3888	"<e1>Zidovudine</e1> induced <e2>pure red cell aplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3889	"CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from <e1>hydroxychloroquine</e1> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or <e2>objective visual field loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3890	"CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with <e1>visual field loss</e1> from <e2>hydroxychloroquine</e2> toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective <e1>visual field loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3891	"PURPOSE: To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3892	"Spectral-domain optical coherence tomography and adaptive optics may detect <e1>hydroxychloroquine</e1> <e2>retinal toxicity</e2> before symptomatic vision loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3893	"Transient <e1>trazodone</e1>-induced <e2>hypomanic symptoms</e2> occurred in three depressed patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3894	"<e1>Trazodone</e1>-induced <e2>transient hypomanic symptoms</e2> and their management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3895	"Introduction of <e1>etanercept</e1> was also clinically effective but followed by development of <e2>severe heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3896	"<e1>Reversible heart failure</e1> in a patient receiving <e2>etanercept</e2> for ankylosing spondylitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3897	"Combining <e1>methylephedrine</e1> and Chinese herbal drugs might carry a risk of <e2>stroke</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3898	"We describe a patient who experienced <e1>chronic nausea</e1> and an episode of confusion while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3899	"We describe a patient who experienced chronic nausea and an episode of <e1>confusion</e1> while treated with a small, stable dose of oral <e2>morphine</e2> in the setting of mild renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3900	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, <e2>ataxia</e2>, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3901	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, <e2>diplopia</e2>, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3902	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., <e2>dizziness</e2>, ataxia, diplopia, and somnolence)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3903	"Common adverse events (frequency 10%) of <e1>lacosamide</e1> doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and <e2>somnolence</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3904	"A case of <e1>aseptic pleuropericarditis</e1> in a patient with chronic plaque psoriasis under <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3905	"<e1>Methotrexate</e1> may rarely provoke <e2>serositis</e2>, even with low doses and after just a few weeks of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3906	"We report here a rare case of <e1>pleuropericarditis</e1> due to <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3907	"The authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3908	"The authors report five cases of <e1>tremor</e1> related to <e2>itraconazole</e2> therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following <e2>itraconazole</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3909	"<e1>Tremor</e1>: a newly described adverse event with long-term <e2>itraconazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3910	"<e1>Acute kidney injury</e1> caused by <e2>zonisamide</e2>-induced hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3911	"Acute kidney injury caused by <e1>zonisamide</e1>-induced <e2>hypersensitivity syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3912	"<e1>Hypersensitivity</e1> to <e2>zonisamide</e2> was confirmed by the skin patch test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3913	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, <e2>acute kidney injury</e2>, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3914	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and <e2>an increase in antihuman herpesvirus-6 immunoglobulin G titer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3915	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, <e2>eosinophilia</e2>, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3916	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, <e2>high-grade fever</e2>, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3917	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, <e2>liver dysfunction</e2>, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3918	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, <e2>lymphadenopathy</e2> and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3919	"The current report describes a man who was prescribed <e1>zonisamide</e1> for epilepsy and subsequently developed widespread <e2>skin rash</e2>, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3920	"This is the first report of <e1>acute kidney injury</e1> due to <e2>zonisamide</e2>-induced DRESS/DIHS."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3921	"This is the first report of acute kidney injury due to <e1>zonisamide</e1>-induced DRESS/<e2>DIHS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3922	"This is the first report of acute kidney injury due to <e1>zonisamide</e1>-induced <e2>DRESS</e2>/DIHS."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3923	"Only two case reports of adults with <e1>allergic contact dermatitis</e1> to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential <e1>allergic contact dermatitis</e1> to <e2>bisabolol</e2>- a component of the Aquaphor emollient they were using to treat their atopic dermatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3924	"Case report: <e1>acute renal failure</e1> after administering intravenous <e2>immunoglobulin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3925	"The hospital course of the <e1>acute renal failure</e1> is presented with a review of the literature on cases of <e1>acute renal failure</e1> after <e2>IVIG</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3926	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3927	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, <e1>azotemia</e1>, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3928	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3929	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and <e1>hyperkalemia</e1> shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3930	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3931	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with <e1>nausea</e1>, shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3932	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous <e2>immunoglobulin</e2> (IVIG)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3933	"We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, <e1>shortness of breath</e1>, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin (<e2>IVIG</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3934	"However, the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of <e2>cardiac toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3935	"However, the use of <e1>lithium</e1> should be avoided with any patient who is purging, since it may exacerbate the <e2>loss of intracellular potassium</e2>, thereby increasing the risk of cardiac toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3936	"Severe <e1>vancomycin</e1>-induced <e2>anaphylactic reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3937	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an <e2>anaphylactoid</e2> reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3938	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and <e2>anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3939	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, <e2>blood disorders</e2>, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3940	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, <e2>gastrointestinal disturbances</e2>, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3941	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of <e2>hypersensitivity reactions</e2> - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3942	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as <e2>nephrotoxicity</e2>, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3943	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, <e2>ototoxicity</e2>, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "red man syndrome" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3944	"<e1>Vancomycin</e1> is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as "<e2>red man syndrome</e2>" and anaphylaxis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3945	"We report a case of a 23-year-old man who developed a <e1>vancomycin</e1>-induced <e2>anaphylactic reaction</e2> in the treatment of methicillin-resistant Staphylococcus aureus infection."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3946	"Four patients in whom <e1>pulmonary oedema</e1> developed during tocolysis with <e2>hexoprenaline</e2> are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3947	"<e1>Pulmonary oedema</e1> after <e2>hexoprenaline</e2> administration in preterm labour."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3948	"<e1>Fatal interstitial lung disease</e1> after <e2>erlotinib</e2> administration in a patient with radiation fibrosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3949	"High-resolution computed tomography scan findings were consistent with <e1>ILD</e1>, which was sufficient to diagnose as <e2>erlotinib</e2>-induced <e1>ILD</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3950	"INTRODUCTION: Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e2>ILD</e2>), few case reports on erlotinib-induced <e2>ILD</e2> have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3951	"INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (<e1>ILD</e1>), few case reports on <e2>erlotinib</e2>-induced <e1>ILD</e1> have been issued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3952	"INTRODUCTION: Although <e1>gefitinib</e1> used for the treatment of non-small-cell lung cancer is a well-known cause of <e2>interstitial lung disease</e2> (ILD), few case reports on erlotinib-induced ILD have been issued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3953	"RESULTS: We recently experienced a case of fatal <e1>erlotinib</e1>-induced <e2>ILD</e2>, diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3954	"This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of <e1>ILD</e1> in patients taking <e2>erlotinib</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3955	"One patient suffered <e1>coronary artery vasospasm</e1>, attributed to the use of topical 1:1000 <e2>epinephrine</e2> during surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3956	"The other patient developed <e1>transient intraoperative hypertension</e1> immediately after inadvertent submucosal injection of concentrated <e2>epinephrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3957	"<e1>Cisplatin</e1>-induced syndrome of inappropriate antidiuretic hormone (<e2>SIADH</e2>) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3958	"<e1>Cisplatin</e1>-induced <e2>syndrome of inappropriate antidiuretic hormone</e2> (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3959	"We present a case of the syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3960	"We present a case of the <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) secondary to <e2>cisplatin</e2> therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3961	"However, to our knowledge, in newborns there have been no reported cases to date of <e1>thrombocytosis</e1> induced by <e2>enoxaparin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3962	"<e1>Thrombocytosis</e1> associated with <e2>enoxaparin</e2>: A very rare cause in newborns."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3963	"<e1>Thrombocytosis</e1> induced by <e2>enoxaparin</e2> has been reported as a rare adverse effect of this medication in adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3964	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, splenomegaly, and <e2>extreme hyperferritinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3965	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed <e2>fever</e2>, pancytopenia, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3966	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, <e2>pancytopenia</e2>, splenomegaly, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3967	"OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving <e1>adalimumab</e1> who developed fever, pancytopenia, <e2>splenomegaly</e2>, and extreme hyperferritinemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3968	"Visceral leishmaniasis and <e1>macrophagic activation syndrome</e1> in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3969	"<e1>Visceral leishmaniasis</e1> and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with <e2>adalimumab</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3970	"This case presentation is of a patient who had the clinical appearance of <e1>epiglottitis</e1>, but actually had an oro-pharyngeal dystonic reaction to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3971	"This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an <e1>oro-pharyngeal dystonic reaction</e1> to <e2>prochlorperazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3972	"Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe <e1>hydroxychloroquine</e1> <e2>retinopathy</e2> with 19 years follow-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3973	"After other potential causes of liver toxicity were excluded, <e1>TMP-SMX</e1> was determined to be the cause of his <e2>acute liver toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3974	"After other potential causes of <e1>liver toxicity</e1> were excluded, <e2>TMP-SMX</e2> was determined to be the cause of his acute <e1>liver toxicity</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3975	"Although this combination agent has been associated with a hypersensitivity syndrome involving <e1>cutaneous skin eruptions</e1>, pediatric cases of <e2>TMP-SMX</e2>-induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3976	"Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of <e1>TMP-SMX</e1>-induced <e2>hepatotoxicity</e2> are rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3977	"Although this combination agent has been associated with a <e1>hypersensitivity syndrome</e1> involving cutaneous skin eruptions, pediatric cases of <e2>TMP-SMX</e2>-induced hepatotoxicity are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3978	"Due to the increasing use of <e1>TMP-SMX</e1> in children, clinicians should be aware of this potentially life-threatening, <e2>immunemediated hypersensitivity reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3979	"<e1>Trimethoprim-sulfamethoxazole</e1>-induced <e2>hepatotoxicity</e2> in a pediatric patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3980	"Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of <e1>hepatotoxicity</e1> and the <e2>TMP-SMX</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3981	"We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and <e1>soft tissue infection</e1> and was treated with <e2>TMP-SMX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3982	"<e1>Amiodarone</e1> was discontinued, and <e2>thyrotoxicosis</e2> gradually abated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3983	"<e1>Goiter</e1> and hypothyroidism during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2>-induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3984	"Goiter and <e1>hypothyroidism</e1> during re-treatment with <e2>amiodarone</e2> in a patient who previously experienced <e2>amiodarone</e2>-induced thyrotoxicosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3985	"Goiter and hypothyroidism during re-treatment with <e1>amiodarone</e1> in a patient who previously experienced <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3986	"BACKGROUND: <e1>Aphthous stomatitis</e1>, a common mucocutaneous disorder, is a well accepted complication of <e2>sirolimus</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3987	"CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from tacrolimus to <e2>sirolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3988	"CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound <e1>worsening of chronic aphthous ulcers</e1> after immunosuppressive therapy was changed from <e2>tacrolimus</e2> to sirolimus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3989	"<e1>Severe aphthous stomatitis</e1> associated with oral <e2>calcineurin</e2> and mTOR inhibitors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3990	"These findings mean that the effect of the <e1>MP</e1> pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an <e1>MP</e1> therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal-change nephrotic syndrome, may be responsible for the <e1>MP</e1>-induced <e2>transient renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3991	"Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3992	"Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of <e1>MP</e1> developed <e2>transient renal failure</e2> following an <e1>MP</e1> pulse therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3993	"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of <e1>severe cholestasis</e1> 3 months after initiation of <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3994	"It is believed that this is the first reported case of reversible <e1>azathioprine</e1>-induced <e2>cholestasis</e2> associated with histological evidence of bile duct injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

3995	"Reversible cholestasis with <e1>bile duct injury</e1> following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3996	"Reversible <e1>cholestasis</e1> with bile duct injury following <e2>azathioprine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3997	"A case of the Rett syndrome with <e1>acute encephalopathy</e1> induced during <e2>calcium hopantenate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3998	"We report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by <e2>calcium hopantenate</e2> (HOPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

3999	"We report a girl with the Rett syndrome who had <e1>acute encephalopathy</e1> probably induced by calcium hopantenate (<e2>HOPA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4000	"<e1>Persistent light reactivity</e1> from systemic <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4001	"The <e1>photosensitivity</e1> is still present 3 years after the withdrawal of <e2>quinine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4002	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, <e2>doxorubicin</e2>, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4003	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with <e2>etoglucid</e2>, doxorubicin, and mitomycin C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4004	"Two cases are reported of patients who developed a <e1>hematologic malignancy</e1> several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and <e2>mitomycin C</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4005	"A patient with Wegener's granulomatosis rapidly developed a <e1>circumferential subglottic stenosis</e1> while on a <e2>cyclophosphamide</e2> regimen that had caused resolution of systemic symptoms and pulmonary infiltrates."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4006	"<e1>Subglottic stenosis</e1> in Wegener's granulomatosis: development during <e2>cyclophosphamide</e2> treatment with response to carbon dioxide laser therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4007	"A case is described of <e1>severe splenic hemorrhage and rupture</e1> which developed 3 h after completion of <e2>tPA</e2> infusion for suspected acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4008	"<e1>Splenic hemorrhage</e1>: a complication of <e2>tissue plasminogen activator</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4009	"Thrombolytic therapy with <e1>tissue plasminogen activator</e1> (tPA) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4010	"Thrombolytic therapy with tissue plasminogen activator (<e1>tPA</e1>) for acute myocardial infarction may result in major bleeding complications such as <e2>gastrointestinal or intracranial bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4011	"A case of <e1>severe acute hepatitis</e1> caused by <e2>cyproterone acetate</e2> in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4012	"Monitoring of liver function tests should be mandatory in patients receiving high doses of <e1>cyproterone acetate</e1>; the drug should be withdrawn immediately if <e2>abnormal liver function tests</e2> are found."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4013	"<e1>Severe hepatitis</e1> caused by <e2>cyproterone acetate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4014	"A unique case of a transient, nonpigmenting <e1>fixed drug eruption</e1> caused by the radiopaque contrast medium <e2>iothalamate</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4015	"One patient with systemic lupus erythematosus developed <e1>erythema multiforme</e1> after taking <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4016	"<e1>Aminoglutethimide</e1> was discontinued until completion of radiotherapy, and the <e2>rash</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4017	"Concomitant irradiation apparently enhanced the <e1>skin toxicity</e1> of <e2>aminoglutethimide</e2> or possibly <e2>aminoglutethimide</e2> had a radiosensitizing role in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4018	"We report a case of radiotherapy-enhanced <e1>aminoglutethimide</e1> <e2>skin toxicity</e2> in a patient with metastatic breast cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4019	"Data have been published regarding the possibility that <e1>tamoxifen</e1> may be responsible for the subsequent development of <e2>carcinoma of the corpus uteri</e2> in these patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4020	"The authors intend to carry out a case-control study on patients treated with <e1>tamoxifen</e1> for breast carcinoma to reveal the possible presence of <e2>endometrial carcinoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4021	"<e1>Disulfiram</e1>-induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4022	"Our patient had headache, mild fever, nausea, vomiting, rash, and <e1>eosinophilia</e1> after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4023	"Our patient had <e1>headache</e1>, mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4024	"Our patient had headache, <e1>mild fever</e1>, nausea, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4025	"Our patient had headache, mild fever, <e1>nausea</e1>, vomiting, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4026	"Our patient had headache, mild fever, nausea, vomiting, <e1>rash</e1>, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4027	"Our patient had headache, mild fever, nausea, <e1>vomiting</e1>, rash, and eosinophilia after 3 weeks of <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4028	"We reported a case of <e1>disulfiram</e1>-induced <e2>hepatitis</e2> with unique clinical features and compared our case with others in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4029	"An episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4030	"An episode of <e1>leukoencephalopathy</e1> is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 <e2>methotrexate</e2> and 12 mg intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4031	"<e1>Methotrexate</e1>-induced <e2>leukoencephalopathy</e2> is treatable with high-dose folinic acid: a case report and analysis of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4032	"Severe <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4033	"Severe <e1>heparin</e1> associated <e2>thrombocytopenia</e2> is a rare complication of <e1>heparin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4034	"We report a patient who developed <e1>heparin</e1> associated <e2>thrombocytopenia</e2> during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4035	"Acute <e2>alum</e2>inum toxicity after continuous intravesical <e2>alum</e2> irrigation for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4036	"An encephalopathy and <e1>cardiomyopathy</e1> developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4037	"An <e1>encephalopathy</e1> and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical <e2>aluminum</e2> infusion for hemorrhagic cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4038	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, <e2>bleomycin</e2>, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4039	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of <e2>cisplatin</e2>, bleomycin, and methotrexate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4040	"A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related <e1>hemolytic-uremic syndrome</e1> during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4041	"Awareness of this route of intoxication might be important in patients in whom neurologic or <e1>psychiatric symptoms</e1> develop while large amounts of <e2>lidocaine</e2> cream are being used."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4042	"<e1>Nitrendipine</e1>-induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4043	"<e1>Nitrendipine</e1> is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced <e2>gingival hyperplasia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4044	"Physicians using this "new" drug must be aware of the potential danger of <e1>sulfonamide</e1>-induced <e2>injury to the urinary tract</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4045	"<e1>Sulfadiazine</e1> <e2>crystalluria</e2> revisited."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4046	"We describe two cases of <e1>sulfadiazine</e1>-induced <e2>crystalluria</e2> and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4047	"We describe two cases of <e1>sulfadiazine</e1>-induced crystalluria and <e2>renal failure</e2> in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4048	"<e1>Glaucoma</e1> secondary to epithelial downgrowth and <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4049	"We report a case of secondary <e1>glaucoma</e1> caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4050	"Antacid and <e1>sucralfate</e1>-induced <e2>hypophosphatemic osteomalacia</e2>: a case report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4051	"Because of a <e1>hypersensitivity reaction</e1>, initial therapy with penicillin G and <e2>gentamicin</e2> was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4052	"Because of a <e1>hypersensitivity reaction</e1>, initial therapy with <e2>penicillin G</e2> and gentamicin was stopped and substituted with cefazolin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4053	"Prenatal cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4054	"Prenatal cytomegalovirus (CMV) infection associated with severe <e1>brain damage</e1> was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4055	"<e1>Prenatal cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and <e2>azathioprine</e2> for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4056	"<e1>Prenatal cytomegalovirus (CMV) infection</e1> associated with severe brain damage was detected in an infant whose mother had been treated with <e2>prednisolone</e2> and azathioprine for systemic lupus erythematosus (SLE)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4057	"<e1>Acute coronary events</e1> following <e2>cisplatin</e2>-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4058	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4059	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed <e1>acute coronary ischemia</e1>/infarction shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4060	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after <e2>cis-diamine-dichloroplatinum II</e2> (cisplatin) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4061	"Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia/<e1>infarction</e1> shortly after cis-diamine-dichloroplatinum II (<e2>cisplatin</e2>) -based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4062	"<e1>Bowel perforation</e1> associated with intraperitoneal <e2>chromic phosphate</e2> instillation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4063	"Delayed <e1>bowel injury</e1> is an infrequently observed complication of <e2>chromic phosphate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4064	"This report presents a case of <e1>colon perforation</e1> which occurred 4 months after treatment with intraperitoneal <e2>chromic phosphate</e2> for stage IB ovarian papillary serous cystadenocarcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4065	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent <e1>Ara-C</e1> treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4066	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to <e2>death</e2> within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4067	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and <e1>loss of consciousness</e1> which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4068	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a progressive visual loss and <e2>loss of consciousness</e2> which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4069	"Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a <e1>progressive visual loss</e1> and loss of consciousness which worsened during subsequent <e2>Ara-C</e2> treatment and led to death within 3 weeks."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4070	"Despite a response of the meningeal tumor the patient developed in the third week of <e1>MTX</e1> treatment a <e2>progressive visual loss</e2> and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4071	"A 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed postoperative psychosis and was diagnosed as having <e2>bromide intoxication</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4072	"A 59-year-old woman with myasthenia gravis who received a large dose of <e1>pyridostigmine bromide</e1> developed <e2>postoperative psychosis</e2> and was diagnosed as having bromide intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4073	"<e1>Bromide intoxication</e1> secondary to <e2>pyridostigmine bromide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4074	"To our knowledge , this is the first reported case of <e1>bromide intoxication</e1> due to <e2>pyridostigmine bromide</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4075	"<e1>Diazepam</e1> use by pregnant women can be associated with a later presentation of <e2>withdrawal symptoms</e2> in the neonate than that induced by the use of other drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4076	"We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related <e1>ileus</e1> in patients treated with <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4077	"We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of <e1>adynamic ileus</e1>, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4078	"We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening <e1>pseudo-obstruction of the colon</e1>, a variant of adynamic ileus, while being treated with intravenous <e2>nimodipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4079	"After discontinuation of <e1>danazol</e1> the <e2>diabetes</e2> completely resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4080	"<e1>Insulin-dependent diabetes mellitus</e1> associated with <e2>danazol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4081	"<e1>Insulin-dependent diabetes mellitus</e1> developed in a young woman 8 weeks after the initiation of <e2>danazol</e2> for treatment of pelvic endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4082	"An 83-year-old man receiving <e1>glipizide</e1> 10 mg bid developed <e2>symptomatic hypoglycemia</e2> within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4083	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (TMP/<e2>SMX</e2>) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4084	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/<e2>sulfamethoxazole</e2> (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4085	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding trimethoprim/sulfamethoxazole (<e2>TMP</e2>/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4086	"An 83-year-old man receiving glipizide 10 mg bid developed <e1>symptomatic hypoglycemia</e1> within three days of adding <e2>trimethoprim</e2>/sulfamethoxazole (TMP/SMX) to his regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4087	"<e1>Symptomatic hypoglycemia</e1> secondary to a <e2>glipizide</e2>-trimethoprim/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4088	"<e1>Symptomatic hypoglycemia</e1> secondary to a glipizide-trimethoprim/<e2>sulfamethoxazole</e2> drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4089	"<e1>Symptomatic hypoglycemia</e1> secondary to a glipizide-<e2>trimethoprim</e2>/sulfamethoxazole drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4090	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with <e1>anuria</e1>, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4091	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an <e1>irreversible lethal renal failure</e1> with anuria, the day after 5 g/m2 bolus <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4092	"<e1>Ifosfamide</e1> is a known nephrotoxic drug with demonstrated <e2>tubulopathies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4093	"<e1>Lethal anuria</e1> complicating high dose <e2>ifosfamide</e2> chemotherapy in a breast cancer patient with an impaired renal function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4094	"We strongly suspect that this <e1>lethal anuria</e1> was mainly due to <e2>ifosfamide</e2>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4095	"<e1>Ciprofloxacin</e1> is one drug that has been reported to cause <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4096	"<e1>Renal toxicities</e1> have been reported in less than one percent of the patients receiving <e2>ciprofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4097	"Suspected <e1>ciprofloxacin</e1>-induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4098	"This article describes a patient with suspected <e1>ciprofloxacin</e1>-induced <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4099	"In a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, <e2>acute encephalopathy</e2> with high-pressure hydrocephalus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4100	"In a female with acute lymphoblastic leukemia, inadvertent <e1>doxorubicin</e1> administration intrathecally caused severe, life-threatening, acute encephalopathy with <e2>high-pressure hydrocephalus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4101	"<e1>Severe acute encephalopathy</e1> following inadvertent intrathecal <e2>doxorubicin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4102	"<e1>Phenobarbital</e1> <e2>hepatotoxicity</e2> in an 8-month-old infant."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4103	"<e1>Severe hepatotoxicity</e1> from <e2>phenobarbital</e2> occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4104	"Skin rash began after 2 weeks of treatment, and signs of <e1>hepatocellular failure</e1> developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4105	"<e1>Skin rash</e1> began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after <e2>phenobarbital</e2> had been started."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4106	"<e1>Atenolol</e1>-induced <e2>pseudolymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4107	"Although <e1>tardive dyskinesia</e1> is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with <e2>sulpiride</e2>, a selective D2-receptor antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4108	"<e1>Tardive dyskinesia</e1> induced by <e2>sulpiride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4109	"These cases indicate that <e1>sulpiride</e1> can cause <e2>tardive dyskinesia</e2> and that this drug should be administered with caution."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4110	"We describe six patients who developed <e1>tardive dyskinesia</e1> after treatment with <e2>sulpiride</e2> for depression or gastrointestinal symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4111	"A patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4112	"A patient with seropositive rheumatoid arthritis developed <e1>ascites</e1> while taking weekly doses of methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4113	"Hepatitis with <e1>bridging fibrosis</e1> and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4114	"<e1>Hepatitis</e1> with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4115	"Hepatitis with bridging fibrosis and <e1>reversible hepatic insufficiency</e1> in a woman with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4116	"This is the third report of reversible <e1>hepatic decompensation</e1> associated with prolonged <e2>MTX</e2> therapy in patients with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4117	"Upon discontinuation of <e1>MTX</e1>, her <e2>ascites</e2> resolved, and her arthritis became more active."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4118	"Although high-dose <e1>methotrexate</e1> has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a <e2>fatal rise in intracranial pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4119	"A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and <e1>brainstem herniation</e1> after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4120	"A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed <e1>fatal cerebral edema</e1> and brainstem herniation after she received a single dose of intravenous <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4121	"Transtentorial herniation caused by an <e1>intracranial mass lesion</e1> following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4122	"<e1>Transtentorial herniation</e1> caused by an intracranial mass lesion following high-dose <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4123	"<e1>Fever</e1>, pulmonary infiltrates, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4124	"Fever, pulmonary infiltrates, and <e1>pleural effusion</e1> following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4125	"Fever, <e1>pulmonary infiltrates</e1>, and pleural effusion following <e2>acyclovir</e2> therapy for herpes zoster ophthalmicus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4126	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed <e2>fever</e2>, hemoptysis, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4127	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, <e2>hemoptysis</e2>, and a pleural friction rub."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4128	"Following the institution of intravenous therapy with <e1>acyclovir</e1>, the patient developed fever, hemoptysis, and a <e2>pleural friction rub</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4129	"The <e1>fever</e1> abated promptly following discontinuation of <e2>acyclovir</e2>, and radiographic abnormalities resolved over ten days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4130	"To our knowledge, the syndrome of <e1>fever</e1>, pulmonary infiltrates, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4131	"To our knowledge, the syndrome of fever, pulmonary infiltrates, and <e1>pleural effusion</e1> following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4132	"To our knowledge, the syndrome of fever, <e1>pulmonary infiltrates</e1>, and pleural effusion following use of <e2>acyclovir</e2> has not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4133	"<e1>Quinine</e1>-induced <e2>hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4134	"<e1>Sensorineural hearing loss</e1> due to <e2>quinine</e2> therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4135	"The case of a 29-year-old man suffering from falciparum malaria disease who got a <e1>reversible hearing loss</e1> from <e2>quinine</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4136	"The <e1>ototoxicity</e1> of <e2>quinine</e2> can accurately be studied with ultrahigh frequency audiometry (up to 20 kHz)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4137	"<e1>Hemolytic uremic syndrome</e1> in a patient on cis-platinum, vinblastine and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4138	"<e1>Hemolytic uremic syndrome</e1> in a patient on <e2>cis-platinum</e2>, vinblastine and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4139	"<e1>Hemolytic uremic syndrome</e1> in a patient on cis-platinum, <e2>vinblastine</e2> and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4140	"A case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after <e2>bleomycin</e2> and moderate oxygen administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4141	"A case of a 53-year-old man who developed <e1>acute pneumonitis</e1> after bleomycin and moderate <e2>oxygen</e2> administration is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4142	"Autopsy findings were consistent with <e1>bleomycin</e1> and oxygen-induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4143	"Autopsy findings were consistent with bleomycin and <e1>oxygen</e1>-induced <e2>pulmonary damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4144	"<e1>Bleomycin</e1> <e2>pneumonitis</e2> potentiated by oxygen administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4145	"Oxygen potentiation of <e1>bleomycin</e1>-induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4146	"<e1>Oxygen</e1> potentiation of bleomycin-induced <e2>pulmonary toxicity</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4147	"A patient with the Wolff-Parkinson-White syndrome presented with <e1>incessant orthodromic atrioventricular tachycardia</e1> following initiation of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4148	"Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate <e1>tachycardia</e1> in the control state but <e1>tachycardia</e1> was always reinitiated by an identical escape sequence after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4149	"In addition, the <e1>tachycardia</e1> persisted and was repeatedly spontaneously reinitiated for prolonged periods after <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4150	"<e1>Procainamide</e1>-induced <e2>incessant supraventricular tachycardia</e2> in the Wolff-Parkinson-White syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4151	"The <e1>pro-arrhythmic effects</e1> of <e2>procainamide</e2> may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4152	"<e1>Multicentric hepatocellular carcinoma</e1> following <e2>phosphate diethylstilbestrol</e2> therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4153	"This is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to diethylstilbestrol (<e2>DES</e2>) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4154	"This is a unique autopsy case of <e1>hepatocellular carcinoma</e1> closely related to <e2>diethylstilbestrol</e2> (DES) therapy for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4155	"This paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of phosphate diethylstilbestrol (<e2>PDES</e2>) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4156	"This paper reports an autopsy case of a 78-year-old male with <e1>multiple nodules in the liver</e1> developed after long-termed administration of <e2>phosphate diethylstilbestrol</e2> (PDES) for prostatic cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4157	"A 52-year-old woman developed symmetric sensorimotor polyneuropathy and <e1>cerebellar syndrome</e1> after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4158	"A 52-year-old woman developed <e1>symmetric sensorimotor polyneuropathy</e1> and cerebellar syndrome after 24 months of <e2>amiodarone</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4159	"Peripheral neuropathy and <e1>cerebellar syndrome</e1> associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4160	"<e1>Peripheral neuropathy</e1> and cerebellar syndrome associated with <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4161	"Life-threatening <e1>hyponatremia</e1> caused by <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4162	"The most likely cause of such <e1>hyponatremic episode</e1> is <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4163	"Although this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2>-induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4164	"Although this type of <e1>hyperpigmentation</e1> has been previously seen in patients with cancer who are receiving <e2>bleomycin</e2>, this is, to our knowledge, the first reported case of <e2>bleomycin</e2>-induced <e1>hyperpigmentation</e1> in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4165	"We report a case of <e1>hyperpigmentation</e1> due to <e2>bleomycin</e2> treatment in a patient with acquired immune deficiency syndrome (AIDS)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4166	"A typical case of <e1>dextran-40</e1> associated <e2>acute renal failure</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4167	"<e1>Renal failure</e1> associated with the use of <e2>dextran-40</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4168	"Several possible explanations of the mechanism of <e1>renal failure</e1> associated with the use of <e2>dextran-40</e2> are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4169	"While the mechanism of <e1>dextran</e1>-associated <e2>renal failure</e2> remains unsolved, plasma exchange seems to be effective therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4170	"MR findings in <e1>methotrexate</e1>-induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4171	"A 57-year-old man developed <e1>morphea</e1> while taking <e2>bromocriptine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4172	"<e1>Morphea</e1> after <e2>bromocriptine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4173	"A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from <e1>dapsone</e1>-induced <e2>erythroderma</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4174	"<e1>Dapsone</e1>-induced <e2>erythroderma</e2> with Beau's lines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4175	"<e1>Akathisia</e1> appeared to be a common side effect of <e2>fluoxetine</e2> and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4176	"Five patients receiving <e1>fluoxetine</e1> for the treatment of obsessive compulsive disorder or major depression developed <e2>akathisia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4177	"<e1>Fluoxetine</e1>-induced <e2>akathisia</e2>: clinical and theoretical implications."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4178	"The authors suggest that <e1>fluoxetine</e1>-induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1>-induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4179	"The authors suggest that <e1>fluoxetine</e1>-induced <e2>akathisia</e2> may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of <e1>fluoxetine</e1>-induced <e2>akathisia</e2> and tricyclic antidepressant-induced "jitteriness" may be identical."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4180	"The typical <e1>fluoxetine</e1>-induced symptoms of restlessness, <e2>constant pacing</e2>, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4181	"The typical <e1>fluoxetine</e1>-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and <e2>marked anxiety</e2> were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4182	"The typical <e1>fluoxetine</e1>-induced symptoms of restlessness, constant pacing, <e2>purposeless movements of the feet and legs</e2>, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4183	"The typical <e1>fluoxetine</e1>-induced symptoms of <e2>restlessness</e2>, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4184	"Three patients who had experienced neuroleptic-induced <e1>akathisia</e1> in the past reported that the symptoms of <e2>fluoxetine</e2>-induced <e1>akathisia</e1> were identical, although somewhat milder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4185	"Horner's syndrome and <e1>demyelinating peripheral neuropathy</e1> caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4186	"<e1>Horner's syndrome</e1> and demyelinating peripheral neuropathy caused by high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4187	"<e1>Peripheral nerve dysfunction</e1> is a potentially serious complication of high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4188	"<e1>Peripheral nervous system disturbances</e1> caused by <e2>cytosine arabinoside</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4189	"We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to <e1>death</e1> after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4190	"We describe a patient with acute leukemia who developed <e1>Horner's syndrome</e1> and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4191	"We describe a patient with acute leukemia who developed Horner's syndrome and a <e1>severe demyelinating peripheral neuropathy</e1> leading to death after receiving high-dose <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4192	"<e1>Nail-changes</e1> induced by <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4193	"Peculiar <e1>nail-changes</e1> in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of <e2>penicillamine</e2> treatment are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4194	"Reinstitution of <e1>penicillamine</e1> treatment caused a recurrence thus proving a causal relationship between <e1>penicillamine</e1> and the described <e2>nail-changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4195	"<e1>Ibuprofen</e1>-induced <e2>meningitis</e2>: detection of intrathecal IgG synthesis and immune complexes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4196	"We report a case of <e1>ibuprofen</e1>-induced <e2>meningitis</e2> in an otherwise healthy individual."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4197	"<e1>Metoclopramide</e1>-induced <e2>parkinsonism</e2> is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4198	"<e1>Metoclopramide</e1>-induced <e2>parkinsonism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4199	"Their <e1>parkinsonism</e1> improved on discontinuation of <e2>metoclopramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4200	"We have reported six cases of <e1>metoclopramide</e1>-induced <e2>parkinsonism</e2> seen in consultation over a two-year period."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4201	"It is suggested that the fatal stroke may have resulted from <e1>arterial spasm</e1> caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4202	"It is suggested that the <e1>fatal stroke</e1> may have resulted from arterial spasm caused by <e2>ergotamine</e2> overdosage and possibly complicated by thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4203	"Life-threatening <e1>acute hyponatraemia</e1> induced by low dose <e2>cyclophosphamide</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4204	"Life-threatening <e1>acute hyponatraemia</e1> induced by low dose cyclophosphamide and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4205	"We report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral indomethacin and low dose intravenous <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4206	"We report the case of a patient with multiple myeloma who developed acute <e1>life-threatening water intoxication</e1> following treatment with oral <e2>indomethacin</e2> and low dose intravenous cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4207	"<e1>Clofazimine</e1> induced <e2>nail changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4208	"These <e1>nail changes</e1> gradually disappeared when the dose of <e2>clofazimine</e2> was reduced."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4209	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed <e2>discoloration of nail plate</e2>, subungual hyperkeratosis and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4210	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, subungual hyperkeratosis and <e2>onycholysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4211	"Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of <e1>clofazimine</e1>, showed discoloration of nail plate, <e2>subungual hyperkeratosis</e2> and onycholysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4212	"Attenuation of <e1>asparaginase</e1>-induced <e2>hyperglycemia</e2> after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4213	"Development of <e1>persistent late onset asthma</e1> following treatment with <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4214	"We describe the first case of de novo <e1>asthma</e1> following treatment with the angiotensin converting enzyme (ACE) inhibitor <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4215	"A case report of a patient with probable cisplatin and <e1>bleomycin</e1>-induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4216	"A case report of a patient with probable <e1>cisplatin</e1> and bleomycin-induced <e2>TMA</e2> is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4217	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with <e2>ascites</e2>, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4218	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, oesophageal varices and <e2>jaundice</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4219	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and portal hypertension with ascites, <e2>oesophageal varices</e2> and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4220	"A patient with chronic myeloid leukaemia treated with <e1>busulphan</e1> for 4-5 years, developed signs of <e1>busulphan</e1> toxicity and <e2>portal hypertension</e2> with ascites, oesophageal varices and jaundice."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4221	"Although a lot of <e1>amiodarone</e1>-induced <e2>torsades de pointe</e2> have been published, a review of all these cases and the underlying risk-factors has never been made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4222	"<e1>Amiodarone</e1> induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4223	"We report three cases of <e1>amiodarone</e1>-induced <e2>torsades de pointe</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4224	"The syndrome of irreversible <e1>lithium</e1>-effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4225	"Long lasting <e1>respiratory depression</e1> induced by <e2>morphine-6-glucuronide</e2>?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4226	"We report a case of long lasting <e1>respiratory depression</e1> after intravenous administration of <e2>morphine</e2> to a 7 year old girl with haemolytic uraemic syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4227	"<e1>Rifampin</e1>-associated <e2>thrombocytopenia</e2> secondary to poor compliance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4228	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, <e2>acute renal failure</e2>, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4229	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, acute renal failure, <e2>hemolytic anemia</e2>, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4230	"<e1>Rifampin</e1> can be associated with severe adverse effects such as <e2>hepatitis</e2>, acute renal failure, hemolytic anemia, and thrombocytopenia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4231	"<e1>Rifampin</e1> can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4232	"This article reports the occurrence of <e1>rifampin</e1>-associated <e2>thrombocytopenia</e2> in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4233	"We present the first case of <e1>WES</e1> in an infant born to a mother taking <e2>haloperidol</e2> during her pregnancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4234	"<e1>Withdrawal emergent syndrome</e1> in an infant associated with maternal <e2>haloperidol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4235	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, methotrexate, and <e2>5-fluorouracil</e2> adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4236	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to <e2>cyclophosphamide</e2>, methotrexate, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4237	"This report describes two patients who developed <e1>acute myelocytic leukemia</e1> only after exposure to cyclophosphamide, <e2>methotrexate</e2>, and 5-fluorouracil adjuvant therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4238	"<e1>Ibuprofen</e1> rarely causes lower <e2>gastrointestinal adverse reactions</e2> but has been implicated in systemic and local side effects in patients with lupus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4239	"<e1>Ulcerative proctitis</e1> in juvenile systemic lupus erythematosus after <e2>ibuprofen</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4240	"We describe a case of <e1>ulcerative proctitis</e1> after <e2>ibuprofen</e2> treatment in a girl with juvenile systemic lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4241	"Intravenous <e1>cytarabine</e1> and methotrexate appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4242	"Intravenous cytarabine and <e1>methotrexate</e1> appear to act synergistically to enhance the potential for <e2>central nervous system toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4243	"We present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous <e2>ara = C</e2> and methotrexate during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4244	"We present two children with acute lymphocytic leukemia who developed <e1>leukoencephalopathy</e1> following administration of a combination of intravenous ara = C and <e2>methotrexate</e2> during the consolidation phase of chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4245	"Dexamethasone treatment of <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2> (AIT) with or without persistent administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4246	"Treatment of <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2> (AIT) with thionamide, lithium or radioactive iodine is ineffective."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4247	"<e1>Acute myelogenous leukemia</e1> in patients receiving <e2>chlorambucil</e2> as long-term adjuvant chemotherapy for stage II breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4248	"After the <e1>chlorambucil</e1> was discontinued, the wbc count began to slowly rise and the patient developed clinical <e2>AML</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4249	"<e1>Panic anxiety</e1> after abrupt discontinuation of <e2>mianserin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4250	"This <e1>panic anxiety</e1> was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of <e2>mianserin</e2> 30 mg/day, and because of that the depressive symptom also disappeared."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4251	"Prior neurologic illness and the syndrome of irreversible <e1>lithium</e1>-effectuated <e2>neurotoxicity</e2> (SILENT)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4252	"Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to <e1>neurotoxicity</e1> of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4253	"The authors describe a patient with hemiparesis who developed the syndrome of irreversible <e1>lithium</e1>-effectuated <e2>neurotoxicity</e2> (SILENT) while being treated with <e1>lithium</e1> for a manic episode."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4254	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and <e2>acute respiratory difficulties</e2>, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4255	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the <e2>cranial dystonia</e2> associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4256	"Abrupt, accidental withdrawal of <e1>trihexyphenidyl</e1> triggered severe exacerbation of the cranial dystonia associated with <e2>inspiratory stridor</e2> and acute respiratory difficulties, prompting emergency admission."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4257	"Life-threatening <e1>cranial dystonia</e1> following <e2>trihexyphenidyl</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4258	"MR findings in <e1>methotrexate</e1>-induced <e2>CNS abnormalities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4259	"Administration of intrathecal <e1>Ara-C</e1> in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms (<e2>paresthesias</e2>) in only one of 30 patients so treated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4260	"<e1>Paraplegia</e1> following intrathecal <e2>cytosine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4261	"<e1>Paraplegia</e1> following prophylactic intrathecal cytosine arabinoside (<e2>Ara-C</e2>) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4262	"<e1>Paraplegia</e1> following prophylactic intrathecal <e2>cytosine arabinoside</e2> (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4263	"Both patients developed <e1>hypoadrenalism</e1> while on <e2>o,p'-DDD</e2> and apparently adequate dexamethasone replacement therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4264	"<e1>Alprazolam</e1>-induced <e2>mania</e2>: two clinical cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4265	"The authors caution that treatment with <e1>alprazolam</e1> may be complicated by the induction of <e2>mania</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4266	"Two patients treated with <e1>alprazolam</e1> had histories suggestive of a bipolar disorder and developed lithium-responsive <e2>manic episodes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4267	"A case is presented in which a 68-year-old man became <e1>delirious</e1> after being withdrawn from a low dosage of <e2>alprazolam</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4268	"<e1>Alprazolam</e1> withdrawal <e2>delirium</e2> unresponsive to diazepam: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4269	"<e1>Sulfasalazine</e1> has been associated with <e2>bronchopulmonary complications of inflammatory bowel disease</e2> (IBD) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4270	"<e1>Sulfasalazine</e1> has been associated with bronchopulmonary complications of inflammatory bowel disease (<e2>IBD</e2>) in adults."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4271	"We discuss a variety of bronchopulmonary complications of <e1>IBD</e1> and their association with <e2>sulfasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4272	"Administration of <e1>amantadine</e1> was associated with <e2>psychotic decompensations</e2> in two schizophrenic patients being maintained on concomitant neuroleptic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4273	"Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of <e1>amantadine</e1>'s <e2>precipitating psychosis</e2> in a schizophrenic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4274	"Exacerbation of <e1>schizophrenia</e1> associated with <e2>amantadine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4275	"Soon after its introduction in 1952, <e1>chlorpromazine</e1> was noted to induce <e2>symptoms resembling Parkinson's disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4276	"It is suggested that the patient had <e1>sulfasalazine</e1>-induced <e2>lupus</e2>, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4277	"It is suggested that the patient had <e1>sulfasalazine</e1>-induced lupus, which manifested with serositis and <e2>pulmonary parenchymal involvement</e2> in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4278	"It is suggested that the patient had <e1>sulfasalazine</e1>-induced lupus, which manifested with <e2>serositis</e2> and pulmonary parenchymal involvement in the absence of joint symptoms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4279	"Physicians who use <e1>sulfasalazine</e1> to treat patients with inflammatory bowel disease should be aware of the signs of <e1>sulfasalazine</e1>-induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4280	"Pneumonitis, <e1>bilateral pleural effusions</e1>, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4281	"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of <e1>cardiac tamponade</e1>, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4282	"<e1>Pneumonitis</e1>, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4283	"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and <e1>positive autoantibodies</e1> developed in a 43-year-old man, who was receiving long-term <e2>sulfasalazine</e2> therapy for chronic ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4284	"<e1>Sulfasalazine</e1>-induced <e2>lupus erythematosus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4285	"<e1>Acute myocardial infarction</e1> due to coronary spasm associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4286	"Acute myocardial infarction due to <e1>coronary spasm</e1> associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4287	"Electrocardiographic findings and laboratory data indicated a diagnosis of <e1>acute myocardial infarction</e1> due to the <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4288	"We believe this is the first report of myocardial infarction due to <e1>coronary spasm</e1>, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4289	"We believe this is the first report of <e1>myocardial infarction</e1> due to coronary spasm, demonstrated by angiography associated with <e2>L-thyroxine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4290	"A study of in vitro reactivity to <e1>L-T4</e1>, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed <e2>leukopenia</e2> during treatment with <e1>L-T4</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4291	"<e1>L-Thyroxine</e1>-induced <e2>leukopenia</e2> in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4292	"<e1>Ampicillin</e1>-induced interstitial nephritis with <e2>generalised exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4293	"<e1>Ampicillin</e1>-induced <e2>interstitial nephritis</e2> with generalised exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4294	"However, there are few reports in the literature of <e1>ampicillin</e1> as a cause of <e2>acute interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4295	"In the following case report, a patient developed <e1>acute interstitial nephritis</e1> with renal failure and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4296	"In the following case report, a patient developed acute interstitial nephritis with renal failure and <e1>exfoliative dermatitis</e1> following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4297	"In the following case report, a patient developed acute interstitial nephritis with <e1>renal failure</e1> and exfoliative dermatitis following <e2>ampicillin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4298	"The diagnosis was based on the rapid onset of renal failure, presence of <e1>eosinophilia</e1>, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4299	"The diagnosis was based on the rapid onset of <e1>renal failure</e1>, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4300	"The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, <e1>skin rash</e1>, and characteristic renal biopsy finding, following the administration of <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4301	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and <e2>erythema of the cartilage of both ears</e2>, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4302	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and <e2>hemorrhagic lesions of the finger tips</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4303	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a <e2>lupus-like syndrome</e2> characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4304	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a <e2>malar rash</e2>, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4305	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, <e2>pain</e2> and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4306	"A patient receiving <e1>vancomycin</e1> for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and <e2>tender erythematous</e2> and hemorrhagic lesions of the finger tips."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4307	"The possible development of a drug-induced vasculitis or <e1>lupus-like syndrome</e1> should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4308	"The possible development of a drug-induced <e1>vasculitis</e1> or lupus-like syndrome should be added to the list of rare toxic effects of <e2>vancomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4309	"<e1>Vancomycin</e1>-induced <e2>vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4310	"<e1>Abnormal retinal function</e1> associated with <e2>isotretinoin</e2> therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4311	"Three of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of poor night vision and/or <e2>excessive glare sensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4312	"Three of 50 patients treated with <e1>isotretinoin</e1> (1 mg/kg/day) for cystic acne complained of <e2>poor night vision</e2> and/or excessive glare sensitivity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4313	"<e1>Neurologic toxicity</e1> associated with hepatic artery infusion HAI of <e2>FUdR</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4314	"<e1>Ethambutol</e1> is frequently used in the treatment of tuberculosis, and, although <e2>optic neuropathies</e2> have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4315	"However, we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom visual loss from <e2>toxic optic neuropathies</e2> was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4316	"However, we recently saw two patients with renal tuberculosis treated with <e1>ethambutol</e1> in whom <e2>visual loss</e2> from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4317	"<e1>Optic neuropathy</e1> in <e2>ethambutol</e2>-treated renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4318	"Since <e1>ethambutol</e1> is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of <e1>ethambutol</e1> sufficient to produce <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4319	"A 57-year-old woman presented with a 3-week history of <e1>dysphagia for solids</e1>, 6 months after starting treatment with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4320	"<e1>Gastro-oesophageal reflux</e1> associated with <e2>nifedipine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4321	"<e1>Nifedipine</e1> may induce, or aggravate, pre-existing, <e2>gastro-oesophageal reflux</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4322	"A young diamond dealer developed visual impairment attributed to <e1>bilateral posterior subcapsular cataracts</e1> following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4323	"A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for <e1>cisplatin</e1>-associated <e2>nausea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4324	"A young diamond dealer developed <e1>visual impairment</e1> attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent <e2>Decadron</e2> used as part of a five-drug antiemetic regimen for cisplatin-associated nausea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4325	"<e1>Cataracts</e1> induced by intermittent <e2>Decadron</e2> used as an antiemetic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4326	"Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on <e1>cisplatin</e1>-induced <e2>vomiting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4327	"Transient <e1>phenytoin</e1> induced <e2>IgA deficiency</e2> and permanent IgE increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4328	"Transient <e1>phenytoin</e1> induced IgA deficiency and permanent <e2>IgE increase</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4329	"The pharmacology and toxicology of <e1>chloral hydrate</e1> are discussed with particular reference to the <e2>cardiac arrhythmias</e2> that are seen with overdosage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4330	"<e1>Adrenaline</e1> <e2>dacryolith</e2>: detection by ultrasound examination of the nasolacrimal duct."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4331	"Histological examination of the <e1>dacryolith</e1> suggested its derivation from breakdown products of <e2>adrenaline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4332	"Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of <e1>valproic acid</e1>; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through <e1>valproic acid</e1>-induced <e2>hyperammonemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4333	"Reversible <e1>valproic acid</e1>-induced <e2>dementia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4334	"Reversible <e1>valproic acid</e1>-induced <e2>dementia</e2> was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4335	"<e1>Co-trimoxazole</e1> <e2>red cell aplasia</e2> in leukaemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4336	"When <e1>co-trimoxazole</e1> was stopped the <e2>red cell aplasia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4337	"A patient developed <e1>optic neuropathy</e1> while being treated with isoniazid and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4338	"A patient developed <e1>optic neuropathy</e1> while being treated with <e2>isoniazid</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4339	"A well-recognized complication of ethambutol use is optic neuropathy, but the potential <e1>ocular toxicity</e1> of <e2>isoniazid</e2> is often overlooked."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4340	"A well-recognized complication of <e1>ethambutol</e1> use is <e2>optic neuropathy</e2>, but the potential ocular toxicity of isoniazid is often overlooked."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4341	"Isoniazid and <e1>ethambutol</e1> as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4342	"<e1>Isoniazid</e1> and ethambutol as a cause of <e2>optic neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4343	"A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal <e1>Depo-Medrol</e1>, developed a <e2>spastic paraparesis at the lower limbs</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4344	"<e1>Calcification</e1> and ossification of the spinal arachnoid after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4345	"Calcification and <e1>ossification of the spinal arachnoid</e1> after intrathecal administration of <e2>Depo-Medrol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4346	"A young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with <e2>adriamycin</e2> and cisplatin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4347	"A young woman with epilepsy had <e1>tonic-clonic seizures</e1> during antineoplastic therapy with adriamycin and <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4348	"<e1>Hyperkalemia</e1> as a late side effect of prolonged <e2>adrenocorticotropic hormone</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4349	"Two infants developed <e1>hyperkalemia</e1> shortly after cessation of prolonged <e2>ACTH</e2> therapy for infantile spasms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4350	"We wish to call for cautious approach at time of cessation of prolonged <e1>ACTH</e1> therapy because of possible unexpected and only partially understood hazardous side effects such as <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4351	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4352	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and <e2>acute renal impairment</e2>) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4353	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4354	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, <e2>hyperkalaemia</e2> and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4355	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4356	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and <e2>hyperphosphataemia</e2> with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4357	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4358	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (<e2>hyper-uricaemia</e2>, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4359	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4360	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with <e2>hypocalcaemia</e2> and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4361	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4362	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with <e2>metabolic acidosis</e2> and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4363	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4364	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the '<e2>phosphate shower syndrome</e2>' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4365	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with <e1>folinic acid</e1> rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4366	"Three patients, in whom tumour overkill by cytotoxic treatment, including high dose <e1>methotrexate</e1> with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and <e2>tetany</e2>, with metabolic acidosis and acute renal impairment) are described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4367	"Accordingly, <e1>camptocormia</e1> is a dose-dependent side effect of <e2>valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4368	"A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an <e1>abnormal posture of extreme forward flexion</e1>, called camptocormia, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4369	"A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called <e1>camptocormia</e1>, during <e2>valproate</e2> monotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4370	"<e1>Camptocormia</e1>, a new side effect of <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4371	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of <e2>carbamazepine</e2>, lynestrenol and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4372	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, <e2>lynestrenol</e2> and sodium valproate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4373	"Four weeks earlier she had developed <e1>hepatopathy</e1> during a regimen of carbamazepine, lynestrenol and <e2>sodium valproate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4374	"<e1>Hepatopathy</e1> subsided after the cessation of <e2>carbamazepine</e2> and lynestrenol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4375	"<e1>Hepatopathy</e1> subsided after the cessation of carbamazepine and <e2>lynestrenol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4376	"A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous <e1>lorazepam</e1> for atypical absence status <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4377	"<e1>Paradoxical precipitation of tonic seizures</e1> by <e2>lorazepam</e2> in a child with atypical absence seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4378	"<e1>Atrial fibrillation</e1> following <e2>methylprednisolone</e2> pulse therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4379	"<e1>Isotretinoin</e1>, a drug used for the treatment of acne, has been shown to have <e2>teratogenic effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4380	"<e1>Isotretinoin</e1> <e2>teratogenicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4381	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and <e2>abnormalities of the corticospinal tracts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4382	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had <e2>agenesis of the cerebellar vermis</e2>, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4383	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, <e2>hydrocephalus</e2>, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4384	"We report an additional case of <e1>isotretinoin</e1> teratogenicity in which the patient had agenesis of the cerebellar vermis, <e2>multiple leptomeningeal neuroglial heterotopias</e2>, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4385	"We report an additional case of <e1>isotretinoin</e1> <e2>teratogenicity</e2> in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4386	"A case of <e1>allopurinol</e1> <e2>hypersensitivity</e2>, possibly the first in a black African, is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4387	"<e1>Allopurinol</e1> <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4388	"The <e1>allopurinol</e1> <e2>hypersensitivity syndrome</e2> is a rare adverse drug reaction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4389	"<e1>Bone formation</e1> induced in an infant by systemic <e2>prostaglandin-E2</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4390	"A case of <e1>severe visual loss</e1> following a single dose of <e2>vincristine</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4391	"Although differential diagnostic alternatives can be considered in all described cases it is very likely that <e1>vincristine</e1> does cause <e2>severe visual loss</e2> in a small number of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4392	"<e1>Severe visual loss</e1> after a single dose of <e2>vincristine</e2> in a patient with spinal cord astrocytoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4393	"The literature of <e1>vincristine</e1> <e2>optic nerve toxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4394	"<e1>Visual loss</e1> after a single small dose of <e2>vincristine</e2> has never been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4395	"<e1>Niacin</e1> causes a <e2>reversible toxic cystoid maculopathy</e2> that occurs in approximately 0.67% of patients taking high doses of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4396	"<e1>Niacin</e1> <e2>maculopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4397	"The authors conclude that among patients taking high doses of oral <e1>niacin</e1> only those who experience <e2>visual symptoms</e2> need to be ophthalmologically evaluated."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4398	"Three patients with <e1>niacin</e1>-induced visual symptoms had <e2>cystoid maculopathy</e2> without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4399	"Three patients with <e1>niacin</e1>-induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4400	"Three patients with <e1>niacin</e1>-induced <e2>visual symptoms</e2> had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of <e2>visual symptoms</e2> upon discontinuation of <e1>niacin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4401	"A case report of the <e1>hypersensitivity syndrome</e1> occurring in a patient being treated with <e2>dapsone</e2> for a brown recluse spider bite is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4402	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of <e2>fever</e2>, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4403	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, <e2>headache</e2>, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4404	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, <e2>hemolysis</e2>, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4405	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, <e2>hepatitis</e2>, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4406	"A <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2>, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4407	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, <e2>leukopenia</e2>, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4408	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, <e2>lymphadenopathy</e2>, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4409	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and <e2>mononucleosis</e2>, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4410	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, <e2>nausea</e2>, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4411	"A <e1>dapsone</e1> hypersensitivity syndrome, consisting of fever, headache, nausea, <e2>vomiting</e2>, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4412	"Case report: <e1>dapsone</e1> <e2>hypersensitivity syndrome</e2> associated with treatment of the bite of a brown recluse spider."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4413	"<e1>Rifampicin</e1>-induced <e2>adrenal insufficiency</e2> in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4414	"We report the case of a patient with the acquired immunodeficiency syndrome treated with <e1>rifampicin</e1> who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of <e2>adrenal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4415	"Two cases of widespread <e1>cutaneous vasculitis</e1> are described in association with <e2>diltiazem</e2>, a recently introduced calcium antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4416	"Widespread <e1>cutaneous vasculitis</e1> associated with <e2>diltiazem</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4417	"Intraventricular <e1>nafcillin</e1>-induced <e2>seizures</e2> in a neonate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4418	"We report a premature infant who developed <e1>seizures</e1> associated with intraventricular administration of <e2>nafcillin</e2> and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4419	"A 58-year old patient is reported who developed an <e1>ischaemic cerebrovascular accident</e1> 22 hours after successful thrombolysis with <e2>streptokinase</e2> for life-threatening pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4420	"<e1>Thrombo-embolic complication</e1> after <e2>streptokinase</e2> therapy of pulmonary emboli."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4421	"<e1>Renal hypophosphatemia</e1> in this patient was caused by the erroneous intake of 1 g <e2>doxycycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4422	"A clinically atypical, neuropathologically verified case of <e1>Creutzfeldt-Jakob disease</e1> is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with <e2>human growth hormone</e2> processed from pooled cadaveric pituitary glands."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4423	"A new case of <e1>Creutzfeldt-Jakob disease</e1> associated with <e2>human growth hormone</e2> therapy in New Zealand."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4424	"A case of a 21-year-old woman who had developed mild <e1>hepatotoxicity</e1> while receiving <e2>choline magnesium trisalicylate</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4425	"Hepatotoxicity associated with choline magnesium tri<e1>salicylate</e1>: case report and review of <e1>salicylate</e1>-induced <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4426	"<e1>Hepatotoxicity</e1> associated with <e2>choline magnesium trisalicylate</e2>: case report and review of salicylate-induced hepatotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4427	"<e1>Salicylate</e1>-induced <e2>hepatotoxicity</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4428	"They continued to rise for five more days before <e1>salicylate</e1> <e2>hepatotoxicity</e2> was suspected."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4429	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when <e2>captopril</e2> was added to the nadolol and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4430	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the nadolol and <e2>dyazide</e2> treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4431	"A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed <e1>attacks of asthma</e1> when captopril was added to the <e2>nadolol</e2> and dyazide treatment for his high blood pressure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4432	"<e1>Captopril</e1>-related (and -induced?) <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4433	"This confirmed the history of <e1>captopril</e1>-related <e2>asthma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4434	"We also describe a case of <e1>timolol</e1>-induced <e2>ocular pemphigoid</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4435	"<e1>Deposits of plasma proteins in the skin</e1> during treatment with <e2>carbamazepine</e2> and diphenylhydantoin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4436	"<e1>Deposits of plasma proteins in the skin</e1> during treatment with carbamazepine and <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4437	"The observations suggest that testicular swelling and <e1>pain</e1> are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4438	"The observations suggest that <e1>testicular swelling</e1> and pain are side effects of <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4439	"Two patients are described who developed testicular swelling and <e1>pain</e1> during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4440	"Two patients are described who developed <e1>testicular swelling</e1> and pain during treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4441	"<e1>Benzocaine</e1>, an ester-type local anesthetic, was believed responsible for apparent <e2>methemoglobinemia</e2> in a cat."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4442	"<e1>Benzocaine</e1>-induced <e2>methemoglobinemia</e2> has been reported in man, dogs, and cats."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4443	"<e1>Methemoglobinemia</e1> associated with dermal application of <e2>benzocaine</e2> cream in a cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4444	"A 43-year-old white man developed a shallow <e1>erosion of a psoriatic plaque</e1> after chronic administration of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4445	"<e1>Erosion of psoriatic plaques</e1> after chronic <e2>methotrexate</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4446	"After a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible loss of glomerular filtration rate and <e2>effective renal plasma flow</e2> despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4447	"After a six-week course of low-dose <e1>cyclosporine A</e1>, she developed a severe but reversible <e2>loss of glomerular filtration rate</e2> and effective renal plasma flow despite of low <e1>cyclosporine A</e1> plasma levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4448	"Based upon the observed <e1>fall of the filtration fraction</e1>, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4449	"Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the <e1>increase in proteinuria</e1>, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4450	"Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e1>cyclosporine A</e1> <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4451	"Based upon the observed fall of the filtration fraction, the <e1>rise in the relative clearance of 99Tc-dimercaptosuccinic acid</e1> and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for <e2>cyclosporine A</e2> nephrotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4452	"Unexpected severe reversible <e1>cyclosporine A</e1>-induced <e2>nephrotoxicity</e2> in a patient with systemic lupus erythematosus and tubulointerstitial renal disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4453	"A patient is presented with typical <e1>hyperthyroidism</e1>, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for <e1>hyperthyroidism</e1> with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4454	"A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a <e1>raised creatine phosphokinase</e1> after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4455	"A patient is presented with typical hyperthyroidism, who developed a <e1>severe proximal muscle weakness</e1> and a raised creatine phosphokinase after treatment for hyperthyroidism with <e2>propylthiouracil</e2> (100 mg orally, three times a day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4456	"<e1>Polymyositis</e1> after <e2>propylthiouracil</e2> treatment for hyperthyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4457	"<e1>Cardiopulmonary arrest</e1> following intravenous <e2>phenytoin</e2> loading."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4458	"Evidence obtained indicated that the Reye-like syndrome might be caused by <e1>calcium hopantenate</e1> possibly due to the induction of <e2>pantothenic acid deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4459	"Evidence obtained indicated that the <e1>Reye-like syndrome</e1> might be caused by <e2>calcium hopantenate</e2> possibly due to the induction of pantothenic acid deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4460	"<e1>Reye-like syndrome</e1> following treatment with the pantothenic acid antagonist, <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4461	"Three senile patients developed <e1>fatal acute encephalopathy</e1> while receiving <e2>calcium hopantenate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4462	"<e1>Dyspnea</e1> possibly associated with controlled-release <e2>morphine sulfate</e2> tablets."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4463	"<e1>Anhedonic ejaculation</e1> with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4464	"We report two patients with <e1>anhedonic ejaculation</e1> (ejaculation without orgasm) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4465	"We report two patients with anhedonic ejaculation (<e1>ejaculation without orgasm</e1>) associated with initiation of treatment with <e2>desipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4466	"<e1>Myoclonic spasms</e1> following intrathecal <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4467	"A case of <e1>halothane</e1> induced <e2>hepatitis</e2> is reported in a middle aged woman who underwent gastric surgery for morbid obesity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4468	"<e1>Halothane</e1> <e2>hepatitis</e2> and prompt resolution with methionine therapy: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4469	"Development of <e1>porphyria cutanea tarda</e1> after treatment with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4470	"We report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with <e2>cisplatin</e2> and cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4471	"We report a 46-yr-old woman with ovarian carcinoma who developed <e1>porphyria cutanea tarda</e1> while undergoing treatment with cisplatin and <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4472	"<e1>Acute renal failure</e1> in a patient treated by continuous povidone-<e2>iodine</e2> mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4473	"<e1>Acute renal failure</e1> in a patient treated by continuous <e2>povidone</e2>-iodine mediastinal irrigation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4474	"We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous <e1>PI</e1> irrigation who developed an <e2>acute oliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4475	"A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with <e1>epithelial crescents</e1> associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4476	"A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with <e1>hemoptysis</e1> after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4477	"A 56-year-old woman with scleroderma developed <e1>rapidly progressive glomerulonephritis</e1> with epithelial crescents associated with hemoptysis after 27 months of <e2>D-penicillamine</e2> therapy and a cumulative dose of 1,200 g."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4478	"<e1>D-penicillamine</e1> induced <e2>crescentic glomerulonephritis</e2>: report and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4479	"The 9 other reported cases of <e1>D-penicillamine</e1> induced <e2>rapidly progressive glomerulonephritis</e2> have been reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4480	"<e1>Gold</e1>-induced <e2>pneumonitis</e2> is a rare complication of gold salt therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4481	"<e1>Gold</e1>-induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4482	"This case supports the view that in <e1>gold</e1>-induced <e2>pneumonitis</e2> a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4483	"We describe a patient with rheumatoid arthritis treated with <e1>gold</e1> salts, who developed <e2>bilateral interstitial pulmonary abnormalities</e2> and showed a dramatic response on corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4484	"<e1>Gold</e1>-induced <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4485	"Three patients receiving <e1>gold</e1> salt treatment for rheumatoid arthritis developed severe <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4486	"Pharmacokinetic determinants of <e1>6-mercaptopurine</e1> <e2>myelotoxicity</e2> and therapeutic failure in children with acute lymphoblastic leukemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4487	"Because the <e1>cerebellar toxicity</e1> may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of <e2>HDARAC</e2> is recommended."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4488	"<e1>Cytarabine</e1>-induced <e2>cerebellar syndrome</e2>: case report and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4489	"During the first treatment, dysarthria and <e1>ataxia</e1> were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4490	"During the first treatment, <e1>dysarthria</e1> and ataxia were seen after completion of the patient's eighth and final dose of <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4491	"The <e1>neurotoxicity</e1> seen with <e2>HDARAC</e2> is dose-related and has occurred in up to 60 percent of treated patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4492	"This case report illustrates the <e1>neurotoxicity</e1> unique to <e2>HDARAC</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4493	"<e1>Macular infarction</e1> after endophthalmitis treated with vitrectomy and intravitreal <e2>gentamicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4494	"We are concerned that the <e1>macular lesion</e1> was a retinal toxic effect of <e2>gentamicin</e2> because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4495	"A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a <e1>B-cell lymphoma</e1> of the lip following 4 1/2 years of treatment with <e2>razoxane</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4496	"Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed <e1>hypogammaglobulinemia</e1> in the course of <e2>gold</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4497	"<e1>Hypogammaglobulinemia</e1> associated with <e2>gold</e2> therapy: evidence for a partial maturation blockade of B cells."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4498	"Transient <e1>leucopenia</e1> and thrombocytopenia associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4499	"Transient leucopenia and <e1>thrombocytopenia</e1> associated with <e2>sodium nitroprusside</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4500	"<e1>Herpes simplex esophagitis</e1> in a renal transplant patient treated with <e2>cyclosporine A</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4501	"We report the first case of <e1>herpes esophagitis</e1> in a renal transplant patient treated with <e2>Cyclosporine A</e2> while on chronic steroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4502	"With the increasing use of <e1>Cyclosporine A</e1> in transplant patients, the incidence of <e2>herpes esophagitis</e2> may increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4503	"Administration of excessive <e1>insulin</e1> induced <e2>hypoglycemia</e2> within 4 to 8 hours, followed by rebound hyperglycemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4504	"Administration of excessive <e1>insulin</e1> induced hypoglycemia within 4 to 8 hours, followed by <e2>rebound hyperglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4505	"<e1>Posthypoglycemic hyperglycemia</e1> (rebound hyperglycemia) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4506	"Posthypoglycemic hyperglycemia (<e1>rebound hyperglycemia</e1>) after overdosing of <e2>insulin</e2> was diagnosed in 6 cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4507	"Rebound <e1>hyperglycemia</e1> following overdosing of <e2>insulin</e2> in cats with diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4508	"<e1>Rebound hyperglycemia</e1> was observed with both intermediate (neutral <e2>protamine hagedorn</e2>) and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4509	"<e1>Rebound hyperglycemia</e1> was observed with both intermediate (neutral protamine hagedorn) and long-acting (<e2>protamine zinc iletin</e2>) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4510	"<e1>Captopril</e1>-induced <e2>lichen planus pemphigoides</e2> with pemphigus-like features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4511	"We report a case of a <e1>bullous lichenoid eruption</e1> due to the intake of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4512	"An 8-year-old girl, who had been vaccinated with <e1>BCG</e1> without subsequent regional reactions, developed <e2>osteomyelitis in the left calcaneus</e2> 7 months later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4513	"<e1>Metastatic osteomyelitis</e1> following <e2>BCG</e2> vaccination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4514	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and <e2>arteriosclerotic disease</e2> and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4515	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had <e2>hypertension</e2> and arteriosclerotic disease and the other died of a myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4516	"One of the subjects who was using extemporaneous topical <e1>minoxidil</e1> had hypertension and arteriosclerotic disease and the other died of a <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4517	"<e1>Amoxapine</e1>-induced <e2>cognitive impairment</e2> in two patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4518	"Two patients are described in whom subtle <e1>cognitive impairments</e1> are associated with therapeutic doses of <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4519	"A 23-year-old woman with systemic lupus erythematosus had a <e1>severe hypersensitivity reaction</e1> to the drug <e2>ibuprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4520	"<e1>Severe systemic hypersensitivity reaction</e1> to <e2>ibuprofen</e2> occurring after prolonged therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4521	"A brief review of reported cases of <e1>chloramphenicol</e1> <e2>hypersensitivity</e2> in the English-language literature, as well as possible alternative explanations in this case, are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4522	"<e1>Hypersensitivity reaction</e1> following <e2>chloramphenicol</e2> administration in a patient with typhoid fever."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4523	"<e1>Hypersensitivity reactions</e1> due to <e2>chloramphenicol</e2> are rarely reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4524	"We present a case report of a patient with typhoid fever who experienced a <e1>hypersensitivity reaction</e1> subsequent to the infusion of <e2>chloramphenicol sodium succinate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4525	"Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of <e1>penicillamine</e1> therapy documented the development of new <e2>brain lesions</e2> during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4526	"To develop information on the relative rarity or frequency of neurologic worsening with the initiation of <e1>penicillamine</e1> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with <e2>neurologic disease</e2> and having been treated with <e1>penicillamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4527	"To develop information on the relative rarity or frequency of <e1>neurologic worsening</e1> with the initiation of <e2>penicillamine</e2> therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4528	"We describe a patient with Wilson's disease who presented with neurologic disease, was treated with <e1>D-penicillamine</e1>, and suffered sudden <e2>neurologic deterioration</e2> coincident with therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4529	"<e1>Worsening of neurologic syndrome</e1> in patients with Wilson's disease with initial <e2>penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4530	"Other <e1>upper tract neoplasms</e1> after <e2>cyclophosphamide</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4531	"<e1>Upper tract urothelial malignancy</e1> after <e2>cyclophosphamide</e2> therapy: a case report and literature review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4532	"We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and <e1>distal ureter without transitional cell carcinoma of the bladder</e1> occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4533	"We report an unusual case of simultaneous <e1>transitional cell carcinoma of the renal pelvis</e1> and distal ureter without transitional cell carcinoma of the bladder occurring after chronic <e2>cyclophosphamide</e2> therapy for nonHodgkin's lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4534	"<e1>Progressive pulmonary fibrosis</e1> complicating <e2>cyclophosphamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4535	"The changes were progressive regardless of discontinuation of <e1>cyclophosphamide</e1> and led to <e2>severe restrictive ventilatory defect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4536	"<e1>Torsade de pointes</e1> during loading with <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4537	"<e1>Torsade de pointes</e1> represents a potential complication of chronic <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4538	"We report a case of <e1>torsade de pointes</e1> following a single oral dose of <e2>amiodarone</e2> (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4539	"<e1>Pulmonary edema</e1> as a delayed complication of <e2>ritodrine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4540	"<e1>Pulmonary edema</e1> occurred 24 hours after intravenous <e2>ritodrine</e2> therapy and 10 hours after subcutaneous terbutaline therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4541	"<e1>Pulmonary edema</e1> occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous <e2>terbutaline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4542	"<e1>Cyclosporin</e1> side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and <e2>abnormalities in liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4543	"<e1>Cyclosporin</e1> side effects included <e2>hirsutism</e2>, hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4544	"<e1>Cyclosporin</e1> side effects included hirsutism, <e2>hypertension</e2>, increased blood levels of urea and creatinine, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4545	"<e1>Cyclosporin</e1> side effects included hirsutism, hypertension, <e2>increased blood levels of urea and creatinine</e2>, and abnormalities in liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4546	"<e1>Rupture of a cerebral aneurysm</e1> associated with <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4547	"We describe <e1>rupture of a cerebral arterial aneurysm</e1> in a 32 year old hypertensive woman following the introduction of <e2>nifedipine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4548	"A small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4549	"A small initial dose of <e1>prazosin</e1> ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and <e2>severe drop in blood pressure</e2> after the administration of the first dose of <e1>prazosin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4550	"<e1>Prazosin</e1>-induced first-dose phenomenon possibly associated with <e2>hemorrhagic stroke</e2>: a report of three cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4551	"A <e1>fatal massive pulmonary embolus</e1> developed in a patient treated with <e2>streptokinase</e2> for acute deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4552	"<e1>Massive pulmonary embolism</e1> complicating <e2>streptokinase</e2> treatment for deep vein thrombosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4553	"Fatal <e2>digoxin</e2> poisoning: an unsuccessful resuscitation with use of <e2>digoxin</e2>-immune Fab."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4554	"A case of <e1>phenytoin</e1>-induced <e2>hepatitis</e2> with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4555	"A case of <e1>phenytoin</e1>-induced hepatitis with mononucleosis is reported, and syndromes associated with <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4556	"A case of <e1>phenytoin</e1>-induced hepatitis with <e2>mononucleosis</e2> is reported, and syndromes associated with <e1>phenytoin</e1> hypersensitivity reactions are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4557	"<e1>Phenytoin</e1>-induced <e2>hypersensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4558	"Phenytoin was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and <e2>pruritus</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4559	"Phenytoin was discontinued after admission; however, <e1>phenytoin</e1> 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which <e2>swelling of the face and legs</e2> and pruritus developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4560	"Serious <e1>phenytoin</e1> hypersensitivity reactions may appear as <e2>dermatologic, lymphoid, or hepatic syndromes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4561	"Serious <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> may appear as dermatologic, lymphoid, or hepatic syndromes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4562	"She was receiving phenytoin sodium 300 mg/day; <e1>carbamazepine</e1> 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4563	"She was receiving <e1>phenytoin sodium</e1> 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of <e2>leukopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4564	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4565	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly <e2>fever</e2>, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4566	"The possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4567	"The possibility of <e1>phenytoin</e1> <e2>hypersensitivity reactions</e2> should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4568	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4569	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, rash, and <e2>lymphadenopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4570	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4571	"The possibility of <e1>phenytoin</e1> hypersensitivity reactions should be considered when patients receiving <e1>phenytoin</e1> have unusual symptoms, particularly fever, <e2>rash</e2>, and lymphadenopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4572	"It was restarted 6 weeks later, and 10 weeks after that, the patient presented with <e1>fulminant hepatic failure</e1>, which resolved rapidly after cessation of <e2>nicotinic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4573	"<e1>Nicotinic acid</e1>-induced <e2>fulminant hepatic failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4574	"We suggest that <e1>nicotinic acid</e1> was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of <e2>hepatotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4575	"We suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4576	"We suggest that <e1>nicotinic acid</e1> was the cause of his <e2>liver disease</e2>, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of <e1>nicotinic acid</e1> for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4577	"An infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4578	"An infant girl with choanal atresia, <e1>athelia</e1>, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4579	"An infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4580	"An infant girl with <e1>choanal atresia</e1>, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4581	"An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with <e2>methimazole</e2> and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4582	"An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate <e1>mental retardation</e1> was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4583	"Choanal atresia and <e1>athelia</e1>: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4584	"<e1>Choanal atresia</e1> and athelia: <e2>methimazole</e2> teratogenicity or a new syndrome?"
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4585	"Choanal atresia and athelia: <e1>methimazole</e1> <e2>teratogenicity</e2> or a new syndrome?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4586	"The patient's defects may be due to <e1>methimazole</e1> <e2>teratogenicity</e2> or could represent a previously undescribed syndrome affecting ectodermal structures."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4587	"<e1>Toxic epidermal necrolysis</e1> resulted after 19 days of treatment with <e2>5-fluorocytosine</e2> and amphotericin B."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4588	"<e1>Toxic epidermal necrolysis</e1> resulted after 19 days of treatment with 5-fluorocytosine and <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4589	"Five and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe <e2>abdominal right lower quadrant pain</e2> due to a large cecal lymphoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4590	"Five and one-half years after the diagnosis of myeloma, while in remission on <e1>cyclophosphamide</e1> therapy, the patient experienced severe abdominal right lower quadrant pain due to a large <e2>cecal lymphoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4591	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and <e2>fall in prothrombin time</e2>, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4592	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed <e2>jaundice</e2>, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4593	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, <e2>marked increase in serum transaminase levels</e2> and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4594	"After therapy with parenteral <e1>amiodarone</e1> (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of <e2>severe centrilobular necrosis</e2> were observed in hepatic biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4595	"A patient with acute changes suggesting <e1>acute hepatitis</e1> after parenteral <e2>amiodarone</e2> administration is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4596	"Probable early <e1>acute hepatitis</e1> with parenteral <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4597	"Therefore, parenteral <e1>amiodarone</e1> was implicated as the cause of <e2>acute hepatitis</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4598	"He became <e1>hyperkalemic</e1> on rechallenge with <e2>timolol</e2> and normokalemic following its withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4599	"<e1>Severe hyperkalemia</e1> as a complication of <e2>timolol</e2>, a topically applied beta-adrenergic antagonist."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4600	"<e1>Severe hyperkalemia</e1> occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning <e2>prednisone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4601	"<e1>Noncardiogenic pulmonary edema</e1> during intrabiliary infusion of <e2>mono-octanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4602	"We describe a patient in whom <e1>noncardiogenic pulmonary edema</e1> developed during intrabiliary infusion of <e2>monooctanoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4603	"<e1>Paroxysmal supraventricular tachycardia</e1> during treatment with <e2>cisplatin</e2> and etoposide combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4604	"<e1>Paroxysmal supraventricular tachycardia</e1> during treatment with cisplatin and <e2>etoposide</e2> combination."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4605	"We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during <e2>cisplatin</e2> and etoposide combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4606	"We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed <e1>paroxysmal supraventricular tachycardia</e1> during cisplatin and <e2>etoposide</e2> combination chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4607	"A case is reported of theophylline intoxication due to a dramatic <e1>decrease in theophylline clearance</e1> following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4608	"A case is reported of <e2>theophylline</e2> intoxication due to a dramatic decrease in <e2>theophylline</e2> clearance following concomitant administration of viloxazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4609	"A case is reported of <e1>theophylline intoxication</e1> due to a dramatic decrease in theophylline clearance following concomitant administration of <e2>viloxazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4610	"Theophylline intoxication following <e1>viloxazine</e1> induced <e2>decrease in clearance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4611	"<e2>Theophylline</e2> intoxication following viloxazine induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4612	"<e1>Theophylline intoxication</e1> following <e2>viloxazine</e2> induced decrease in clearance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4613	"Idiosyncratic pulmonary reactions to <e1>nitrofurantoin</e1> are not unusual, often presenting as <e2>eosinophilic pneumonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4614	"<e1>Idiosyncratic pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are not unusual, often presenting as eosinophilic pneumonia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4615	"<e1>Acute myocardial necrosis</e1> during administration of <e2>amsacrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4616	"In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of <e1>amsacrine</e1>-related <e2>cardiotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4617	"In addition to the recognized arrhythmic complications, the authors emphasize <e1>myocardial necrosis</e1> as a possible further manifestation of <e2>amsacrine</e2>-related cardiotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4618	"The authors report a case of focal myocardial necrosis, presenting clinically as an <e1>acute myocardial infarction</e1> during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4619	"The authors report a case of <e1>focal myocardial necrosis</e1>, presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, <e2>amsacrine</e2>, in a patient without coronary artery disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4620	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, <e2>alopecia</e2>, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4621	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, <e2>a pruritic desquamating erythrodermic rash</e2>, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4622	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of <e2>fever</e2>, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4623	"A child in whom a <e1>phenobarbital</e1> <e2>hypersensitivity</e2> drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4624	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, <e2>icterus</e2>, protein-losing enteropathy, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4625	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, <e2>myositis</e2>, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4626	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and <e2>nephritis</e2>, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4627	"A child in whom a <e1>phenobarbital</e1> hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, <e2>protein-losing enteropathy</e2>, myositis, and nephritis, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4628	"<e1>Graft versus host-like illness</e1> in a child with <e2>phenobarbital</e2> hypersensitivity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4629	"Graft versus host-like illness in a child with <e1>phenobarbital</e1> <e2>hypersensitivity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4630	"The clinical findings and laboratory studies suggested an <e1>autoimmune cell-mediated hypersensitivity</e1> reaction triggered by <e2>phenobarbital</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4631	"<e1>Duodenal ulceration</e1>: a complication of <e2>tolazoline</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4632	"Two patients who were receiving <e1>Tolazoline</e1> by infusion developed <e2>duodenal ulceration</e2> and subsequent intestinal perforation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4633	"Two patients who were receiving <e1>Tolazoline</e1> by infusion developed duodenal ulceration and subsequent <e2>intestinal perforation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4634	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, <e2>acute and chronic pulmonary reactions</e2>, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4635	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and <e2>allergic reactions</e2>--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4636	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, <e2>blood dyscrasias</e2> and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4637	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--<e2>liver damage</e2>, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4638	"The latter form (<e1>Macrodantin</e1>) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, <e2>peripheral neuropathy</e2>, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4639	"<e1>Generalized pustular psoriasis</e1> precipitated by <e2>trazodone</e2> in the treatment of depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4640	"We report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4641	"We report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked <e2>generalized pustular psoriasis</e2> (GPP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4642	"We report a patient in whom the anti-depressant trazodone hydrochloride (<e1>Molipaxin</e1>, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4643	"We report a patient in whom the anti-depressant <e1>trazodone hydrochloride</e1> (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis (<e2>GPP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4644	"Intravenous verapamil therapy in babies may cause <e1>apnea</e1>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e2>quinidine</e2> may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4645	"Intravenous <e1>verapamil</e1> therapy in babies may cause <e2>apnea</e2>, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4646	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of <e2>atrial flutter</e2> in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4647	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and <e2>bradycardia</e2>; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4648	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden <e1>death</e1>; <e2>quinidine</e2> may be related to the <e1>death</e1>; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4649	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, <e2>hypotension</e2>, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4650	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; <e1>quinidine</e1> may be related to the death; children with "familial seizure disorders" may in fact have the <e2>long QT interval syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4651	"Intravenous <e1>verapamil</e1> therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause <e2>sudden death</e2>; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4652	"<e1>Methimazole</e1>-associated <e2>cholestatic liver injury</e2>: case report and brief literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4653	"The authors report a further case of <e1>methimazole</e1>-associated <e2>liver damage</e2> and present a brief review of eleven previous cases found in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4654	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and <e1>bile stasis</e1>, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4655	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and <e1>cholestasis</e1>, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4656	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of <e1>fatty liver parenchyma degeneration</e1> with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4657	"The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with <e1>granulocytic portal infiltration</e1> and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4658	"The main clinical features of this 58-year-old female patient were laboratory evidence of <e1>leucopenia</e1> and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg <e2>methimazole</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4659	"<e1>Fibrosis of corpus cavernosum</e1> after intracavernous injection of phentolamine/<e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4660	"<e1>Fibrosis of corpus cavernosum</e1> after intracavernous injection of <e2>phentolamine</e2>/papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4661	"We report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of phentolamine and <e2>papaverine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4662	"We report a case of <e1>penile fibrosis</e1> after intracavernous self-injection of a combination of <e2>phentolamine</e2> and papaverine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4663	"A 57-year-old woman developed <e1>pulmonary sarcoidosis</e1> during therapy with <e2>interferon beta</e2> for advanced renal cell carcinoma metastatic to mediastinal lymph nodes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4664	"The possible role of <e1>interferon beta</e1> in the pathogenesis of <e2>sarcoidosis</e2> in this patient is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4665	"<e1>Fatal outcome</e1> of intravesical <e2>formalin</e2> instillation, with changes mimicking renal tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4666	"We present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of <e2>alopecia</e2> and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4667	"We present a case report of a patient with alveolar hydatid disease, whose treatment with <e1>mebendazole</e1> was brief due to side effects of alopecia and <e2>granulocytopenia</e2>; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4668	"Antibiotic-associated <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4669	"Antibiotic-associated <e1>colitis</e1> (pseudomembranous <e1>colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4670	"Antibiotic-associated colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4671	"Antibiotic-associated colitis (<e1>pseudomembranous colitis</e1>) developed in four patients with spinal cord injury and taking oral <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4672	"<e1>Pseudomembranous colitis</e1> readily occurs in at least certain population groups receiving trimethoprim-<e2>sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4673	"<e1>Pseudomembranous colitis</e1> readily occurs in at least certain population groups receiving <e2>trimethoprim</e2>-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4674	"A <e1>lethal complication</e1> of peripheral vein <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4675	"The condition should be suspected in patients who develop unexplained <e1>abdominal pain</e1> or collapse following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4676	"The condition should be suspected in patients who develop unexplained abdominal pain or <e1>collapse</e1> following <e2>vasopressin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4677	"Although adverse reactions to <e1>protamine</e1> are reported infrequently and are usually mild, we recently observed the first fatal case of <e2>type I anaphylaxis</e2> resulting from <e1>protamine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4678	"<e1>Protamine</e1>-induced <e2>fatal anaphylaxis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4679	"<e1>Ototoxicity</e1> as a result of <e2>cis-platinum</e2> administration is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4680	"Controversy concerning the <e1>nephrotoxicity</e1> of <e2>lithium</e2> is discussed, and recommendations for the evaluation of renal failure during <e2>lithium</e2> therapy are provided."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4681	"Controversy concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4682	"Controversy concerning the nephrotoxicity of <e1>lithium</e1> is discussed, and recommendations for the evaluation of <e2>renal failure</e2> during <e1>lithium</e1> therapy are provided."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4683	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a <e2>decrease in blood flow</e2> that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4684	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an <e2>increase in pulmonary artery pressure</e2> associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4685	"Administration of intravenous <e1>nitroglycerin</e1> in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an <e2>increase in pulmonary vascular resistance</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4686	"<e1>Paradoxical pulmonary vasoconstriction</e1> induced by <e2>nitroglycerin</e2> in idiopathic pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4687	"<e1>Atrioventricular block</e1> complicating <e2>amiodarone</e2>-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4688	"Atrioventricular block complicating <e1>amiodarone</e1>-induced <e2>hypothyroidism</e2> in a patient with pre-excitation and rate-dependent bilateral bundle branch block."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4689	"Such a case induced by <e1>hypothyroidism</e1> complicating long-term therapy with <e2>amiodarone</e2> in a 45 year old woman with pre-excitation is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4690	"<e1>Ampicillin</e1> increased the preexisting <e2>electrical decrement</e2> in three rabbits with experimental autoimmune myasthenia gravis while the drug had no deleterious effects in less affected or normal animals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4691	"<e1>Ampicillin</e1> may aggravate clinical and experimental <e2>myasthenia gravis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4692	"Myasthenic patients receiving <e1>ampicillin</e1> should be closely monitored for possible <e2>acute exacerbations</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4693	"One patient had <e1>severe temporary weakness</e1> after an <e2>ampicillin sodium</e2> challenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4694	"A study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4695	"A study following large patient groups on <e1>theophylline</e1> and a combination of <e1>theophylline</e1> and steroids might clarify the risk of <e2>ulcer</e2> formation in patients being treated with these medications for asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4696	"We presented a patient with status asthmaticus treated with a combination of theophylline and <e1>prednisone</e1> who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4697	"We presented a patient with status asthmaticus treated with a combination of <e1>theophylline</e1> and prednisone who developed a <e2>perforated gastric ulcer</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4698	"A case of <e1>propranolol</e1> overdose complicated by <e2>esophageal spasm</e2> preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4699	"<e1>Esophageal spasm</e1> following <e2>propranolol</e2> overdose relieved by glucagon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4700	"<e1>Hypotension</e1> and sinus arrest with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4701	"Hypotension and <e1>sinus arrest</e1> with <e2>nifedipine</e2> in pulmonary hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4702	"A patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of <e2>diamorphine</e2> and methylphenidate into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4703	"A patient presented with a <e1>painful, oedematous, cyanosed hand</e1> having injected a solution of diamorphine and <e2>methylphenidate</e2> into his radial artery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4704	"<e1>Ischaemia</e1> following selfadministered intra-arterial injection of methylphenidate and <e2>diamorphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4705	"<e1>Ischaemia</e1> following selfadministered intra-arterial injection of <e2>methylphenidate</e2> and diamorphine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4706	"<e1>Chronic photosensitivity</e1> associated with <e2>hydrochlorothiazide</e2> ingestion occurred in four patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4707	"<e1>Cardiac decompensation</e1> following <e2>verapamil</e2> therapy in infants with supraventricular tachycardia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4708	"However, each infant demonstrated <e1>hemodynamic decompensation</e1> shortly after <e2>verapamil</e2> administration and required cardiopulmonary resuscitation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4709	"The risk of <e1>cardiac decompensation</e1> in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4710	"Pneumonitis with pleural and pericardial effusion and <e1>neuropathy</e1> during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4711	"Pneumonitis with <e1>pleural and pericardial effusion</e1> and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4712	"<e1>Pneumonitis</e1> with pleural and pericardial effusion and neuropathy during <e2>amiodarone</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4713	"Review of this and previously reported cases indicates the need for early diagnosis of <e1>amiodarone</e1> <e2>pneumonitis</e2>, immediate withdrawal of <e1>amiodarone</e1>, and prompt but continued steroid therapy to ensure full recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4714	"<e1>Heparin</e1>-induced <e2>hyperkalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4715	"Our findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4716	"Our findings suggest that <e1>hyperkalemia</e1> can develop with the use of low-dose <e2>heparin</e2>, within seven days of initiating <e2>heparin</e2> therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4717	"We present four cases in which the use of <e1>heparin</e1> was associated with <e2>hyperkalemia</e2> and discuss the pathophysiology."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4718	"While most physicians are aware of <e1>heparin</e1>-induced thrombocytopenia and skin necrosis, the association of <e1>heparin</e1> and <e2>hyperkalemia</e2> is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4719	"While most physicians are aware of <e1>heparin</e1>-induced thrombocytopenia and <e2>skin necrosis</e2>, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4720	"While most physicians are aware of <e1>heparin</e1>-induced <e2>thrombocytopenia</e2> and skin necrosis, the association of <e1>heparin</e1> and hyperkalemia is less well recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4721	"Careful follow-up of so-called "self-limited" <e1>insulin</e1> <e2>edema</e2> is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4722	"<e1>Insulin</e1>-induced <e2>cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4723	"<e1>Self-limited edema</e1> is a well-recognized complication of <e2>insulin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4724	"This report describes the first case of <e1>insulin</e1>-induced <e2>cardiac failure</e2> in a patient without underlying heart disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4725	"A case of <e1>pyridoxine</e1>-dependent <e2>seizures</e2> is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4726	"Administration of <e1>pyridoxine</e1> to an infant after a long period of convulsions was followed by <e2>acute hypotonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4727	"Prolonged <e1>severe cholestasis</e1> induced by <e2>oxacillin</e2> derivatives."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4728	"Two patients with osteomyelitis who developed <e1>reversible cholestatic jaundice</e1> during treatment with <e2>oxacillin</e2> derivatives are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4729	"In all the patients, <e1>pellagra</e1> symptoms appeared during <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4730	"<e1>Isoniazid</e1> inhibits the conversion of tryptophan to niacin and may induce <e2>pellagra</e2>, particularly in poorly nourished patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4731	"<e1>Pellagra encephalopathy</e1> among tuberculous patients: its relation to <e2>isoniazid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4732	"Pellagra should be suspected whenever tuberculous patients under treatment with <e1>isoniazid</e1> develop <e2>mental, neurological or gastrointestinal symptoms</e2>, even in the absence of typical pellagra dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4733	"Physicians should be aware of the potential for the development of <e1>RS</e1> among children who are receiving long-term <e2>aspirin</e2> therapy for the treatment of systemic inflammatory illnesses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4734	"<e1>Reye syndrome</e1> (RS) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4735	"Reye syndrome (<e1>RS</e1>) is believed to occur infrequently among children receiving long-term <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4736	"These findings support previous studies that showed that the use of <e1>aspirin</e1> during the antecedent illness may be a risk factor for the development of <e2>RS</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4737	"<e1>Atrial fibrillation</e1> was induced by <e2>diltiazem</e2> in two patients and verapamil induced syncope in one patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4738	"Atrial fibrillation was induced by diltiazem in two patients and <e1>verapamil</e1> induced <e2>syncope</e2> in one patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4739	"A 54-year-old man, treated with <e1>amiodarone</e1>, developed <e2>thyrotoxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4740	"<e1>Amiodarone</e1>-induced <e2>dysthyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4741	"IV <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a <e2>decrease in heart rate</e2> but a paroxsymal increase in blood pressure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4742	"IV <e1>propranolol</e1> was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a <e2>paroxsymal increase in blood pressure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4743	"<e1>Propranolol</e1>-induced <e2>hypertension</e2> in treatment of cocaine intoxication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4744	"According to the literature, <e1>chlorambucil</e1> <e2>central nervous toxicity</e2> is found almost exclusively in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4745	"<e1>Chlorambucil</e1> <e2>central nervous toxicity</e2>: a significant side effect of chlorambucil therapy in childhood nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4746	"<e1>EEG abnormalities</e1> were observed in two of the nine children during <e2>chlorambucil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4747	"A 35-year-old man with seropositive rheumatoid arthritis developed selective <e1>IgA deficiency</e1> during treatment with <e2>fenclofenac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4748	"<e1>Fenclofenac</e1>-induced selective <e2>IgA deficiency</e2> in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4749	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as <e2>aurothiomalate</e2> and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4750	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by <e2>fenclofenac</e2> as well as aurothiomalate and sulphasalazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4751	"This case demonstrates the association of selective <e1>IgA deficiency</e1> with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and <e2>sulphasalazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4752	"A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance <e1>lithium</e1> therapy developed a <e2>movement disorder</e2> following high doses of trazodone for treatment of an acute depression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4753	"A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a <e1>movement disorder</e1> following high doses of <e2>trazodone</e2> for treatment of an acute depression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4754	"Although the <e1>movement disorder</e1> could not with certainty be attributed to <e2>trazodone</e2> alone, the drug at least acted as an eliciting agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4755	"The elicitation of a <e1>movement disorder</e1> by <e2>trazodone</e2>: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4756	"When the <e1>trazodone</e1> was reduced, the <e2>involuntary movements</e2> promptly ceased."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4757	"A review of the literature showed no previous description of this pattern in <e1>benzodiazepine</e1> <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4758	"<e1>Spindle coma</e1> in <e2>benzodiazepine</e2> toxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4759	"Two reports of <e1>spindle coma</e1> are noted with alcohol and <e2>imipramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4760	"A literature review revealed 83 other reported cases of <e1>rifampicin</e1>-induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4761	"<e1>Renal failure</e1> is a rare complication associated with the use of <e2>rifampicin</e2> for the treatment of tuberculosis, usually occurring well into the course of therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4762	"<e1>Rifampicin</e1>-induced <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4763	"The following is a report of 2 cases of <e1>rifampicin</e1>-induced <e2>renal insufficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4764	"<e1>Cerebral and ocular toxicity</e1> induced by <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4765	"Subsequent in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of <e2>desferrioxamine</e2> and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4766	"Subsequent in vivo/vitro studies clearly demonstrated that the <e1>neurological effects</e1> were due to a synergistic action of desferrioxamine and <e2>prochlorperazine</e2>, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4767	"Two of these patients, who also received the anti-emetic <e1>prochlorperazine</e1>, <e2>lost consciousness</e2> for 48-72 h and then fully recovered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4768	"Two other patients who did not receive prochlorperazine, developed <e1>retinal problems</e1> which later improved, one after only 15 g of <e2>desferrioxamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4769	"<e1>Gold</e1> <e2>nephropathy</e2>: tissue analysis by X-ray fluorescent spectroscopy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4770	"These findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4771	"These findings are consistent with an immune-complex form of glomerulopathy in which <e1>gold</e1> is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by <e1>gold</e1> therapy may be a causative factor in the <e2>renal disease</e2> associated with <e1>gold</e1> therapy in rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4772	"Three patients developed <e1>proteinuria</e1> following <e2>gold</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4773	"Four cases of <e1>fat embolism</e1> are described in infants receiving prolonged intravenous infusion of fat (<e2>Intralipid</e2> 20%)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4774	"Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving <e1>methotrexate</e1> who develop <e2>bilateral pulmonary infiltrates</e2> seen on chest roentgenograms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4775	"Conversely, <e1>diffuse interstitial pulmonary fibrosis</e1> should be considered in the differential diagnosis of patients receiving <e2>methotrexate</e2> who develop bilateral pulmonary infiltrates seen on chest roentgenograms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4776	"In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman-Rich syndrome, and <e1>methotrexate</e1> <e2>hepatotoxicity</e2> was present in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4777	"It is suggested therefore that <e1>methotrexate</e1> be added to the list of agents capable of inducing <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4778	"<e1>Methotrexate</e1>-induced <e2>diffuse interstitial pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4779	"Pulmonary eosinophilia or <e1>granulomas</e1>, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4780	"Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of <e1>methotrexate</e1> <e2>pneumonitis</e2>, were not observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4781	"<e1>Pulmonary eosinophilia</e1> or granulomas, classically seen in previously reported cases of <e2>methotrexate</e2> pneumonitis, were not observed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4782	"Three patients received respectively 190 mg, 175 mg, and 196 mg of <e1>methotrexate</e1> and developed <e2>bilateral pulmonary infiltrates</e2> without evidence of peripheral blood eosinophilia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4783	"A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound <e1>hyponatremia</e1> secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4784	"A patient with disseminated herpes zoster developed a <e1>syndrome of inappropriate antidiuretic hormone</e1> and profound hyponatremia secondary to the administration of <e2>adenine arabinoside</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4785	"<e1>Inappropriate antidiuretic hormone</e1> following <e2>adenine arabinoside</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4786	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), <e2>abdominal pain</e2> (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4787	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), <e2>bone pain</e2> (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4788	"The toxic effects of <e1>methotrexate</e1> included <e2>elevated liver transaminases</e2> (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4789	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), <e2>mild neutropenia</e2> (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4790	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and <e2>mild pruritus</e2> (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4791	"The toxic effects of <e1>methotrexate</e1> included elevated liver transaminases (3/4), <e2>nausea</e2> (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4792	"<e1>Dystonia</e1> associated with <e2>carbamazepine</e2> administration: experience in brain-damaged children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4793	"In one child, a second course of <e1>carbamazepine</e1> resulted in a return of the <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4794	"The currently available clinical and neuropharmacologic data suggest that <e1>carbamazepine</e1> may be an antagonist of dopamine and that this property is responsible for the production of <e2>dystonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4795	"We have cared for three children in whom four episodes of <e1>dystonia</e1> proceeding to opisthotonus occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4796	"We have cared for three children in whom four episodes of dystonia proceeding to <e1>opisthotonus</e1> occurred in association with <e2>carbamazepine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4797	"Aplastic anemia and <e1>agranulocytosis</e1> in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4798	"<e1>Aplastic anemia</e1> and agranulocytosis in patients using <e2>methazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4799	"Several case reports of <e1>aplastic anemia</e1> with use of <e2>acetazolamide</e2>, and two cases with use of methazolamide, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4800	"Several case reports of <e1>aplastic anemia</e1> with use of acetazolamide, and two cases with use of <e2>methazolamide</e2>, have appeared in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4801	"This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of <e1>methazolamide</e1>, and one case of <e2>agranulocytosis</e2> related to the use of <e1>methazolamide</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4802	"This article describes two cases of <e1>aplastic anemia</e1>, at least one of which was almost certainly induced by the use of <e2>methazolamide</e2>, and one case of agranulocytosis related to the use of <e2>methazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4803	"<e1>Squamous-cell carcinoma</e1> arising in a basal-cell epithelioma treated with <e2>5-fluorouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4804	"We report the development of <e1>squamous-cell carcinoma</e1> within a basal-cell epithelioma that was treated with intralesional injections of <e2>5-FU</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4805	"Lower extremity <e1>arterial insufficiency</e1> after long-term <e2>methysergide maleate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4806	"The patient whose case is reviewed had <e1>migraine headaches</e1> and received <e2>methysergide</e2> maleate for 13 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4807	"A case of <e1>Erythema Multiforme Bullosum</e1> in patient of lepromatous leprosy with pulmonary tuberculosis due to <e2>Rifampicin</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4808	"<e1>Erythema multiforme bullosum</e1> due to <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4809	"<e1>Renal damage</e1> associated with long term use of <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4810	"The authors report 2 cases of <e1>renal damage</e1> associated with <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4811	"In two patients with mycosis fungoides, a <e1>squamous cell carcinoma</e1> developed during therapy with <e2>psoralens</e2> plus long-wave ultraviolet radiation (PUVA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4812	"Hyperglycemia and <e1>diabetic coma</e1>: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4813	"<e1>Hyperglycemia</e1> and diabetic coma: possible relationship to diuretic-<e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4814	"Two patients developed <e1>diabetic coma</e1> when taking a combination of a thiazide diuretic and <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4815	"Two patients developed <e1>diabetic coma</e1> when taking a combination of a <e2>thiazide</e2> diuretic and propranolol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4816	"An insulin-dependent diabetic patient with nephropathy developed <e1>severe acidosis</e1> after treatment with <e2>acetazolamide</e2> for glaucoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4817	"<e1>Severe acidosis</e1> from <e2>acetazolamide</e2> in a diabetic patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4818	"This progressed to <e1>tracheal compression</e1> with stridor after he had taken some <e2>aspirin</e2> for relief of the neck pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4819	"Five cases of <e1>clindamycin</e1>-associated <e2>pseudomembranous colitis</e2> in leukaemic patients are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4820	"An infertile patient with amenorrhea-galactorrhea syndrome <e1>lost vision</e1> during a pregnancy occurring after <e2>Bromocryptine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4821	"<e1>Fatal acute tubular necrosis</e1> occurred in 1 patient in whom intravesical <e2>formalin</e2> was used to control massive persistent hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4822	"<e1>Fatal complication</e1> of intravesical <e2>formalin</e2> during control of intractable hemorrhage from radiation cystitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4823	"Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated <e1>metabolic acidosis</e1> due to absorbed <e2>formic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4824	"A young woman developed <e1>galactorrhea</e1> during treatment with a new dibenzoxazepine antidepressant, <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4825	"A young woman developed <e1>galactorrhea</e1> during treatment with a new <e2>dibenzoxazepine</e2> antidepressant, amoxapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4826	"A <e1>15-kg weight gain</e1> developed in a patient during the third week of <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4827	"<e1>Edema</e1> associated with <e2>ibuprofen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4828	"It should be recognized that <e1>ibuprofen</e1> may be associated with <e2>salt and water retention</e2> in the same fashion as previously described with phenylbutazone and indomethacin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4829	"It should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with phenylbutazone and <e2>indomethacin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4830	"It should be recognized that ibuprofen may be associated with <e1>salt and water retention</e1> in the same fashion as previously described with <e2>phenylbutazone</e2> and indomethacin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4831	"<e1>Allopurinol</e1>-associated <e2>hand and foot deformities</e2> in chronic tophaceous gout."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4832	"<e1>Telescoped digits of the hands and feet</e1> developed in a 69-year-old male with severe chronic tophaceous gout during <e2>allopurinol</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4833	"A patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an <e2>acute toxic delirium</e2> with EEG abnormalities developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4834	"A patient with coccidioidal meningitis was treated with intrathecally administered <e1>amphotericin B</e1>, and an acute toxic delirium with <e2>EEG abnormalities</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4835	"<e1>Neurotoxicity</e1> of intrathecal administration of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4836	"In keeping with findings in the literature, the <e1>aortic wall in this case was damaged</e1> by secondary changes following irradiation and <e2>Bleomycin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4837	"Cardiac glycosides are thought to prevent <e1>doxorubicin</e1> <e2>cardiomyopathy</e2> by competitively inhibiting <e1>doxorubicin</e1> at its receptor sites, but ouabain has a much shorter half life than <e1>doxorubicin</e1> and its metabolites and so is less effective than digoxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4838	"<e1>Doxorubicin</e1> <e2>cardiotoxicity</e2>: possible role of digoxin in its prevention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4839	"<e1>Minor electrocardiographical changes</e1> were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving <e2>ouabain</e2>, and none of the 16 who were receiving digoxin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4840	"One other patient on <e1>digoxin</e1> stopped taking it and developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4841	"One patient on <e1>ouabain</e1> also developed <e2>cardiomyopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4842	"A healthy, 30-year-old man, exposed to <e1>sulindac</e1> on two separate occasions, had an incapacitating <e2>isolated idential sensory neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4843	"Sulindac (<e1>Clinoril</e1>), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4844	"<e1>Sulindac</e1> (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported <e2>neurologic toxic effects</e2>, all of which have been associated with systemic disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4845	"To our knowledge, we describe the first reported case of <e1>isolated paresthesia</e1> and peripheral neuropathy, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4846	"To our knowledge, we describe the first reported case of isolated paresthesia and <e1>peripheral neuropathy</e1>, without systemic involvement, secondary to <e2>sulindac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4847	"In addition, loading with one low oral dose of <e1>serine</e1> produced <e2>psychotic symptoms</e2> 5 h later which lasted 3-6 h."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4848	"Reversal of <e1>ergotamine</e1>-induced <e2>arteriospasm</e2> by mechanical intra-arterial dilatation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4849	"Two patients with imminent gangrene of the extremities caused by <e1>ergot</e1>-induced <e2>arteriospasm</e2> underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4850	"Two patients with imminent <e1>gangrene of the extremities</e1> caused by <e2>ergot</e2>-induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4851	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4852	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by <e2>hyperpyrexia</e2>, severe rigidity, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4853	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4854	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of <e2>irreversible tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4855	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4856	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, <e2>mutism</e2>, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4857	"The authors describe a case of combined lithium and <e1>haloperidol</e1> toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4858	"The authors describe a case of combined <e1>lithium</e1> and haloperidol toxicity characterized by hyperpyrexia, <e2>severe rigidity</e2>, mutism, and development of irreversible tardive dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4859	"The authors postulate that two types of combined <e1>lithium</e1>-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4860	"The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a <e1>lithium toxicity</e1> that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4861	"The authors postulate that two types of combined <e1>lithium</e1>-neuroleptic toxicity occur: a <e2>neuroleptic malignant extrapyramidal syndrome</e2> and a <e1>lithium</e1> toxicity that occurs in combination with phenothiazines, primarily thioridazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4862	"The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a <e1>neuroleptic malignant extrapyramidal syndrome</e1> and a lithium toxicity that occurs in combination with phenothiazines, primarily <e2>thioridazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4863	"<e1>Chlorambucil</e1>-induced <e2>chromosome damage</e2> to human lymphocytes is dose-dependent and cumulative."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4864	"<e1>Anaphylactoid reaction</e1> to 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4865	"Preliminary results suggest that the higher concentrations of <e1>dextrose</e1> induce <e2>increased histamine release</e2> from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4866	"Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an <e1>anaphylactoid reaction</e1> after the intravenous administration of 50% solution of <e2>dextrose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4867	"<e1>Salicylate</e1> <e2>hepato toxicity</e2> in rheumatic fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4868	"Two children with rheumatic fever developed <e1>anicteric hepatitis</e1> while on high-dose <e2>aspirin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4869	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4870	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4871	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, <e2>encephalopathy</e2>, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4872	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4873	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4874	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense <e2>left homonymous hemianopsia</e2>, encephalopathy, and a partial nondominant parietal lobe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4875	"A 36-year-old man being treated with cisplatinum, vinblastine, and <e1>bleomycin</e1> for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4876	"A 36-year-old man being treated with <e1>cisplatinum</e1>, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4877	"A 36-year-old man being treated with cisplatinum, <e1>vinblastine</e1>, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a <e2>partial nondominant parietal lobe syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4878	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4879	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4880	"Transient left homonymous hemianopsia and <e1>encephalopathy</e1> following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4881	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and <e2>bleomycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4882	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with <e2>cisplatinum</e2>, vinblastine, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4883	"<e1>Transient left homonymous hemianopsia</e1> and encephalopathy following treatment of testicular carcinoma with cisplatinum, <e2>vinblastine</e2>, and bleomycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4884	"An association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4885	"An association of granulocytopenia, <e1>eosinophilia</e1>, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4886	"An association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4887	"An association of <e1>granulocytopenia</e1>, eosinophilia, skin reaction and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4888	"An association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4889	"An association of granulocytopenia, eosinophilia, skin reaction and <e1>hepatitis</e1> during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4890	"An association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during <e2>propylthiouracil</e2> (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4891	"An association of granulocytopenia, eosinophilia, <e1>skin reaction</e1> and hepatitis during propylthiouracil (<e2>PTU</e2>) therapy for thyrotoxicosis in a 47 year old black female is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4892	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, <e2>eosinophilia</e2>, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4893	"Multiple complications of <e1>propylthiouracil</e1> treatment: <e2>granulocytopenia</e2>, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4894	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and <e2>hepatitis</e2> with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4895	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with <e2>lymphocyte sensitization</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4896	"Multiple complications of <e1>propylthiouracil</e1> treatment: granulocytopenia, eosinophilia, <e2>skin reaction</e2> and hepatitis with lymphocyte sensitization."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4897	"A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4898	"A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and <e1>ataxia</e1> developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4899	"A toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4900	"A toxic encephalopathy characterized by <e1>depressed level of consciousness</e1>, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4901	"A toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4902	"A toxic encephalopathy characterized by depressed level of consciousness, <e1>marked irritability</e1>, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4903	"A <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of <e2>pentobarbital</e2> and pyrilamine maleate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4904	"A <e1>toxic encephalopathy</e1> characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and <e2>pyrilamine maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4905	"<e1>Optic neuropathy</e1> associated with <e2>penicillamine</e2> therapy in a patient with rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4906	"<e1>Optic neuropathy</e1> developed in a patient with rheumatoid arthritis who had been receiving <e2>D-penicillamine</e2> for about 1 year."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4907	"The case resembles two previously reported cases of <e1>optic neuropathy</e1> which occurred in patients with Wilson's disease who were receiving <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4908	"A patient developed transient, <e1>acute myopia</e1> while on isotretinoin (<e2>Accutane</e2>) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4909	"A patient developed transient, <e1>acute myopia</e1> while on <e2>isotretinoin</e2> (Accutane) therapy for acne."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4910	"There was a clear relationship between restarting the <e1>Accutane</e1> and recurrence of the <e2>transient myopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4911	"<e1>Transient acute myopia</e1> resulting from isotretinoin (<e2>accutane</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4912	"<e1>Transient acute myopia</e1> resulting from <e2>isotretinoin</e2> (accutane) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4913	"<e1>Allergic contact dermatitis</e1> to compound tincture of <e2>benzoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4914	"Nineteen cases of <e1>allergic contact dermatitis</e1> to compound tincture of <e2>benzoin</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4915	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; <e2>Ara-C</e2>) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4916	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of <e2>cytarabine</e2> (cytosine arabinoside; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4917	"Autopsy evidence of <e1>herpesvirus infection</e1> was found in visceral organs of four leukemic patients who had received large doses of cytarabine (<e2>cytosine arabinoside</e2>; Ara-C) shortly before their death."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4918	"In three of these patients the infection was clinically unsuspected; in the fourth, <e1>cutaneous herpes zoster</e1> developed after administration of 300 mg of <e2>cytarabine</e2> daily for the preceding five days."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4919	"<e1>Visceral herpesvirus infections</e1> in leukemic patients receiving <e2>cytarabine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4920	"Clinical and morphological features of <e1>gold</e1> <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4921	"Three cases of <e1>gold</e1>-related <e2>neuropathy</e2> are reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4922	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (<e2>B663</e2>; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4923	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with <e2>clofazimine</e2> (B663; Lamprene)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4924	"<e1>Intra-neural ceroid-like pigment</e1> following the treatment of lepromatous leprosy with clofazimine (B663; <e2>Lamprene</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4925	"One of these was <e1>clofazimine</e1>, an aniline aposafranine derivative known to produce a <e2>ceroid-like pigment</e2> in the tissues of patients treated with this drug or lepromatous leprosy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4926	"<e1>Severe neurotoxicity</e1> with <e2>methyl G: CALGB</e2> experience."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4927	"A young patient experienced marked <e1>sinus tachycardia</e1> while smoking marijuana and receiving therapeutic doses of <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4928	"Marked <e1>sinus tachycardia</e1> resulting from the synergistic effects of marijuana and <e2>nortriptyline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4929	"It is concluded that '<e1>cerebral atrophy</e1>' on CT scans may represent an accumulative effect of <e2>ACTH</e2> and that <e2>ACTH</e2> should be given with the utmost discretion, and in as low a dose as possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4930	"<e1>Disulfiram-like reactions</e1> with newer cephalosporins: <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4931	"This is the first report of a <e1>disulfiram-like reaction</e1> with <e2>cefmenoxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4932	"k bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, <e2>akathisia</e2> at therapeutic serum <e1>lithium</e1> levels and subsequently bucco-linguo-masticatory dyskinesia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4933	"k bipolar manic-depressive patient, developed while on <e1>lithium</e1> prophylaxis, akathisia at therapeutic serum <e1>lithium</e1> levels and subsequently <e2>bucco-linguo-masticatory dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4934	"<e1>Acute leukopenia</e1> associated with <e2>silver sulfadiazine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4935	"Patients from endemic areas referred to transplant centers may be at high risk for <e1>disseminated histoplasmosis</e1> when treated with long-term <e2>prednisone</e2> for graft-versus-host disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4936	"<e1>Acute renal failure</e1> most likely was secondary to the nephrotoxic effect of <e2>captopril</e2> on chronically hypoperfused kidneys."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4937	"In a patient with severe renovascular hypertension, <e1>nonoliguric acute renal failure</e1> developed after she received <e2>captopril</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4938	"<e1>Nonoliguric acute renal failure</e1> after <e2>captopril</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4939	"<e1>Captopril</e1>-induced <e2>acute reversible renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4940	"The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of <e1>captopril</e1>-induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4941	"We report 5 cases of <e1>acute reversible renal failure</e1> coinciding with the onset of treatment with <e2>captopril</e2> in patients with severe drug-resistant hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4942	"A case of <e1>mania</e1> associated with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4943	"A depressed woman with no history of bipolar illness developed a <e1>manic episode</e1> during treatment with <e2>fluoxetine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4944	"<e1>Alopecia</e1>, nausea, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4945	"Alopecia, <e1>nausea</e1>, and vomiting were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4946	"Alopecia, nausea, and <e1>vomiting</e1> were attributed to the <e2>cyclophosphamide</e2> component of the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4947	"<e1>Haemolytic-uraemic syndrome</e1> complicating long-term mitomycin C and <e2>5-fluorouracil</e2> therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4948	"<e1>Haemolytic-uraemic syndrome</e1> complicating long-term <e2>mitomycin C</e2> and 5-fluorouracil therapy for gastric carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4949	"Three cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with mitomycin C and <e2>5-fluorouracil</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4950	"Three cases of <e1>acute renal toxicity</e1> in patients receiving long-term therapy with <e2>mitomycin C</e2> and 5-fluorouracil are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4951	"Oral <e1>25-hydroxyvitain D3</e1> in treatment of osteomalacia associated with <e2>ileal resection</e2> and cholestyramine therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4952	"Severe histological <e1>osteomalacia</e1> developed in a woman with Crohn's disease 2 years after ileal resection and the start of <e2>cholestyramine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4953	"Treatment of <e1>lithium</e1> <e2>tremor</e2> with metoprolol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4954	"Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced <e1>tremor</e1> during <e2>lithium carbonate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4955	"Intravenous <e1>diazepam</e1> exacerbated the <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4956	"A 52-year-old Black woman on <e1>phenytoin</e1> therapy for post-traumatic epilepsy developed <e2>transient hemiparesis</e2> contralateral to the injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4957	"A possible mechanism for <e1>focal neurological deficit</e1> in brain-damaged patients on <e2>phenytoin</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4958	"<e1>Transient hemiparesis</e1> caused by <e2>phenytoin</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4959	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (<e2>2-propylpentanoic acid</e2>, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4960	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (<e2>phenobarbitone</e2> therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4961	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later <e2>valproate</e2> (2-propylpentanoic acid, VPA) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4962	"A 7-year-old boy developed a <e1>severe unilateral grand mal seizure</e1> at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, <e2>VPA</e2>) was added to the therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4963	"<e1>Cefoxitin</e1> therapy for Mycobacterium fortuitum bacteremia with associated <e2>granulomatous hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4964	"<e1>Stroke-like syndrome</e1> after <e2>gold sodium thiomalate</e2> induced vasomotor reaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4965	"Stroke-like syndrome after <e1>gold sodium thiomalate</e1> induced <e2>vasomotor reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4966	"<e1>Vasomotor reactions</e1> after <e2>gold sodium thiomalate</e2> are well recognized."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4967	"<e1>Gold nephropathy</e1> due to <e2>auranofin</e2> obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4968	"<e2>Gold</e2> nephropathy due to auranofin obscured by tolmetin pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4969	"<e1>Gold nephropathy</e1> due to auranofin obscured by <e2>tolmetin</e2> pseudoproteinuria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4970	"Gold nephropathy due to auranofin obscured by <e1>tolmetin</e1> <e2>pseudoproteinuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4971	"A 52-year-old, white female developed low-grade fever, <e1>cough</e1>, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4972	"A 52-year-old, white female developed low-grade fever, cough, and <e1>dyspnea</e1> after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4973	"A 52-year-old, white female developed <e1>low-grade fever</e1>, cough, and dyspnea after 8 weeks treatment with <e2>sodium aurothiomalate</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4974	"Pulmonary <e2>gold</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4975	"<e1>Cyclophosphamide</e1> can rarely cause interstitial pneumonitis and <e2>fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4976	"<e1>Cyclophosphamide</e1> can rarely cause <e2>interstitial pneumonitis</e2> and fibrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4977	"<e1>Cyclophosphamide</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4978	"The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that <e1>cyclophosphamide</e1> was aetiologically responsible for the <e2>lung disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4979	"The temporal sequence of the <e1>respiratory insufficiency</e1> and the histopathology, when compared to the previous examples in the literature, suggest that <e2>cyclophosphamide</e2> was aetiologically responsible for the lung disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4980	"A <e1>reversible toxic liver damage</e1> was observed in a non-alcoholic woman treated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4981	"<e1>Toxic hepatitis</e1> induced by <e2>disulfiram</e2> in a non-alcoholic."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4982	"One type of SMON is associated with <e1>acrodermatitis enteropathica</e1> which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4983	"One type of <e1>SMON</e1> is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of <e2>clioquinol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4984	"Four patients receiving high-dose <e1>tamoxifen</e1> for greater than 1 year have demonstrated similar <e2>retinal changes</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4985	"<e1>Tamoxifen</e1> <e2>retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4986	"These findings suggest that the <e1>corneal and retinal changes</e1> are the result of a toxic effect of <e2>tamoxifen</e2> when used in the doses and duration described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4987	"<e1>Mammary gigantism</e1> is a rare complication of <e2>D-penicillamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4988	"Although they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4989	"Although they had complex medical problems, the high serum concentrations of <e1>ampicillin</e1> at the time of <e2>seizures</e2> without their recurrence after discontinuing the antibiotic suggest that the <e2>seizures</e2> were related to the <e1>ampicillin</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4990	"<e1>Ampicillin</e1>-associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4991	"Two patients had <e1>ampicillin</e1>-associated <e2>seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4992	"After the patient discontinued <e1>rifampicin</e1>, the <e2>skin lesions</e2> cleared completely within 5 weeks without any systemic medication."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

4993	"<e1>Pemphigus foliaceus</e1> induced by <e2>rifampicin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4994	"<e1>Pemphigus foliaceus</e1> was seen in a patient with pulmonary tuberculosis during <e2>rifampicin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4995	"<e1>Hyponatremia</e1> in patients treated with <e2>lorcainide</e2>, a new antiarrhythmic drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4996	"In eight patients, a mean <e1>decrease in serum Na+</e1> of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4997	"It is concluded that <e1>SIADH</e1> is an important side effect of <e2>lorcainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4998	"One patient developed <e1>severe hyponatremia</e1> with serum Na+ of 108 mEq/L when <e2>hydrochlorothiazide</e2> was given to control hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

4999	"Sixteen of 33 patients developed significant <e1>hyponatremia</e1> and hypoosmolality during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5000	"Sixteen of 33 patients developed significant hyponatremia and <e1>hypoosmolality</e1> during oral treatment with <e2>lorcainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5001	"<e1>Acute intravascular hemolysis</e1> developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, <e2>chlorpropamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5002	"<e1>Acute intravascular hemolysis</e1> developed when a diabetic patient, previously treated with <e2>glyburide</e2>, was started on another oral sulfonylurea drug, chlorpropamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5003	"<e1>Chlorpropamide</e1>-induced <e2>hemolytic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5004	"In a 61-year-old man receiving chronic low-dosage <e1>amiodarone</e1> an <e2>interstitial pneumopathy</e2> was observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5005	"<e1>Interstitial pneumopathy</e1> and low-dosage <e2>amiodarone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5006	"<e1>Alternating sinus rhythm</e1> and intermittent sinoatrial block induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5007	"Alternating sinus rhythm and <e1>intermittent sinoatrial block</e1> induced by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5008	"<e1>Alternating sinus rhythm</e1> and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5009	"Alternating sinus rhythm and <e1>intermittent sinoatrial (S-A) block</e1> was observed in a 57-year-old woman, under treatment for angina with 80 mg <e2>propranolol</e2> daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5010	"The <e1>abnormal rhythm</e1> disappeared with the withdrawal of <e2>propranolol</e2> and when the drug was restarted a 2/1 S-A block was seen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5011	"This was accepted as evidence for <e1>propranolol</e1> being the cause of this <e2>conduction disorder</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5012	"A further case of <e1>anaphylactoid reaction</e1> to <e2>methylprednisolone</e2> is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5013	"<e1>Anaphylactoid reaction</e1> to <e2>methylprednisolone</e2> pulsed therapy for multiple sclerosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5014	"Although lung specimens were lacking from these three patients, it is suggested that the <e1>pulmonary toxicity</e1> of <e2>CCNU</e2> may be dose-related."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5015	"<e1>Pulmonary fibrosis</e1> subsequent to high doses of <e2>CCNU</e2> for chronic myeloid leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5016	"The responsibility of <e1>CCNU</e1> in the pathogenesis of <e2>pulmonary fibrosis</e2> seems very likely."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5017	"Two patients treated for chronic myeloid leukemia with high doses of <e1>CCNU</e1> (1100 mg/m2 and 1240 mg/m2, respectively) developed a <e2>fatal pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5018	"<e1>Additive pulmonary toxicity</e1> with melphalan and <e2>busulfan</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5019	"<e1>Additive pulmonary toxicity</e1> with <e2>melphalan</e2> and busulfan therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5020	"We report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with melphalan and <e2>busulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5021	"We report a 59-year-old patient with chronic myeloid leukemia, who developed <e1>severe interstitial lung fibrosis</e1> after short term and sequential treatment with <e2>melphalan</e2> and busulfan."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5022	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, <e2>confusion</e2> and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5023	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with lethargy, confusion and <e2>drowsiness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5024	"After taking <e1>cholestyramine II</e1> sachets twice daily for two months she presented with <e2>lethargy</e2>, confusion and drowsiness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5025	"<e1>Cholestyramine</e1> induced <e2>hyperchloremic metabolic acidosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5026	"It is presumed that her <e1>hyperchloremic metabolic acidosis</e1> was secondary to <e2>cholestyramine</e2> because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5027	"The first reported case, in an adult, of <e1>cholestyramine</e1> induced <e2>hyperchloremic metabolic acidosis</e2> is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5028	"Although myelosuppression is mild, <e1>immunosuppression</e1> and superinfection are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5029	"Although myelosuppression is mild, immunosuppression and <e1>superinfection</e1> are potential hazards of treatment with <e2>DCF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5030	"The ocular toxicity of <e1>DCF</e1>, previously described as <e2>conjunctivitis</e2>, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5031	"The ocular toxicity of <e1>DCF</e1>, previously described as conjunctivitis, appears to be a <e2>keratitis</e2> of moderate severity which requires further study."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5032	"The <e1>ocular toxicity</e1> of <e2>DCF</e2>, previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5033	"Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during <e1>vasopressin</e1> infusion, followed by release of myoglobin and <e2>renal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5034	"Because there were no other obvious causes of renal failure in either patient, we propose that <e1>skeletal muscle ischemia</e1> developed during <e2>vasopressin</e2> infusion, followed by release of myoglobin and renal damage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5035	"Myoglobinuria and <e1>acute renal failure</e1> associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5036	"<e1>Myoglobinuria</e1> and acute renal failure associated with intravenous <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5037	"Myoglobinuria and <e1>acute renal failure</e1> were observed in two patients with <e2>vasopressin</e2>-treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5038	"<e1>Myoglobinuria</e1> and acute renal failure were observed in two patients with <e2>vasopressin</e2>-treated gastrointestinal hemorrhage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5039	"A major limitation in the use of <e1>amphotericin B</e1> is its potential to cause <e2>nephrotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5040	"<e1>Amphotericin B</e1> <e2>nephrotoxicity</e2> in humans decreased by salt repletion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5041	"Experience with five patients in whom <e1>impaired renal function</e1> developed early during <e2>amphotericin B</e2> therapy is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5042	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral <e2>fluoresone</e2> 750 mg daily to the phenobarbital and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5043	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the <e2>phenobarbital</e2> and phenytoin already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5044	"<e1>Gynecomastia</e1> developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and <e2>phenytoin</e2> already being administered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5045	"<e1>Gynecomastia</e1> in epileptics treated with phenobarbital, phenytoin and <e2>fluoresone</e2>: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5046	"<e1>Gynecomastia</e1> in epileptics treated with <e2>phenobarbital</e2>, phenytoin and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5047	"<e1>Gynecomastia</e1> in epileptics treated with phenobarbital, <e2>phenytoin</e2> and fluoresone: two case reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5048	"Case report of withdrawal <e1>dyskinesia</e1> associated with <e2>amoxapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5049	"Occurrence of withdrawal <e1>dyskinesia</e1> indicates that the neuroleptic effects of <e2>amoxapine</e2> may be clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5050	"The authors describe a case of <e1>oral-facial dyskinesia</e1> that occurred after discontinuation of <e2>amoxapine</e2>, and antidepressant which may also have neuroleptic effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5051	"A case of <e1>toxic hepatitis</e1> caused by combination therapy with methotrexate and <e2>etretinate</e2> in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5052	"A case of <e1>toxic hepatitis</e1> caused by combination therapy with <e2>methotrexate</e2> and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5053	"<e1>Toxic hepatitis</e1> due to combination therapy with methotrexate and <e2>etretinate</e2> in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5054	"<e1>Toxic hepatitis</e1> due to combination therapy with <e2>methotrexate</e2> and etretinate in psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5055	"Metabolic balance studies and rechallenge with <e1>hydrochlorothiazide</e1> were undertaken to investigate the mechanism of the thiazide-induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5056	"A 58-year-old woman developed <e1>unilateral acute angle-closure glaucoma</e1> four days after the application of a patch of transdermal <e2>scopolamine</e2> delivery system (TRANSDERM-V)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5057	"A case history of a 15-year-old boy who developed incapacitating <e1>tardive dyskinesia</e1> that resolved during treatment with <e2>deanol</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5058	"<e1>Cephalosporins</e1> are most likely associated with <e2>Vitamin K deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5059	"<e1>Coagulopathy</e1> associated with the use of <e2>cephalosporin</e2> or moxalactam antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5060	"<e1>Coagulopathy</e1> associated with the use of cephalosporin or <e2>moxalactam</e2> antibiotics in acute and chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5061	"<e1>Moxalactam</e1> is more likely to be associated with <e2>platelet dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5062	"Nevertheless, the <e1>coagulopathy</e1> seemed to be most closely associated with the administration of the <e2>cephalosporin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5063	"Nine azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either <e2>cephalosporin</e2> or moxalactam antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5064	"Nine azotemic patients who developed a <e1>coagulopathy</e1> associated with the use of either cephalosporin or <e2>moxalactam</e2> antibiotics are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5065	"A case is reported of a child with <e1>fatal pulmonary fibrosis</e1> following <e2>BCNU</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5066	"<e1>Fatal pulmonary fibrosis</e1> following <e2>1,3-bis(2-chloroethyl)-1-nitrosourea</e2> (BCNU) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5067	"<e1>Fatal pulmonary fibrosis</e1> following 1,3-bis(2-chloroethyl)-1-nitrosourea (<e2>BCNU</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5068	"<e1>Thrombotic thrombocytopenic purpura</e1> during <e2>penicillamine</e2> therapy in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5069	"<e1>Thrombotic thrombocytopenic purpura</e1> (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5070	"Thrombotic thrombocytopenic purpura (<e1>TTP</e1>) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5071	"To our knowledge, no prior cases of <e1>penicillamine</e1>-induced <e2>TTP</e2> in RA have been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5072	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by <e2>cough</e2>, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5073	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and <e2>diffuse pulmonary infiltrates</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5074	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, <e2>dyspnea</e2> and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5075	"<e1>Amiodarone hydrochloride</e1>, a new antiarrhythmic agent, has been associated with <e2>pulmonary toxicity</e2> characterized by cough, dyspnea and diffuse pulmonary infiltrates."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5076	"Possible recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> following corticosteroid therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5077	"To our knowledge, this recurrence of <e1>amiodarone</e1> <e2>pulmonary toxicity</e2> has not been reported previously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5078	"We describe a case of <e1>fibrosing alveolitis</e1>, diagnosed by lung biopsy, in a patient receiving <e2>amiodarone</e2> which responded to corticosteroid therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5079	"A 61 year-old male patient developed <e1>gynecomastia</e1> after starting <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5080	"<e1>Gynecomastia</e1> associated with <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5081	"No other endogenous or exogenous cause for the <e1>gynecomastia</e1> could be found except for the <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5082	"The <e1>gynecomastia</e1> regressed when the <e2>theophylline</e2> was discontinued."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5083	"Parenteral-<e1>verapamil</e1>-induced <e2>sustained hypotension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5084	"The incidence of oral-<e1>verapamil</e1>-induced <e2>hypotension</e2> in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5085	"We report a case of <e1>sustained hypotension</e1> after administration of parenteral <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5086	"A 69-year-old man developed <e1>pure red cell aplasia</e1> after taking <e2>fenoprofen</e2> for ten months."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5087	"<e1>Pure red cell aplasia</e1> associated with <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5088	"This case represents the third example of <e1>erythroid aplasia</e1> associated with an anti-inflammatory agent and the first instance due to <e2>fenoprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5089	"Drug-induced <e1>psychosis</e1> resulted from the administration of <e2>quinacrine hydrochloride</e2> at a dosage of 100 mg twice daily for the treatment of discoid lupus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5090	"A case of <e1>priapism</e1> associated with <e2>trazodone</e2> is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5091	"<e1>Priapism</e1> associated with <e2>trazodone</e2> therapy: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5092	"Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the <e1>paracetamol</e1> from the body and consequently prevented the development of <e2>severe hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5093	"<e1>Anaphylactoid shock</e1>, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5094	"Anaphylactoid shock, disseminated intravascular coagulation, and <e1>anuric renal failure</e1> requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5095	"Anaphylactoid shock, <e1>disseminated intravascular coagulation</e1>, and anuric renal failure requiring dialysis occurred in a patient receiving <e2>zomepirac</e2> sodium for toothache."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5096	"<e1>Focal renal cortical necrosis</e1> associated with <e2>zomepirac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5097	"The mechanism of <e1>anaphylactoid reaction</e1> to <e2>zomepirac</e2> in this case, therefore, remains unclear."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5098	"<e1>Cimetidine</e1>-induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5099	"<e1>Cimetidine</e1> is a rare cause of drug-induced <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5100	"A 56-year-old male parkinsonian patient developed a unique <e1>behavioral change</e1> following the oral administration of <e2>cinepazide</e2>, a cerebral vasodilator."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5101	"Unique <e1>behavioral change</e1> with <e2>cinepazide</e2> in parkinsonism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5102	"A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a <e1>small-bowel obstruction</e1> due to <e2>Amphojel</e2> concretions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5103	"A patient with alcoholic cerebellar degeneration had <e1>periodic alternating nystagmus</e1> during a period of <e2>phenytoin</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5104	"Although the data indicate an immune-complex cause for <e1>gold-salt</e1> <e2>nephropathy</e2>, the incident antigen (or antigens) and mechanism of action remain unidentified."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5105	"<e1>Gold</e1> <e2>nephropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5106	"<e1>Gold-salt</e1> therapy may result in <e2>damage to proximal tubules</e2> that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5107	"The <e1>nephrotic syndrome</e1> developed in a patient receiving therapy with <e2>gold</e2> for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5108	"Intrahepatic cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5109	"<e1>Intrahepatic cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5110	"Intrahepatic cholestasis and <e1>cutaneous bullae</e1> associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5111	"<e1>Intrahepatic cholestasis</e1> and cutaneous bullae associated with <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5112	"These features have not previously been reported as side effects of glibenclamide therapy, but <e1>intrahepatic cholestasis</e1> may occur with <e2>chlorpropamide</e2>, a similar sulphonylurea agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5113	"In four patients, <e1>spasm</e1> occurred spontaneous and in one patient after 0.05 mg of <e2>ergonovine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5114	"The authors describe a woman with chronic schizophrenia who experienced <e1>delirium</e1>, grand mal seizure, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5115	"The authors describe a woman with chronic schizophrenia who experienced delirium, <e1>grand mal seizure</e1>, and photosensitivity after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5116	"The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and <e1>photosensitivity</e1> after the addition of <e2>propranolol</e2> to her neuroleptic regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5117	"<e1>Catatonia</e1> associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5118	"Neurophysiological mechanisms which aid in elucidating the role of <e1>disulfiram</e1> in the etiology of <e2>catatonia</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5119	"This is the first report of a <e1>catatonic syndrome</e1> occurring in a patient receiving <e2>disulfiram</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5120	"<e1>Hepatic reactions</e1> to <e2>cyclofenil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5121	"Thirty patients with <e1>hepatic reactions</e1> to <e2>cyclofenil</e2>, a non-steroidal drug with a stimulating effect on ovulation, are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5122	"Since early symptoms of the toxic effects of <e1>theophylline</e1> can mimic <e2>peptic ulcer disease</e2>, cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of <e1>theophylline</e1> poisoning."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5123	"A case of <e1>SIADH</e1> associated with <e2>desipramine</e2> treatment in an elderly depressed woman is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5124	"<e1>Desipramine</e1>-associated <e2>SIADH</e2> in an elderly woman: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5125	"Prior reports have emphasized the <e1>tubular and interstitial lesions</e1> associated with intermittent or discontinuous <e2>rifampin</e2> therapy for tuberculosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5126	"The spectrum of <e1>renal lesions</e1> occurring during antituberculous therapy, particularly in association with <e2>rifampin</e2>, may be wider than previously suspected."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5127	"Within 3 weeks of beginning continuous daily <e1>isoniazid</e1> and rifampin therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5128	"Within 3 weeks of beginning continuous daily isoniazid and <e1>rifampin</e1> therapy for pulmonary tuberculosis, a patient developed <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5129	"<e1>Nephrotic range pseudoproteinuria</e1> in a <e2>tolmetin</e2>-treated patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5130	"When tuberculosis patients on <e1>isoniazid</e1> eat certain varieties of fish they may develop a <e2>histamine reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5131	"<e1>Fulminant hepatitis</e1> associated with <e2>disulfiram</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5132	"We report a case of <e1>fatal fulminant hepatitis</e1> caused by the use of <e2>disulfiram</e2> in a man with previously normal hepatocellular function."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5133	"A 45-year-old woman with thyrotoxicosis developed <e1>agranulocytosis</e1> after treatment with <e2>propylthiouracil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5134	"The patient was given <e1>methimazole</e1> instead of propylthiouracil but, 10 weeks later, <e2>agranulocytosis</e2> again occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5135	"This is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both propylthiouracil and <e2>methimazole</e2> in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5136	"This is, to the best of our knowledge, the first report of a case in which <e1>agranulocytosis</e1> followed treatment with both <e2>propylthiouracil</e2> and methimazole in the same patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5137	"A 55-yr-old man developed <e1>prolonged jaundice</e1> and sicca complex after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5138	"A 55-yr-old man developed prolonged jaundice and <e1>sicca complex</e1> after a course of <e2>thiabendazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5139	"<e1>Intrahepatic cholestasis</e1> and sicca complex after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5140	"Intrahepatic cholestasis and <e1>sicca complex</e1> after <e2>thiabendazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5141	"The literature on <e1>thiabendazole</e1>-induced <e2>cholestasis</e2> and its association with sicca complex is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5142	"The literature on <e1>thiabendazole</e1>-induced cholestasis and its association with <e2>sicca complex</e2> is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5143	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5144	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later died of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5145	"She was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later died of <e2>Adriamycin toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5146	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5147	"She was placed on adjuvant <e1>Adriamycin</e1> (doxorubicin) chemotherapy, but 6 months later <e2>died</e2> of <e1>Adriamycin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5148	"She was placed on adjuvant Adriamycin (<e1>doxorubicin</e1>) chemotherapy, but 6 months later <e2>died</e2> of Adriamycin toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5149	"Intracranial hemorrhage and <e1>focal seizures</e1> secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5150	"<e1>Intracranial hemorrhage</e1> and focal seizures secondary to use of <e2>L-asparaginase</e2> during induction therapy of acute lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5151	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and <e2>asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5152	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, <e2>prednisone</e2>, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5153	"<e1>Dural sinus thrombosis</e1> developed in two children with acute lymphoblastic leukemia during induction treatment with <e2>vincristine sulfate</e2>, prednisone, and asparaginase."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5154	"The cause is presumed to be secondary to hypercoagulability due to <e1>asparaginase</e1>-induced <e2>antithrombin III deficiency</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5155	"Six patients with rheumatoid arthritis developed a syndrome resembling <e1>lupus erythematosus</e1> while being treated with <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5156	"<e1>Systemic lupus erythematosus</e1> during <e2>penicillamine</e2> therapy for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5157	"However, the amount of <e1>prednisone</e1> required to maintain normotension resulted in <e2>Cushingoid features</e2> and has been discontinued."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5158	"Clinicians should be aware of <e1>fasting hypoglycemia</e1> as an unusual but potentially serious complication of <e2>disopyramide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5159	"<e1>Disopyramide</e1> (Norpace)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5160	"Disopyramide (<e1>Norpace</e1>)-induced <e2>hypoglycemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5161	"<e1>Cefoxitin</e1>-associated <e2>renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5162	"The other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with gentamicin and <e2>cefoxitin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5163	"The other woman had rheumatoid arthritis and developed <e1>acute tubular necrosis</e1> after treatment with <e2>gentamicin</e2> and cefoxitin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5164	"Two elderly women suffered an <e1>acute deterioration of renal function</e1> after treatment with <e2>cefoxitin sodium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5165	"<e1>Transient anuria</e1> following administration of angiotensin I-converting enzyme inhibitor (<e2>SQ 14225</e2>) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5166	"We report on a patient with renal artery stenosis who had only 1 kidney and in whom <e1>acute renal impairment</e1> developed with transient anuria after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5167	"We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with <e1>transient anuria</e1> after the administration of <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5168	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5169	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5170	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced <e2>atypical ventricular tachycardia</e2> (AVT, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5171	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5172	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5173	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (<e2>AVT</e2>, torsade de pointes)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5174	"A 44-year-old woman is described in whom <e1>amiodarone</e1>, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5175	"A 44-year-old woman is described in whom amiodarone, <e1>disopyramide</e1>, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5176	"A 44-year-old woman is described in whom amiodarone, disopyramide, and <e1>quinidine</e1>, administered alone separately, induced atypical ventricular tachycardia (AVT, <e2>torsade de pointes</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5177	"<e1>Amiodarone</e1> was the third drug to induce <e2>AVT</e2> in this patient; she received 200 mg/day six days per week for six months."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5178	"Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by quinidine and <e2>disopyramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5179	"Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: <e1>arrhythmia</e1> previously induced by <e2>quinidine</e2> and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5180	"<e1>Atypical ventricular tachycardia</e1> (torsade de pointes) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5181	"Atypical ventricular tachycardia (<e1>torsade de pointes</e1>) induced by <e2>amiodarone</e2>: arrhythmia previously induced by quinidine and disopyramide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5182	"Two years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, <e2>AVT</e2> with syncope occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5183	"Two years later, 24 hours following an increase in the dose of <e1>disopyramide</e1> from 300 to 600 mg/day, AVT with <e2>syncope</e2> occurred; isoproterenol abolished the arrhythmia instantly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5184	"Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient <e1>coronary vasoconstriction</e1> induced by the <e2>dopamine</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5185	"Complete remission of the <e1>nephrosis</e1> occurred after discontinuation of <e2>hydroxychloroquine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5186	"<e1>Hepatitis</e1> following <e2>cimetidine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5187	"The case of an adult who developed both <e1>hepatic dysfunction</e1> and an impaired macrophage migration after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5188	"The case of an adult who developed both hepatic dysfunction and an <e1>impaired macrophage migration</e1> after exposure to <e2>cimetidine</e2> is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5189	"There have been only two reports of <e1>cimetidine</e1>-induced <e2>hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5190	"A 66-year-old mand suffering from severe coronary heart disease took <e1>digoxin</e1> with suicidal intent an was treated for the ensuing <e2>complete atrioventricular block</e2> with <e1>digoxin</e1>-specific antibody fragments."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5191	"<e1>Verapamil</e1> in effort-induced <e2>angina pectoris</e2> in patients with normal coronary arteries."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5192	"<e1>Flucytosine</e1>-associated <e2>diarrhea</e2> has been previously described in 6%-10% of patients receiving the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5193	"This report describes a case of <e1>flucytosine</e1>-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and <e2>marked separation of loops of bowel</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5194	"This report describes a case of <e1>flucytosine</e1>-associated ulcerating enteritis in which the small bowel x-ray demonstrated <e2>severe luminal narrowing</e2>, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5195	"This report describes a case of <e1>flucytosine</e1>-associated <e2>ulcerating enteritis</e2> in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5196	"This report describes a case of <e1>flucytosine</e1>-associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, <e2>ulceration</e2>, and marked separation of loops of bowel."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5197	"<e1>Ulcerating enteritis</e1> associated with <e2>flucytosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5198	"<e1>Papilledema</e1> without peripheral neuropathy in a patient taking <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5199	"An adolescent male developed <e1>acute pancreatitis</e1> and pseudocyst of the pancreas 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5200	"An adolescent male developed acute pancreatitis and <e1>pseudocyst of the pancreas</e1> 16 weeks after cessation of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5201	"<e1>Delayed pseudocyst of the pancreas</e1> can be a complication of intramuscular <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5202	"<e1>L-asparaginase</e1>-induced <e2>pancreatitis</e2> has been reported during or closely following administration of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5203	"Three cases of <e1>pseudocyst of the pancreas</e1> in two women and one man have previously been reported with the use of intravenous <e2>L-asparaginase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5204	"In one patient, treatment with <e1>DCA</e1> was associated with a <e2>decrease in blood lactate levels</e2> from 11.2 mM before treatment to 0.8 mM 16 h later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5205	"Nine <e1>delirious</e1> patients suffering from <e2>lithium</e2> intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5206	"The course of <e1>delirium</e1> due to <e2>lithium</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5207	"Life-threatening <e1>hyperkalemia</e1> induced by <e2>arginine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5208	"<e1>Marked hyperkalemia</e1> was observed during and immediately after an infusion of <e2>arginine monohydrochloride</e2> in two patients with severe hepatic disease and moderate renal insufficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5209	"A 58-year-old man with rheumatoid arthritis developed <e1>lichen planus</e1> during treatment with <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5210	"<e1>Acne</e1> provoked by <e2>gold</e2> seems not to have been described elsewhere."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5211	"Lichen planus and <e1>acne</e1> provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5212	"<e1>Lichen planus</e1> and acne provoked by <e2>gold</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5213	"The case history confirms that <e1>gold</e1> treatment, even in the same patient, can give rise to a wide range of <e2>skin disturbances</e2>, which in many cases do not break out until long after the drug has been withdrawn."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5214	"Secondary hyperparathyroidism in certain patients with <e1>lithium</e1> <e2>nephrotoxicity</e2> is also possible."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5215	"<e1>Secondary hyperparathyroidism</e1> in certain patients with <e2>lithium</e2> nephrotoxicity is also possible."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5216	"These results indicate that <e1>lithium</e1> may cause <e2>biochemical hyperparathyroidism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5217	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5218	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block (<e1>CHB</e1>) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5219	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of <e2>disopyramide phosphate</e2> (Norpace)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5220	"A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed <e1>complete heart block</e1> (CHB) following administration of disopyramide phosphate (<e2>Norpace</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5221	"<e1>Disopyramide</e1>-induced <e2>heart block</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5222	"Although transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to <e2>cardiac arrest</e2> has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5223	"Although transient increases in ectopy after <e1>bretylium</e1> therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening <e2>ventricular arrhythmia</e2> leading to cardiac arrest has not previously been emphasized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5224	"In the first patient, two episodes of <e1>ventricular tachycardia</e1> requiring cardioversion occurred in close temporal sequence with administering <e2>bretylium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5225	"In the second case, five <e1>cardiac arrests</e1> due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5226	"In the second case, five cardiac arrests due to ventricular tachycardia and <e1>fibrillation</e1> occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5227	"In the second case, five cardiac arrests due to <e1>ventricular tachycardia</e1> and fibrillation occurred during several hours after beginning a trial of <e2>bretylium</e2> maintenance therapy for complex ventricular ectopy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5228	"Paradoxical ventricular tachycardia and <e1>fibrillation</e1> after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5229	"<e1>Paradoxical ventricular tachycardia</e1> and fibrillation after intravenous <e2>bretylium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5230	"<e1>Lithium</e1> is known to cause <e2>acute renal failure</e2> and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5231	"<e1>Lithium</e1> is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or <e2>nephrotic syndrome</e2> is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5232	"<e1>Lithium</e1> is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with <e2>proteinuria</e2> or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5233	"<e1>Lithium</e1> is known to cause acute renal failure and <e2>tubulo-interstitial disease</e2>, but the recently described association with proteinuria or nephrotic syndrome is little recognized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5234	"<e1>Nephrotic syndrome</e1> associated with <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5235	"Two patients on long-term <e1>lithium</e1> therapy developed the <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5236	"A 67-year-old man developed <e1>diarrhea</e1> shortly after a 10-day course of oral <e2>ampicillin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5237	"A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, <e1>sensori-neural hearing loss</e1> after <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5238	"<e1>Acute acoustic nerve palsy</e1> associated with <e2>vincristine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5239	"<e1>Bilateral acoustic (VIII) nerve palsy</e1> in this patient was most likely a manifestation of <e2>vincristine</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5240	"Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of <e1>vincristine</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5241	"A case of <e1>timolol</e1>-associated <e2>heart failure</e2> in a 73-year old white man is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5242	"<e1>Bradycardia</e1> and congestive heart failure associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5243	"Bradycardia and <e1>congestive heart failure</e1> associated with ocular <e2>timolol maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5244	"On the second day of hospitalization, it was noted that the patient's <e1>dyspnea</e1> and sinus bradycardia could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5245	"On the second day of hospitalization, it was noted that the patient's dyspnea and <e1>sinus bradycardia</e1> could be related to a recent increase in his <e2>timolol</e2> dosage."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5246	"<e1>Fatal ventricular fibrillation</e1> after treatment with <e2>digoxin</e2> in a 27-year-old man with mitral leaflet prolapse syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5247	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and <e2>functional impairment</e2>; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5248	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated <e2>left ventricular dilatation</e2> and functional impairment; he died of ventricular fibrillation 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5249	"He was started on <e1>digoxin</e1>, 0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of <e2>ventricular fibrillation</e2> 15 days later."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5250	"Induction of <e1>rapid mood cycling</e1> during <e2>L-dopa</e2> treatment in a bipolar patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5251	"The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which <e1>L-dopa</e1> <e2>shortened the manic-depressive cycle</e2> length when administered in a double-blind trial."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5252	"<e1>Liver disease</e1> induced by <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5253	"This paper reports a case of fatal <e2>perhexiline maleate</e2> liver injury."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5254	"<e1>Acute non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5255	"<e1>Acute non-lymphocytic leukemia</e1> in patients with ovarian carcinoma following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5256	"<e1>Acute non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with Treosulfan (= <e2>dihydroxybusulfan</e2>) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5257	"<e1>Acute non-lymphocytic leukemia</e1> occurred in eight women following long-term treatment with <e2>Treosulfan</e2> (= dihydroxybusulfan) for ovarian carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5258	"Seven of the eight cases of <e1>acute leukemia</e1> occurred in a series of 553 patients treated with <e2>Treosulfan</e2> for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5259	"The probability of developing <e1>acute leukemia</e1> in this study was not significantly correlated to the total cumulative dosage of <e2>Treosulfan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5260	"<e1>Propranolol</e1>-related <e2>bronchospasm</e2> in patients without history of asthma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5261	"Regardless of a negative history of asthma, therefore, life-threatening <e1>bronchospasm</e1> must be considered a possible complication of <e2>propranolol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5262	"Since the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5263	"Since the <e1>bronchospasm</e1> was relieved with discontinuation of <e2>propranolol</e2> and supportive bronchodilator therapy, the <e1>bronchospasm</e1> was believed to be caused by <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5264	"Three patients with no history of asthma or allergy developed <e1>bronchospasm</e1> while taking <e2>propranolol</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5265	"<e1>Propranolol</e1>: an unrecognized cause of <e2>central nervous system dysfunction</e2> in patients undergoing cardiopulmonary bypass."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5266	"The potential role of <e1>propranolol</e1> in inducing <e2>central nervous system disturbances</e2> is emphasized, and the literature on the subject is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5267	"<e1>Interstitial fibrosis of the lung</e1> is a potential complication of <e2>methotrexate</e2> therapy for psoriasis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5268	"<e1>Progressive interstitial fibrosis</e1> with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of <e2>methotrexate</e2> for 18 years."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5269	"<e1>Progressive interstitial lung disease</e1> from prolonged <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5270	"<e1>Abnormalities of the pupil</e1> and visual-evoked potential in <e2>quinine</e2> amblyopia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5271	"Abnormalities of the pupil and visual-evoked potential in <e1>quinine</e1> <e2>amblyopia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5272	"A transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5273	"A transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5274	"A <e1>transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials in <e2>quinine</e2> toxicity, to our knowledge, have not been previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5275	"Total blindness with a transient tonic pupillary response, denervation supersensitivity, and <e1>abnormal visual-evoked potentials</e1> developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5276	"Total blindness with a transient tonic pupillary response, <e1>denervation supersensitivity</e1>, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5277	"<e1>Total blindness with a transient tonic pupillary response</e1>, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e2>quinine sulfate</e2> for leg cramps."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5278	"Diagnosis: <e1>practolol</e1> induced <e2>sclerosing peritonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5279	"A case of <e1>skeletal fluorosis</e1> induced by prolonged treatment with <e2>niflumic acid</e2>, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5280	"After ruling out a hydrotelluric source of fluorine, the patient's <e1>fluorosis</e1> was linked to chronic use of <e2>niflumic acid</e2>, following the publication in 1978 of the 2 previously reported cases affected by this drug."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5281	"<e1>Niflumic acid</e1>-induced <e2>skeletal fluorosis</e2>: iatrogenic disease or therapeutic perspective for osteoporosis?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5282	"The fluorine contained in <e1>niflumic acid</e1> induced a marked <e2>densification of trabecular bone</e2> in all 3 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5283	"<e1>Hepatotoxicity</e1> associated with use of <e2>D-penicillamine</e2> in rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5284	"These cases and a review of the literature suggested that <e1>hepatotoxicity</e1>, though rare, should be added to the list of adverse reactions to <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5285	"Two patients with rheumatoid arthritis developed evidence of <e1>hepatotoxicity</e1> while receiving <e2>D-penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5286	"A 62-year-old Indian with diabetic nephropathy controlled with <e1>metformin</e1>, developed <e2>miliary tuberculosis</e2> for which he was treated with rifampicin, isoniazid and ethambutol."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5287	"<e1>Para-aminosalicylic acid</e1>-induced <e2>hypoglycaemia</e2> in a patient with diabetic nephropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5288	"The induction of <e1>hypoglycaemia</e1> with <e2>PAS</e2> in this patient suggests a potential role for <e2>PAS</e2> in the treatment of diabetes mellitus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5289	"The introduction of <e1>para-aminosalicylic acid</e1> (PAS) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5290	"The introduction of para-aminosalicylic acid (<e1>PAS</e1>) led to <e2>hypoglycaemic coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5291	"A patient developed papilloedema and <e1>hepatic dysfunction</e1> while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5292	"A patient developed <e1>papilloedema</e1> and hepatic dysfunction while being treated with <e2>perhexiline maleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5293	"Papilloedema and <e1>hepatic dysfunction</e1> apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5294	"Papilloedema and <e1>hepatic dysfunction</e1> apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5295	"<e1>Papilloedema</e1> and hepatic dysfunction apparently induced by <e2>perhexiline maleate</e2> (Pexid)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5296	"<e1>Papilloedema</e1> and hepatic dysfunction apparently induced by perhexiline maleate (<e2>Pexid</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5297	"Markedly <e1>increased pigmementation of skin</e1> immediately overlying veins used for multiple <e2>5-fluorouracil</e2> infusions was noted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5298	"Unusual <e1>pigmentary changes</e1> associated with <e2>5-fluorouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5299	"Although useful in the management of chronic alcoholism, <e1>disulfiram</e1> is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include <e2>catatonia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5300	"<e1>Disulfiram</e1> encephalopathy as a cause of the <e2>catatonia syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5301	"<e1>Disulfiram</e1> <e2>encephalopathy</e2> as a cause of the catatonia syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5302	"The authors describe a case of the <e1>catatonia syndrome</e1> associated with <e2>disulfiram</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5303	"<e1>Inappropriate antidiuretic hormone secretion</e1> after high dose <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5304	"We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of <e1>inappropriate secretion of antidiuretic hormone</e1> after receiving a high dose of <e2>vinblastine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5305	"Four cases of <e1>oesophageal damage</e1> associated with ingestion of the urinary anti-spasmodic agent <e2>emepronium bromide</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5306	"<e1>Oesophageal ulceration</e1> due to <e2>emepronium bromide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5307	"<e1>Cardiorespiratory toxicity</e1> due to <e2>miconazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5308	"None of them had a history of cardiac disease, and with the possible exception of one case of <e1>cardiac arrest</e1>, where the patient received <e2>doxorubicin</e2>, no predisposing factors could be found."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5309	"Seven patients with hematologic malignancies who were treated with <e1>miconazole</e1> for either suspected or proven fungal infections developed eight episodes of major adverse <e2>cardiorespiratory and anaphylactic reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5310	"<e1>Clofibrate</e1>-induced <e2>myopathy</e2> in patients with diabetes insipidus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5311	"However, we have recently had four cases of <e1>clofibrate</e1>-induced <e2>myopathy</e2> in patients with diabetes insipidus due to hypothalamic lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5312	"Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with <e1>clofibrate</e1>, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of <e2>myopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5313	"<e1>Hepatotoxicity</e1> of <e2>hycanthone</e2> in patients with metastatic breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5314	"In a phase II study of <e1>hycanthone</e1> in patients with breast cancer we have recently observed <e2>severe hepatotoxicity</e2>, even at lower doses, which resulted in two drug-related deaths."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5315	"<e1>Fatal interstitial pneumonitis</e1> following high-dose intermittent <e2>chlorambucil</e2> therapy for chronic lymphocyte leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5316	"Following several of these courses of therapy, <e1>respiratory distress</e1> occurred 9 to 12 days after the <e2>chlorambucil</e2> was given."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5317	"A case of <e1>barbiturate</e1>-induced <e2>submassive hepatic necrosis</e2> is presented and the literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5318	"<e1>Barbiturate</e1>-induced <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5319	"The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that <e1>barbiturates</e1> can be added to the list of agents which can cause <e2>submassive hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5320	"A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited <e1>granulocytopenia</e1> 8 days following the administration of oral sustained-release <e2>procainamide</e2> (750 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5321	"Sustained-release <e1>procainamide</e1>-induced <e2>reversible granulocytopenia</e2> after myocardial infarction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5322	"The frequency and relationship of <e1>granulocytopenia</e1> caused by sustained-release <e2>procainamide</e2> in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5323	"<e1>Monoclonal gammopathy</e1> and subsequent multiple myeloma in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5324	"Monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in a patient on chronic <e2>diphenylhydantoin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5325	"The development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5326	"The development of an <e1>IgG lambda-type monoclonal gammopathy</e1> and subsequent multiple myeloma in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5327	"The development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on diphenylhydantoin (<e2>DILANTIN</e2>) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5328	"The development of an IgG lambda-type monoclonal gammopathy and subsequent <e1>multiple myeloma</e1> in an epilepsy patient on <e2>diphenylhydantoin</e2> (DILANTIN) therapy for 20 years is reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5329	"We recommended periodic examination of the serum proteins in patients receiving <e1>diphenylhydantoin</e1> in order to detect development of <e2>monoclonal gammopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5330	"CONCLUSION: <e1>Atovaquone</e1> should be added to the list of agents causing <e2>vortex keratopathy</e2> involving the corneal epithelium."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5331	"PURPOSE: We studied a case of <e1>vortex keratopathy</e1> that was associated with the use of <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5332	"RESULTS: Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5333	"RESULTS: Similar to previous findings of drug-induced <e1>vortex keratopathy</e1>, <e2>atovaquone</e2> <e1>vortex keratopathy</e1> is presumably caused by its lipophilic properties."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5334	"<e1>Vortex keratopathy</e1> associated with <e2>atovaquone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5335	"Used injudiciously, <e1>naloxone</e1> can lead to withdrawal syndrome, return of <e2>severe pain</e2>, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5336	"Used injudiciously, <e1>naloxone</e1> can lead to <e2>withdrawal syndrome</e2>, return of severe pain, and other adverse effects."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5337	"However, there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5338	"However, there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with aplasia cutis congenita (<e2>ACC</e2>) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5339	"However, there remain questions concerning whether these drugs, especially <e1>methimazole</e1> (MMI), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5340	"However, there remain questions concerning whether these drugs, especially methimazole (<e1>MMI</e1>), may be associated with <e2>aplasia cutis congenita</e2> (ACC) and how best to avoid impairment of fetal thyroid function during their use."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5341	"A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an <e1>acute reversible encephalopathy</e1> within 15 days of initiation of <e2>flecainide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5342	"<e1>Acute reversible ataxo-myoclonic encephalopathy</e1> with <e2>flecainide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5343	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5344	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and <e1>bone marrow aplasia</e1> 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5345	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 <e2>methotrexate</e2> (MTX)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5346	"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed <e1>severe skin rash</e1> and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (<e2>MTX</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5347	"<e1>Bone marrow aplasia</e1> and severe skin rash after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5348	"Bone marrow aplasia and <e1>severe skin rash</e1> after a single low dose of <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5349	"Development of an <e1>extensive skin rash</e1> following a single dose of <e2>MTX</e2> may be an early warning sign for life-threatening bone marrow aplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5350	"In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or <e1>acute hypersensitivity reaction</e1> to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5351	"In the absence of mucositis or diarrhea, <e1>severe dermatologic toxicity</e1> following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to <e2>MTX</e2> in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5352	"<e1>Chlormadinone acetate</e1> <e2>withdrawal syndrome</e2> under combined androgen blockade for advanced prostate cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5353	"The second had acute cystitis and was treated by sulphonamide and the third developed <e1>myopia</e1> coincident with <e2>metronidazole</e2> treatment for trichomonas vaginalis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5354	"The second had acute cystitis and was treated by <e1>sulphonamide</e1> and the third developed <e2>myopia</e2> coincident with metronidazole treatment for trichomonas vaginalis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5355	"<e1>Nephrotic syndrome</e1> related to systemic lupus erythematosus after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5356	"Nephrotic syndrome related to <e1>systemic lupus erythematosus</e1> after <e2>griseofulvin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5357	"To our knowledge, this is the first case of <e1>griseofulvin</e1>-exacerbated <e2>lupus</e2> in which nephrotic syndrome has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5358	"To our knowledge, this is the first case of <e1>griseofulvin</e1>-exacerbated lupus in which <e2>nephrotic syndrome</e2> has been observed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5359	"We report a 16-year-old male who developed <e1>nephrotic syndrome</e1> related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5360	"We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of <e1>systemic lupus erythematosus</e1> after treatment with <e2>griseofulvin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5361	"<e1>Neurological side effects</e1> in two patients receiving <e2>gold</e2> injections for rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5362	"The first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5363	"The first patient developed <e1>mild nitritoid symptoms</e1> and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5364	"The first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5365	"The first patient developed mild nitritoid symptoms and <e1>pain</e1> in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5366	"The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after <e2>gold sodium thiomalate</e2> (GSTM) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5367	"The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to <e1>T10-T12 dermatomes</e1>, shortly after gold sodium thiomalate (<e2>GSTM</e2>) injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5368	"The second patient experienced <e1>mild nitritoid symptoms</e1> following several <e2>GSTM</e2> injections prior experiencing a cerebrovascular accident within several hours of her next injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5369	"<e1>Acute sensorineural hearing loss</e1> following intravenous <e2>ketoralac</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5370	"Both PAN and <e1>methotrexate</e1> have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5371	"Both <e1>PAN</e1> and methotrexate have been independently demonstrated to cause <e2>sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5372	"We recommend the cautious use of <e1>ketorolac</e1> in patients with underlying illnesses where NSAID-induced <e2>ototoxicity</e2> could result in adverse otologic consequences."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5373	"We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed <e1>bilateral sensorineural hearing loss</e1> 25 minutes after receiving 30 mg of intravenous <e2>ketoralac</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5374	"<e1>Anaphylactoid reactions</e1> with intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5375	"CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal <e1>cisplatin</e1> and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit <e2>anaphylactoid reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5376	"CONCLUSIONS: We conclude that a high dose combined with a short infusion time increases the risk of <e1>anaphylactoid reactions</e1> with the administration of intraperitoneal <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5377	"DISCUSSION: <e1>Anaphylactoid reactions</e1> have been described previously with <e2>cisplatin</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5378	"During her third cycle, she again received <e1>cisplatin</e1> <e2>100 mg/m2</e2> over 30 minutes and developed palmar pruritus, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5379	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5380	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed <e2>palmar pruritus</e2>, urticaria, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5381	"During her third cycle, she again received <e1>cisplatin</e1> 100 mg/m2 over 30 minutes and developed palmar pruritus, <e2>urticaria</e2>, and edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5382	"OBJECTIVE: To report the occurrence of <e1>anaphylactoid reactions</e1> to intraperitoneal <e2>cisplatin</e2> in 3 patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5383	"We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating <e1>anaphylactoid reactions</e1> with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5384	"<e1>Etoposide</e1>-related <e2>myocardial infarction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5385	"The occurrence of a <e1>myocardial infarction</e1> is reported after chemotherapy containing <e2>etoposide</e2>, in a man with no risk factors for coronary heart disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5386	"A 9-year-old boy developed <e1>acute renal failure</e1> following intravenous <e2>acyclovir</e2> (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5387	"<e1>Acute renal failure</e1> in a child associated with <e2>acyclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5388	"<e1>Anterior ischemic optic neuropathy</e1> secondary to <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5389	"CONCLUSION: <e1>Anterior ischemic optic neuropathy</e1> may complicate treatment with <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5390	"OBJECTIVE: To report the occurrence of <e1>anterior ischemic optic neuropathy</e1> as a complication of treatment with <e2>interferon alfa</e2> and to consider the possible underlying mechanisms for this association."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5391	"PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with <e1>interferon alfa</e1> for malignant neoplasms experienced <e2>sudden bilateral, sequential visual loss</e2> with disc-related field defects and segmental optic disc edema."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5392	"The interval between initiating treatment with <e1>interferon alfa</e1> and onset of <e2>anterior ischemic optic neuropathy</e2> was similar to that of interferon-associated vascular retinopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5393	"The interval between initiating treatment with <e1>interferon</e1> alfa and onset of anterior ischemic optic neuropathy was similar to that of <e1>interferon</e1>-associated <e2>vascular retinopathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5394	"The authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on <e2>amitriptyline</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5395	"The authors describe a case of <e1>neuroleptic malignant syndrome</e1> that occurred in a patient on amitriptyline and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5396	"CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with <e1>increased serum thyroid-stimulating hormone</e1> (TSH) concentrations after switching from 1 <e2>levothyroxine</e2> product to another."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5397	"Evidence is shown in this report that <e1>adenosine</e1> was associated with dangerous worsening of <e2>arrhythmia</e2> in patients with atrial flutter."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5398	"Life-threatening <e1>alterations in heart rate</e1> after the use of <e2>adenosine</e2> in atrial flutter."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5399	"Comparable adverse effects, such as <e1>disorientation</e1> and temporary amnesia, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5400	"Comparable adverse effects, such as disorientation and <e1>temporary amnesia</e1>, have been reported in patients in the analogous agent, <e2>propranolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5401	"OBJECTIVE: To describe a probable case of <e1>transient global amnesia</e1> caused by <e2>propafenone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5402	"Probable <e1>propafenone</e1>-induced <e2>transient global amnesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5403	"A case of <e1>acute subdural haematoma</e1> originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic <e2>aspirin</e2> therapy is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5404	"<e1>Intracranial haemorrhage</e1> from a meningioma in a patient receiving <e2>aspirin</e2> prophylaxis: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5405	"Beneficial effect of low-dose mianserin on <e1>fluvoxamine</e1>-induced <e2>akathisia</e2> in an obsessive-compulsive patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5406	"<e1>Extrapyramidal side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. <e2>fluoxetine</e2> and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5407	"<e1>Extrapyramidal side effects</e1> induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and <e2>sertraline</e2>, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5408	"However, the occurrence and management of <e1>akathisia</e1> induced by <e2>fluvoxamine</e2> have not been described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5409	"In the presented case <e1>fluvoxamine</e1>-induced <e2>akathisia</e2> in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5410	"A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included <e1>bleomycin</e1>, developed life threatening <e2>interstitial pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5411	"Severe <e1>bleomycin</e1> <e2>lung toxicity</e2>: reversal with high dose corticosteroids."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5412	"This report suggests that <e1>bleomycin</e1> <e2>lung toxicity</e2> may be reversible if treated aggressively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5413	"Reversal of <e1>gold</e1>-induced <e2>neutropenia</e2> with granulocyte colony-stimulating factor (G-CSF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5414	"We have successfully overcome <e1>severe neutropenia</e1> in an RA patient treated with <e2>gold</e2> salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5415	"<e1>Arrhythmias</e1> and cardiac arrest have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5416	"Arrhythmias and <e1>cardiac arrest</e1> have been reported during <e2>amphotericin B</e2> administration but no effective technique has been described to prevent them."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5417	"Correction of serum electrolyte imbalance prevents <e1>cardiac arrhythmia</e1> during <e2>amphotericin B</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5418	"I saw two patients with kala-azar resistant to sodium stibogluconate who developed <e1>cardiac arrest</e1> after <e2>amphotericin</e2> infusion (in spite of tolerating a test dose)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5419	"We describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with irritability or <e2>angry outbursts</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5420	"We describe two cases that illustrate the use of <e1>lithium</e1> in the treatment of veterans with PTSD who complained of serious problems with <e2>irritability</e2> or angry outbursts."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5421	"<e1>Graves' hyperthyroidism</e1> following transient thyrotoxicosis during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5422	"Graves' hyperthyroidism following <e1>transient thyrotoxicosis</e1> during <e2>interferon</e2> therapy for chronic hepatitis type C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5423	"This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of <e1>Graves' hyperthyroidism</e1> during <e2>IFN</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5424	"We report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term interferon (<e2>IFN</e2>) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5425	"We report a case of <e1>Graves' hyperthyroidism</e1> induced by long-term <e2>interferon</e2> (IFN) therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5426	"Acute <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5427	"Acute <e1>INH</e1> <e2>neurotoxicity</e2> was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute <e1>INH</e1> <e2>neurotoxicity</e2> was made."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5428	"Acute <e1>isoniazid</e1> <e2>neurotoxicity</e2> in an urban hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5429	"CONCLUSIONS: We have seen an increased incidence of acute <e1>INH</e1> <e2>neurotoxicity</e2> because of the resurgence of TB in New York City."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5430	"In patients with a known access to <e1>INH</e1>, <e2>seizures</e2> should be considered to be caused by <e1>INH</e1> toxicity unless proved otherwise."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5431	"OBJECTIVES: To describe the presentation and treatment of acute isoniazid (<e1>INH</e1>) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5432	"OBJECTIVES: To describe the presentation and treatment of acute <e1>isoniazid</e1> (INH) <e2>neurotoxicity</e2> appearing at an inner-city municipal hospital."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5433	"Parenteral pyridoxine, the specific antidote for <e1>INH</e1>-induced <e2>refractory seizures</e2>, should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5434	"RESULTS: At our institution, no children appeared with acute <e1>INH</e1> <e2>neurotoxicity</e2> in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5435	"<e1>Arterial hypertension</e1> associated with topical ocular use of <e2>phenylephrine</e2> in dogs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5436	"CONCLUSION: <e1>Squamous metaplasia</e1> in these cases appears to be a consequence of <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5437	"OBJECTIVE: To report the finding of <e1>squamous metaplasia within endometrial glands</e1> occurring as a result of <e2>progestin</e2> therapy of hyperplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5438	"RESULTS: Extensive <e1>squamous metaplasia</e1> was found in endometrial glands following <e2>progestin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5439	"<e1>Fever</e1> caused by the use of <e2>furosemide</e2> was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5440	"<e1>Furosemide</e1>-associated <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5441	"The dose-limiting toxicity of <e1>KW-2149</e1> is <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5442	"<e1>Musculoskeletal complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5443	"<e1>Musculoskeletal complaints</e1> were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with <e2>ifosfamide</e2>, a derivative of cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5444	"Recognition of a potential drug-induced <e1>Fanconi syndrome</e1> is important when managing pediatric oncology patients previously treated with <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5445	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5446	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and <e2>cirrhosis</e2> related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5447	"Our cases constitute the most severe cases of <e1>benzarone</e1> <e2>hepatotoxicity</e2> reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5448	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5449	"Our cases constitute the most severe cases of <e1>benzarone</e1> hepatotoxicity reported so far, and comprise the first cases of <e2>(sub)fulminant hepatitis</e2> and cirrhosis related to <e1>benzarone</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5450	"<e1>Severe hepatotoxicity</e1> related to <e2>benzarone</e2>: a report of three cases with two fatalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5451	"We report three cases of <e1>severe hepatotoxicity</e1> related to <e2>benzarone</e2>, a benzofuran derivative."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5452	"We stress the potential of <e1>benzarone</e1> to cause <e2>hepatotoxicity</e2>, which usually resembles severe chronic active hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5453	"We stress the potential of <e1>benzarone</e1> to cause hepatotoxicity, which usually resembles <e2>severe chronic active hepatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5454	"Case study: a modified topical treatment regimen for sodium <e1>warfarin</e1>-induced <e2>necrotizing fasciitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5455	"This case study describes an atypical case of refractory, <e1>sodium warfarin</e1>-induced necrotizing fasciitis and <e2>myonecrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5456	"This case study describes an atypical case of refractory, <e1>sodium warfarin</e1>-induced <e2>necrotizing fasciitis</e2> and myonecrosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5457	"Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including <e1>mefloquine</e1>, should be aware of the risk of <e2>severe hypoglycaemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5458	"Mechanisms and triggering factors of <e1>hypoglycaemia</e1> induced by <e2>mefloquine</e2> and some other anti-malarial quinine analogues are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5459	"<e1>Mefloquine</e1>-associated <e2>hypoglycaemia</e2> in a cachectic AIDS patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5460	"Quinine and its isomer <e1>quinidine</e1> are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5461	"<e1>Quinine</e1> and its isomer quinidine are well-known causes of <e2>iatrogenic hypoglycaemia</e2>, due to excessive insulin secretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5462	"We report a case of <e1>hypoglycaemia</e1> after <e2>mefloquine</e2> therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5463	"Because <e1>sumatriptan</e1> can cause <e2>coronary artery vasospasm</e2>, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of <e1>sumatriptan</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5464	"<e1>Cardiac arrest</e1> following use of <e2>sumatriptan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5465	"I report a 35-year-old woman with occult coronary artery disease who experienced <e1>cardiac arrest</e1> within minutes after receiving a first-time dose of subcutaneous <e2>sumatriptan</e2> for migraine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5466	"<e1>Sotalol</e1>-induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5467	"We present a case of <e1>sotalol</e1>-induced <e2>bradycardia</e2> reversed by glucagon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5468	"<e1>Secretory endometrial adenocarcinoma</e1> in a patient on <e2>tamoxifen</e2> for breast cancer: a report of a case."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5469	"This unusual pattern of <e1>low-grade endometrial carcinoma</e1> adds to the spectrum of uterine neoplasia associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5470	"This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of <e1>uterine neoplasia</e1> associated with <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5471	"We believe that this is the first report of <e1>secretory carcinoma of the endometrium</e1> associated with <e2>tamoxifen</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5472	"Well-differentiated <e1>endometrial adenocarcinoma of the secretory type</e1> (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on <e2>tamoxifen</e2> therapy 5 years after mastectomy for breast carcinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5473	"<e1>Esophageal candidiasis</e1> following <e2>omeprazole</e2> therapy: a report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5474	"<e1>Esophageal candidiasis</e1> was diagnosed at endoscopy in two patients receiving <e2>omeprazole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5475	"<e1>High-grade atrioventricular block</e1> during <e2>dipyridamole</e2> stress testing."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5476	"We present a case in which <e1>dipyridamole</e1> induced <e2>high-grade atrioventricular (AV) block</e2> that responded promptly to intravenous aminophylline but not to atropine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5477	"Aggressive management of <e1>doxorubicin</e1>-induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5478	"Aggressive management of <e1>doxorubicin</e1>-induced <e2>cardiomyopathy</e2> associated with 'low' doses of <e1>doxorubicin</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5479	"There is a dose-effect relationship between <e1>doxorubicin</e1> and the incidence of <e2>symptomatic cardiac failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5480	"Ovarian endometrioid carcinoma and <e1>endometriosis</e1> developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5481	"<e1>Ovarian endometrioid carcinoma</e1> and endometriosis developing in a postmenopausal breast cancer patient during <e2>tamoxifen</e2> therapy: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5482	"The association with prolonged unopposed estrogen-like stimulation with <e1>tamoxifen</e1> as a possible factor in the development of <e2>ovarian endometrioid carcinoma</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5483	"We present the first case of ovarian endometrioid carcinoma and <e1>endometriosis</e1> in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5484	"We present the first case of <e1>ovarian endometrioid carcinoma</e1> and endometriosis in a postmenopausal patient who was treated with <e2>tamoxifen</e2> for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5485	"<e1>Cerebral demyelinating disease</e1> developed in a patient during adjuvant therapy with <e2>levamisole</e2> for malignant melanoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5486	"<e1>Multifocal inflammatory leukoencephalopathy</e1> associated with <e2>levamisole</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5487	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received <e2>5-fluorouracil</e2> and levamisole may have been caused at least partly by levamisole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5488	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5489	"Observations in our patient suggest that the <e1>leukoencephalopathy</e1> that developed in previously reported patients who received 5-fluorouracil and <e2>levamisole</e2> may have been caused at least partly by <e2>levamisole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5490	"A case of <e1>noncardiogenic pulmonary edema</e1> by <e2>ethanolamine oleate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5491	"However, <e1>EO</e1>-induced <e2>noncardiogenic pulmonary edema</e2> has not been reported in human."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5492	"We report a case of <e1>noncardiogenic pulmonary edema</e1> developed after therapeutic trial of <e2>EO</e2> as sclerosing agent for esophageal varix."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5493	"Five patients are described in whom only <e1>gentamicin sulfate</e1> appeared responsible for <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5494	"<e1>Gentamicin</e1>-associated <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5495	"<e1>Renal failure</e1> appeared 8 to 17 days after beginning <e2>gentamicin</e2> therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5496	"A 15-year follow-up of <e1>phenytoin</e1>-induced <e2>unilateral gingival hyperplasia</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5497	"INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with <e1>phenytoin</e1> (PHT) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5498	"INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin (<e1>PHT</e1>) intoxication with <e2>unilateral gingival hyperplasia</e2> (GH)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5499	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and <e2>aminotriazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5500	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing <e2>bromocil</e2>, diuron and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5501	"We report a case of <e1>generalized cutaneous sclerosis</e1> associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, <e2>diuron</e2> and aminotriazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5502	"<e1>Albuterol</e1>-induced hypokalemia and its potential <e2>cardiac toxicity</e2> are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5503	"<e1>Albuterol</e1>-induced <e2>hypokalemia</e2> and its potential cardiac toxicity are discussed briefly."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5504	"<e1>Hypokalemia</e1> after normal doses of neubulized <e2>albuterol</e2> (salbutamol)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5505	"<e1>Hypokalemia</e1> after normal doses of neubulized albuterol (<e2>salbutamol</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5506	"The cases of two asthmatic patients who became <e1>hypokalemic</e1> after inhalation of normal doses of <e2>albuterol</e2> are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5507	"<e1>Propoxyphene</e1>-induced <e2>wide complex dysrhythmia</e2> responsive to sodium bicarbonate therapy has not been previously reported in the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5508	"<e1>Propoxyphene</e1>-induced <e2>wide QRS complex dysrhythmia</e2> responsive to sodium bicarbonate--a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5509	"Case report: <e1>mannitol</e1> <e2>nephrotoxicity syndrome</e2>: role of hemodialysis and postulate of mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5510	"Hemodialysis should be performed for rapid reversal of <e1>mannitol</e1>-induced <e2>ARF</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5511	"High-dose intravenous <e1>mannitol</e1> infusion in various clinical settings may result in <e2>acute renal failure</e2> (ARF)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5512	"High-dose intravenous <e1>mannitol</e1> infusion in various clinical settings may result in acute renal failure (<e2>ARF</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5513	"<e1>Mannitol</e1>-induced <e2>ARF</e2> responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5514	"The literature is also reviewed for <e1>ARF</e1> associated with <e2>mannitol</e2> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e2>mannitol</e2> nephrotoxicity are discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5515	"The literature is also reviewed for ARF associated with <e1>mannitol</e1> infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of <e1>mannitol</e1> <e2>nephrotoxicity</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5516	"This is a report of a case of <e1>anuric ARF</e1> after high-dose <e2>mannitol</e2> infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5517	"Two patients with <e1>extrapyramidal side effects</e1> after the use of <e2>fluphenazine decanoate</e2> were evaluated by means of IBZM-SPECT."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5518	"Flumazenil reversal of <e1>benzodiazepine</e1>-induced <e2>sedation</e2> for a patient with severe pre-ECT anxiety."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5519	"CASE SUMMARY: A 68-year-old woman developed a dry, <e1>irritating cough</e1> within one month of starting <e2>quinapril</e2> therapy for the treatment of essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5520	"<e1>Cough</e1> induced by <e2>quinapril</e2> with resolution after changing to fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5521	"OBJECTIVE: To report a case of chronic, nonproductive <e1>cough</e1> secondary to the angiotensin-converting enzyme (ACE) inhibitor <e2>quinapril</e2>, with complete resolution after switching to another ACE inhibitor, fosinopril."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5522	"The <e1>cough</e1> continued for the duration of therapy with <e2>quinapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5523	"We report a case of <e1>cough</e1> following the administration of <e2>quinapril</e2>, with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5524	"<e1>Fracture of the femoral neck</e1> occurred in one patient during <e2>PSL</e2> therapy, although the relationship between the fracture and <e2>PSL</e2> therapy was uncertain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5525	"<e1>Cefuroxime</e1>-induced <e2>acute renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5526	"In our patient, <e1>DIAN</e1> possibly was related to <e2>cefuroxime</e2>, but the patient did not experience associated allergic symptoms."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5527	"The diagnosis was supported by the temporal course of <e1>renal deterioration</e1> during exposure to <e2>cefuroxime</e2> and improvement on its discontinuation; the pattern repeated with rechallenge."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5528	"This is the first reported case of suspected <e1>DIAN</e1> due to <e2>cefuroxime</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5529	"A case of <e1>basilar invagination</e1> which is thought to have arisen from the patient's intrauterine exposure to <e2>phenytoin</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5530	"<e1>Basilar invagination</e1> and mid-line skeletal abnormalities due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5531	"Basilar invagination and <e1>mid-line skeletal abnormalities</e1> due to in utero exposure to <e2>phenytoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5532	"His symptoms of brain stem compression were alleviated and the role of <e1>phenytoin</e1> in the production of his <e2>craniocervical abnormality</e2> is discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5533	"<e1>Temporary neurologic abnormalities</e1> were observed in one out of 23 patients undergoing chemotherapy with high-dose <e2>methotrexate</e2> (HD-MTX) for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5534	"This patient developed sequential symptoms including alternative hemiparesis, dysarthria and <e1>altered consciousness</e1> 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5535	"This patient developed sequential symptoms including alternative hemiparesis, <e1>dysarthria</e1> and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5536	"This patient developed sequential symptoms including alternative <e1>hemiparesis</e1>, dysarthria and altered consciousness 5 days after the second course of <e2>HD-MTX</e2> (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5537	"<e1>Transient neurological disturbances</e1> induced by the chemotherapy of high-dose <e2>methotrexate</e2> for osteogenic sarcoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5538	"We report a 5-year-old boy with CF who had a <e1>stricture of the hepatic flexure region with associated narrowing</e1> due to submucosal fibrosis of the transverse colon, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5539	"We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to <e1>submucosal fibrosis of the transverse colon</e1>, secondary to <e2>high-lipase pancreatin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5540	"<e1>Acute pancreatitis</e1> associated with <e2>danazol</e2> treatment for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5541	"Additionally, <e1>danazol</e1> produces <e2>hepatocellular damage</e2> in approximately 10% of women."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5542	"<e1>Hypo-oestrogenic and anabolic/androgenic side-effects</e1> of <e2>danazol</e2> are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5543	"The present report describes the first case of <e1>acute pancreatitis</e1> associated with <e2>danazol</e2> treatment of endometriosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5544	"<e1>Acyclovir</e1> <e2>neurotoxicity</e2>: clinical experience and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5545	"<e1>Acyclovir</e1> produces <e2>neurologic symptoms</e2> that resemble extension of viral infection into the central nervous system."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5546	"Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of <e1>acyclovir</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5547	"We discuss our observations in the cases of two patients with <e1>acyclovir</e1> <e2>neurotoxicity</e2> and review the findings of all previous reports in the English language literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5548	"Response of a <e1>promethazine</e1>-induced <e2>coma</e2> to flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5549	"We report the first case of a patient in a <e1>promethazine</e1>-induced <e2>coma</e2> responding to treatment with flumazenil."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5550	"<e1>Amebic abscess of the spleen</e1> complicated by <e2>metronidazole</e2>-induced neurotoxicity: case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5551	"Amebic abscess of the spleen complicated by <e1>metronidazole</e1>-induced <e2>neurotoxicity</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5552	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and <e2>ataxia</e2> and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5553	"We describe a patient with a <e1>liver abscess</e1> due to Entamoeba histolytica, in whom <e2>metronidazole</e2> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5554	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by <e2>reversible deafness</e2>, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5555	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a <e2>splenic abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5556	"We describe a patient with a liver abscess due to Entamoeba histolytica, in whom <e1>metronidazole</e1> therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, <e2>tinnitus</e2>, and ataxia and who relapsed 5 months later with a splenic abscess."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5557	"<e1>Actinomycin D</e1> associated <e2>hepatic veno-occlusive disease</e2>--a report of 2 cases."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5558	"There are now reports of <e1>liver failure</e1> following treatment of childhood cancers with <e2>AMD</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5559	"<e1>Phenylpropanolamine</e1>-induced <e2>psychosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5560	"We report a cae of <e1>paranoid psychosis</e1> following use of a decongestant containing <e2>PPA</e2> and summarize the case report literature of psychiatric adverse effects to <e2>PPA</e2> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5561	"We report a cae of paranoid psychosis following use of a decongestant containing <e1>PPA</e1> and summarize the case report literature of <e2>psychiatric adverse effects</e2> to <e1>PPA</e1> in which doses were known and stated to be within recommended guidelines."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5562	"CONCLUSIONS: Although <e1>budesonide</e1> may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5563	"<e1>Contact dermatitis</e1> due to <e2>budesonide</e2>: report of five cases and review of the Japanese literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5564	"METHODS: Five cases of <e1>contact dermatitis</e1> due to <e2>budesonide</e2>, a nonhalogenated steroid, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5565	"RESULTS: <e1>Budesonide</e1> use can cause <e2>contact dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5566	"Although other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5567	"Although other nitrites induce <e1>methemoglobinemia</e1>, exposure to <e2>methyl nitrite</e2> during phenylpropanolamine production appears to be a new cause of occupational <e1>methemoglobinemia</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5568	"<e1>Methemoglobinemia</e1>: an occupational hazard of <e2>phenylpropanolamine</e2> production."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5569	"During and after <e1>IFN</e1> therapy we should consider the possibility of occurrence of <e2>IDDM</e2> as well as other autoimmune diseases and observe the clinical course carefully."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5570	"Four years after the beginning of <e1>IFN</e1> therapy, he acutely developed <e2>moderate hyperglycemia</e2> and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5571	"Four years after the beginning of <e1>IFN</e1> therapy, he acutely developed moderate hyperglycemia and <e2>severe ketonuria</e2> with positive islet cell antibody, and then 28 units/day of insulin injection was started."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5572	"Occurrence of <e1>IDDM</e1> during <e2>interferon</e2> therapy for chronic viral hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5573	"We report a case of <e1>IDDM</e1> which occurred during <e2>interferon</e2> therapy for chronic hepatitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5574	"Four patients who manifested symptoms of the antiepileptic drug (AED) <e1>hypersensitivity syndrome</e1> during therapy with <e2>carbamazepine</e2> are reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5575	"<e1>Recurrent hypotension</e1> immediately after seizures in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5576	"Recurrent hypotension immediately after <e1>seizures</e1> in <e2>nortriptyline</e2> overdose."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5577	"The use of <e1>methotrexate</e1> (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5578	"The use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5579	"The use of methotrexate (<e1>MTX</e1>) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which <e1>MTX</e1> appeared to potentiate opportunistic infections and <e2>accelerate HIV disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5580	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and <e2>5-FU</e2> to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5581	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of <e2>levamisole</e2> and 5-FU to a previous regimen of warfarin alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5582	"CONCLUSIONS: This case describes the clinically significant <e1>increase of INR</e1> in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of <e2>warfarin</e2> alone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5583	"However, prolongation of <e1>5-FU</e1> half-life and an <e2>increase in INR</e2> have been reported with the concurrent use of <e1>5-FU</e1> and warfarin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5584	"However, prolongation of 5-FU half-life and an <e1>increase in INR</e1> have been reported with the concurrent use of 5-FU and <e2>warfarin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5585	"<e1>Cholestatic liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5586	"<e1>Cholestatic liver disease</e1> with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5587	"Cholestatic liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5588	"Cholestatic liver disease with <e1>ductopenia</e1> (vanishing bile duct syndrome) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5589	"Cholestatic liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of <e2>clindamycin</e2> and trimethoprim-sulfamethoxazole."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5590	"Cholestatic liver disease with ductopenia (<e1>vanishing bile duct syndrome</e1>) after administration of clindamycin and <e2>trimethoprim-sulfamethoxazole</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5591	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, <e2>bile duct injury</e2> and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5592	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and <e2>bile duct paucity</e2> (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5593	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (<e2>ductopenia</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5594	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of <e2>marked cholestasis</e2>, portal inflammation, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5595	"One patient who received <e1>clindamycin</e1> had liver biopsy findings of marked cholestasis, <e2>portal inflammation</e2>, bile duct injury and bile duct paucity (ductopenia)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5596	"The second patient, who developed <e1>cholestasis</e1> after receiving <e2>trimethoprim-sulfamethoxazole</e2>, had marked duct paucity in the liver biopsy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5597	"The second patient, who developed cholestasis after receiving <e1>trimethoprim-sulfamethoxazole</e1>, had marked <e2>duct paucity</e2> in the liver biopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5598	"This is the first description, to our knowledge, of <e1>ductopenia</e1> apparently caused by <e2>clindamycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5599	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with <e2>cholestasis</e2> and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5600	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of <e2>cholestatic hepatitis</e2> with cholestasis and duct paucity on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5601	"Three years later, treatment with <e1>ampicillin</e1> caused another episode of cholestatic hepatitis with cholestasis and <e2>duct paucity</e2> on rebiopsy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5602	"METHODS: A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with <e2>ethambutol</e2> and isoniazid for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5603	"METHODS: A patient who developed dramatic, permanent <e1>vision loss</e1> after a 9-month course of treatment with ethambutol and <e2>isoniazid</e2> for pulmonary tuberculosis is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5604	"RESULTS: <e1>Ethambutol</e1>, and to a lesser extent isoniazid, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5605	"RESULTS: Ethambutol, and to a lesser extent <e1>isoniazid</e1>, are both implicated in the <e2>development of visually related side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5606	"There is documentation of <e1>ocular toxicity</e1> with <e2>ethambutol</e2> when administered at dosages generally pronounced as being safe."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5607	"<e1>Toxic optic neuropathy</e1> associated with <e2>ethambutol</e2>: implications for current therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5608	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for <e2>fetal damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5609	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially teratogenic and <e2>fetotoxic</e2> agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5610	"Currently the use of <e1>zidovudine</e1> is one of the few specific measures available, and as a potentially <e2>teratogenic</e2> and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5611	"In a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of <e2>fetal abnormality</e2> occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5612	"In a series of 104 cases of intentional or inadvertent use of <e1>zidovudine</e1> at differing gestations in pregnancy, there were eight spontaneous <e2>first trimester abortions</e2>, eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5613	"<e1>Zidovudine</e1> use in pregnancy: a report on 104 cases and the occurrence of <e2>birth defects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5614	"<e1>Celiprolol</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5615	"Inadvertent subsequent rechallenge with <e1>celiprolol</e1> led to recurrence of the <e2>pneumonitis</e2>, 10 weeks after drug readministration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5616	"We report on a patient who developed <e1>hypersensitivity pneumonitis</e1> during treatment with the beta-blocker, <e2>celiprolol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5617	"<e1>Ibopamine</e1>-induced reversible <e2>leukopenia</e2> during treatment for congestive heart failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5618	"<e1>Reversible leukopenia</e1> was documented in an 81-year-old woman treated with adjunctive <e2>ibopamine</e2> 100 mg t.i.d. for chronic congestive heart failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5619	"<e1>Diphenylhydantoin</e1> apparently adversely affected both the clinical and biochemical parameters of the <e2>acute intermittent porphyria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5620	"Significant clinical improvement of the <e1>porphyria</e1> followed withdrawal of the <e2>diphenylhydantoin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5621	"A 53-year-old male, without any prior history of psychosis, developed <e1>schizophrenia</e1> 4 days after starting low-dose <e2>bromocriptine</e2> therapy for a macroprolactinoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5622	"<e1>Bromocriptine</e1>-induced <e2>schizophrenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5623	"<e1>Concurrent acute megaloblastic anaemia</e1> and pneumonitis: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5624	"Concurrent acute megaloblastic anaemia and <e1>pneumonitis</e1>: a severe side-effect of low-dose <e2>methotrexate</e2> therapy during rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5625	"In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an <e2>acute megaloblastic anaemia</e2> and a pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5626	"In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose <e1>methotrexate</e1>: an acute megaloblastic anaemia and a <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5627	"An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (<e1>Levemepromazine</e1>) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5628	"An 11-year-old boy who was treated with a relatively high dose of <e1>methotrimeprazine meleate</e1> (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from <e2>respiratory distress syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5629	"The association of <e1>phenothiazine</e1> overdose and <e2>respiratory distress syndrome</e2> merits consideration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5630	"In two patients, <e1>apomorphine</e1> remained effective in the morning, but increased the intensity of the <e2>dyskinesias</e2> in the afternoon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5631	"We report on three observations of parkinsonian patients with <e1>levo-dopa</e1>-induced <e2>diphasic dyskinesias</e2>, who received subcutaneous apomorphine to reduce the duration of abnormal movements."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5632	"<e1>Fulminant hepatitis</e1> with severe lactate acidosis in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5633	"Fulminant hepatitis with <e1>severe lactate acidosis</e1> in HIV-infected patients on <e2>didanosine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5634	"This prompted us to suspect that <e1>ddI</e1> might be responsible for <e2>fulminant hepatitis</e2> in all three AIDS patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5635	"We report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with didanosine (<e2>ddI</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5636	"We report two cases of <e1>fulminant hepatic failure</e1> in HIV-1-infected patients treated with <e2>didanosine</e2> (ddI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5637	"<e1>Generalized argyria</e1> after habitual use of <e2>AgNO3</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5638	"A case of <e1>fluoxetine</e1> induced <e2>seizures</e2>, in a person with Down syndrome, is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5639	"<e1>Seizures</e1> associated with <e2>fluoxetine</e2> therapy are uncommon."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5640	"<e1>Seizures</e1> associated with <e2>fluoxetine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5641	"Although <e1>fluoxetine</e1>-induced <e2>headache</e2> occurred in one patient, the other five reported no side effects at the doses used."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5642	"Sodium valproate and <e1>carbamazepine</e1>, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5643	"<e1>Sodium valproate</e1> and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce <e2>psoriasiform eruptions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5644	"We present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents sodium valproate and <e2>carbamazepine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5645	"We present findings from three patients who experienced a <e1>psoriasiform eruption</e1> apparently due to the antiepileptic agents <e2>sodium valproate</e2> and carbamazepine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5646	"<e1>Severe diffuse interstitial pneumonitis</e1> induced by carmustine (<e2>BCNU</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5647	"<e1>Severe diffuse interstitial pneumonitis</e1> induced by <e2>carmustine</e2> (BCNU)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5648	"We report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with carmustine (<e2>BCNU</e2>) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5649	"We report a <e1>fatal case of acute interstitial pneumonitis</e1> in a patient treated with <e2>carmustine</e2> (BCNU) for a brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5650	"A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent <e1>shocks</e1> during oral <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5651	"<e1>Electrical proarrhythmia</e1> with <e2>procainamide</e2>: a new ICD-drug interaction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5652	"The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported <e1>electrophysiologic effect</e1> of, or idiosyncratic response to, <e2>procainamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5653	"Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on <e1>valproic acid</e1> therapy who present with <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5654	"<e1>Hyperammonemia</e1> has been described as a complication of <e2>valproic acid</e2> therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5655	"Hyperammonemia has been described as a complication of <e1>valproic acid</e1> therapy but may often be overlooked as a cause of <e2>lethargy</e2> in the postictal patient who presents to the emergency department."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5656	"<e1>Hyperammonemia</e1> secondary to <e2>valproic acid</e2> as a cause of lethargy in a postictal patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5657	"Hyperammonemia secondary to <e1>valproic acid</e1> as a cause of <e2>lethargy</e2> in a postictal patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5658	"We present the case of a postictal patient with lethargy, <e1>hyperammonemia</e1>, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5659	"We present the case of a postictal patient with <e1>lethargy</e1>, hyperammonemia, otherwise normal liver function tests, and a therapeutic <e2>valproic acid</e2> level."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5660	"<e1>Central nervous system toxicity</e1> associated with <e2>meperidine</e2> use in hepatic disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5661	"In patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to <e2>accumulation of the parent drug</e2> and possible CNS depressive effects similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5662	"In patients with cirrhosis, the metabolism of <e1>meperidine</e1> is decreased, leading to accumulation of the parent drug and possible <e2>CNS depressive effects</e2> similar to hepatic encephalopathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5663	"<e1>Meperidine</e1>-associated central nervous system (CNS) excitatory toxicities are believed to be caused by <e2>accumulation of the active metabolite normeperidine</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5664	"<e1>Meperidine</e1>-associated <e2>central nervous system (CNS) excitatory toxicities</e2> are believed to be caused by accumulation of the active metabolite normeperidine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5665	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed <e2>hypertension</e2>, status epilepticus, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5666	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, <e2>intracerebral hemorrhage</e2>, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5667	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5668	"She received an accidental 450-mg bolus injection of <e1>morphine</e1> intrathecally and developed hypertension, <e2>status epilepticus</e2>, intracerebral hemorrhage, and respiratory failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5669	"<e1>Mitomycin C</e1> (MMC) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5670	"Mitomycin C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the <e2>hemolytic-uremic syndrome</e2> (HUS)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5671	"<e1>Mitomycin C</e1> (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5672	"Mitomycin C (<e1>MMC</e1>) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (<e2>HUS</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5673	"Pulmonary hemorrhage as a clinical manifestation of <e1>hemolytic-uremic syndrome</e1> associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5674	"<e1>Pulmonary hemorrhage</e1> as a clinical manifestation of hemolytic-uremic syndrome associated with <e2>mitomycin C</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5675	"Pulmonary hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5676	"Pulmonary hemorrhage is an uncommon feature in the <e1>HUS</e1>, and seems to appear especially in the <e1>HUS</e1> associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5677	"<e1>Pulmonary hemorrhage</e1> is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with <e2>MMC</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5678	"We describe two women who developed <e1>HUS</e1> after <e2>MMC</e2> therapy and presented massive pulmonary bleeding."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5679	"We describe two women who developed HUS after <e1>MMC</e1> therapy and presented <e2>massive pulmonary bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5680	"<e1>Clonidine</e1>-induced <e2>bradycardia</e2> in patients with spinal cord injury."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5681	"Possible mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5682	"Possible mechanisms by which <e1>clonidine</e1> decreases spasticity are described, probable mechanisms of induced <e2>bradycardia</e2> are reviewed, and specific treatment recommendations for the use of <e1>clonidine</e1> in spinal cord injured patients are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5683	"Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e1>clonidine</e1>-induced <e2>bradycardia</e2> is less well recognized and is rare."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5684	"Though hypotension, dry mouth, and <e1>constipation</e1> are well-documented possible adverse effects, the possibility of <e2>clonidine</e2>-induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5685	"Though hypotension, <e1>dry mouth</e1>, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2>-induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5686	"Though <e1>hypotension</e1>, dry mouth, and constipation are well-documented possible adverse effects, the possibility of <e2>clonidine</e2>-induced bradycardia is less well recognized and is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5687	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the <e2>elevation of serum creatinine and blood urea</e2>, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5688	"A high dose of <e1>cotrimoxazole</e1> induced <e2>hyperkalaemia</e2> with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5689	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and <e2>increased urinary N-acetyl glucosaminase</e2> after several days of the drug administration in these patients; one patient became unconscious."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5690	"A high dose of <e1>cotrimoxazole</e1> induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; <e2>one patient became unconscious</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5691	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5692	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5693	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by oral therapy of sulfamethoxazole-trimethoprim (<e2>co-trimoxazole</e2>) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5694	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by oral therapy of <e2>sulfamethoxazole-trimethoprim</e2> (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5695	"<e1>Hyperkalaemia</e1> with renal tubular dysfunction by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5696	"Hyperkalaemia with <e1>renal tubular dysfunction</e1> by <e2>sulfamethoxazole-trimethoprim</e2> for Pneumocystis carinii pneumonia in patients with lymphoid malignancy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5697	"Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed <e1>subacute combined degeneration of the spinal cord</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5698	"<e1>Neurologic degeneration</e1> associated with <e2>nitrous oxide</e2> anesthesia in patients with vitamin B12 deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5699	"Patients with vitamin B12 deficiency are exceedingly sensitive to <e1>neurologic deterioration</e1> following <e2>nitrous oxide</e2> anesthesia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5700	"BACKGROUND: <e1>Fluoxetine</e1>, a highly specific serotonin reuptake inhibitor, has been reported to cause <e2>sexual dysfunction</e2> in a minority of patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5701	"<e1>Captopril</e1>-induced <e2>bone marrow suppression</e2> in two cardiac patients with trisomy 21."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5702	"<e1>Neutropenia</e1> is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, <e2>captopril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5703	"We report two cases of <e1>neutropenia</e1> following <e2>captopril</e2> use in cardiac patients with trisomy 21."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5704	"Can <e1>magnesium sulfate</e1> therapy impact <e2>lactogenesis</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5705	"No explanation for this delay was found, other than the possibility that <e1>magnesium sulfate</e1> treatment <e2>impeded lactogenesis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5706	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a <e2>flare-up</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5707	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, <e2>severe dyspnea</e2> developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5708	"Four days after the initial injection of 3.6 mg of <e1>goserelin acetate</e1>, severe dyspnea developed due to <e2>worsening pleuritis carcinomatosa</e2>, which was considered as a flare-up."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5709	"<e2>Imidazoline</e2> intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5710	"<e2>Imidazoline</e2> intoxication in children."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5711	"Cerebrovascular complications of <e1>L-asparaginase</e1> therapy in children with leukemia: <e2>aphasia</e2> and other neuropsychological deficits."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5712	"<e1>Cerebrovascular complications</e1> of <e2>L-asparaginase</e2> therapy in children with leukemia: aphasia and other neuropsychological deficits."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5713	"Cerebrovascular complications of <e1>L-asparaginase</e1> therapy in children with leukemia: aphasia and other <e2>neuropsychological deficits</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5714	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for <e2>cerebral thrombosis</e2> or hemorrhage because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5715	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or hemorrhage because of <e2>coagulation protein deficiencies</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5716	"Children with acute lymphoblastic leukemia (ALL), treated with <e1>L-asparaginase</e1> are at risk for cerebral thrombosis or <e2>hemorrhage</e2> because of coagulation protein deficiencies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5717	"<e1>Myoclonus</e1> and seizures disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5718	"Myoclonus and <e1>seizures</e1> disappeared after discontinuation of <e2>L-dopa</e2> and the introduction of valproate sodium (VPA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5719	"<e1>Myoclonus</e1> and seizures in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5720	"Myoclonus and <e1>seizures</e1> in a patient with parkinsonism: induction by <e2>levodopa</e2> and its confirmation on SEPs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5721	"Myoclonus was induced and enhanced by <e1>L-dopa</e1>, developing into <e2>generalized seizures</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5722	"<e1>Myoclonus</e1> was induced and enhanced by <e2>L-dopa</e2>, developing into generalized seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5723	"We described the occurrence of <e1>L-dopa</e1>-induced <e2>myoclonus</e2> and seizures in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5724	"We described the occurrence of <e1>L-dopa</e1>-induced myoclonus and <e2>seizures</e2> in a case of parkinsonism with its SEPs findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5725	"Unintended exposure to <e1>acyclovir</e1> early in pregnancy, which is not uncommon, may cause <e2>excessive maternal and physician anxiety</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5726	"A severe form of <e1>exophthalmos</e1> resulting from <e2>lithium</e2> therapy has not been described in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5727	"<e1>Lithium</e1> therapy was discontinued because of poor compliance to the medication and intolerable <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5728	"Regression of <e1>thyrotoxic ophthalmopathy</e1> following <e2>lithium</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5729	"The case of a bipolar patient who developed thyrotoxicosis with <e1>severe exophthalmos</e1> while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5730	"The case of a bipolar patient who developed <e1>thyrotoxicosis</e1> with severe exophthalmos while on <e2>lithium</e2> therapy is described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5731	"The <e1>exophthalmos</e1> improved dramatically within 72 hours of the withdrawal of <e2>lithium</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5732	"Severe <e1>abdominal pain</e1> in low dosage <e2>clofazimine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5733	"We describe a 41 yr old leprosy patient treated for 10 yrs with <e1>clofazimine</e1> who underwent laparotomy for severe <e2>abdominal pain</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5734	"<e1>Amphotericin B</e1> overdose in pediatric patients with associated <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5735	"CONCLUSIONS: <e1>Amphotericin B</e1> overdose can be <e2>fatal</e2> in children and infants."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5736	"Hydrocortisone may decrease the incidence of mortality associated with <e1>cardiac arrhythmias</e1> in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5737	"Hydrocortisone may decrease the incidence of <e1>mortality</e1> associated with cardiac arrhythmias in children receiving <e2>amphotericin B</e2> overdoses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5738	"INTERVENTIONS AND RESULTS: <e1>Cardiac complications</e1> were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of <e2>amphotericin B</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5739	"OBJECTIVE: To report the first five cases of <e1>amphotericin B</e1> overdose with secondary <e2>cardiac complications</e2> in a pediatric population."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5740	"<e1>Hypertension</e1> develops in most patients after transplantation when immunosuppression is based on <e2>cyclosporine</e2> and prednisone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5741	"<e1>Hypertension</e1> develops in most patients after transplantation when immunosuppression is based on cyclosporine and <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5742	"<e1>Sudden death</e1> in an infant from methemoglobinemia after administration of "<e2>sweet spirits of nitre</e2>"."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5743	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5744	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by <e2>acute methemoglobinemia</e2> and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5745	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5746	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin <e2>died</e2> from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5747	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5748	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of <e2>hypoxemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5749	"The administration of "sweet spirits of nitre" (<e1>4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol</e1>) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5750	"The administration of "<e1>sweet spirits of nitre</e1>" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and <e2>severe anoxic metabolic acidosis</e2> in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5751	"<e1>Hepatotoxic effects</e1> in a child receiving valproate and <e2>carnitine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5752	"<e1>Hepatotoxic effects</e1> in a child receiving <e2>valproate</e2> and carnitine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5753	"L-Carnitine supplementation has been recommended to prevent the <e1>fatal hepatotoxic effects</e1> associated with <e2>valproic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5754	"We report on a child with <e1>fatal</e1> <e2>valproate</e2>-related hepatotoxic effects despite this supplementation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5755	"We report on a child with fatal <e1>valproate</e1>-related <e2>hepatotoxic effects</e2> despite this supplementation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5756	"A case is reported of a 40 year old woman treated with intraventricular <e1>IL-2</e1> for leptomeningeal disease who developed progressive <e2>cognitive dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5757	"Delayed <e1>neurotoxicity</e1> of intraventricular <e2>interleukin-2</e2>: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5758	"The potential for progressive <e1>brain injury</e1> and subsequent disability related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5759	"The potential for progressive brain injury and subsequent <e1>disability</e1> related to intraventricular <e2>IL-2</e2> therapy is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5760	"Albeit rare among Western patients, such <e1>lithium</e1>-associated <e2>thyroid dysfunctions</e2> appeared to be more likely to occur in Hong Kong Chinese."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5761	"Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of <e1>thyrotoxicosis</e1> during maintenance <e2>lithium</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5762	"<e1>Lithium</e1>-associated <e2>transient thyrotoxicosis</e2> in 4 Chinese women with autoimmune thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5763	"They seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the <e1>toxic and immunomodulatory roles</e1> of <e2>lithium</e2> and perhaps genetic and dietary factors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5764	"Although <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially <e2>fatal complication</e2> of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5765	"Although <e1>retinoic acid</e1> is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: "the <e1>retinoic acid</e1> syndrome"."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5766	"CONCLUSIONS: It is probable that <e1>foscarnet</e1> contributed to the <e2>electrolyte disorders</e2> and symptomatology in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5767	"DISCUSSION: <e1>Electrolyte disorders</e1> associated with <e2>foscarnet</e2> are reviewed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5768	"<e1>Foscarnet</e1>-induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5769	"<e1>Foscarnet</e1>-induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5770	"OBJECTIVE: To report a case of possible <e1>foscarnet</e1>-induced severe hypomagnesemia and other <e2>electrolyte disorders</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5771	"OBJECTIVE: To report a case of possible <e1>foscarnet</e1>-induced <e2>severe hypomagnesemia</e2> and other electrolyte disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5772	"The patient experienced muscle twitches, tremulousness, and <e1>anxiety</e1> on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5773	"The patient experienced <e1>muscle twitches</e1>, tremulousness, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5774	"The patient experienced muscle twitches, <e1>tremulousness</e1>, and anxiety on day 17 of <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5775	"<e1>Interference with the cortisol axis</e1> by the microtubule antagonist, <e2>CPH82</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5776	"The results clearly demonstrate that <e1>CPH82</e1> was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical <e2>hypercortisolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5777	"The results clearly demonstrate that <e1>CPH82</e1> was associated with <e2>suppression of the endogeneous production of ACTH and cortisol</e2> with a concomitant paradoxical picture of clinical hypercortisolism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5778	"A variety of <e1>movement disorders</e1> are known to occur in association with <e2>carbamazepine</e2> (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5779	"A variety of <e1>movement disorders</e1> are known to occur in association with carbamazepine (<e2>CBZ</e2>) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other <e1>movement disorders</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5780	"A variety of movement disorders are known to occur in association with <e1>carbamazepine</e1> (CBZ) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5781	"A variety of movement disorders are known to occur in association with carbamazepine (<e1>CBZ</e1>) therapy in adults and children, but development of <e2>tics</e2> has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5782	"<e1>Carbamazepine</e1>-induced <e2>tics</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5783	"In the third child, the <e1>tics</e1> ceased after <e2>CBZ</e2> discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5784	"These cases demonstrate that <e1>CBZ</e1> can induce simple <e2>motor tics</e2> in children."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5785	"We report 3 children with epilepsy who developed <e1>facial motor tics</e1> after initiation of <e2>CBZ</e2> for complex partial seizures."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5786	"<e1>Acyclovir</e1>-induced <e2>neurotoxicity</e2>: concentration-side effect relationship in acyclovir overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5787	"CONCLUSIONS: The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5788	"CONCLUSIONS: The observation that <e1>neurotoxicity</e1> developed with a delay of 24 to 48 hours after <e2>acyclovir</e2> peak serum concentrations could explain the wide range of <e2>acyclovir</e2> levels reported in similar cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5789	"METHODS: Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed <e2>coma</e2> and nonoliguric renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5790	"METHODS: Repeated blood samples were drawn in a patient with severe <e1>acyclovir</e1> overdose who developed coma and <e2>nonoliguric renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5791	"PURPOSE: To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1>-induced neurotoxicity and to summarize the information available in the literature about <e2>central nervous system side effects</e2> due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5792	"PURPOSE: To investigate the concentration-side effect relationship in a patient with severe <e1>acyclovir</e1>-induced <e2>neurotoxicity</e2> and to summarize the information available in the literature about central nervous system side effects due to <e1>acyclovir</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5793	"A 16-year-old white male with acute biphenotypic leukemia developed evidence of the <e1>eosinophilia myalgia syndrome</e1> associated with total parenteral nutritional support with solutions containing <e2>tryptophan</e2>, which were given during his initial induction chemotherapy and also after autologous marrow transplantation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5794	"<e1>Fatal eosinophilia myalgia syndrome</e1> in a marrow transplant patient attributed to total parenteral nutrition with a solution containing <e2>tryptophan</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5795	"Thus, the <e1>eosinophilia myalgia syndrome</e1> can be associated with parenteral <e2>tryptophan</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5796	"A patient with acute esophageal variceal bleeding developed <e1>fatal rhabdomyolysis</e1> during treatment with a continuous intravenous infusion of <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5797	"Idiosyncratic factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1>-associated vasodilation in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to <e2>impaired tissue perfusion</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5798	"Idiosyncratic factors involving <e1>vasopressin</e1> receptor affinity and distribution, <e1>vasopressin</e1>-associated <e2>vasodilation</e2> in some vascular beds, and the effect of <e1>vasopressin</e1> on the renin-angiotensin system may further contribute to impaired tissue perfusion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5799	"<e1>Rhabdomyolysis</e1> associated with the use of intravenous <e2>vasopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5800	"These multiple overlapping factors probably lead to <e1>rhabdomyolysis</e1> in a minority of patients receiving <e2>vasopressin</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5801	"In one case, <e1>disulfiram</e1> was the only potential <e2>teratogen</e2> exposed to the fetus."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5802	"Nonspecific but <e1>significant abnormalities</e1> have been described in the infants of women treated with <e2>disulfiram</e2> in the first trimester of their pregnancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5803	"Although the essential cause of <e1>PV</e1> is unclear, its onset has occasionally been associated with drug therapy, in particular <e2>penicillamine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5804	"<e1>Pemphigus vulgaris</e1> precipitated by <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5805	"The patient described in this paper was a 78-year-old diabetic man who developed <e1>oral lesions of PV</e1> following institution of <e2>glibenclamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5806	"<e1>Piritrexim</e1>-induced <e2>pulmonary toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5807	"The <e1>pulmonary toxicity</e1> is probably induced by <e2>piritrexim</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5808	"We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an <e1>abnormal chest x-ray with diffuse interstitial opacities</e1> while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5809	"We describe a patient with transitional cell carcinoma of the renal pelvis who developed <e1>respiratory dysfunction</e1> and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with <e2>piritrexim</e2>, a methotrexate analog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5810	"A 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by <e2>acceleration of the heart rate</e2> to a potentially dangerous arrhythmia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5811	"A 12 year old patient with atrial flutter is presented, in whom intravenous <e1>adenosine</e1> was followed by acceleration of the heart rate to a potentially dangerous <e2>arrhythmia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5812	"<e1>Acceleration of ventricular response</e1> to atrial flutter after intravenous <e2>adenosine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5813	"<e1>Lymphoma</e1> developing in a patient with rheumatoid arthritis taking <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5814	"The mild immunosuppression that occurs with <e1>methotrexate</e1> therapy probably places patients with rheumatoid arthritis at added risk of developing <e2>lymphoproliferative diseases</e2>, but coincidence cannot be excluded."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5815	"We report one case of <e1>non-Hodgkin lymphoma</e1> in a patient, with a 30-year history of rheumatoid arthritis, taking low dose <e2>methotrexate</e2> weekly over a 10-month period."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5816	"<e1>Hepatotoxicity</e1> of <e2>paracetamol</e2> enhanced by ingestion of alcohol: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5817	"The biochemistry of <e1>paracetamol</e1> hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the <e2>hepatotoxic effects</e2> of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5818	"The biochemistry of <e1>paracetamol</e1> <e2>hepatotoxicity</e2> is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of <e1>paracetamol</e1> is remarked upon."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5819	"Two <e1>fatal</e1> cases of poisoning by <e2>paracetamol</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5820	"We report a case of drug-induced <e1>Kaposi's sarcoma</e1> (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy (<e2>prednisolone</e2> 25 mg/day) for pericardial effusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5821	"<e1>Acute dystonic reaction</e1> with low-dose <e2>pimozide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5822	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5823	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with <e2>pimozide</e2> administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following <e2>pimozide</e2> withdrawal, as well as during subsequent thioridazine administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5824	"This paper reports on a 6.9-year-old autistic male who developed repeated episodes of <e1>acute dystonic reactions</e1> associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent <e2>thioridazine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5825	"Although there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of <e2>atheroembolic acute renal failure</e2> following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5826	"Although there is one case report of <e1>cholesterol crystal embolization</e1> following <e2>t-PA</e2> therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e2>t-PA</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5827	"Although there is one case report of cholesterol crystal embolization following <e1>t-PA</e1> therapy with only <e2>extrarenal manifestations</e2> (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following <e1>t-PA</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5828	"<e1>Cholesterol crystal embolization</e1>-associated renal failure after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5829	"Cholesterol crystal embolization-associated <e1>renal failure</e1> after therapy with recombinant <e2>tissue-type plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5830	"We report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5831	"We report the occurrence of renal failure due to <e1>cholesterol crystal embolization</e1> following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5832	"We report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous <e2>recombinant tissue-type plasminogen activator</e2> (t-PA)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5833	"We report the occurrence of <e1>renal failure</e1> due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (<e2>t-PA</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5834	"Intravenous <e1>haloperidol</e1> is generally well tolerated, but <e2>multiform ventricular tachycardia</e2> has been reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5835	"All developed <e1>mucocutaneous side effects</e1> within 20 weeks of beginning im <e2>gold</e2> therapy, at a time when RA had improved markedly compared to pretreatment status."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5836	"How low can you go? Use of very low dosage of <e1>gold</e1> in patients with <e2>mucocutaneous reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5837	"<e1>Anterior spinal artery syndrome</e1>--a complication of cervical intrathecal <e2>phenol</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5838	"We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of <e1>anterior spinal artery syndrome</e1>, developed following the injection of 0.3 ml of 10% <e2>phenol-glycerine</e2> into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5839	"One patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5840	"One patient required nursing home placement and a <e1>feeding gastrostomy</e1> as a result of the worsening parkinsonism during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5841	"One patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5842	"One patient required nursing home placement and a feeding gastrostomy as a result of the <e1>worsening parkinsonism</e1> during <e2>risperidone</e2> treatment, but was able to return home and have the gastrostomy removed after switching from <e2>risperidone</e2> to clozapine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5843	"Two of the five patients who worsened motorically also developed <e1>encephalopathy</e1> during <e2>risperidone</e2> treatment; the <e1>encephalopathy</e1> resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5844	"Two of the five patients who <e1>worsened motorically</e1> also developed encephalopathy during <e2>risperidone</e2> treatment; the encephalopathy resolved when the patients were switched to clozapine treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5845	"<e1>Azathioprine</e1> can cause severe <e2>myelosuppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5846	"<e1>Azathioprine</e1>-induced <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5847	"The <e1>azathioprine</e1> dose was low (1 mg/kg) and <e2>pancytopenia</e2> occurred after 56 days therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5848	"Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound <e1>myelosuppression</e1> after a short course of <e2>azathioprine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5849	"We describe the first documented case of <e1>azathioprine</e1>-induced severe <e2>myelosuppression</e2> due to thiopurine methyltransferase deficiency in autoimmune liver disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5850	"<e1>Nabumetone</e1>-associated <e2>interstitial nephritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5851	"She had been taking <e1>nabumetone</e1> for 6 months, but had discontinued the agent 2 weeks before admission due to progressive <e2>edema</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5852	"<e1>Acute myeloid leukemia</e1> evolving from essential thrombocythemia in two patients treated with <e2>hydroxyurea</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5853	"In this report, two cases of ET which evolved into <e1>AL</e1> without prior exposure to radiation or alkylating agents, and which were treated with long-term <e2>hydroxyurea</e2> therapy, are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5854	"Prolonged used of <e1>hydroxyurea</e1> in patients with ET may lead to therapy-associated <e2>acute leukemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5855	"However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed <e1>cardiac effects</e1> of antimalarial treatment with <e2>halofantrine</e2>, including one sudden death after the treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5856	"However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with <e1>halofantrine</e1>, including one <e2>sudden death</e2> after the treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5857	"In the present paper, we discuss the first Japanese vivax malaria patient whose <e1>QT interval was prolonged</e1> after treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5858	"<e1>Prolongation of the QT interval</e1> observed in a Japanese patient with vivax malaria following treatment with <e2>halofantrine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5859	"The pharmaceutical company producing <e1>Halfan</e1> has reported 8 <e2>cardiac arrests</e2>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5860	"The pharmaceutical company producing Halfan has reported 8 <e1>cardiac arrests</e1>, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5861	"The pharmaceutical company producing <e1>Halfan</e1> has reported 8 cardiac arrests, leading to 6 <e2>deaths</e2>, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5862	"The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 <e1>deaths</e1>, when a higher dose than recommended was used, there was recent or concomitant treatment with <e2>mefloquine</e2>, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5863	"<e1>Supravenous hyperpigmentation</e1> in association with <e2>CHOP</e2> chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5864	"We report an unusual pattern of <e1>supravenous hyperpigmentation</e1> occurring after <e2>CHOP</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5865	"<e2>Phenytoin</e2> toxicity due to concomitant antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5866	"Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on <e1>phenytoin</e1> and 11.6% of these had <e2>blood levels in the toxic range</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5867	"Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of <e2>phenytoin</e2> toxicity when this drug is given together with antituberculosis therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5868	"The wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5869	"The wide use of <e1>phenytoin</e1> during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to <e1>phenytoin</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5870	"<e1>Nephrogenic diabetes insipidus</e1> and renal tubular acidosis secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5871	"Nephrogenic diabetes insipidus and <e1>renal tubular acidosis</e1> secondary to <e2>foscarnet</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5872	"No cases of renal acidosis, and only one case of <e1>nephrogenic diabetes insipidus</e1>, has been previously reported as a complication of <e2>foscarnet</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5873	"Our patient developed both <e1>nephrogenic diabetes insipidus</e1> and renal tubular acidosis with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5874	"Our patient developed both nephrogenic diabetes insipidus and <e1>renal tubular acidosis</e1> with a temporal pattern that demonstrated a link between <e2>foscarnet</e2> therapy and these abnormalities."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5875	"We present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of thirst and <e2>polyuria</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5876	"We present a patient with human immunodeficiency virus infection under treatment with <e1>foscarnet</e1> for CMV retinitis who complained of <e2>thirst</e2> and polyuria."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5877	"<e1>Choroidal hemorrhage</e1> associated with systemic <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5878	"CONCLUSION: The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of <e2>hemorrhage</e2> and should be considered in the differential diagnosis of hemorrhagic choroidal detachment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5879	"CONCLUSION: The administration of <e1>tissue plasminogen activator</e1> was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of <e2>hemorrhagic choroidal detachment</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5880	"PURPOSE: To determine the cause of <e1>spontaneous choroidal hemorrhage</e1> in a 67-year-old man after a myocardial infarction and administration of <e2>tissue plasminogen activator</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5881	"<e1>Accelerated nodulosis</e1> during <e2>methotrexate</e2> therapy for juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5882	"Although they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5883	"Although they had only a few <e1>nodules</e1> at diagnosis, the <e1>nodules</e1> increased in number and size 3 to 4 months after the start of <e2>methotrexate</e2> therapy in both patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5884	"Physicians treating patients with <e1>methotrexate</e1> for juvenile rheumatoid arthritis must be aware of this <e2>extraarticular side effect</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5885	"The <e1>nodules</e1> regressed after withdrawal of <e2>methotrexate</e2> therapy in one patient and were arrested with the addition of hydroxychloroquine in the other."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5886	"We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom <e1>accelerated nodulosis</e1> developed during <e2>methotrexate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5887	"A <e1>macrophage activation syndrome</e1>, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5888	"A macrophage activation syndrome, possibly related to <e2>methotrexate</e2> toxicity, developed in a boy with systemic juvenile rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5889	"<e1>Jaundice</e1> induced by <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5890	"Only a few reports of overt <e1>jaundice</e1> are associated with <e2>streptokinase</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5891	"Although both patients recovered from the <e1>colitis</e1> after the administration of vancomycin, the first case demonstrated a relapse of the <e1>colitis</e1> after receiving a subsequent course of the same chemotherapy with <e2>cisplatin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5892	"Based on our findings, it is thus concluded that <e1>cisplatin</e1> may cause <e2>C. difficile colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5893	"Both patients were then treated with a carboplatin alternative to <e1>cisplatin</e1> in the following courses, which resulted in neither a relapse of the <e2>colitis</e2> nor a recurrence of the malignancies up to this time."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5894	"<e1>Clostridium difficile colitis</e1> associated with <e2>cisplatin</e2>-based chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5895	"Severe <e1>C. difficile colitis</e1> occurred in 2 patients (6.1%) after receiving <e2>cisplatin</e2>-based combination chemotherapy for ovarian malignancies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5896	"The purpose of this study was to examine the incidence and cause of <e1>Clostridium difficile colitis</e1> occurring after <e2>cisplatin</e2>-based combination chemotherapy in ovarian cancer patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5897	"A patient with <e1>severe cholestatic jaundice</e1> induced by <e2>captopril</e2> is presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5898	"<e1>Captopril</e1>-associated "<e2>pseudocholangitis</e2>'."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5899	"<e1>Captopril</e1> is known to be associated with <e2>dermatologic, hematologic, and pulmonary adverse effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5900	"Patients treated with <e1>captopril</e1> who develop "<e2>atypical cholangitis</e2>" should be suspected of having <e1>captopril</e1>-associated liver damage."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5901	"Patients treated with <e1>captopril</e1> who develop "atypical cholangitis" should be suspected of having <e1>captopril</e1>-associated <e2>liver damage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5902	"Development of <e1>nephrotic syndrome</e1> in a patient with acute myeloblastic leukemia after treatment with <e2>macrophage-colony-stimulating factor</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5903	"It should be emphasized that the recurrence of <e1>nephrotic syndrome</e1> was observed after the following chemotherapy, including <e2>M-CSF</e2>, whereas the bone marrow still remained completely remitted."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5904	"The possibility can be raised that <e1>M-CSF</e1> accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of <e2>nephrotic syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5905	"The possibility can be raised that <e1>M-CSF</e1> accelerated the underlying <e2>renal disease</e2> in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5906	"These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the <e1>M-CSF</e1> treatment and <e2>macrophage-related glomerular injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5907	"We describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including <e2>macrophage-colony-stimulating factor</e2> (M-CSF)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5908	"We describe a patient with acute myeloblastic leukemia (AML) who developed <e1>nephrotic syndrome</e1> after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor (<e2>M-CSF</e2>)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5909	"On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and <e1>betamethasone</e1>, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5910	"On the fifth day of tocolysis with <e1>magnesium sulfate</e1>, nifedipine, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5911	"On the fifth day of tocolysis with magnesium sulfate, <e1>nifedipine</e1>, terbutaline and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5912	"On the fifth day of tocolysis with magnesium sulfate, nifedipine, <e1>terbutaline</e1> and betamethasone, <e2>edema</e2> developed in both labia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5913	"<e1>Milk-alkali syndrome</e1> induced by <e2>1,25(OH)2D</e2> in a patient with hypoparathyroidism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5914	"This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <e1>calcitriol</e1> resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5915	"This article presents a patient with hypoparathyroidism who was treated with <e1>calcium carbonate</e1> and calcitriol resulting in two admissions to the hospital for <e2>milk-alkali syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5916	"After receiving 3 doses of <e1>ifosfamide</e1>/mesna, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5917	"After receiving 3 doses of ifosfamide/<e1>mesna</e1>, she was found to be <e2>unresponsive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5918	"CONCLUSIONS: There was a temporal relationship between the onset of <e1>nonconvulsive status epilepticus</e1> and initiation of <e2>ifosfamide</e2> infusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5919	"DISCUSSION: <e1>Central nervous system (CNS) toxicity</e1> has been described with <e2>ifosfamide</e2>, with most cases reported in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5920	"<e1>Ifosfamide</e1>-induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5921	"OBJECTIVE: To describe a patient with <e1>ifosfamide</e1>-induced <e2>nonconvulsive status epilepticus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5922	"This represents the first report of <e1>nonconvulsive status epilepticus</e1> induced by <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5923	"<e1>Albendazole</e1>-induced <e2>pseudomembranous colitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5924	"Although a few case reports link <e1>metronidazole</e1> with the development of <e2>pseudomembranous colitis</e2>, albendazole has not been associated with the development of this condition."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5925	"While undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with <e2>abdominal pain</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5926	"While undergoing treatment with <e1>albendazole</e1>, he developed worsening diarrhea with abdominal pain and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5927	"While undergoing treatment with <e1>albendazole</e1>, he developed <e2>worsening diarrhea</e2> with abdominal pain and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5928	"<e2>Aluminum</e2> intoxication, along with other factors, was considered to be the cause of TC development."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5929	"<e1>Aluminum</e1> intoxication, along with other factors, was considered to be the cause of <e2>TC</e2> development."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5930	"<e1>Oculomotor disturbances</e1> associated with <e2>5-fluorouracil</e2> chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5931	"The ocular motor disturbances are probably an expression of regional <e1>5-FU</e1> <e2>neurotoxicity</e2> primarily affecting the brain stem."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5932	"The <e1>ocular motor disturbances</e1> are probably an expression of regional <e2>5-FU</e2> neurotoxicity primarily affecting the brain stem."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5933	"Two patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of 5-FU neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5934	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5935	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed <e2>cerebellar dysfunction</e2> typical of <e1>5-FU</e1> neurotoxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5936	"Two patients treated with <e1>5-fluorouracil</e1> (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5937	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5938	"Two patients treated with 5-fluorouracil (<e1>5-FU</e1>) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of <e1>5-FU</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5939	"Assessment of cortisol response was by <e1>insulin</e1>-induced <e2>hypoglycaemia</e2> in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5940	"FINDINGS: Six children with growth retardation noted after treatment with high-dose <e1>fluticasone propionate</e1> were found to have <e2>adrenal suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5941	"FINDINGS: Six children with <e1>growth retardation</e1> noted after treatment with high-dose <e2>fluticasone propionate</e2> were found to have adrenal suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5942	"<e1>Growth and adrenal suppression</e1> in asthmatic children treated with high-dose <e2>fluticasone propionate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5943	"INTERPRETATION: When high doses of <e1>fluticasone propionate</e1> are used, growth may be retarded and <e2>adrenal suppression</e2> may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5944	"INTERPRETATION: When high doses of <e1>fluticasone propionate</e1> are used, <e2>growth may be retarded</e2> and adrenal suppression may occur."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5945	"METHODS: <e1>Growth retardation</e1> was observed in six severely asthmatic children after introduction of high-dose <e2>fluticasone propionate</e2> treatment (dry powder)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5946	"<e1>Metipranolol</e1> associated <e2>granulomatous anterior uveitis</e2>: not so uncommon as thought."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5947	"Two case reports of <e1>bilateral granulomatous anterior uveitis</e1> are described in patients with open angle glaucoma treated with <e2>metripranolol</e2> 0.6% eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5948	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced seizures or <e2>altered mental status</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5949	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with <e2>hyponatremia</e2>, all of whom experienced seizures or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5950	"A review of the literature found 11 children and 2 adults in whom intranasal <e1>desmopressin</e1> was associated with hyponatremia, all of whom experienced <e2>seizures</e2> or altered mental status."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5951	"Intranasal <e1>desmopressin</e1>-induced <e2>hyponatremia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5952	"When vague symptoms develop during <e1>desmopressin</e1> therapy, <e2>hyponatremia</e2> must be considered as part of the differential diagnosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5953	"When <e1>vague symptoms</e1> develop during <e2>desmopressin</e2> therapy, hyponatremia must be considered as part of the differential diagnosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5954	"Within 24 hours of fluid restriction and cessation of <e1>desmopressin</e1>, her symptoms and <e2>hyponatremia</e2> resolved."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5955	"Without other causes for the <e1>hyponatremia</e1>, she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5956	"Without other causes for the hyponatremia, she was diagnosed with the <e1>syndrome of inappropriate antidiuretic hormone</e1>, presumably caused by <e2>desmopressin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5957	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, <e2>clarithromycin</e2> and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5958	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and <e2>ethambutol</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5959	"<e1>Uveitis</e1> during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of <e2>rifabutin</e2>, clarithromycin and ethambutol."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5960	"Does <e1>acyclovir</e1> <e2>increase serum lithium levels</e2>?"
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5961	"Six days after starting <e1>acyclovir</e1> she exhibited signs of <e2>lithium toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5962	"Six days after starting acyclovir she exhibited signs of <e2>lithium</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5963	"This case suggests that <e1>acyclovir</e1> when given intravenously in doses of 10 mg/kg may result in <e2>increased serum lithium</e2> concentrations."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5964	"This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum <e2>lithium</e2> concentrations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5965	"Until additional data are available, if intravenous <e1>acyclovir</e1> is administered concurrently with lithium, we recommend closely monitoring patients for signs of <e2>lithium toxicity</e2> and measuring serum lithium levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5966	"Until additional data are available, if intravenous acyclovir is administered concurrently with <e1>lithium</e1>, we recommend closely monitoring patients for signs of <e1>lithium</e1> toxicity and measuring serum <e1>lithium</e1> levels every second or third day."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5967	"When measured, the <e1>serum lithium level had increased</e1> 4-fold during <e2>acyclovir</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5968	"When measured, the serum <e2>lithium</e2> level had increased 4-fold during acyclovir therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5969	"<e2>Dapsone</e2> syndrome in cutaneous lupus erythematosus."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5970	"Physicians should be aware of the potentially <e1>lethal</e1> side effects of <e2>dapsone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5971	"We describe 2 patients with cutaneous lupus erythematosus who developed severe <e2>dapsone</e2> reaction after low dose therapy, with a fatal outcome in one."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5972	"We describe 2 patients with cutaneous lupus erythematosus who developed severe <e1>dapsone</e1> reaction after low dose therapy, with a <e2>fatal</e2> outcome in one."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5973	"A case is presented which illustrates a probably <e1>fatal interaction</e1> between <e2>minoxidil</e2> and a coagulation disorder."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5974	"Nephrogenic diabetes insipidus (<e1>NDI</e1>) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5975	"<e1>Nephrogenic diabetes insipidus</e1> (NDI) is a well-documented complication of <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5976	"Potential mechanisms regarding the pathophysiology of <e1>lithium</e1>-associated <e2>CDI</e2> are discussed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5977	"The association of central diabetes insipidus (<e1>CDI</e1>) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5978	"The association of <e1>central diabetes insipidus</e1> (CDI) with <e2>lithium</e2> use is rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5979	"This case emphasizes the importance of the evaluation of <e1>lithium</e1>-associated <e2>polyuria</e2> with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5980	"To the best of our knowledge, this is the first case of <e1>lithium</e1>-associated <e2>CDI</e2> and NDI presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5981	"To the best of our knowledge, this is the first case of <e1>lithium</e1>-associated CDI and <e2>NDI</e2> presenting concurrently."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5982	"<e1>Transient central diabetes insipidus</e1> in the setting of underlying chronic nephrogenic diabetes insipidus associated with <e2>lithium</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5983	"We report a patient receiving chronic <e1>lithium</e1> therapy who presented with a transient <e2>CDI</e2> occurring in the setting of underlying chronic NDI."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5984	"CASE: We report a case of a woman with severe <e1>human insulin</e1>-induced <e2>lipoatrophy</e2> who has been treated exclusively with recombinant DNA <e1>human insulin</e1> since the onset of IDDM."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5985	"CASE: We report a case of a woman with severe human insulin-induced <e1>lipoatrophy</e1> who has been treated exclusively with <e2>recombinant DNA human insulin</e2> since the onset of IDDM."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5986	"CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe <e1>human insulin</e1>-induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5987	"<e1>Human insulin</e1>-induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5988	"OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe <e1>human insulin</e1>-induced <e2>lipoatrophy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5989	"Improved awareness of and further investigation into the <e1>neurotoxic effects</e1> of <e2>ofloxacin</e2> may enhance its safe use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5990	"<e1>Seizures</e1> associated with <e2>ofloxacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5991	"The <e1>renal insufficiency</e1> of three patients and the timing of the seizures implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5992	"The renal insufficiency of three patients and the timing of the <e1>seizures</e1> implicate accumulation of <e2>ofloxacin</e2> as a contributing factor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5993	"We describe four patients who had <e1>seizures</e1> while receiving <e2>ofloxacin</e2>; no other causes were evident."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5994	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and <e2>abnormal liver function tests</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5995	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, <e2>erythroderma</e2>, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5996	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including <e2>fever</e2>, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5997	"A patient is described with the characteristic features of <e2>phenytoin</e2> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

5998	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, <e2>pinhead-sized facial pustules</e2> and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

5999	"A patient is described with the characteristic features of <e1>phenytoin</e1> hypersensitivity syndrome (PHS) including fever, erythroderma, <e2>tibial and facial oedema</e2>, pinhead-sized facial pustules and abnormal liver function tests."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6000	"Systemic corticosteroids in the <e2>phenytoin</e2> hypersensitivity syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6001	"A patient is described who developed a poorly differentiated <e1>sarcoma</e1> after <e2>cyclophosphamide</e2> was used to treat his rheumatoid arthritis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6002	"<e1>Sarcoma</e1> complicating therapy with <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6003	"A chronic reaction associated with long-term treatment with <e1>nitrofurantoin</e1> has also been reported and causes irreversible <e2>pulmonary fibrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6004	"<e1>Acute pulmonary reactions</e1> to <e2>nitrofurantoin</e2> are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6005	"Acute pulmonary reactions to <e1>nitrofurantoin</e1> are an uncommon side effect of therapy and can cause minor or life-threatening <e2>pulmonary dysfunction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6006	"Despite the known <e1>pulmonary side effects</e1> of <e2>nitrofurantoin</e2>, there is no report of this toxicity occurring in pregnant patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6007	"<e1>Nitrofurantoin</e1>-induced <e2>pulmonary toxicity</e2> during pregnancy: a report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6008	"We present a case of <e1>respiratory failure</e1> occurring in a woman at 16 weeks' gestation who was being treated with <e2>nitrofurantoin</e2> for a urinary tract infection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6009	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and <e2>agranulocytosis</e2>, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6010	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, <e2>an infectious mononucleosis-like syndrome</e2>, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6011	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, <e2>cholestatic jaundice</e2>, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6012	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, <e2>cutaneous eruptions</e2>, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6013	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of <e2>leukopenia</e2> and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6014	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and <e2>minor neurological and gastrointestinal complaints</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6015	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, <e2>nephrotic syndrome</e2>, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6016	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, <e2>peripheral neuropathy</e2>, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6017	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, <e2>psychosis</e2>, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6018	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, <e2>renal papillary necrosis</e2>, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6019	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, <e2>severe hypoalbuminemia without proteinuria</e2>, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6020	"Less common adverse events to <e1>dapsone</e1> include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, <e2>toxic hepatitis</e2>, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6021	"<e1>Methemoglobinemia</e1> is another common finding among patients receiving <e2>dapsone</e2> therapy, but rarely does it result in prominent symptoms other than transient pallor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6022	"<e1>Acetazolamide</e1>-accelerated anticonvulsant <e2>osteomalacia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6023	"<e1>Acetazolamide</e1> may have accelerated the development of <e2>osteomalacia</e2> by several mechanisms, including increased renal calcium excretion."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6024	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and <e2>acetazolamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6025	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, <e2>phenobarbital</e2>, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6026	"<e1>Severe osteomalacia</e1> was present in two epileptic patients who were under long-term treatment with congeners of <e2>phenytoin</e2>, phenobarbital, and acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6027	"The delayed <e1>encephalopathy</e1> developed 9 and 22 months respectively after the first dose of intrathecal <e2>methotrexate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6028	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6029	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and <e1>hydrocephalus</e1> related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6030	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6031	"We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed <e1>leukoencephalopathy</e1> and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered <e2>methotrexate</e2> and, in the second by intrathecally administered <e2>methotrexate</e2> and cranial irradiation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6032	"A retrospective study was conducted of 40 <e2>loperamide</e2> poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6033	"<e2>Loperamide</e2> poisoning in the dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6034	"a 67-year-old man with bipolar disorder developed a <e1>Creutzfeldt-Jakob like syndrome</e1> during <e2>lithium carbonate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6035	"<e1>Lithium</e1>-induced <e2>Creutzfeldt-Jakob syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6036	"<e1>Lithium</e1> neurotoxicity should be considered in <e2>Creutzfeldt-Jakob disease</e2> differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6037	"<e2>Lithium</e2> neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6038	"Several cases of <e1>lithium</e1>-induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6039	"Several cases of <e1>lithium</e1>-induced <e2>Creutzfeldt-Jakob syndrome</e2> have been reported to date; all of them were elderly patients and a half had "therapeutic" <e1>lithium</e1> serum levels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6040	"A noninvasive method in the differential diagnosis of vecuronium-induced and <e1>magnesium</e1>-induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6041	"A noninvasive method in the differential diagnosis of <e1>vecuronium</e1>-induced and magnesium-induced <e2>protracted neuromuscular block</e2> in a severely preeclamptic patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6042	"The occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6043	"The occurrence of <e1>neuromuscular blockade</e1> and the resulting potentiation of muscle relaxants during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6044	"The occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during <e2>magnesium sulfate</e2> (MgSO4) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6045	"The occurrence of neuromuscular blockade and the resulting <e1>potentiation of muscle relaxants</e1> during magnesium sulfate (<e2>MgSO4</e2>) administration is well known."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6046	"We also describe a new, noninvasive method to assess <e1>magnesium</e1>-induced <e2>neuromuscular block</e2> when curariform muscle relaxant was given simultaneously."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6047	"<e1>Hepatobiliary disorders</e1> associated with orally administered <e2>terbinafine</e2> have rarely been reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6048	"<e1>Terbinafine</e1>-induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6049	"We describe a case of prolonged <e1>terbinafine</e1>-induced <e2>cholestatic liver disease</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6050	"A patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of <e2>cetrimide</e2>-chlorhexidine solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6051	"A patient with a large hydatid cyst of the left lobe of the liver developed <e1>metabolic acidosis</e1> following rather liberal use of cetrimide-<e2>chlorhexidine</e2> solution as a scolicidal agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6052	"<e1>Metabolic acidosis</e1> induced by <e2>cetrimide</e2>-chlorhexidine solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6053	"<e1>Metabolic acidosis</e1> induced by cetrimide-<e2>chlorhexidine</e2> solution in hydatid cyst surgery."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6054	"An unusual case of <e2>Ecstasy</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6055	"We describe a case of <e1>poisoning</e1> with <e2>3,4-methylenedioxymet-amphetamine Ecstasy</e2> that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6056	"However, dermatologists should be cautious about a <e1>photosensitivity</e1> reaction induced by <e2>mequitazine</e2> or other phenothiazine-derivative drugs."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6057	"In addition, an immediate <e1>erythematous macule</e1> was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6058	"In addition, an <e1>immediate erythema</e1>tous macule was observed on the photopatch test site of <e2>mequitazine</e2> directly after UV exposure which was similar to the <e1>immediate erythema</e1> noted in chlorpromazine photoallergy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6059	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6060	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, <e2>cross-reaction to promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6061	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6062	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6063	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6064	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, <e2>decreased MED to both UVA and UVB</e2>, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6065	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6066	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate <e2>erythema</e2> reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6067	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate <e1>erythema</e1> reaction, cross-reaction to <e2>promethazine</e2>, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6068	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6069	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken <e1>mequitazine</e1> for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the <e1>mequitazine</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6070	"In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to <e1>promethazine</e1>, decreased MED to both UVA and UVB, and <e2>persistence of the photosensitivity</e2> over a 3-year follow-up period after discontinuation of the mequitazine."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6071	"Mequitazine seemed to play a part similar to chlorpromazine, and absence of <e1>mequitazine</e1>-induced <e2>photosensitivity</e2> may be due to a relatively low dosage of the drug."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6072	"Two cases of <e1>mequitazine</e1>-induced <e2>photosensitivity reactions</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6073	"We experienced 2 cases of <e1>mequitazine</e1>-induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6074	"We experienced 2 cases of <e1>mequitazine</e1>-induced <e2>photosensitivity reaction</e2> in patients who took <e1>mequitazine</e1> for their dermatologic problems."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6075	"<e1>Keratitis</e1> in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6076	"<e1>Methamphetamine</e1>'s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for <e2>injury to the cornea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6077	"Potential causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6078	"Potential causes of <e1>methamphetamine</e1>-related <e2>keratitis</e2> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6079	"Potential causes of methamphetamine-related <e1>keratitis</e1> can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6080	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as <e2>lidocaine</e2> and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6081	"Potential causes of <e1>methamphetamine</e1>-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of <e1>methamphetamine</e1>; (b) the <e2>toxic effects</e2> of diluting or "cutting" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6082	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the <e1>toxic effects</e1> of diluting or "cutting" agents such as lidocaine and <e2>quinine</e2>; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6083	"The increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of <e1>methamphetamine</e1>-related <e2>keratitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6084	"The increasing prevalence of <e1>methamphetamine</e1> abuse and the severity of the associated <e2>ulcers</e2> should alert ophthalmologists to the problem of <e1>methamphetamine</e1>-related keratitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6085	"We report four cases of <e1>severe corneal ulceration</e1> in <e2>methamphetamine</e2> abusers."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6086	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6087	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to fibrosis or <e2>cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6088	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6089	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce liver damage, which in some psoriatics will lead to <e2>fibrosis</e2> or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6090	"BACKGROUND: <e1>Methotrexate</e1> (MTX) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6091	"BACKGROUND: Methotrexate (<e1>MTX</e1>) may induce <e2>liver damage</e2>, which in some psoriatics will lead to fibrosis or cirrhosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6092	"CONCLUSIONS: This study confirmed that in most patients <e1>MTX</e1>-induced <e2>liver cirrhosis</e2> is not aggressive."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6093	"However, continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and <e2>death</e2> in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6094	"However, continued low-dose <e1>MTX</e1> led, in spite of normal liver tests, 8 years after the last biopsy to <e2>liver failure</e2> and death in 1 of our patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6095	"<e1>Methotrexate</e1>-induced <e2>liver cirrhosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6096	"Studies performed 10 years ago on 25 patients with <e1>MTX</e1>-induced liver <e2>cirrhosis</e2> indicated that this type of <e2>cirrhosis</e2> was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6097	"Studies performed 10 years ago on 25 patients with <e1>MTX</e1>-induced <e2>liver cirrhosis</e2> indicated that this type of cirrhosis was not of an aggressive nature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6098	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6099	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a <e2>high fever</e2> and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6100	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6101	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of <e2>increasing myalgia</e2>, developed a high fever and respiratory and metabolic acidosis and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6102	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6103	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and <e2>lost consciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6104	"After therapy for diabetic coma with insulin (containing the preservative <e1>cresol</e1>) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6105	"After therapy for diabetic coma with <e1>insulin</e1> (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and <e2>respiratory and metabolic acidosis</e2> and lost consciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6106	"However, other factors or drugs (e.g. <e1>cresol</e1>) are thought to induce <e2>MH</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6107	"This case supports the assessment that <e1>MH</e1> and diabetes are associated diseases and that <e2>cresol</e2> could possibly trigger <e1>MH</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6108	"The use of <e1>beclomethasone diproprionate</e1> inhaler complicated by the development of an <e2>eosinophilic pneumonia reaction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6109	"<e1>Fatal intravascular autoimmune hemolytic anemia</e1> after <e2>fludarabine</e2> treatment for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6110	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6111	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6112	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6113	"Physicians should be aware of the risk of severe <e1>AIHA</e1> in CLL patients with a history of <e1>AIHA</e1> or positivation of the DAT during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6114	"Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6115	"Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or <e1>positivation of the DAT</e1> during previous <e2>fludarabine</e2> administration, or in case of secondary fixation of complement to the red cell membrane occurring during <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6116	"The occurrence of severe <e1>AIHA</e1> in CLL patients treated with <e2>fludarabine</e2> has been reported by several authors."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6117	"We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia (<e1>AIHA</e1>) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6118	"We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed <e1>fatal intravascular autoimmune hemolytic anemia</e1> (AIHA) after <e2>fludarabine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6119	"When the patient was treated again with <e1>fludarabine</e1> nine months later, the <e2>DAT became positive with anti-IgG and anti-C3d antiglobulins</e2> after the second course of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6120	"She had just finished a 3-week course of intravenous <e1>tobramycin</e1> for bronchiectasis and had an elevated serum <e1>tobramycin</e1> trough level 1 week before the onset of <e2>tetany</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6121	"<e1>Tetany</e1> in a child with AIDS receiving intravenous <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6122	"This pattern is suggestive of <e1>renal toxicity</e1> due to <e2>tobramycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6123	"CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected <e1>insulin</e1> could explain the <e2>dedifferentiation of the adipocytes</e2> of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6124	"CONCLUSIONS: In our reported case, a local <e1>hyperproduction of TNF-alpha</e1> from macrophages that was induced by the injected <e2>insulin</e2> could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6125	"<e1>Insulin</e1>-induced <e2>lipoatrophy</e2> in type I diabetes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6126	"OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the <e1>insulin</e1>-induced <e2>lipoatrophies</e2> of a diabetic patient who presented extensive lesions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6127	"<e1>Erosion of psoriatic plaques</e1>: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6128	"Erosion of psoriatic plaques: an early sign of <e2>methotrexate</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6129	"<e1>Methotrexate</e1> is an effective but <e2>potentially toxic</e2> treatment for psoriasis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6130	"Painful erosion of psoriatic plaques is a less common sign of <e1>methotrexate</e1> toxicity that may precede evidence of <e2>bone marrow suppression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6131	"Painful erosion of psoriatic plaques is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6132	"<e1>Painful erosion of psoriatic plaques</e1> is a less common sign of <e2>methotrexate</e2> toxicity that may precede evidence of bone marrow suppression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6133	"We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6134	"We describe two patients in whom <e1>painful erosions of their psoriasis</e1> developed as the presenting sign of <e2>methotrexate</e2> toxicity and review the literature, emphasizing the risk factors associated with this manifestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6135	"Well-known signs of <e1>methotrexate</e1> toxicity include <e2>bone marrow suppression</e2> and oral and gastrointestinal ulceration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6136	"Well-known signs of <e2>methotrexate</e2> toxicity include bone marrow suppression and oral and gastrointestinal ulceration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6137	"Well-known signs of <e1>methotrexate</e1> toxicity include bone marrow suppression and <e2>oral and gastrointestinal ulceration</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6138	"After treatment with <e1>cimetidine</e1>, there was a rapid deterioration with <e2>decreased oxygen saturation and arterial PO2</e2> values."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6139	"Caution with use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6140	"Caution with use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal bleeding</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6141	"However, given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6142	"However, given the clinically significant result to the interaction between tolazoline and <e1>cimetidine</e1> we report, the use of <e1>cimetidine</e1> in tolazoline induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6143	"However, given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6144	"However, given the clinically significant result to the interaction between <e1>tolazoline</e1> and cimetidine we report, the use of cimetidine in <e1>tolazoline</e1> induced <e2>upper gastrointestinal hemorrhage</e2> should deserve more attention."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6145	"Hypoxemia improved during continuous <e1>tolazoline</e1> infusion, but <e2>gastrointestinal bleeding</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6146	"Zolpidem (<e1>Ambien</e1>), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6147	"<e1>Zolpidem</e1> (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the <e2>death</e2> of a 39-year-old obese male who was being treated for depression and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6148	"Zolpidem tissue concentrations in a multiple drug related <e1>death</e1> involving <e2>Ambien</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6149	"<e1>Zolpidem</e1> tissue concentrations in a multiple drug related <e2>death</e2> involving Ambien."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6150	"Acute <e2>nitrite</e2> toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic <e2>nitrite</e2>s as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6151	"Infants are particularly susceptible to chronic <e1>nitrate</e1>-induced <e2>methemoglobinemia</e2> because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6152	"Acute <e2>esmolol</e2> toxicity may be self-limiting because of its extremely short half-life."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6153	"After induction of general anesthesia and administration of a standard dose of intravenous <e1>esmolol hydrochloride</e1>, her cardiac rhythm progressed to <e2>asystole</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6154	"<e1>Cardiac arrest</e1> after <e2>esmolol</e2> administration: a review of acute beta-blocker toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6155	"<e1>Atenolol</e1> induced <e2>memory impairment</e2>: a case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6156	"His <e1>impaired memory</e1> was found to be due to the <e2>atenolol</e2> he was on and he made a complete recovery on withdrawing the beta-blocker."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6157	"A potential role for renal and hepatic impairment in the observed protracted course of <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2> is suggested."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6158	"Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted <e1>amiodarone</e1>-induced <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6159	"We report a case of <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2> of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6160	"<e1>Psychotic disorder</e1> associated with <e2>isoniazid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6161	"We evaluated a patient who developed a <e1>psychotic disorder</e1> after 4 months of <e2>isoniazid</e2> prophylaxis for a positive tuberculosis tine test."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6162	"A case report is presented concerning the administration of ketanserin in the treatment of <e1>pulmonary vasoconstriction</e1> and right ventricular failure following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6163	"A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and <e1>right ventricular failure</e1> following the infusion of <e2>protamine</e2> in a patient undergoing coronary artery bypass surgery and mitral valve replacement."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6164	"Ketanserin in the treatment of <e1>protamine</e1>-induced <e2>pulmonary hypertension</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6165	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and <e2>bronchoconstriction</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6166	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by systemic hypotension, <e2>pulmonary hypertension</e2>, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6167	"The reversal of heparin by <e1>protamine</e1> may cause <e2>severe hemodynamic deterioration</e2>, characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6168	"The reversal of heparin by <e1>protamine</e1> may cause severe hemodynamic deterioration, characterized by <e2>systemic hypotension</e2>, pulmonary hypertension, and bronchoconstriction."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6169	"A drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed massive proteinuria and <e2>acute nephritic syndrome</e2> is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6170	"A drug addict with staphylococcal endocarditis treated with <e1>methicillin</e1>, who developed <e2>massive proteinuria</e2> and acute nephritic syndrome is described."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6171	"<e1>Focal glomerulonephritis</e1> and interstitial nephritis in <e2>methicillin</e2>-treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6172	"Focal glomerulonephritis and <e1>interstitial nephritis</e1> in <e2>methicillin</e2>-treated, heroin-related infective endocarditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6173	"METHODS/RESULTS: This paper presents a new case of <e1>rifabutin</e1> <e2>uveitis</e2> and a review of the various published reports to date."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6174	"over the past 3 years there have been several reports of <e1>uveitis</e1> associated with <e2>rifabutin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6175	"<e1>Uveitis</e1> associated with <e2>rifabutin</e2> therapy: a clinical alert."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6176	"CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a <e1>large cerebral infarction</e1> during <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6177	"<e1>Large cerebral infarction</e1> during <e2>praziquantel</e2> therapy in neurocysticercosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6178	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6179	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., <e2>diarrhea</e2>, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6180	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6181	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, <e2>mucositis</e2>, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6182	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6183	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, <e2>myelosuppression</e2>, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6184	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6185	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, <e2>neurotoxicity</e2>) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6186	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6187	"DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for <e1>5-FU</e1> catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, <e2>stomatitis</e2>, mucositis, myelosuppression, neurotoxicity) to standard doses of <e1>5-FU</e1>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6188	"Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing <e1>severe adverse reactions</e1> to <e2>5-fluorouracil</e2>-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6189	"PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following <e2>5-fluorouracil</e2> (5-FU)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6190	"PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially <e1>lethal adverse reactions</e1> following 5-fluorouracil (<e2>5-FU</e2>)-based chemotherapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6191	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6192	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced neurologic symptoms such as encephalopathy and <e2>coma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6193	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6194	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced neurologic symptoms such as <e2>encephalopathy</e2> and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6195	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6196	"The principle treatment for DPD-deficient patients with severe acute <e1>5-FU</e1> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e1>5-FU</e1>-induced <e2>neurologic symptoms</e2> such as encephalopathy and coma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6197	"The principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2>-induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6198	"The principle treatment for DPD-deficient patients with severe acute <e2>5-FU</e2> reactions is supportive care; however, the administration of thymidine potentially may reverse severe <e2>5-FU</e2>-induced neurologic symptoms such as encephalopathy and coma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6199	"A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6200	"A 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6201	"A 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed worsening respiratory distress and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6202	"A 49-year-old man with Crohn's disease treated with prednisone and mesalamine (<e1>5-ASA</e1>) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6203	"A 49-year-old man with Crohn's disease treated with prednisone and <e1>mesalamine</e1> (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6204	"A 49-year-old man with Crohn's disease treated with <e1>prednisone</e1> and mesalamine (5-ASA) developed <e2>worsening respiratory distress</e2> and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6205	"<e1>Mesalamine</e1>-induced <e2>hypersensitivity pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6206	"<e1>Mesalamine</e1> may cause <e2>hypersensitivity pneumonitis</e2> in patients with Crohn's disease."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6207	"Immunosuppression elicited by the extensive administration of <e1>prednisolone</e1> was suspected for the initiation of the generalized <e2>mite infestation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6208	"BACKGROUND: <e1>Colchicine</e1> has a known <e2>adverse effect on wound healing</e2> through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6209	"BACKGROUND: <e1>Colchicine</e1> has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through <e2>collagenase activation</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6210	"CONCLUSION: The findings in these two patients suggest that <e1>colchicine</e1> may <e2>delay corneal wound healing</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6211	"<e1>Delay of corneal wound healing</e1> in patients treated with <e2>colchicine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6212	"The authors report on two patients with <e1>corneal ulcers refractory to conventional treatment</e1> while the patients were undergoing oral <e2>colchicine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6213	"The authors suggest that in patients with <e1>corneal ulcers refractory to conventional treatment</e1> who are receiving <e2>colchicine</e2>, cessation of <e2>colchicine</e2> therapy should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6214	"<e1>Fulminant hepatic failure</e1> associated with <e2>bicalutamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6215	"A 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an <e2>eruption</e2> that progressed to an exfoliative dermatitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6216	"A 17-year-old female patient who had been taking oral <e1>minocycline</e1> (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an <e2>exfoliative dermatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6217	"Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and <e1>dermatitis</e1>: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6218	"Fever, lymphadenopathy, <e1>eosinophilia</e1>, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6219	"<e1>Fever</e1>, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6220	"Fever, lymphadenopathy, eosinophilia, lymphocytosis, <e1>hepatitis</e1>, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6221	"Fever, <e1>lymphadenopathy</e1>, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6222	"Fever, lymphadenopathy, eosinophilia, <e1>lymphocytosis</e1>, hepatitis, and dermatitis: a severe adverse reaction to <e2>minocycline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6223	"This severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing <e2>lymphocyte over-activation</e2> and massive cytokine release."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6224	"This severe illness was likely caused by <e1>minocycline</e1>, and we speculate that <e1>minocycline</e1> may have acted as a superantigen, causing lymphocyte over-activation and <e2>massive cytokine release</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6225	"This <e1>severe illness</e1> was likely caused by <e2>minocycline</e2>, and we speculate that <e2>minocycline</e2> may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6226	"<e1>Delayed hypersensitivity</e1> to <e2>flurbiprofen</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6227	"<e1>Eye movement disorders</e1> in bone marrow transplant patients on <e2>cyclosporin</e2> and ganciclovir."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6228	"<e1>Eye movement disorders</e1> in bone marrow transplant patients on cyclosporin and <e2>ganciclovir</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6229	"One patient had <e1>MRI T2 abnormalities</e1> compatible with <e2>cyclosporin</e2> neurotoxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6230	"One patient had MRI T2 abnormalities compatible with <e1>cyclosporin</e1> <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6231	"We postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6232	"We postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce transient brain stem or neuromuscular dysfunction with <e2>eye movement abnormality</e2> in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6233	"We postulate that <e1>cyclosporin</e1>, possibly together with ganciclovir, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6234	"We postulate that cyclosporin, possibly together with <e1>ganciclovir</e1>, can produce <e2>transient brain stem or neuromuscular dysfunction</e2> with eye movement abnormality in occasional patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6235	"CONCLUSION: While <e1>thrombosis</e1> has been reported with <e2>GnRH-a</e2> therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6236	"The possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with <e2>endometrial carcinoma</e2> and endometriosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6237	"The possible effects of <e1>tamoxifen</e1> upon the uterus are discussed in this article, in view of reports of <e1>tamoxifen</e1> associated with endometrial carcinoma and <e2>endometriosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6238	"Case study: <e1>adverse response</e1> to <e2>clonidine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6239	"Four cases of <e1>adverse experiences</e1> with <e2>clonidine</e2> are described."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6240	"In one instance a systemic hypoglycemic reaction resulting in head trauma and <e1>confusion</e1> ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6241	"In one instance a systemic hypoglycemic reaction resulting in <e1>head trauma</e1> and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6242	"In one instance a <e1>systemic hypoglycemic reaction</e1> resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of <e2>acetohexamide</e2> for acetazolamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6243	"Discontinuation of the <e1>itraconazole</e1> caused resolution of the <e2>drug eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6244	"Primary cutaneous coccidioidomycosis and subsequent <e1>drug eruption</e1> to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6245	"<e1>Primary cutaneous coccidioidomycosis</e1> and subsequent drug eruption to <e2>itraconazole</e2> in a dog."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6246	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a <e1>potentially fatal symptom</e1> complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6247	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6248	"Its overall <e1>toxicity</e1> is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as "<e2>retinoic acid</e2> syndrome." This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6249	"Eleven days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced syncope and was noted to have recurrent episodes of <e2>polymorphous ventricular tachycardia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6250	"Eleven days after initiation of therapy with <e1>amiodarone</e1>, the patient experienced <e2>syncope</e2> and was noted to have recurrent episodes of polymorphous ventricular tachycardia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6251	"<e1>Nonsustained polymorphous ventricular tachycardia</e1> during <e2>amiodarone</e2> therapy for atrial fibrillation complicating cardiomyopathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6252	"The probable <e1>proarrhythmic</e1> action of <e2>amiodarone</e2>, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6253	"<e1>Acute asthma</e1> associated with sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6254	"Although dyspnea associated with <e1>verapamil</e1> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an <e2>acute asthma</e2> attack following sustained-release <e1>verapamil</e1> administration."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6255	"Although <e1>dyspnea</e1> associated with <e2>verapamil</e2> administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release <e2>verapamil</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6256	"CONCLUSIONS: Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6257	"CONCLUSIONS: Sustained-release <e1>verapamil</e1> is thought to be the cause of the <e2>asthma attack</e2> in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release <e1>verapamil</e1> and were relieved after its discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6258	"OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an <e1>acute asthma</e1> attack after receiving sustained-release <e2>verapamil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6259	"She continued taking <e1>verapamil</e1> for 6 months, then, on her own, stopped all medications including the sustained-release <e1>verapamil</e1>, and her <e2>asthma</e2> symptoms disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6260	"<e2>Cephalexin</e2> rash in infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6261	"The <e2>ampicillin</e2> rash occurring in cases of infectious mononucleosis is well documented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6262	"The case of a patient with infectious mononucleosis treated with <e1>cephalexin</e1> who later showed a <e2>rash</e2> is presented and the previous literature is reviewed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6263	"The <e1>rash</e1> seen in this patient, who was treated with <e2>cephalexin</e2>, may be similar to the <e1>rash</e1> seen with ampicillin treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6264	"The <e1>rash</e1> seen in this patient, who was treated with cephalexin, may be similar to the <e1>rash</e1> seen with <e2>ampicillin</e2> treatment of patients with infectious mononucleosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6265	"A possible case of <e1>carbamazepine</e1> induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6266	"The authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with <e2>carbamazepine</e2> (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6267	"The authors report a case of acute <e1>pancreatitis</e1> (AP) occurring in a patient under treatment with carbamazepine (<e2>CBZ</e2>) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6268	"The evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6269	"The evidence of high plasmatic levels of <e1>CBZ</e1> and the absence of other aetiologic factors lead the authors to conclude that the overdose of <e1>CBZ</e1> could have represented the precipitating of the episode of <e2>acute pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6270	"Although risk factors for <e1>MTX</e1>-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6271	"Although risk factors for <e1>MTX</e1>-induced <e2>pulmonary toxicity</e2> are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of <e1>MTX</e1> pneumonitis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6272	"<e1>Methotrexate</e1>-induced <e2>pneumonitis</e2> in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6273	"On the other hand, <e1>MTX</e1>-induced <e2>pneumonitis</e2> seems to be very rare in psoriatic arthritis (PsA)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6274	"Our review of 194 RA patients and 38 PsA patients receiving <e1>MTX</e1> has identified four RA patients and one PsA patient with <e1>MTX</e1>-induced <e2>pneumonitis</e2>, giving a prevalence of 2.1% and 0.03%, respectively."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6275	"<e1>Pneumonitis</e1> is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with <e2>MTX</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6276	"The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in <e1>MTX</e1>-induced <e2>pneumonitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6277	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and <e2>inorganic arsenic</e2>) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6278	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, '<e2>Thorotrast</e2>', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6279	"A retrospective epidemiological study of deaths from <e1>hepatic angiosarcoma</e1> (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (<e2>vinyl chloride</e2>, 'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6280	"Recent studies have shown that under experimental conditions <e1>ferrous sulfate</e1> may <e2>reduce the gastrointestinal absorption of orally administered levothyroxine sodium</e2> in patients with primary hypothyroidism."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6281	"We describe a patient who became <e1>hypothyroid</e1> while taking <e2>ferrous sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6282	"However, as the use of <e1>hepatitis B vaccination</e1> is growing, adverse side effects, including <e2>mental nerve neuropathy</e2>, should be observed with an increased frequency."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6283	"<e1>Mental nerve neuropathy</e1> as a result of <e2>hepatitis B vaccination</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6284	"Although its side effects are few, <e1>tamoxifen</e1> increases the incidence of <e2>proliferative lesions of the endometrium</e2>, which theoretically should be preventable with progestational agents."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6285	"CASES: Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed uterine enlargement and <e2>intermittent spotting</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6286	"CASES: Two postmenopausal women treated with <e1>tamoxifen</e1> and progestational agents for breast carcinoma developed <e2>uterine enlargement</e2> and intermittent spotting."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6287	"CONCLUSIONS: The value of multihormonal therapy in breast <e1>carcinoma</e1> is not established, and the addition of progestogens to <e2>tamoxifen</e2> may not reduce of developing endometrial lesions, including <e1>carcinoma</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6288	"CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to <e1>tamoxifen</e1> may not reduce of developing <e2>endometrial lesions</e2>, including carcinoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6289	"<e1>Bleomycin</e1> and cyclophosphamide toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6290	"Bleomycin and <e1>cyclophosphamide</e1> toxicity simulating <e2>metastatic nodules</e2> to the lungs in childhood cancer."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6291	"Thoracoscopic biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to <e2>bleomycin</e2> or cyclophosphamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6292	"Thoracoscopic biopsy to confirm metastasis revealed instead <e1>fibrotic lesions</e1> apparently attributable to bleomycin or <e2>cyclophosphamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6293	"An elderly man with <e1>procainamide hydrochloride</e1>-induced <e2>lupus syndrome</e2> had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6294	"Circulating anticoagulant in the <e1>procainamide</e1>-induced <e2>lupus syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6295	"Clinical signs of <e1>hypermagnesemia</e1> are an uncommon complication following oral administration of <e2>magnesium sulfate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6296	"Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of <e2>magnesium</e2> toxicosis in horses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6297	"<e2>Magnesium</e2> toxicosis in two horses."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6298	"Overdose of <e1>magnesium</e1> sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e1>magnesium</e1> toxicosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6299	"Overdose of <e1>magnesium sulfate</e1> in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to <e2>magnesium toxicosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6300	"CASE SUMMARIES: In each case, the patients were treated over 5 years with <e1>lovastatin</e1> and developed <e2>rhabdomyolysis</e2> that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6301	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and <e2>azithromycin</e2> or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6302	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between lovastatin and azithromycin or <e2>clarithromycin</e2> should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6303	"CONCLUSIONS: The risk of drug-induced <e1>rhabdomyolysis</e1> due to the potential interaction between <e2>lovastatin</e2> and azithromycin or clarithromycin should be considered before the concomitant use of these agents."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6304	"DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with <e1>rhabdomyolysis</e1>, including <e2>lovastatin</e2>, a hydroxymethylglutaryl-coenzyme A reductase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6305	"<e1>Erythromycin</e1> is a macrolide antibiotic that may increase the risk of lovastatin-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6306	"Erythromycin is a macrolide antibiotic that may increase the risk of <e1>lovastatin</e1>-induced <e2>rhabdomyolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6307	"Lovastatin-induced <e1>rhabdomyolysis</e1> possibly associated with clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6308	"Lovastatin-induced <e1>rhabdomyolysis</e1> possibly associated with <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6309	"<e1>Lovastatin</e1>-induced <e2>rhabdomyolysis</e2> possibly associated with clarithromycin and azithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6310	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and <e2>azithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6311	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics <e2>clarithromycin</e2> and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6312	"OBJECTIVE: To describe two cases of <e1>rhabdomyolysis</e1> in patients taking <e2>lovastatin</e2> that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6313	"To our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with <e2>azithromycin</e2> and clarithromycin."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6314	"To our knowledge, these cases are the first published reports of lovastatin-induced <e1>rhabdomyolysis</e1> associated with azithromycin and <e2>clarithromycin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6315	"To our knowledge, these cases are the first published reports of <e1>lovastatin</e1>-induced <e2>rhabdomyolysis</e2> associated with azithromycin and clarithromycin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6316	"These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients <e1>died</e1> of PCP occurring during the first month of treatment with <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6317	"We report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical phenylephrine, submucosal <e2>epinephrine</e2>, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6318	"We report the specifics of 12 cases of <e1>severe hypertension</e1> after the intraoperative use of topical <e2>phenylephrine</e2>, submucosal epinephrine, or both."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6319	"<e1>Acute leukaemia</e1> during <e2>tamoxifen</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6320	"<e1>Tamoxifen</e1> is suggested to be <e2>carcinogenic</e2> both through direct genotoxic and epigenetic mechanisms."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6321	"We report two cases that developed <e1>acute myeloid leukaemia</e1> (AML) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6322	"We report two cases that developed acute myeloid leukaemia (<e1>AML</e1>) during <e2>tamoxifen</e2> therapy for breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6323	"<e1>Relapse in the external auditory canal of acute promyelocytic leukemia</e1> after treatment with <e2>all-trans retinoic acid</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6324	"This case suggests the importance of careful observation for <e1>extramedullary relapse</e1> in patients who are treated with <e2>ATRA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6325	"<e1>Cutaneous reactions</e1> to propylthiouracil and <e2>methimazole</e2> occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6326	"<e1>Cutaneous reactions</e1> to <e2>propylthiouracil</e2> and methimazole occur in 3%-5% of adults."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6327	"<e1>Generalized maculopapular and papular purpuric eruptions</e1> are perhaps the most common <e2>thionamide</e2>-induced reactions."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6328	"<e1>Propylthiouracil</e1>-induced <e2>cutaneous vasculitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6329	"The observation of <e1>cutaneous vasculitis</e1> during administration of <e2>propylthiouracil</e2> suggested that clinical awareness of this complication should be of considerable importance."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6330	"A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled <e1>heat stroke</e1> during the administration of <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6331	"Children receiving <e1>zonisamide</e1> should be monitored for oligohidrosis and the development of <e2>neurological symptoms</e2> associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6332	"Children receiving <e1>zonisamide</e1> should be monitored for <e2>oligohidrosis</e2> and the development of neurological symptoms associated with an elevation of body temperature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6333	"<e1>Heat stroke-like episode</e1> in a child caused by <e2>zonisamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6334	"The <e1>oligohidrosis</e1> caused by <e2>zonisamide</e2> was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6335	"<e1>Acute renal failure</e1> in a patient receiving treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6336	"Acute <e1>renal failure</e1> should be recognized as a potential complication of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6337	"Other potential causes of <e1>renal failure</e1> were not present in our patient and his renal function gradually recovered with the cessation of <e2>suramin</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6338	"We describe a patient with metastatic prostate cancer who developed <e1>nonoliguric renal failure</e1> during treatment with <e2>suramin</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6339	"<e1>Clozapine</e1> induced <e2>polyserositis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6340	"We report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6341	"We report the case of a patient who developed polyserositis (<e1>pericardial effusion</e1>, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6342	"We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6343	"We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and <e1>pericarditis</e1>) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6344	"We report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6345	"We report the case of a patient who developed polyserositis (pericardial effusion, <e1>pleural effusion</e1>, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6346	"We report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6347	"We report the case of a patient who developed <e1>polyserositis</e1> (pericardial effusion, pleural effusion, and pericarditis) after being started on <e2>clozapine</e2>, and whose symptoms remitted upon discontinuation of <e2>clozapine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6348	"When the disease recurred conventional <e1>amphotericin B</e1> was used again, but had to be stopped because of <e2>severe side effects</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6349	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6350	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced <e2>fever</e2>, infectious complications, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6351	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6352	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, <e2>gastrointestinal tract symptoms</e2> and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6353	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6354	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, <e2>infectious complications</e2>, gastrointestinal tract symptoms and severe myalgias."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6355	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside (<e1>ARA-C</e1>); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6356	"Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, <e1>cytosine arabinoside</e1> (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and <e2>severe myalgias</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6357	"CONCLUSION: We believe this to be the first reported case of <e1>rhGH</e1>-induced <e2>hypercalcemia</e2> in an HIV-infected patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6358	"<e1>Hypercalcemia</e1> in an AIDS patient treated with <e2>growth hormone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6359	"The <e1>hypercalcemia</e1> responded to discontinuation of <e2>rhGH</e2> and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6360	"We report a male patient with advanced AIDS who developed <e1>hypercalcemia</e1> 2 weeks after institution of <e2>rhGH</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6361	"<e1>Hypersensitivity reactions</e1> to <e2>cisplatin</e2> following multiple uncomplicated courses: a report on two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6362	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6363	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested <e2>abdominal pain</e2>, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6364	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6365	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, <e2>dyspnea</e2>, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6366	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6367	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and <e2>fever</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6368	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6369	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6370	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6371	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested <e2>general erythema</e2>, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, <e2>general erythema</e2>, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6372	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6373	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced <e2>hypersensitivity reactions</e2> to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6374	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6375	"Two patients with ovarian cancer who had received multiple courses of <e1>cisplatin</e1> without complications experienced hypersensitivity reactions to <e1>cisplatin</e1>: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and <e2>hypotension</e2>; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6376	"We report an unusually short lived and asymptomatic episode of severe <e1>cisplatin</e1>-induced <e2>renal tubular salt wasting</e2> in a fit 41-year-old patient with malignant teratoma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6377	"Clinicians should include <e1>phenolphthalein</e1> in their list of possible causes of drug-induced <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6378	"DISCUSSION: <e1>Phenolphthalein</e1> is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6379	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1>-induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6380	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1>-induced toxic epidermal necrolysis (<e2>TEN</e2>) in a patient maintained on several other medications more commonly known to be associated with <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6381	"OBJECTIVE: To report a case of <e1>phenolphthalein</e1>-induced <e2>toxic epidermal necrolysis</e2> (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6382	"<e1>Phenolphthalein</e1>-induced <e2>toxic epidermal necrolysis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6383	"The patient's previous <e1>rash</e1> and the temporal relation of this event and the ingestion of <e2>phenolphthalein</e2>, as well as the similarity of this case to other reports, point to <e2>phenolphthalein</e2> as the cause of TEN in this patient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6384	"The patient's previous rash and the temporal relation of this event and the ingestion of <e1>phenolphthalein</e1>, as well as the similarity of this case to other reports, point to <e1>phenolphthalein</e1> as the cause of <e2>TEN</e2> in this patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6385	"<e2>Carbamazepine</e2> toxicity induced by clarithromycin coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6386	"<e1>Carbamazepine toxicity</e1> induced by <e2>clarithromycin</e2> coadministration in psychiatric patients."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6387	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6388	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6389	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and <e2>ataxia</e2>, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6390	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6391	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6392	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, <e2>dizziness</e2>, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6393	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of <e1>carbamazepine</e1>, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6394	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6395	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as <e2>drowsiness</e2>, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6396	"During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe <e1>toxic symptoms</e1> of <e2>carbamazepine</e2>, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6397	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6398	"During <e1>clarithromycin</e1> coadministration, four out of the seven patients developed moderate-to-severe <e2>toxic symptoms</e2> of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after <e1>clarithromycin</e1> discontinuation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6399	"The present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6400	"The present report suggests that clarithromycin coadministration induces increased plasma <e1>carbamazepine</e1> concentrations, which may result in <e1>carbamazepine</e1> toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6401	"The present report suggests that <e1>clarithromycin</e1> coadministration induces increased plasma carbamazepine concentrations, which may result in <e2>carbamazepine toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6402	"The present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6403	"The present report suggests that clarithromycin coadministration induces increased plasma <e2>carbamazepine</e2> concentrations, which may result in <e2>carbamazepine</e2> toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6404	"The present report suggests that <e1>clarithromycin</e1> coadministration induces <e2>increased plasma carbamazepine</e2> concentrations, which may result in carbamazepine toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6405	"Acute hemorrhagic gastritis associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6406	"<e1>Acute hemorrhagic gastritis</e1> associated with <e2>acetazolamide</e2> intoxication in a patient with chronic renal failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6407	"As far as we know, this is the first case report of <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6408	"As far as we know, this is the first case report of acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6409	"She was thus diagnosed as having <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6410	"We experienced a case of chronic renal failure in a patient suffering from <e1>acute hemorrhagic gastritis</e1> associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6411	"We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with <e2>AZ</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6412	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably <e2>destroyed the gastric mucosal barrier</e2> or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6413	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of <e2>hemorrhagic gastritis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6414	"We thus concluded that an excessive dose of <e1>AZ</e1> had probably destroyed the gastric mucosal barrier or <e2>thrombocytopenia due to bone marrow disorder</e2> and thus eventually led to the development of hemorrhagic gastritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6415	"In association with this tocolysis, <e1>urinary calculus</e1> of <e2>magnesium ammonium phosphate</e2> occurred at 34 weeks gestation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6416	"<e1>Magnesium</e1> tocolysis as the cause of <e2>urinary calculus</e2> during pregnancy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6417	"<e1>Danazol</e1> induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6418	"On the next day, after a total dose of only 600 mg of <e1>danazol</e1>, <e2>gingival bleeding</e2> and purpura occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6419	"On the next day, after a total dose of only 600 mg of <e1>danazol</e1>, gingival bleeding and <e2>purpura</e2> occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6420	"We diagnosed this case as <e1>danazol</e1> induced <e2>thrombocytopenia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6421	"It occasionally accompanies the <e1>heparin</e1>-associated <e2>thrombocytopenia</e2> and thrombosis syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6422	"It occasionally accompanies the <e1>heparin</e1>-associated thrombocytopenia and <e2>thrombosis syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6423	"<e1>Skin necrosis</e1> is a rare complication of subcutaneous <e2>heparin</e2> therapy that usually occurs at injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6424	"<e1>Skin necrosis</e1> secondary to <e2>low-molecular weight heparin</e2> in a patient with antiphospholipid antibody syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6425	"We describe a patient with the antiphospholipid syndrome who had <e1>skin necrosis</e1> develop from <e2>low-molecular weight heparin</e2> therapy at sites distant from injection sites."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6426	"Finally, <e2>reserpine</e2> toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6427	"A case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in an ophthalmic solution."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6428	"Therefore, we diagnosed her eruption as <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6429	"Therefore, we diagnosed her <e1>eruption</e1> as contact dermatitis due to <e2>sodium bisulfite</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6430	"We report a case of <e1>contact dermatitis</e1> due to <e2>sodium bisulfite</e2> in Tathion eye drops."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6431	"<e1>Acute pancreatitis</e1> after long-term <e2>5-aminosalicylic acid</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6432	"<e1>Acute pancreatitis</e1> is a known, although rare, complication of <e2>mesalamine</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6433	"A rechallenge, performed in both patients, confirmed the diagnosis of <e1>mesalamine</e1>-induced <e2>pancreatitis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6434	"These case reports provide evidence that <e1>5-aminosalicylic acid</e1> may induce <e2>acute pancreatitis</e2> after long term treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6435	"We describe two cases of <e1>acute pancreatitis</e1> that occurred after long term <e2>mesalamine</e2> therapy for ulcerative colitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6436	"A 35-year-old nephrotic man developed <e1>acute renal failure</e1> with serum creatinine to 1543 micromol/l after a month of therapy with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6437	"<e1>Acute renal failure</e1> with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6438	"Acute renal failure with <e1>severe tubulointerstitial changes</e1> in a patient with minimal change nephrotic syndrome treated with <e2>enalapril</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6439	"Early <e1>ritonavir</e1>-induced <e2>maculopapular eruption</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6440	"<e1>Ritonavir</e1> should be added to the list of drugs that can induce <e2>adverse cutaneous reactions</e2> in HIV patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6441	"We report 2 cases of maculopapular eruption and <e1>fever</e1> in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6442	"We report 2 cases of <e1>maculopapular eruption</e1> and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of <e2>ritonavir</e2>, a protease inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6443	"<e1>Nephropathy</e1> caused by <e2>methicillin</e2> therapy for staphylococcal septicemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6444	"Review of the literature relating to <e1>methicillin</e1>-induced <e2>nephropathy</e2> suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6445	"A 25-year-old woman sought medical attention because of iliocaval manifestations of <e1>retroperitoneal fibrosis</e1> while she was taking <e2>methysergide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6446	"<e1>Methysergide</e1>-induced <e2>retroperitoneal fibrosis</e2>: successful outcome and two new laboratory features."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6447	"<e1>Vitiligo</e1> associated with <e2>alpha-interferon</e2> in a patient with chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6448	"We report a case of <e1>vitiligo</e1> that occurred during the second month of <e2>interferon alpha 2a</e2> therapy for chronic active hepatitis C."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6449	"A case is reported of an elderly woman who developed <e1>febrile agranulocytosis</e1> several weeks after commencing <e2>ticlopidine</e2> but who had a favorable outcome after cessation of that drug and treatment with filgastrim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6450	"<e1>Agranulocytosis</e1> associated with <e2>ticlopidine</e2>: a possible benefit with filgastim."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6451	"<e1>Ticlopidine</e1> is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically <e2>aplastic anemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6452	"<e1>Ticlopidine</e1> is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with <e2>severe bone marrow suppression</e2>, typically aplastic anemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6453	"Hemodialysis was also shown to reverse <e1>ifosfamide</e1>-related <e2>neurotoxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6454	"<e1>Ifosfamide</e1>-associated <e2>neurotoxicity</e2> was noted within hours of drug administration and improved rapidly following hemodialysis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6455	"PURPOSE: We evaluated the in vitro hemodialysis ratio and subsequent <e1>toxicity</e1> and pharmacokinetics of <e2>ifosfamide</e2> in an anephric patient with Wilms' tumor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6456	"The <e1>toxicity</e1> and plasma concentrations of ifosfamide, chloroacetaldehyde, and <e2>4-hydroxyifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6457	"The <e1>toxicity</e1> and plasma concentrations of ifosfamide, <e2>chloroacetaldehyde</e2>, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6458	"The <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6459	"The <e1>toxicity</e1> and plasma concentrations of <e2>ifosfamide</e2>, chloroacetaldehyde, and 4-hydroxy<e2>ifosfamide</e2> were then determined over 24 h after a single 1.6 g/m2 dose of <e2>ifosfamide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6460	"<e1>Toxicity</e1>, pharmacokinetics, and in vitro hemodialysis clearance of <e2>ifosfamide</e2> and metabolites in an anephric pediatric patient with Wilms' tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6461	"A 55-year-old woman developed symptoms suggestive of <e1>hepatitis</e1> 12 weeks after first receiving <e2>methyldopa</e2> for hypertension."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6462	"<e1>Methyldopa</e1>-induced <e2>liver injury</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6463	"Such a rapid and relentless progression of <e1>methyldopa</e1>-induced <e2>liver injury</e2> is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6464	"<e1>Acute respiratory depression</e1> as a complication of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6465	"Approximately 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly <e2>bradypneic</e2> (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6466	"Approximately 15 min after the first administration of nebulised <e1>morphine</e1> the patient became markedly bradypneic (respiratory rate: 4-5 bpm), <e2>hypotensive</e2> (BP 70/40 mmHg), and responded only partially to command."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6467	"PURPOSE: To present a case of <e1>respiratory depression</e1> following the administration of nebulised <e2>morphine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6468	"<e1>Acute dystonia</e1> with thalamic and brainstem lesions after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6469	"Acute dystonia with <e1>thalamic and brainstem lesions</e1> after initial <e2>penicillamine</e2> treatment in Wilson's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6470	"From these data, <e1>acute generalized dystonia</e1> with brainstem and thalamic lesions may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6471	"From these data, acute generalized dystonia with <e1>brainstem and thalamic lesions</e1> may occur in WD patients after an initial <e2>d-penicillamine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6472	"We reported 3 patients who developed <e1>acute generalized dystonia</e1> and akinetic rigid syndrome following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6473	"We reported 3 patients who developed acute generalized dystonia and <e1>akinetic rigid syndrome</e1> following an initial therapy with <e2>d-penicillamine</e2> 125-500 mg daily."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6474	"<e1>Ballistic movements</e1> due to ischemic infarcts after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6475	"Ballistic movements due to <e1>ischemic infarcts</e1> after intravenous <e2>heroin</e2> overdose: report of two cases."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6476	"Patient 1 presented <e1>bilateral ballism</e1> 1 week after intravenous <e2>heroin</e2> injection."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6477	"<e1>Stroke</e1> is an infrequent but recognized complication of <e2>heroin</e2> addiction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6478	"Two <e1>heroin</e1> addicts, aged 34 and 19 years, developed <e2>ballistic movements</e2> after intravenous <e1>heroin</e1> overdose."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6479	"A MEDLINE search identified all the reported cases of <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6480	"<e1>Anaphylaxis</e1> to intravenous <e2>cyclosporine</e2> and tolerance to oral <e2>cyclosporine</e2>: case report and review."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6481	"BACKGROUND: <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are rare."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6482	"CONCLUSIONS: <e1>Hypersensitivity reactions</e1> to cyclosporine are due to <e2>Cremophor EL</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6483	"CONCLUSIONS: <e1>Hypersensitivity reactions</e1> to <e2>cyclosporine</e2> are due to Cremophor EL."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6484	"Fortunately, a <e1>hypersensitivity reaction</e1> to one formulation of <e2>cyclosporine</e2> does not preclude use of a different formulation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6485	"METHODS: We report a patient who had an <e1>anaphylactic reaction</e1> during the intravenous infusion of <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6486	"OBJECTIVE: To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6487	"OBJECTIVE: To investigate the mechanisms involved in <e1>hypersensitivity reactions</e1> to <e2>cyclosporine</e2> and determine the feasibility of future <e2>cyclosporine</e2> use."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6488	"The literature search revealed 22 cases of <e1>hypersensitivity reaction</e1> to <e2>cyclosporine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6489	"<e1>Prothipendylhydrochloride</e1>-induced <e2>priapism</e2>: case report."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6490	"We present the first case of a patient with <e1>priapism</e1> after oral intake of the phenothiazine <e2>prothipendylhydrochloride</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6491	"The chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6492	"The chemotherapeutics, including vincristine, <e1>actinomycin D</e1>, and epirubicin in case 1 and vincristine and <e1>actinomycin D</e1> in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6493	"The chemotherapeutics, including vincristine, actinomycin D, and <e1>epirubicin</e1> in case 1 and vincristine and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6494	"The chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6495	"The chemotherapeutics, including <e1>vincristine</e1>, actinomycin D, and epirubicin in case 1 and <e1>vincristine</e1> and actinomycin D in case 2, were given before the <e2>hepatotoxicity</e2> developed."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6496	"We conclude that vincristine and <e1>actinomycin D</e1> were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6497	"We conclude that <e1>vincristine</e1> and actinomycin D were the cause of this rare from of <e2>hepatotoxicity</e2> and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6498	"Because the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking <e2>acral necrosis</e2> in patients who develop Raynaud's phenomenon under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6499	"Because the combination of <e1>bleomycin</e1> and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop <e2>Raynaud's phenomenon</e2> under chemotherapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6500	"In this report, one patient who developed <e1>gangrene</e1> after <e2>bleomycin</e2> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6501	"In this report, one patient who developed <e1>gangrene</e1> after bleomycin and vincristine/<e2>vinblastine</e2> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6502	"In this report, one patient who developed <e1>gangrene</e1> after bleomycin and <e2>vincristine</e2>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6503	"In this report, one patient who developed gangrene after <e1>bleomycin</e1> and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6504	"In this report, one patient who developed gangrene after bleomycin and vincristine/<e1>vinblastine</e1> chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6505	"In this report, one patient who developed gangrene after bleomycin and <e1>vincristine</e1>/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of <e2>severe Raynaud's phenomenon</e2> related to the same regimen are presented."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6506	"Development of essential <e1>thrombocythemia</e1> in a patient treated with <e2>interferon alfa</e2> and pentostatin for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6507	"Development of essential <e1>thrombocythemia</e1> in a patient treated with interferon alfa and <e2>pentostatin</e2> for hairy cell leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6508	"Second cancers including various types of <e1>hematological malignancy</e1> have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6509	"<e1>Second cancers</e1> including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or <e2>interferon alfa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6510	"Effect of beta-blockade on symptomatic <e1>dexamethasone</e1>-induced <e2>hypertrophic obstructive cardiomyopathy</e2> in premature infants: three case reports and literature review."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6511	"One patient had a <e1>lower average heart rate</e1> and two patients had lower average mean blood pressure values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6512	"One patient had a lower average heart rate and two patients had <e1>lower average mean blood pressure</e1> values during <e2>propranolol</e2> treatment, none of which was clinically significant."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6513	"STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and <e1>left ventricular outflow tract obstruction</e1> developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6514	"STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant <e1>septal hypertrophy</e1> and left ventricular outflow tract obstruction developed during <e2>dexamethasone</e2> treatment for bronchopulmonary dysplasia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6515	"CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and <e1>abdominal cramping</e1> on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6516	"CASE SUMMARY: A 25-year-old postpartum white woman developed <e1>multiple watery stools</e1> and abdominal cramping on day 6 of therapy with <e2>clindamycin</e2> vaginal cream for bacterial vaginosis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6517	"<e1>Clostridium difficile toxin-induced colitis</e1> after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6518	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6519	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of <e2>CDIC</e2> due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6520	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6521	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of <e2>C. difficile toxin</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6522	"CONCLUSIONS: This report indicates <e1>clindamycin</e1> phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and <e1>clindamycin</e1> administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6523	"CONCLUSIONS: This report indicates <e1>clindamycin phosphate</e1> vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of <e2>diarrhea</e2> and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6524	"DISCUSSION: No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented <e2>C. difficile toxin in stool</e2> samples of patients with diarrhea."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6525	"DISCUSSION: No published clinical studies in patients receiving <e1>clindamycin</e1> vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with <e2>diarrhea</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6526	"OBJECTIVE: To report a case of <e1>toxin-positive Clostridium difficile-induced colitis</e1> (CDIC) after use of <e2>clindamycin phosphate</e2> vaginal cream."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6527	"A 54-year-old man developed <e1>TEN</e1> 4 weeks after beginning <e2>lamotrigine</e2> for complex partial seizures related to a glioblastoma multiforme brain tumor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6528	"Administration of <e1>lamotrigine</e1>, especially in combination with valproic acid, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6529	"Administration of lamotrigine, especially in combination with <e1>valproic acid</e1>, may lead to the development of <e2>TEN</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6530	"<e1>Fatal toxic epidermal necrolysis</e1> related to <e2>lamotrigine</e2> administration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6531	"It was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6532	"It was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in <e2>accumulation of a toxic intermediate metabolite</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6533	"It was hypothesized that valproic acid may interfere with glucuronidation of <e1>lamotrigine</e1>, leading to increased serum <e1>lamotrigine</e1> levels, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6534	"It was hypothesized that <e1>valproic acid</e1> may interfere with glucuronidation of lamotrigine, leading to <e2>increased serum lamotrigine levels</e2>, or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6535	"To date, eight cases of TEN and one of <e1>SJS</e1> related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6536	"To date, eight cases of <e1>TEN</e1> and one of SJS related to <e2>lamotrigine</e2> administration have been reported in the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6537	"A <e1>syndrome of increased affect</e1> in response to <e2>risperidone</e2> among patients with schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6538	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and <e2>depression</e2> and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6539	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including <e2>feelings of agitation</e2> and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6540	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and <e2>insomnia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6541	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of <e2>intolerable affect</e2>, including feelings of agitation and depression and periods of crying and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6542	"Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of <e1>risperidone</e1> had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and <e2>periods of crying</e2> and insomnia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6543	"The authors suggest that <e1>risperidone</e1> may <e2>increase affect</e2> in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6544	"<e1>Methanol</e1> toxicity can cause severe central nervous system insult in which a characteristic pattern of <e2>bilateral putaminal injury</e2> is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6545	"<e2>Methanol</e2> toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6546	"<e1>Methanol</e1> toxicity can cause <e2>severe central nervous system insult</e2> in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6547	"Putaminal infarct in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6548	"<e1>Putaminal infarct</e1> in <e2>methanol</e2> intoxication: case report and role of brain imaging studies."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6549	"Theoretical basal ganglia toxicologic mechanisms of <e2>methanol</e2> poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6550	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including <e2>bilateral putaminal necrosis</e2> and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6551	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and <e2>cerebral edema</e2> with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6552	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated <e2>diffuse brain involvement</e2>, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6553	"We present a <e1>fatal</e1> case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6554	"We present a fatal case of subacute <e2>methanol</e2> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6555	"We present a fatal case of subacute <e1>methanol</e1> toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with <e2>ventricular compression</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6556	"A 28 year old white schizophrenic male has been under <e1>risperidone</e1> monotherapy for about one year when he developed <e2>dyskinetic movements</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6557	"<e1>Risperidone</e1>-induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6558	"This report presents a potential case of <e1>risperidone</e1>-induced <e2>tardive dyskinesia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6559	"<e1>Increased ocular pressure</e1> in two patients with narrow angle glaucoma treated with <e2>venlafaxine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6560	"A 61-year-old man developed <e1>clinical lupus syndrome</e1> with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6561	"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and <e1>diffuse proliferative glomerulonephritis</e1> following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6562	"A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive <e1>lupus erythematosus</e1> (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of <e2>procainamide</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6563	"<e1>Glomerulonephritis</e1> in <e2>procainamide</e2> induced lupus erythematosus: report of a case and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6564	"Glomerulonephritis in <e1>procainamide</e1> induced <e2>lupus erythematosus</e2>: report of a case and review of the literature."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6565	"We report a 76-year-old man who developed an <e1>acute blistering eruption</e1> following high-dose <e2>penicillin</e2> treatment for pneumococcal septicaemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6566	"A case of prolonged <e1>suxamethonium</e1> <e2>apnoea</e2> successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6567	"<e1>Suxamethonium</e1> <e2>apnoea</e2> terminated with commercial serumcholinesterase."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6568	"<e1>Cardiac arrest</e1> associated with <e2>sulprostone</e2> use during caesarean section."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6569	"We postulate that the bolus of <e1>sulprostone</e1> resulted in possible coronary spasm that resulted in <e2>cardiac arrest</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6570	"We postulate that the bolus of <e1>sulprostone</e1> resulted in possible <e2>coronary spasm</e2> that resulted in cardiac arrest."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6571	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6572	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e2>lamotrigine</e2> blood level with symptoms of toxicity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6573	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6574	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a <e2>doubling of the lamotrigine blood level</e2> with symptoms of toxicity."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6575	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and <e1>desmethylsertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6576	"In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the <e1>lamotrigine</e1> blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6577	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6578	"In case 1, a total daily dose of 25 mg <e1>sertraline</e1>, with nondetectable <e1>sertraline</e1> and desmethyl<e1>sertraline</e1> blood levels, resulted in a doubling of the lamotrigine blood level with <e2>symptoms of toxicity</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6579	"<e2>Lamotrigine</e2> toxicity secondary to sertraline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6580	"<e1>Lamotrigine toxicity</e1> secondary to <e2>sertraline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6581	"<e1>Flutamide</e1> withdrawal syndrome is characterized by a <e2>decrease in prostate-specific antigen</e2> (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6582	"Flutamide withdrawal syndrome is characterized by a <e1>decrease in prostate-specific antigen</e1> (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6583	"<e2>Flutamide</e2> withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6584	"<e1>Flutamide withdrawal syndrome</e1> is characterized by a decrease in prostate-specific antigen (PSA) after <e2>flutamide</e2> withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6585	"Prolonged prostate-specific antigen response in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6586	"<e1>Prolonged prostate-specific antigen response</e1> in <e2>flutamide</e2> withdrawal syndrome despite disease progression."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6587	"This case illustrates the potential <e1>decoupling of PSA response</e1> from disease status in <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6588	"We describe a patient with androgen-independent prostate cancer in whom <e1>PSA continued to decrease</e1> for a period of 15 months after <e2>flutamide</e2> withdrawal."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6589	"<e1>Anaphylactic reaction</e1> to oral <e2>prednisone</e2>: a case report and review of the literature."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6590	"We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic <e1>anaphylactic reaction</e1> to oral <e2>prednisone</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6591	"Animals treated with <e1>HAL</e1> showed a highly <e2>significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons</e2> in the substantia nigra, and 20% contraction of the TH stained dendritic arbour."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6592	"METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with Viokase and <e2>Pancrease MT 16</e2>, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6593	"METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite <e1>vomiting</e1> within 1 to 1.5 hours after challenges with <e2>Viokase</e2> and Pancrease MT 16, but not with placebo."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6594	"She was treated with <e1>Pancrease MT 16</e1>, but had consistent <e2>vomiting</e2> 1 to 2 hours after administration of enzymes."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6595	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, <e2>Creon 10</e2>, Viokase, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6596	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and <e2>Pancrease MT 16</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6597	"The <e1>vomiting</e1> occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, <e2>Viokase</e2>, and Pancrease MT 16."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6598	"Acute <e1>valproate</e1> ingestion induces <e2>symptomatic methemoglobinemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6599	"We report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of divalproex sodium (<e2>Depakote</e2>), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6600	"We report for the first time the development of <e1>symptomatic methemoglobinemia</e1> after an acute ingestion of <e2>divalproex sodium</e2> (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6601	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6602	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by <e2>hemolytic anemia</e2>, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6603	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6604	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated <e2>hemolytic uremic syndrome</e2>, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6605	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6606	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and <e2>progressive renal failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6607	"In rare cases <e1>mitomycin C</e1> (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6608	"In rare cases mitomycin C (<e1>MMC</e1>) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, <e2>thrombocytopenia</e2> and progressive renal failure."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6609	"<e1>Mitomycin C</e1>-related <e2>hemolytic uremic syndrome</e2> in cancer patients."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6610	"We report a case of <e1>MMC</e1>-related <e2>hemolytic uremic syndrome</e2>, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6611	"<e1>CD4 T-lymphocyte depletion</e1>, myelosuppression, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6612	"CD4 T-lymphocyte depletion, <e1>myelosuppression</e1>, and subsequent severe infections are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6613	"CD4 T-lymphocyte depletion, myelosuppression, and subsequent <e1>severe infections</e1> are the major side effects of <e2>fludarabine phosphate</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6614	"<e1>Severe respiratory syncytial virus pulmonary infection</e1> in a patient treated with <e2>fludarabine</e2> for chronic lymphocytic leukemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6615	"We report here on a heretofore undescribed <e1>respiratory syncytial virus (RSV) infection</e1> in a patient with a long-standing history of refractory CLL that was treated with <e2>fludarabine phosphate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6616	"<e1>Serotonin syndrome</e1> induced by transitioning from <e2>phenelzine</e2> to venlafaxine: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6617	"<e1>Serotonin syndrome</e1> induced by transitioning from phenelzine to <e2>venlafaxine</e2>: four patient reports."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6618	"Although this <e1>G-CSF</e1>-driven <e2>leucocytosis</e2> was alarming it did not appear to have adversely affected the patient's prognosis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6619	"<e1>Leukaemoid monocytosis</e1> in M4 AML following chemotherapy and <e2>G-CSF</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6620	"We describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6621	"We describe a patient with M4 AML treated with standard chemotherapy followed by <e1>G-CSF</e1> who developed marked <e2>monocytosis</e2> on day 8 of <e1>G-CSF</e1> therapy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6622	"Case 2 demonstrated after 40 months on <e1>chlorambucil</e1> the presence of a <e2>balanced translocation</e2>, t (1;5) (p36;q31) in 90% of the cells."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6623	"<e1>Chromosome abnormalities</e1> after <e2>chlorambucil</e2> therapy of polycythaemia vera."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6624	"Administration of steroid and decreasing the dose of <e1>PTU</e1> produced a good clinical response and the <e2>ANCA</e2> disappeared."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6625	"<e1>Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis</e1> associated with <e2>propylthiouracil</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6626	"A teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received <e2>propylthiouracil</e2> (PTU) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6627	"A teenage girl with crescentic glomerulonephritis had <e1>antineutrophil cytoplasmic antibody</e1> (ANCA) detected after she had received propylthiouracil (<e2>PTU</e2>) for hyperthyroidism without cutaneous vasculitis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6628	"It was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6629	"It was concluded that <e1>ANCA</e1> is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with <e2>PTU</e2> appeared to induce <e1>ANCA</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6630	"A <e1>drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6631	"A <e1>drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6632	"Attempts were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6633	"Attempts were made to stop and then restart the <e1>theophylline</e1> therapy at progressively lower doses; however, with each attempt, the patient's <e2>reaction to the drug became more toxic</e2>, with serum <e1>theophylline</e1> levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6634	"One explanation for the noted increase in the <e2>theophylline</e2> level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6635	"One explanation for the noted <e1>increase in the theophylline level</e1> is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of <e2>zafirlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6636	"Recently, her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (<e2>Accolate</e2>, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6637	"Recently, her serum <e2>theophylline</e2> levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6638	"Recently, her serum <e1>theophylline levels had increased to the toxic range</e1> (133.2 micromol/L [24 microg/mL]) shortly after the addition of <e2>zafirlukast</e2> (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6639	"The noted increase in the <e2>theophylline</e2> level after zafirlukast administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6640	"The noted <e1>increase in the theophylline level</e1> after <e2>zafirlukast</e2> administration is in contrast to the original reports by the manufacturer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6641	"We present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between zafirlukast and <e2>theophylline</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6642	"We present the first case (to our knowledge) of a potentially serious <e1>drug-drug interaction</e1> between <e2>zafirlukast</e2> and theophylline."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6643	"A 21-year-old patient developed <e1>rhabdomyolysis</e1> during his nineteenth week of treatment with <e2>clozapine</e2> for drug-resistant schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6644	"<e1>Clozapine</e1> is speculated to cause <e2>rhabdomyolysis</e2> in patients with defective calcium-activated K+ channels."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6645	"<e1>Rhabdomyolysis</e1> associated with <e2>clozapine</e2> treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6646	"We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or <e1>anticholinergic symptoms</e1> with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6647	"We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited <e1>drug-seeking behavior</e1> or anticholinergic symptoms with the use of <e2>diphenhydramine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6648	"Excluding other causes, <e1>Pentasa</e1>-associated <e2>pancytopenia</e2> was considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6649	"He developed fever, nausea, <e1>diarrhea</e1>, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6650	"He developed <e1>fever</e1>, nausea, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6651	"He developed fever, nausea, diarrhea, and <e1>malaise</e1> and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6652	"He developed fever, <e1>nausea</e1>, diarrhea, and malaise and stopped taking on the third day after commencing <e2>Pentasa</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6653	"<e1>Pancytopenia</e1> associated with <e2>5-aminosalicylic acid</e2> use in a patient with Crohn's disease."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6654	"We report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with <e2>5-aminosalicylic acid</e2> (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6655	"We report a case of <e1>pancytopenia</e1> in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (<e2>Pentasa</e2>; Nisshin, Tokyo, Japan) 3.0 g/day."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6656	"1. <e1>Changes in the plasma cortisol level</e1> were reported in a male patient with panic disorder during the period of low-dose <e2>alprazolam</e2> treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6657	"3. Thus, the <e1>decreased plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder was suggested to be caused not by symptom alleviation due to <e2>alprazolam</e2> but by <e2>alprazolam</e2> administration itself."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6658	"<e1>Decreased plasma cortisol level</e1> during <e2>alprazolam</e2> treatment of panic disorder: a case report."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6659	"We describe a renal transplant recipient maintained on <e1>cyclosporine</e1> and prednisone developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6660	"We describe a renal transplant recipient maintained on cyclosporine and <e1>prednisone</e1> developing <e2>Nocardia Asteroides brain abscess</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6661	"Young children undergoing <e1>cisplatin</e1> chemotherapy are known to be at risk for <e2>progressive sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6662	"A 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed <e2>gradual stiffness</e2> and weakness of the lower extremities."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6663	"A 47 year-old woman who had a 4-year history of intramuscular <e1>pentazocine</e1> injections in the lower extremities, developed gradual stiffness and <e2>weakness of the lower extremities</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6664	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6665	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a <e2>neuromuscular complication</e2> are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6666	"Caution in longterm usage and early recognition of <e1>pentazocine</e1> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6667	"Caution in longterm usage and early recognition of <e2>pentazocine</e2> toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6668	"<e1>Pentazocine</e1>-induced <e2>fibrous myopathy</e2> and localized neuropathy."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6669	"<e1>Pentazocine</e1>-induced fibrous myopathy and localized <e2>neuropathy</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6670	"In two of these cases <e1>akathisia</e1> resolved after withdrawal of <e2>olanzapine</e2> and substitution by a classical or an atypical neuroleptic agent, respectively."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6671	"Like other atypical neuroleptics <e1>olanzapine</e1> is considered to show a reduced prevalence of <e2>extrapyramidal side effects</e2> when compared to classical neuroleptic drugs."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6672	"One should therefore be aware of possible <e1>extrapyramidal side effects</e1> with <e2>olanzapine</e2> that are reduced compared to classical neuroleptic drugs but not completely eliminated."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6673	"<e1>Severe akathisia</e1> during <e2>olanzapine</e2> treatment of acute schizophrenia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6674	"We report on three patients with acute schizophrenia, who developed <e1>severe akathisia</e1> during treatment with <e2>olanzapine</e2> (20-25 mg/d)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6675	"<e1>Seizures</e1> occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with <e2>metrifonate</e2>, an irreversible acetylcholinesterase inhibitor."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6676	"However, 1 eye had <e1>vitreous hemorrhage</e1> after repeated injections of <e2>tPA</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6677	"However, repeated intracameral <e1>tPA</e1> injections may cause unwanted complications such as <e2>vitreous hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6678	"Although <e1>praziquantel</e1> administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked <e2>inflammation</e2> as a result of treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6679	"<e1>NMS</e1> is a drug-related response to various medications, such as <e2>Haloperidol</e2>, which the patient was receiving."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6680	"<e1>Methimazole</e1>-induced <e2>aplastic anemia</e2> in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6681	"We present a case of a 58-year-old female patient with Graves' disease who developed <e1>AA</e1> in the third exposure to <e2>methimazole</e2> (MMI)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6682	"<e1>FSGS</e1> induced by <e2>Adriamycin</e2> (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6683	"The case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6684	"The case demonstrates that hypersensitivity reaction to <e1>pranlukast</e1> and resultant <e2>ATIN</e2> is possible, and that periodic urine testing in patients receiving <e1>pranlukast</e1> should be considered."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6685	"The case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6686	"The case demonstrates that <e1>hypersensitivity reaction</e1> to <e2>pranlukast</e2> and resultant ATIN is possible, and that periodic urine testing in patients receiving <e2>pranlukast</e2> should be considered."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6687	"<e1>Tubulointerstitial nephritis</e1> induced by the leukotriene receptor antagonist <e2>pranlukast</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6688	"Within 6 months of <e1>pranlukast</e1> withdrawal, <e2>anemia</e2> resolved and urinary sediment and renal function normalized."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6689	"A 65-year-old woman with angina pectoris presented with <e1>syncope</e1> after sublingual ingestion of <e2>isosorbide dinitrate</e2> (5 mg)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6690	"Elderly patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of <e2>hypotension</e2>, leading to unconsciousness."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6691	"Elderly patients for whom <e1>nitrate</e1> has been prescribed should be warned of the occurrence of hypotension, leading to <e2>unconsciousness</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6692	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), <e2>blood pressure decreased</e2> from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6693	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a <e2>sudden decrease in pulse rate</e2> from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6694	"In a postural challenge test after administration of <e1>isosorbide dinitrate</e1> (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by <e2>syncope</e2> with a sudden decrease in pulse rate from 85 to 60 beats/min."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6695	"<e1>Syncope</e1> in a 65-year-old woman after <e2>nitrate</e2> ingestion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6696	"Three diabetic cases of <e1>acute dizziness</e1> due to initial administration of <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6697	"We observed 3 diabetic patients with <e1>intolerable dizziness</e1> followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6698	"We observed 3 diabetic patients with intolerable dizziness followed by <e1>nausea</e1> and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6699	"We observed 3 diabetic patients with intolerable dizziness followed by nausea and <e1>vomiting</e1> immediately after an initial administration of the alpha-glucosidase inhibitor, <e2>voglibose</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6700	"<e1>Naproxen</e1>-associated <e2>sudden sensorineural hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6701	"<e1>Naproxen</e1> is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include <e2>tinnitus</e2> and transient hearing loss."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6702	"<e1>Naproxen</e1> is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and <e2>transient hearing loss</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6703	"This article reports the case of an otherwise healthy patient who experienced permanent <e1>sensorineural hearing loss</e1> after a brief course of <e2>naproxen</e2> and reviews the literature on NSAID-related permanent <e1>sensorineural hearing loss</e1>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6704	"<e1>Dental and gingival pain</e1> as side effects of <e2>niacin</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6705	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, <e2>hyperalgesia of sensory nerve receptors</e2>, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6706	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of <e2>pain to the teeth</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6707	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and <e2>potentiation of inflammation in the gingiva</e2> with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6708	"The cause of these previously unreported side effects of <e1>niacin</e1> therapy is uncertain but may be related to <e2>prostaglandin-mediated vasodilatation</e2>, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6709	"Two 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6710	"Two 65-year-old white men with coronary heart disease, given <e1>niacin</e1> therapy for dyslipidemia for 5 months, developed <e2>intense dental and gingival pain</e2> that was associated with increases in dose and that was relieved with discontinuance of <e1>niacin</e1> treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6711	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6712	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, <e2>potassium loss</e2> also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6713	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6714	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are <e2>secondary hyperparathyroidism</e2> and vitamin D intoxication, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6715	"Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and <e1>calcitriol</e1> are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6716	"Although major hazards of treatment of hypo<e1>phosphate</e1>mic osteomalacia with <e1>phosphate</e1> and calcitriol are secondary hyperparathyroidism and <e2>vitamin D intoxication</e2>, potassium loss also should be kept in mind."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6717	"High-dose <e1>phosphate</e1> treatment leads to <e2>hypokalemia</e2> in hypo<e1>phosphate</e1>mic osteomalacia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6718	"It was concluded that potassium loss occurred by a non-renal (intestinal) route in <e1>phosphate</e1>-induced <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6719	"It was concluded that <e1>potassium loss</e1> occurred by a non-renal (intestinal) route in <e2>phosphate</e2>-induced hypokalemia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6720	"<e1>Progressive hypokalemia</e1> developed during <e2>phosphate</e2> treatment."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6721	"The mechanism of the <e1>decrease in plasma potassium</e1> induced by <e2>phosphate</e2> treatment was investigated in a 24-year-old hypertensive patient with hypo<e2>phosphate</e2>mic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6722	"<e1>Transtubular potassium gradient (TTKG) also decreased</e1> and an inverse correlation was found between TTKG and doses of <e2>phosphate</e2> (r = -0.37; p < 0.02; N = 38)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6723	"<e1>Alveolar-interstitial pneumopathy</e1> after <e2>gold</e2>-salts compounds administration, requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6724	"The <e1>pulmonary toxicity</e1> of <e2>gold</e2> salts is an uncommon cause of life-threatening respiratory failure."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6725	"The pulmonary toxicity of <e1>gold</e1> salts is an uncommon cause of life-threatening <e2>respiratory failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6726	"We report a case of severe <e1>respiratory failure</e1> due to <e2>gold</e2> salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6727	"As this relapse coincided with development of a strong delayed-type <e1>hypersensitivity response</e1> to <e2>tuberculin</e2> and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6728	"A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and <e1>glycosuria</e1> during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6729	"A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed <e1>postprandial hyperglycemia</e1> and glycosuria during a period of topical administration of a corticosteroid cream, <e2>halcinonide</e2> cream 0.1%, under occlusion."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6730	"A second patient with a similar glucose tolerance test result showed <e1>postprandial hyperglycemia</e1> when treated similarly with <e2>betamethasone valerate</e2> cream 0.1%."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6731	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, <e2>confusion</e2>, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6732	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced headache, confusion, and "<e2>gray areas</e2>" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6733	"After 1 week of <e1>nefazodone</e1> therapy the patient experienced <e2>headache</e2>, confusion, and "gray areas" in her vision, without abnormal ophthalmologic findings."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6734	"Coadministration of antidepressant agents such as <e1>nefazodone</e1>, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to <e2>interfere with tacrolimus metabolism</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6735	"Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to interfere with <e2>tacrolimus</e2> metabolism."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6736	"<e1>Interaction</e1> between tacrolimus and <e2>nefazodone</e2> in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6737	"<e1>Interaction</e1> between <e2>tacrolimus</e2> and nefazodone in a stable renal transplant recipient."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6738	"We suspect that <e1>nefazodone</e1> <e2>inhibits metabolism of tacrolimus</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6739	"We suspect that nefazodone inhibits metabolism of <e2>tacrolimus</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6740	"We report the case of <e1>intoxication</e1> of a 41-year-old female patient suffering from major depression with <e2>mirtazapine</e2> complicated by severe hypothermia."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6741	"CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6742	"CONCLUSION: We report a case of the use of pamidronate for significant <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6743	"Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6744	"Pamidronate therapy should be considered in patients with <e1>hypercalcemia</e1> secondary to acute <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6745	"The patient was initially treated with hydration and <e1>furosemide</e1> but developed <e2>congestive heart failure</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6746	"The use of pamidronate for hypercalcemia secondary to acute <e2>vitamin D</e2> intoxication."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6747	"We report the use of pamidronate for acute, <e1>severe hypercalcemia</e1> secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6748	"We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic <e2>vitamin D</e2> poisoning."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6749	"A 40-year-old man with a long standing history of rheumatoid arthritis was treated with <e1>MTX</e1> over a 6 month period and developed an <e2>overwhelming hepatic necrosis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6750	"<e1>Methotrexate</e1>-induced <e2>hepatic necrosis</e2> requiring liver transplantation in a patient with rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6751	"<e1>MTX</e1>-induced <e2>hepatic injury</e2> and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6752	"<e1>MTX</e1>-induced hepatic injury and <e2>liver enzyme elevations</e2> have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6753	"Clinicians should be aware of the possibility that <e1>vinorelbine</e1> may cause SIADH and possibly <e2>hypokalemia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6754	"Clinicians should be aware of the possibility that <e1>vinorelbine</e1> may cause <e2>SIADH</e2> and possibly hypokalemia."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6755	"CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, <e1>vinorelbine</e1> is believed to be responsible for <e2>SIADH</e2> in our patient."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6756	"OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone (<e1>SIADH</e1>) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6757	"OBJECTIVE: To describe onset of <e1>syndrome of inappropriate antidiuretic hormone</e1> (SIADH) associated with <e2>vinorelbine</e2> therapy for advanced breast cancer."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6758	"<e1>Syndrome of inappropriate antidiuretic hormone</e1> associated with <e2>vinorelbine</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6759	"<e1>Pirmenol hydrochloride</e1>-induced <e2>QT prolongation</e2> and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6760	"<e1>Pirmenol hydrochloride</e1>-induced QT prolongation and <e2>T wave inversion</e2> on electrocardiogram during treatment for symptomatic atrial fibrillation."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6761	"Thus, an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1>-induced <e2>QT prolongation</e2> and T wave inversion on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6762	"Thus, an immunological mechanism might be involved in the mechanism of <e1>pirmenol</e1>-induced QT prolongation and <e2>T wave inversion</e2> on the electrocardiogram."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6763	"We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked <e1>prolongation of the QT interval</e1> and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6764	"We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and <e1>T wave inversion</e1> on electrocardiogram was demonstrated reproducibly shortly after the administration of oral <e2>pirmenol</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6765	"Disseminated muscular cysticercosis with <e1>myositis</e1> induced by <e2>praziquantel</e2> therapy."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6766	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, <e1>diffuse myalgia</e1>, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6767	"We describe a case of disseminated muscular cysticercosis followed by myositis (<e1>fever</e1>, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6768	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and <e1>inflammatory reaction around dying cysticerci</e1>) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6769	"We describe a case of disseminated muscular cysticercosis followed by <e1>myositis</e1> (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6770	"We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, <e1>weakness of the lower limbs</e1>, and inflammatory reaction around dying cysticerci) induced by <e2>praziquantel</e2> therapy, an event not described previously."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6771	"<e1>Massive subfascial hematoma</e1> after <e2>alteplase</e2> therapy for acute myocardial infarction."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6772	"Physicians should be aware of the possible association between the use of <e1>alteplase</e1> and the development of <e2>subfascial hemorrhage</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6773	"The authors report a case of a patient who received <e1>alteplase</e1> for acute myocardial infarction and developed spontaneous <e2>subfascial hematoma</e2> without any evidence of direct trauma."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6774	"The development of <e1>cutaneous ecchymosis</e1> associated with a sudden fall in hemoglobin after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6775	"The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of <e1>alteplase</e1> should strongly suggest the possibility of <e2>diffuse subfascial hematoma</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6776	"The development of cutaneous ecchymosis associated with a <e1>sudden fall in hemoglobin</e1> after the administration of <e2>alteplase</e2> should strongly suggest the possibility of diffuse subfascial hematoma."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6777	"A <e1>fatal case of pancytopenia</e1> due to <e2>levomepromazine</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6778	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, <e2>diazepam</e2> and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6779	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with <e2>levomepromazine</e2>, diazepam and lithium carbonate."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6780	"A <e1>fatal pancytopenia</e1> occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and <e2>lithium carbonate</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6781	"<e1>Amiodarone</e1>-induced <e2>thyrotoxicosis</e2> associated with thyrotropin receptor antibody."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6782	"<e1>Amiodarone</e1>-induced thyrotoxicosis associated with <e2>thyrotropin receptor antibody</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6783	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed <e2>thyrotoxicosis</e2> with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6784	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or <e2>thyrotropin-binding inhibiting immunoglobulin</e2> (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6785	"Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking <e1>amiodarone</e1> for 4 years, developed thyrotoxicosis with subacute onset, accompanied by <e2>transiently positive thyrotropin (TSH) receptor antibody</e2> (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6786	"Since <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1>-induced thyrotoxicosis (<e2>AIT</e2>) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6787	"Since <e1>amiodarone</e1> was first marketed in 1992 in Japan, the incidence of <e1>amiodarone</e1>-induced <e2>thyrotoxicosis</e2> (AIT) has been increasing."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6788	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1>-induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6789	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1>-induced <e2>destructive thyroiditis</e2>, as reported in patients with <e2>destructive thyroiditis</e2>, such as subacute and silent thyroiditis."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6790	"These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with <e1>amiodarone</e1>-induced destructive <e2>thyroiditis</e2>, as reported in patients with destructive <e2>thyroiditis</e2>, such as subacute and silent <e2>thyroiditis</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6791	"These in vitro findings and clinical course suggest that <e1>TRAb/TBII without thyroid-stimulating activity</e1> may develop in patients with <e2>amiodarone</e2>-induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6792	"CONCLUSION: <e1>Lipoid pneumonia</e1> as a result of <e2>mineral oil</e2> aspiration still occurs in the pediatric population."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6793	"In patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6794	"In patients with swallowing dysfunction and pneumonia, a history of <e1>mineral oil</e1> use should be obtained and a diagnosis of <e2>ELP</e2> should be considered in the differential diagnoses if <e1>mineral oil</e1> use has occurred."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6795	"In patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6796	"In patients with swallowing dysfunction and <e1>pneumonia</e1>, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6797	"In patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6798	"In patients with <e1>swallowing dysfunction</e1> and pneumonia, a history of <e2>mineral oil</e2> use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if <e2>mineral oil</e2> use has occurred."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6799	"<e1>Lipoid pneumonia</e1>: a silent complication of <e2>mineral oil</e2> aspiration."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6800	"<e1>Mineral oil</e1>, a hydrocarbon, may not elicit a normal protective cough reflex and may <e2>impair mucociliary transport</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6801	"Our case points to the need for increased awareness by the general pediatricians of the <e1>potential hazards</e1> of <e2>mineral oil</e2> use for chronic constipation."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6802	"Treatment of <e1>ELP</e1> in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6803	"Treatment of ELP in children is generally supportive, with the symptoms and <e1>roentgenographic abnormalities</e1> resolving within months after stopping the use of <e2>mineral oil</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6804	"We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic exogenous lipoid pneumonia (<e2>ELP</e2>)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6805	"We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic <e1>mineral oil</e1> ingestion presenting as asymptomatic <e2>exogenous lipoid pneumonia</e2> (ELP)."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6806	"An unusual cause of <e1>burn injury</e1>: unsupervised use of drugs that contain <e2>psoralens</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6807	"Because <e1>psoralens</e1> sensitize skin to ultraviolet A light, <e2>phototoxic reactions</e2> are the most frequent adverse effect of this treatment."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6808	"In this article, we present the case of a vitiligo patient who was admitted to our facility with an <e1>intense burn</e1> after the topical use of <e2>8-methoxypsoralen</e2> solution as a suntanning agent."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6809	"Sunburn may sometimes be a major injury in <e1>psoralen</e1> users because high doses or inappropriate use of the drug may render the <e2>skin extremely sensitive</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6810	"<e1>Sunburn</e1> may sometimes be a major injury in <e2>psoralen</e2> users because high doses or inappropriate use of the drug may render the skin extremely sensitive."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6811	"CONCLUSIONS: <e1>Metoclopramide</e1> may cause reversible <e2>nonthrombocytopenic vascular-type palpable purpura</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6812	"OBJECTIVE: To report a case of reversible <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6813	"Reversible <e1>nonthrombocytopenic palpable purpura</e1> associated with <e2>metoclopramide</e2>."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6814	"<e1>Lithium</e1> treatment was terminated in 1975 because of lithium intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6815	"Lithium treatment was terminated in 1975 because of <e1>lithium</e1> intoxication with a <e2>diabetes insipidus-like syndrome</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6816	"<e1>Lithium</e1> treatment was terminated in 1975 because of <e2>lithium intoxication</e2> with a diabetes insipidus-like syndrome."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

6817	"Lithium treatment was terminated in 1975 because of <e2>lithium</e2> intoxication with a diabetes insipidus-like syndrome."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6818	"<e1>Eosinophilia</e1> caused by <e2>clozapine</e2> was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01)."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6819	"<e1>Eosinophilia</e1> has been encountered from 0.2 to 61.7% in <e2>clozapine</e2>-treated patients, mostly with a transient course and spontaneous remission."
DRUG-ADE(e2,e1)
Comment: DRUG-AE

6820	"Successful challenge with <e1>clozapine</e1> in a history of <e2>eosinophilia</e2>."
DRUG-ADE(e1,e2)
Comment: DRUG-AE

